Entry,Entry name,Status,Protein names,Gene names,Organism,Length,Gene ontology IDs,Cross-reference (GeneID),Sequence,Involvement in disease,Disulfide bond,Domain [CC],Cross-reference (Pfam),Cross-reference (KEGG),Cross-reference (PeroxiBase),Cross-reference (MoonProt),Subunit structure [CC],Helix,Beta strand,Turn,Domain [FT],yourlist:M2015021713LSWDEUXW,,,,%C,GRAVY,MW,Abundance,Abundance +1P61221,ABCE1_HUMAN,reviewed,ATP-binding cassette sub-family E member 1 (2'-5'-oligoadenylate-binding protein) (HuHP68) (RNase L inhibitor) (Ribonuclease 4 inhibitor) (RNS4I),ABCE1 RLI RNASEL1 RNASELI RNS4I OK/SW-cl.40,Homo sapiens (Human),599,GO:0005524; GO:0016887; GO:0006401; GO:0005737; GO:0051536; GO:0016020; GO:0005739; GO:0043086; GO:0009615; GO:0008428; GO:0016032,6059;,MADKLTRIAIVNHDKCKPKKCRQECKKSCPVVRMGKLCIEVTPQSKIAWISETLCIGCGICIKKCPFGALSIVNLPSNLEKETTHRYCANAFKLHRLPIPRPGEVLGLVGTNGIGKSTALKILAGKQKPNLGKYDDPPDWQEILTYFRGSELQNYFTKILEDDLKAIIKPQYVDQIPKAAKGTVGSILDRKDETKTQAIVCQQLDLTHLKERNVEDLSGGELQRFACAVVCIQKADIFMFDEPSSYLDVKQRLKAAITIRSLINPDRYIIVVEHDLSVLDYLSDFICCLYGVPSAYGVVTMPFSVREGINIFLDGYVPTENLRFRDASLVFKVAETANEEEVKKMCMYKYPGMKKKMGEFELAIVAGEFTDSEIMVMLGENGTGKTTFIRMLAGRLKPDEGGEVPVLNVSYKPQKISPKSTGSVRQLLHEKIRDAYTHPQFVTDVMKPLQIENIIDQEVQTLSGGELQRVALALCLGKPADVYLIDEPSAYLDSEQRLMAARVVKRFILHAKKTAFVVEHDFIMATYLADRVIVFDGVPSKNTVANSPQTLLAGMNKFLSQLEITFRRDPNNYRPRINKLNSIKDVEQKKSGNYFFLDD,,,,PF00005;PF00037;PF04068;,hsa:6059;,,,"SUBUNIT: Probably heterodimerizes with RNASEL; this interaction inhibits the RNASEL. Associates with HIV-1 Vif and HIV-1, HIV-2 and SIV Gag proteins.",,,,DOMAIN 7 37 4Fe-4S ferredoxin-type 1. {ECO:0000255|PROSITE-ProRule:PRU00711}.; DOMAIN 46 75 4Fe-4S ferredoxin-type 2. {ECO:0000255|PROSITE-ProRule:PRU00711}.; DOMAIN 79 315 ABC transporter 1. {ECO:0000255|PROSITE-ProRule:PRU00434}.; DOMAIN 342 562 ABC transporter 2. {ECO:0000255|PROSITE-ProRule:PRU00434}.,,,,,2.838063439,-0.191,67.32,52.3,53.3Q09666,AHNK_HUMAN,reviewed,Neuroblast differentiation-associated protein AHNAK (Desmoyokin),AHNAK PM227,Homo sapiens (Human),5890,GO:0044548; GO:0030315; GO:0015629; GO:0044291; GO:0043034; GO:0005737; GO:0005829; GO:0070062; GO:0005925; GO:0005765; GO:0016020; GO:0005634; GO:0005886; GO:0044822; GO:0051259; GO:0043484; GO:1901385; GO:0042383; GO:0097493; GO:0031982,79026;,MEKEETTRELLLPNWQGSGSHGLTIAQRDDGVFVQEVTQNSPAARTGVVKEGDQIVGATIYFDNLQSGEVTQLLNTMGHHTVGLKLHRKGDRSPEPGQTWTREVFSSCSSEVVLSGDDEEYQRIYTTKIKPRLKSEDGVEGDLGETQSRTITVTRRVTAYTVDVTGREGAKDIDISSPEFKIKIPRHELTEISNVDVETQSGKTVIRLPSGSGAASPTGSAVDIRAGAISASGPELQGAGHSKLQVTMPGIKVGGSGVNVNAKGLDLGGRGGVQVPAVDISSSLGGRAVEVQGPSLESGDHGKIKFPTMKVPKFGVSTGREGQTPKAGLRVSAPEVSVGHKGGKPGLTIQAPQLEVSVPSANIEGLEGKLKGPQITGPSLEGDLGLKGAKPQGHIGVDASAPQIGGSITGPSVEVQAPDIDVQGPGSKLNVPKMKVPKFSVSGAKGEETGIDVTLPTGEVTVPGVSGDVSLPEIATGGLEGKMKGTKVKTPEMIIQKPKISMQDVDLSLGSPKLKGDIKVSAPGVQGDVKGPQVALKGSRVDIETPNLEGTLTGPRLGSPSGKTGTCRISMSEVDLNVAAPKVKGGVDVTLPRVEGKVKVPEVDVRGPKVDVSAPDVEAHGPEWNLKMPKMKMPTFSTPGAKGEGPDVHMTLPKGDISISGPKVNVEAPDVNLEGLGGKLKGPDVKLPDMSVKTPKISMPDVDLHVKGTKVKGEYDVTVPKLEGELKGPKVDIDAPDVDVHGPDWHLKMPKMKMPKFSVPGFKAEGPEVDVNLPKADVDISGPKIDVTAPDVSIEEPEGKLKGPKFKMPEMNIKVPKISMPDVDLHLKGPNVKGEYDVTMPKVESEIKVPDVELKSAKMDIDVPDVEVQGPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVDISGPKVGVEVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDVDLHMKGPKVKGEYDMTVPKLEGDLKGPKVDVSAPDVEMQGPDWNLKMPKIKMPKFSMPSLKGEGPEFDVNLSKANVDISAPKVDTNAPDLSLEGPEGKLKGPKFKMPEMHFRAPKMSLPDVDLDLKGPKMKGNVDISAPKIEGEMQVPDVDIRGPKVDIKAPDVEGQGLDWSLKIPKMKMPKFSMPSLKGEGPEVDVNLPKADVVVSGPKVDIEAPDVSLEGPEGKLKGPKFKMPEMHFKTPKISMPDVDLHLKGPKVKGDVDVSVPKVEGEMKVPDVEIKGPKMDIDAPDVEVQGPDWHLKMPKMKMPKFSMPGFKGEGREVDVNLPKADIDVSGPKVDVEVPDVSLEGPEGKLKGPKFKMPEMHFKAPKISMPDVDLNLKGPKLKGDVDVSLPEVEGEMKVPDVDIKGPKVDISAPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPEVDVKLPKADVDVSGPKMDAEVPDVNIEGPDAKLKGPKFKMPEMSIKPQKISIPDVGLHLKGPKMKGDYDVTVPKVEGEIKAPDVDIKGPKVDINAPDVEVHGPDWHLKMPKVKMPKFSMPGFKGEGPEVDMNLPKADLGVSGPKVDIDVPDVNLEAPEGKLKGPKFKMPSMNIQTHKISMPDVGLNLKAPKLKTDVDVSLPKVEGDLKGPEIDVKAPKMDVNVGDIDIEGPEGKLKGPKFKMPEMHFKAPKISMPDVDLHLKGPKVKGDMDVSVPKVEGEMKVPDVDIKGPKVDIDAPDVEVHDPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADIDVSGPSVDTDAPDLDIEGPEGKLKGSKFKMPKLNIKAPKVSMPDVDLNLKGPKLKGEIDASVPELEGDLRGPQVDVKGPFVEAEVPDVDLECPDAKLKGPKFKMPEMHFKAPKISMPDVDLHLKGPKVKGDADVSVPKLEGDLTGPSVGVEVPDVELECPDAKLKGPKFKMPDMHFKAPKISMPDVDLHLKGPKVKGDVDVSVPKLEGDLTGPSVGVEVPDVELECPDAKLKGPKFKMPEMHFKTPKISMPDVDLHLKGPKVKGDMDVSVPKVEGEMKVPDVDIKGPKMDIDAPDVDVHGPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVVVSGPKVDVEVPDVSLEGPEGKLKGPKLKMPEMHFKAPKISMPDVDLHLKGPKVKGDVDVSLPKLEGDLTGPSVDVEVPDVELECPDAKLKGPKFKMPEMHFKTPKISMPDVNLNLKGPKVKGDMDVSVPKVEGEMKVPDVDIRGPKVDIDAPDVDVHGPDWHLKMPKMKMPKFSMPGFKGEGPEVDVNLPKADVDVSGPKVDVEVPDVSLEGPEGKLKGPKFKMPEMHFKTPKISMPDVDFNLKGPKIKGDVDVSAPKLEGELKGPELDVKGPKLDADMPEVAVEGPNGKWKTPKFKMPDMHFKAPKISMPDLDLHLKSPKAKGEVDVDVPKLEGDLKGPHVDVSGPDIDIEGPEGKLKGPKFKMPDMHFKAPNISMPDVDLNLKGPKIKGDVDVSVPEVEGKLEVPDMNIRGPKVDVNAPDVQAPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVDISGPKVDIEGPDVNIEGPEGKLKGPKLKMPEMNIKAPKISMPDFDLHLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDINAPDVGVQGPDWHLKMPKVKMPKFSMPGFKGEGPDGDVKLPKADIDVSGPKVDIEGPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDIDLNLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDAPDVDVHGPDWHLKMPKIKMPKISMPGFKGEGPDVDVNLPKADIDVSGPKVDVECPDVNIEGPEGKWKSPKFKMPEMHFKTPKISMPDIDLNLTGPKIKGDVDVTGPKVEGDLKGPEVDLKGPKVDIDVPDVNVQGPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVDVSGPKVDVEGPDVNIEGPEGKLKGPKFKMPEMNIKAPKIPMPDFDLHLKGPKVKGDVDISLPKVEGDLKGPEVDIRGPQVDIDVPDVGVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADLDVSGPKVDIDVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDIDLNLKGPKVKGDMDVSLPKVEGDMKVPDVDIKGPKVDINAPDVDVQGPDWHLKMPKIKMPKISMPGFKGEGPEVDVNLPKADLDVSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDLDLNLKGPKMKGEVDVSLANVEGDLKGPALDIKGPKIDVDAPDIDIHGPDAKLKGPKLKMPDMHVNMPKISMPEIDLNLKGSKLKGDVDVSGPKLEGDIKAPSLDIKGPEVDVSGPKLNIEGKSKKSRFKLPKFNFSGSKVQTPEVDVKGKKPDIDITGPKVDINAPDVEVQGKVKGSKFKMPFLSISSPKVSMPDVELNLKSPKVKGDLDIAGPNLEGDFKGPKVDIKAPEVNLNAPDVDVHGPDWNLKMPKMKMPKFSVSGLKAEGPDVAVDLPKGDINIEGPSMNIEGPDLNVEGPEGGLKGPKFKMPDMNIKAPKISMPDIDLNLKGPKVKGDVDISLPKLEGDLKGPEVDIKGPKVDINAPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPEVDVTLPKADIDISGPNVDVDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDFDLNLKGPKMKGDVVVSLPKVEGDLKGPEVDIKGPKVDIDTPDINIEGSEGKFKGPKFKIPEMHLKAPKISMPDIDLNLKGPKVKGDVDVSLPKMEGDLKGPEVDIKGPKVDINAPDVDVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADLDVSGPKVDIDVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDIDLNLKGPKVKGDMDVSLPKVEGDMQVPDLDIKGPKVDINAPDVDVRGPDWHLKMPKIKMPKISMPGFKGEGPEVDVNLPKADLDVSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDFDLHLKGPKVKGDVDVSLPKMEGDLKAPEVDIKGPKVDIDAPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPEVDVNLPKADIDVSGPKVDIDTPDIDIHGPEGKLKGPKFKMPDLHLKAPKISMPEVDLNLKGPKMKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDVPDVDVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADLDVSGPKVDIDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDFDLHLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDAPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVTLPKADIEISGPKVDIDAPDVSIEGPDAKLKGPKFKMPEMNIKAPKISMPDIDFNLKGPKVKGDVDVSLPKVEGDLKGPEIDIKGPSLDIDTPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDFDLHLKGPKVKGDVDVSLPKVESDLKGPEVDIEGPEGKLKGPKFKMPDVHFKSPQISMSDIDLNLKGPKIKGDMDISVPKLEGDLKGPKVDVKGPKVGIDTPDIDIHGPEGKLKGPKFKMPDLHLKAPKISMPEVDLNLKGPKVKGDMDISLPKVEGDLKGPEVDIRDPKVDIDVPDVDVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADIDVSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMSIKAPKISMPDIDLNLKGPKVKGDVDVTLPKVEGDLKGPEADIKGPKVDINTPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVSLPKADIDVSGPKVDVDIPDVNIEGPDAKLKGPKFKMPEINIKAPKISIPDVDLDLKGPKVKGDFDVSVPKVEGTLKGPEVDLKGPRLDFEGPDAKLSGPSLKMPSLEISAPKVTAPDVDLHLKAPKIGFSGPKLEGGEVDLKGPKVEAPSLDVHMDSPDINIEGPDVKIPKFKKPKFGFGAKSPKADIKSPSLDVTVPEAELNLETPEISVGGKGKKSKFKMPKIHMSGPKIKAKKQGFDLNVPGGEIDASLKAPDVDVNIAGPDAALKVDVKSPKTKKTMFGKMYFPDVEFDIKSPKFKAEAPLPSPKLEGELQAPDLELSLPAIHVEGLDIKAKAPKVKMPDVDISVPKIEGDLKGPKVQANLGAPDINIEGLDAKVKTPSFGISAPQVSIPDVNVNLKGPKIKGDVPSVGLEGPDVDLQGPEAKIKFPKFSMPKIGIPGVKMEGGGAEVHAQLPSLEGDLRGPDVKLEGPDVSLKGPGVDLPSVNLSMPKVSGPDLDLNLKGPSLKGDLDASVPSMKVHAPGLNLSGVGGKMQVGGDGVKVPGIDATTKLNVGAPDVTLRGPSLQGDLAVSGDIKCPKVSVGAPDLSLEASEGSIKLPKMKLPQFGISTPGSDLHVNAKGPQVSGELKGPGVDVNLKGPRISAPNVDFNLEGPKVKGSLGATGEIKGPTVGGGLPGIGVQGLEGNLQMPGIKSSGCDVNLPGVNVKLPTGQISGPEIKGGLKGSEVGFHGAAPDISVKGPAFNMASPESDFGINLKGPKIKGGADVSGGVSAPDISLGEGHLSVKGSGGEWKGPQVSSALNLDTSKFAGGLHFSGPKVEGGVKGGQIGLQAPGLSVSGPQGHLESGSGKVTFPKMKIPKFTFSGRELVGREMGVDVHFPKAEASIQAGAGDGEWEESEVKLKKSKIKMPKFNFSKPKGKGGVTGSPEASISGSKGDLKSSKASLGSLEGEAEAEASSPKGKFSLFKSKKPRHRSNSFSDEREFSGPSTPTGTLEFEGGEVSLEGGKVKGKHGKLKFGTFGGLGSKSKGHYEVTGSDDETGKLQGSGVSLASKKSRLSSSSSNDSGNKVGIQLPEVELSVSTKKE,,,,,hsa:79026;,,,SUBUNIT: Interacts with DYSF; the interaction is direct and Ca(2+)-independent. {ECO:0000269|PubMed:17185750}.,,,,DOMAIN 9 90 PDZ. {ECO:0000255|PROSITE-ProRule:PRU00143}.,,,,,0.152801358,-0.499,629.16,15.7,16.7Q02952,AKA12_HUMAN,reviewed,A-kinase anchor protein 12 (AKAP-12) (A-kinase anchor protein 250 kDa) (AKAP 250) (Gravin) (Myasthenia gravis autoantigen),AKAP12 AKAP250,Homo sapiens (Human),1782,GO:0007186; GO:0008179; GO:0005938; GO:0005737; GO:0005856; GO:0005925; GO:0005886; GO:0030819; GO:0010739; GO:0051018; GO:0006605; GO:0090036,9590;,MGAGSSTEQRSPEQPPEGSSTPAEPEPSGGGPSAEAAPDTTADPAIAASDPATKLLQKNGQLSTINGVAEQDELSLQEGDLNGQKGALNGQGALNSQEEEEVIVTEVGQRDSEDVSKRDSDKEMATKSAVVHDITDDGQEETPEIIEQIPSSESNLEELTQPTESQANDIGFKKVFKFVGFKFTVKKDKTEKPDTVQLLTVKKDEGEGAAGAGDHKDPSLGAGEAASKESEPKQSTEKPEETLKREQSHAEISPPAESGQAVEECKEEGEEKQEKEPSKSAESPTSPVTSETGSTFKKFFTQGWAGWRKKTSFRKPKEDEVEASEKKKEQEPEKVDTEEDGKAEVASEKLTASEQAHPQEPAESAHEPRLSAEYEKVELPSEEQVSGSQGPSEEKPAPLATEVFDEKIEVHQEEVVAEVHVSTVEERTEEQKTEVEETAGSVPAEELVEMDAEPQEAEPAKELVKLKETCVSGEDPTQGADLSPDEKVLSKPPEGVVSEVEMLSSQERMKVQGSPLKKLFTSTGLKKLSGKKQKGKRGGGDEESGEHTQVPADSPDSQEEQKGESSASSPEEPEEITCLEKGLAEVQQDGEAEEGATSDGEKKREGVTPWASFKKMVTPKKRVRRPSESDKEDELDKVKSATLSSTESTASEMQEEMKGSVEEPKPEEPKRKVDTSVSWEALICVGSSKKRARRGSSSDEEGGPKAMGGDHQKADEAGKDKETGTDGILAGSQEHDPGQGSSSPEQAGSPTEGEGVSTWESFKRLVTPRKKSKSKLEEKSEDSIAGSGVEHSTPDTEPGKEESWVSIKKFIPGRRKKRPDGKQEQAPVEDAGPTGANEDDSDVPAVVPLSEYDAVEREKMEAQQAQKSAEQPEQKAATEVSKELSESQVHMMAAAVADGTRAATIIEERSPSWISASVTEPLEQVEAEAALLTEEVLEREVIAEEEPPTVTEPLPENREARGDTVVSEAELTPEAVTAAETAGPLGAEEGTEASAAEETTEMVSAVSQLTDSPDTTEEATPVQEVEGGVPDIEEQERRTQEVLQAVAEKVKEESQLPGTGGPEDVLQPVQRAEAERPEEQAEASGLKKETDVVLKVDAQEAKTEPFTQGKVVGQTTPESFEKAPQVTESIESSELVTTCQAETLAGVKSQEMVMEQAIPPDSVETPTDSETDGSTPVADFDAPGTTQKDEIVEIHEENEVASGTQSGGTEAEAVPAQKERPPAPSSFVFQEETKEQSKMEDTLEHTDKEVSVETVSILSKTEGTQEADQYADEKTKDVPFFEGLEGSIDTGITVSREKVTEVALKGEGTEEAECKKDDALELQSHAKSPPSPVEREMVVQVEREKTEAEPTHVNEEKLEHETAVTVSEEVSKQLLQTVNVPIIDGAKEVSSLEGSPPPCLGQEEAVCTKIQVQSSEASFTLTAAAEEEKVLGETANILETGETLEPAGAHLVLEEKSSEKNEDFAAHPGEDAVPTGPDCQAKSTPVIVSATTKKGLSSDLEGEKTTSLKWKSDEVDEQVACQEVKVSVAIEDLEPENGILELETKSSKLVQNIIQTAVDQFVRTEETATEMLTSELQTQAHVIKADSQDAGQETEKEGEEPQASAQDETPITSAKEESESTAVGQAHSDISKDMSEASEKTMTVEVEGSTVNDQQLEEVVLPSEEEGGGAGTKSVPEDDGHALLAERIEKSLVEPKEDEKGDDVDDPENQNSALADTDASGGLTKESPDTNGPKQKEKEDAQEVELQEGKVHSESDKAITPQAQEELQKQERESAKSELTES,,,DOMAIN: Polybasic regions located between residues 266 and 557 are involved in binding PKC.,PF10522;PF03832;,hsa:9590;,,,SUBUNIT: Binds to dimeric RII-alpha regulatory subunit of PKC.,,,,DOMAIN 604 634 AKAP 1.; DOMAIN 753 783 AKAP 2.; DOMAIN 798 828 AKAP 3.,,,,,0.561167228,-0.941,191.52,9.49,10.49P54886,P5CS_HUMAN,reviewed,Delta-1-pyrroline-5-carboxylate synthase (P5CS) (Aldehyde dehydrogenase family 18 member A1) [Includes: Glutamate 5-kinase (GK) (EC 2.7.2.11) (Gamma-glutamyl kinase); Gamma-glutamyl phosphate reductase (GPR) (EC 1.2.1.41) (Glutamate-5-semialdehyde dehydrogenase) (Glutamyl-gamma-semialdehyde dehydrogenase)],ALDH18A1 GSAS P5CS PYCS,Homo sapiens (Human),795,GO:0005524; GO:0055129; GO:0008652; GO:0034641; GO:0019240; GO:0005737; GO:0004349; GO:0006536; GO:0004350; GO:0005743; GO:0005739; GO:0006592; GO:0044822; GO:0006561; GO:0044281,5832;,MLSQVYRCGFQPFNQHLLPWVKCTTVFRSHCIQPSVIRHVRSWSNIPFITVPLSRTHGKSFAHRSELKHAKRIVVKLGSAVVTRGDECGLALGRLASIVEQVSVLQNQGREMMLVTSGAVAFGKQRLRHEILLSQSVRQALHSGQNQLKEMAIPVLEARACAAAGQSGLMALYEAMFTQYSICAAQILVTNLDFHDEQKRRNLNGTLHELLRMNIVPIVNTNDAVVPPAEPNSDLQGVNVISVKDNDSLAARLAVEMKTDLLIVLSDVEGLFDSPPGSDDAKLIDIFYPGDQQSVTFGTKSRVGMGGMEAKVKAALWALQGGTSVVIANGTHPKVSGHVITDIVEGKKVGTFFSEVKPAGPTVEQQGEMARSGGRMLATLEPEQRAEIIHHLADLLTDQRDEILLANKKDLEEAEGRLAAPLLKRLSLSTSKLNSLAIGLRQIAASSQDSVGRVLRRTRIAKNLELEQVTVPIGVLLVIFESRPDCLPQVAALAIASGNGLLLKGGKEAAHSNRILHLLTQEALSIHGVKEAVQLVNTREEVEDLCRLDKMIDLIIPRGSSQLVRDIQKAAKGIPVMGHSEGICHMYVDSEASVDKVTRLVRDSKCEYPAACNALETLLIHRDLLRTPLFDQIIDMLRVEQVKIHAGPKFASYLTFSPSEVKSLRTEYGDLELCIEVVDNVQDAIDHIHKYGSSHTDVIVTEDENTAEFFLQHVDSACVFWNASTRFSDGYRFGLGAEVGISTSRIHARGPVGLEGLLTTKWLLRGKDHVVSDFSEHGSLKYLHENLPIPQRNTN,"DISEASE: Cutis laxa, autosomal recessive, 3A (ARCL3A) [MIM:219150]: A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities. {ECO:0000269|PubMed:11092761, ECO:0000269|PubMed:18478038}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF00696;PF00171;,hsa:5832;,,,,HELIX 363 379 {ECO:0000244|PDB:2H5G}.; HELIX 382 398 {ECO:0000244|PDB:2H5G}.; HELIX 400 414 {ECO:0000244|PDB:2H5G}.; HELIX 420 424 {ECO:0000244|PDB:2H5G}.; HELIX 430 446 {ECO:0000244|PDB:2H5G}.; HELIX 486 497 {ECO:0000244|PDB:2H5G}.; HELIX 507 509 {ECO:0000244|PDB:2H5G}.; HELIX 510 525 {ECO:0000244|PDB:2H5G}.; HELIX 530 532 {ECO:0000244|PDB:2H5G}.; HELIX 561 570 {ECO:0000244|PDB:2H5G}.; HELIX 597 606 {ECO:0000244|PDB:2H5G}.; HELIX 622 624 {ECO:0000244|PDB:2H5G}.; HELIX 628 639 {ECO:0000244|PDB:2H5G}.; HELIX 648 651 {ECO:0000244|PDB:2H5G}.; HELIX 681 691 {ECO:0000244|PDB:2H5G}.; HELIX 704 713 {ECO:0000244|PDB:2H5G}.; HELIX 725 727 {ECO:0000244|PDB:2H5G}.; HELIX 754 757 {ECO:0000244|PDB:2H5G}.; HELIX 771 774 {ECO:0000244|PDB:2H5G}.,STRAND 454 461 {ECO:0000244|PDB:2H5G}.; STRAND 464 472 {ECO:0000244|PDB:2H5G}.; STRAND 475 482 {ECO:0000244|PDB:2H5G}.; STRAND 500 504 {ECO:0000244|PDB:2H5G}.; STRAND 533 535 {ECO:0000244|PDB:2H5G}.; STRAND 553 559 {ECO:0000244|PDB:2H5G}.; STRAND 572 574 {ECO:0000244|PDB:2H5G}.; STRAND 584 588 {ECO:0000244|PDB:2H5G}.; STRAND 614 621 {ECO:0000244|PDB:2H5G}.; STRAND 643 646 {ECO:0000244|PDB:2H5G}.; STRAND 670 680 {ECO:0000244|PDB:2H5G}.; STRAND 694 700 {ECO:0000244|PDB:2H5G}.; STRAND 716 723 {ECO:0000244|PDB:2H5G}.; STRAND 745 747 {ECO:0000244|PDB:2H5G}.; STRAND 758 765 {ECO:0000244|PDB:2H5G}.,TURN 415 417 {ECO:0000244|PDB:2H5G}.; TURN 526 528 {ECO:0000244|PDB:2H5G}.; TURN 594 596 {ECO:0000244|PDB:2H5G}.; TURN 730 734 {ECO:0000244|PDB:2H5G}.,,,,,,1.635220126,-0.083,87.32,34.6,35.6Q10567,AP1B1_HUMAN,reviewed,AP-1 complex subunit beta-1 (Adaptor protein complex AP-1 subunit beta-1) (Adaptor-related protein complex 1 subunit beta-1) (Beta-1-adaptin) (Beta-adaptin 1) (Clathrin assembly protein complex 1 beta large chain) (Golgi adaptor HA1/AP1 adaptin beta subunit),AP1B1 ADTB1 BAM22 CLAPB2,Homo sapiens (Human),949,GO:0000139; GO:0019886; GO:0030131; GO:0030665; GO:0030659; GO:0005829; GO:0006886; GO:0005765; GO:0061024; GO:0006892; GO:0019901; GO:0008565; GO:0050690; GO:0032588; GO:0005215; GO:0016032,162;,MTDSKYFTTTKKGEIFELKAELNSDKKEKKKEAVKKVIASMTVGKDVSALFPDVVNCMQTDNLELKKLVYLYLMNYAKSQPDMAIMAVNTFVKDCEDPNPLIRALAVRTMGCIRVDKITEYLCEPLRKCLKDEDPYVRKTAAVCVAKLHDINAQLVEDQGFLDTLKDLISDSNPMVVANAVAALSEIAESHPSSNLLDLNPQSINKLLTALNECTEWGQIFILDCLANYMPKDDREAQSICERVTPRLSHANSAVVLSAVKVLMKFMEMLSKDLDYYGTLLKKLAPPLVTLLSAEPELQYVALRNINLIVQKRPEILKHEMKVFFVKYNDPIYVKLEKLDIMIRLASQANIAQVLAELKEYATEVDVDFVRKAVRAIGRCAIKVEQSAERCVSTLLDLIQTKVNYVVQEAIVVIKDIFRKYPNKYESVIATLCENLDSLDEPEARAAMIWIVGEYAERIDNADELLESFLEGFHDESTQVQLQLLTAIVKLFLKKPTETQELVQQVLSLATQDSDNPDLRDRGYIYWRLLSTDPVAAKEVVLAEKPLISEETDLIEPTLLDELICYIGTLASVYHKPPSAFVEGGRGVVHKSLPPRTASSESAESPETAPTGAPPGEQPDVIPAQGDLLGDLLNLDLGPPVSGPPLATSSVQMGAVDLLGGGLDSLMGDEPEGIGGTNFVAPPTAAVPANLGAPIGSGLSDLFDLTSGVGTLSGSYVAPKAVWLPAMKAKGLEISGTFTRQVGSISMDLQLTNKALQVMTDFAIQFNRNSFGLAPATPLQVHAPLSPNQTVEISLPLSTVGSVMKMEPLNNLQVAVKNNIDVFYFSTLYPLHILFVEDGKMDRQMFLATWKDIPNENEAQFQIRDCPLNAEAASSKLQSSNIFTVAKRNVEGQDMLYQSLKLTNGIWVLAELRIQPGNPSCTDLELSLKCRAPEVSQHVYQAYETILKN,,,,PF01602;PF02883;PF09066;,hsa:162;,,,"SUBUNIT: Adaptor protein complex 1 (AP-1) is a heterotetramer composed of two large adaptins (gamma-type subunit AP1G1 and beta-type subunit AP1B1), a medium adaptin (mu-type subunit AP1M1 or AP1M2) and a small adaptin (sigma-type subunit AP1S1 or AP1S2 or AP1S3).",HELIX 15 23 {ECO:0000244|PDB:4P6Z}.; HELIX 27 42 {ECO:0000244|PDB:4P6Z}.; HELIX 48 50 {ECO:0000244|PDB:4P6Z}.; HELIX 51 55 {ECO:0000244|PDB:4P6Z}.; HELIX 63 76 {ECO:0000244|PDB:4P6Z}.; HELIX 83 87 {ECO:0000244|PDB:4P6Z}.; HELIX 88 94 {ECO:0000244|PDB:4P6Z}.; HELIX 100 110 {ECO:0000244|PDB:4P6Z}.; HELIX 116 130 {ECO:0000244|PDB:4P6Z}.; HELIX 135 151 {ECO:0000244|PDB:4P6Z}.; HELIX 153 159 {ECO:0000244|PDB:4P6Z}.; HELIX 161 168 {ECO:0000244|PDB:4P6Z}.; HELIX 174 190 {ECO:0000244|PDB:4P6Z}.; HELIX 201 213 {ECO:0000244|PDB:4P6Z}.; HELIX 216 228 {ECO:0000244|PDB:4P6Z}.; HELIX 234 244 {ECO:0000244|PDB:4P6Z}.; HELIX 245 249 {ECO:0000244|PDB:4P6Z}.; HELIX 253 266 {ECO:0000244|PDB:4P6Z}.; HELIX 267 269 {ECO:0000244|PDB:4P6Z}.; HELIX 275 290 {ECO:0000244|PDB:4P6Z}.; HELIX 291 293 {ECO:0000244|PDB:4P6Z}.; HELIX 296 312 {ECO:0000244|PDB:4P6Z}.; HELIX 321 324 {ECO:0000244|PDB:4P6Z}.; HELIX 332 345 {ECO:0000244|PDB:4P6Z}.; HELIX 351 361 {ECO:0000244|PDB:4P6Z}.; HELIX 367 383 {ECO:0000244|PDB:4P6Z}.; HELIX 387 399 {ECO:0000244|PDB:4P6Z}.; HELIX 404 420 {ECO:0000244|PDB:4P6Z}.; HELIX 428 431 {ECO:0000244|PDB:4P6Z}.; HELIX 432 434 {ECO:0000244|PDB:4P6Z}.; HELIX 442 454 {ECO:0000244|PDB:4P6Z}.; HELIX 462 467 {ECO:0000244|PDB:4P6Z}.; HELIX 478 494 {ECO:0000244|PDB:4P6Z}.; HELIX 500 511 {ECO:0000244|PDB:4P6Z}.; HELIX 517 532 {ECO:0000244|PDB:4P6Z}.; HELIX 534 540 {ECO:0000244|PDB:4P6Z}.; HELIX 557 564 {ECO:0000244|PDB:4P6Z}.; HELIX 570 574 {ECO:0000244|PDB:4P6Z}.; HELIX 578 580 {ECO:0000244|PDB:4P6Z}.,STRAND 191 193 {ECO:0000244|PDB:4P6Z}.,TURN 77 79 {ECO:0000244|PDB:4P6Z}.; TURN 314 319 {ECO:0000244|PDB:4P6Z}.; TURN 348 350 {ECO:0000244|PDB:4P6Z}.; TURN 455 458 {ECO:0000244|PDB:4P6Z}.; TURN 471 475 {ECO:0000244|PDB:4P6Z}.; TURN 565 568 {ECO:0000244|PDB:4P6Z}.,,,,,,1.685985248,-0.054,104.65,69.4,70.4O43747,AP1G1_HUMAN,reviewed,AP-1 complex subunit gamma-1 (Adaptor protein complex AP-1 subunit gamma-1) (Adaptor-related protein complex 1 subunit gamma-1) (Clathrin assembly protein complex 1 gamma-1 large chain) (Gamma1-adaptin) (Golgi adaptor HA1/AP1 adaptin subunit gamma-1),AP1G1 ADTG CLAPG1,Homo sapiens (Human),822,GO:0030119; GO:0030742; GO:0005794; GO:0000139; GO:0090160; GO:0017137; GO:0019886; GO:0030131; GO:0030136; GO:0030665; GO:0005737; GO:0030659; GO:0005829; GO:0035646; GO:0043231; GO:0006886; GO:0019894; GO:0005765; GO:0032438; GO:0016020; GO:0061024; GO:0048471; GO:0043323; GO:0045954; GO:0006892; GO:0008565; GO:0055037; GO:0050690; GO:0032588; GO:0005215; GO:0016032,164;,MPAPIRLRELIRTIRTARTQAEEREMIQKECAAIRSSFREEDNTYRCRNVAKLLYMHMLGYPAHFGQLECLKLIASQKFTDKRIGYLGAMLLLDERQDVHLLMTNCIKNDLNHSTQFVQGLALCTLGCMGSSEMCRDLAGEVEKLLKTSNSYLRKKAALCAVHVIRKVPELMEMFLPATKNLLNEKNHGVLHTSVVLLTEMCERSPDMLAHFRKLVPQLVRILKNLIMSGYSPEHDVSGISDPFLQVRILRLLRILGRNDDDSSEAMNDILAQVATNTETSKNVGNAILYETVLTIMDIKSESGLRVLAINILGRFLLNNDKNIRYVALTSLLKTVQTDHNAVQRHRSTIVDCLKDLDVSIKRRAMELSFALVNGNNIRGMMKELLYFLDSCEPEFKADCASGIFLAAEKYAPSKRWHIDTIMRVLTTAGSYVRDDAVPNLIQLITNSVEMHAYTVQRLYKAILGDYSQQPLVQVAAWCIGEYGDLLVSGQCEEEEPIQVTEDEVLDILESVLISNMSTSVTRGYALTAIMKLSTRFTCTVNRIKKVVSIYGSSIDVELQQRAVEYNALFKKYDHMRSALLERMPVMEKVTTNGPTEIVQTNGETEPAPLETKPPPSGPQPTSQANDLLDLLGGNDITPVIPTAPTSKPSSAGGELLDLLGDINLTGAPAAAPAPASVPQISQPPFLLDGLSSQPLFNDIAAGIPSITAYSKNGLKIEFTFERSNTNPSVTVITIQASNSTELDMTDFVFQAAVPKTFQLQLLSPSSSIVPAFNTGTITQVIKVLNPQKQQLRMRIKLTYNHKGSAMQDLAEVNNFPPQSWQ,,,,PF01602;PF02883;,hsa:164;,,,"SUBUNIT: Adaptor protein complex 1 (AP-1) is a heterotetramer composed of two large adaptins (gamma-type subunit AP1G1 and beta-type subunit AP1B1), a medium adaptin (mu-type subunit AP1M1 or AP1M2) and a small adaptin (sigma-type subunit AP1S1 or AP1S2 or AP1S3). Binds RABEP1 and SYNRG. Interacts (via GAE domain) with AP1AR (via coiled-coil domain). {ECO:0000269|PubMed:12042876, ECO:0000269|PubMed:12773381, ECO:0000269|PubMed:15775984}.",HELIX 772 774 {ECO:0000244|PDB:1IU1}.; HELIX 818 820 {ECO:0000244|PDB:1IU1}.,STRAND 707 712 {ECO:0000244|PDB:1IU1}.; STRAND 715 723 {ECO:0000244|PDB:1IU1}.; STRAND 730 739 {ECO:0000244|PDB:1IU1}.; STRAND 741 743 {ECO:0000244|PDB:1IU1}.; STRAND 745 753 {ECO:0000244|PDB:1IU1}.; STRAND 758 762 {ECO:0000244|PDB:1IU1}.; STRAND 778 785 {ECO:0000244|PDB:1IU1}.; STRAND 795 802 {ECO:0000244|PDB:1IU1}.; STRAND 805 812 {ECO:0000244|PDB:1IU1}.,,DOMAIN 702 817 GAE. {ECO:0000255|PROSITE-ProRule:PRU00093}.,,,,,1.824817518,-0.112,91.37,20,21Q9BXS5,AP1M1_HUMAN,reviewed,AP-1 complex subunit mu-1 (AP-mu chain family member mu1A) (Adaptor protein complex AP-1 subunit mu-1) (Adaptor-related protein complex 1 subunit mu-1) (Clathrin assembly protein complex 1 mu-1 medium chain 1) (Clathrin coat assembly protein AP47) (Clathrin coat-associated protein AP47) (Golgi adaptor HA1/AP1 adaptin mu-1 subunit) (Mu-adaptin 1) (Mu1A-adaptin),AP1M1 CLTNM,Homo sapiens (Human),423,GO:0000139; GO:0019886; GO:0030131; GO:0030665; GO:0030659; GO:0005829; GO:0035646; GO:0070062; GO:0006886; GO:0005765; GO:0032438; GO:0016020; GO:0061024; GO:0006892; GO:0050690; GO:0032588; GO:0016032,8907;,MSASAVYVLDLKGKVLICRNYRGDVDMSEVEHFMPILMEKEEEGMLSPILAHGGVRFMWIKHNNLYLVATSKKNACVSLVFSFLYKVVQVFSEYFKELEEESIRDNFVIIYELLDELMDFGYPQTTDSKILQEYITQEGHKLETGAPRPPATVTNAVSWRSEGIKYRKNEVFLDVIESVNLLVSANGNVLRSEIVGSIKMRVFLSGMPELRLGLNDKVLFDNTGRGKSKSVELEDVKFHQCVRLSRFENDRTISFIPPDGEFELMSYRLNTHVKPLIWIESVIEKHSHSRIEYMIKAKSQFKRRSTANNVEIHIPVPNDADSPKFKTTVGSVKWVPENSEIVWSIKSFPGGKEYLMRAHFGLPSVEAEDKEGKPPISVKFEIPYFTTSGIQVRYLKIIEKSGYQALPWVRYITQNGDYQLRTQ,,,,PF00928;PF01217;,hsa:8907;,,,"SUBUNIT: Adaptor protein complex 1 (AP-1) is a heterotetramer composed of two large adaptins (gamma-type subunit AP1G1 and beta-type subunit AP1B1), a medium adaptin (mu-type subunit AP1M1 or AP1M2) and a small adaptin (sigma-type subunit AP1S1 or AP1S2 or AP1S3). Interacts with MARCH11 (By similarity). Interacts with HIV-1 Nef. Associates with the AP1(MU)-Nef-MHC-I complex; this complex is required for MHC-I internalization. {ECO:0000250, ECO:0000269|PubMed:18073204}.",,,,DOMAIN 168 421 MHD. {ECO:0000255|PROSITE-ProRule:PRU00404}.,,,,,0.709219858,-0.282,48.59,33,34P52565,GDIR1_HUMAN,reviewed,Rho GDP-dissociation inhibitor 1 (Rho GDI 1) (Rho-GDI alpha),ARHGDIA GDIA1,Homo sapiens (Human),204,GO:0005096; GO:0005094; GO:0007266; GO:0006928; GO:0005856; GO:0005829; GO:0070062; GO:0001772; GO:0043066; GO:0050771; GO:0007162; GO:0030336; GO:0048011; GO:0050772; GO:0050770; GO:0032880; GO:0051056; GO:0071526; GO:0007264,396;,MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVVVTGLTLVCSSAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPVEEAPKGMLARGSYSIKSRFTDDDKTDHLSWEWNLTIKKDWKD,"DISEASE: Nephrotic syndrome 8 (NPHS8) [MIM:615244]: A form of nephrotic syndrome, a renal disease clinically characterized by progressive renal failure, severe proteinuria, hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show diffuse mesangial sclerosis, with small glomeruli, hypercellularity, increased extracellular matrix, and contracted/collapsed glomerular tufts surrounded by immature or abnormal podocytes. {ECO:0000269|PubMed:23434736}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF02115;,hsa:396;,,,"SUBUNIT: Monomer. Interacts with FER. Interacts with PLXNB3 (By similarity). Forms a heterodimer with RAC1. Interacts with RHOA, the affinity is increased by three orders of magnitude when RHOA is prenylated. Interacts with PSMD10; the interaction increases ARHGDIA association with RHOA, leading to ARHGDIA-mediated inactivation of RHOA and ROCK and prolonged AKT activation. Interacts with RHOC and CDC42. {ECO:0000250, ECO:0000269|PubMed:20400958, ECO:0000269|PubMed:20628200, ECO:0000269|PubMed:21122136, ECO:0000269|PubMed:23434736}.",HELIX 35 39 {ECO:0000244|PDB:1HH4}.; HELIX 46 56 {ECO:0000244|PDB:1HH4}.; HELIX 94 99 {ECO:0000244|PDB:1KMT}.,STRAND 69 78 {ECO:0000244|PDB:1KMT}.; STRAND 82 84 {ECO:0000244|PDB:1KMT}.; STRAND 87 89 {ECO:0000244|PDB:1KMT}.; STRAND 102 105 {ECO:0000244|PDB:1KMT}.; STRAND 109 118 {ECO:0000244|PDB:1KMT}.; STRAND 123 134 {ECO:0000244|PDB:1KMT}.; STRAND 137 149 {ECO:0000244|PDB:1KMT}.; STRAND 156 159 {ECO:0000244|PDB:1KMT}.; STRAND 173 182 {ECO:0000244|PDB:1KMT}.; STRAND 189 200 {ECO:0000244|PDB:1KMT}.,TURN 169 171 {ECO:0000244|PDB:1KMT}.,,,,,,0.490196078,-0.687,23.21,508,509O95816,BAG2_HUMAN,reviewed,BAG family molecular chaperone regulator 2 (BAG-2) (Bcl-2-associated athanogene 2),BAG2,Homo sapiens (Human),211,GO:0042802; GO:0006457; GO:0019538,9532;,MAQAKINAKANEGRFCRSSSMADRSSRLLESLDQLELRVEALREAATAVEQEKEILLEMIHSIQNSQDMRQISDGEREELNLTANRLMGRTLTVEVSVETIRNPQQQESLKHATRIIDEVVNKFLDDLGNAKSHLMSLYSACSSEVPHGPVDQKFQSIVIGCALEDQKKIKRRLETLLRNIENSDKAIKLLEHSKGAGSKTLQQNAESRFN,,,,PF02179;,hsa:9532;,,,SUBUNIT: Binds to the ATPase domain of HSP/HSC70 chaperones.,,,,DOMAIN 109 189 BAG. {ECO:0000255|PROSITE-ProRule:PRU00369}.,,,,,1.421800948,-0.592,23.78,29.6,30.6Q13838,DX39B_HUMAN,reviewed,Spliceosome RNA helicase DDX39B (EC 3.6.4.13) (56 kDa U2AF65-associated protein) (ATP-dependent RNA helicase p47) (DEAD box protein UAP56) (HLA-B-associated transcript 1 protein),DDX39B BAT1 UAP56,Homo sapiens (Human),428,GO:0005524; GO:0006200; GO:0004004; GO:0043008; GO:0010501; GO:0008380; GO:0008186; GO:0030621; GO:0017070; GO:0005737; GO:0006406; GO:0000398; GO:2000002; GO:0016607; GO:0005654; GO:0005634; GO:0044822; GO:0032786; GO:0005681; GO:0000245; GO:0000346; GO:0046784,7919;,MAENDVDNELLDYEDDEVETAAGGDGAEAPAKKDVKGSYVSIHSSGFRDFLLKPELLRAIVDCGFEHPSEVQHECIPQAILGMDVLCQAKSGMGKTAVFVLATLQQLEPVTGQVSVLVMCHTRELAFQISKEYERFSKYMPNVKVAVFFGGLSIKKDEEVLKKNCPHIVVGTPGRILALARNKSLNLKHIKHFILDECDKMLEQLDMRRDVQEIFRMTPHEKQVMMFSATLSKEIRPVCRKFMQDPMEIFVDDETKLTLHGLQQYYVKLKDNEKNRKLFDLLDVLEFNQVVIFVKSVQRCIALAQLLVEQNFPAIAIHRGMPQEERLSRYQQFKDFQRRILVATNLFGRGMDIERVNIAFNYDMPEDSDTYLHRVARAGRFGTKGLAITFVSDENDAKILNDVQDRFEVNISELPDEIDISSYIEQTR,,,DOMAIN: The helicase C-terminal domain mediates interaction with ALYREF/THOC4. {ECO:0000269|PubMed:15998806}.,PF00270;PF00271;,hsa:7919;,,,"SUBUNIT: Homodimer, and heterodimer with DDX39A. Component of the transcription/export (TREX) complex at least composed of ALYREF/THOC4, DDX39B, SARNP/CIP29, CHTOP and the THO subcomplex; TREX seems to have dynamic structure involving ATP-dependent remodeling; in the complex bridges ALYREF/THOC4 and the THO complex, and, in a ATP-dependent manner, ALYREF/THOC4 and SARNP/CIP29. Component of the spliceosome. Interacts directly with U2AF2. Interacts with RBM8A, RNPS1 and SRRM1, FYTTD1/UIF, THOC1, MX1 and POLDIP3. Interacts with human cytomegalovirus/HHV-5 protein UL69. {ECO:0000269|PubMed:11675789, ECO:0000269|PubMed:12944400, ECO:0000269|PubMed:14667819, ECO:0000269|PubMed:15585580, ECO:0000269|PubMed:15833825, ECO:0000269|PubMed:15870275, ECO:0000269|PubMed:15998806, ECO:0000269|PubMed:16478985, ECO:0000269|PubMed:17984224, ECO:0000269|PubMed:19836239, ECO:0000269|PubMed:20844015, ECO:0000269|PubMed:21859714, ECO:0000269|PubMed:22928037, ECO:0000269|PubMed:23299939, ECO:0000269|PubMed:9242493}.",HELIX 47 50 {ECO:0000244|PDB:1XTI}.; HELIX 54 62 {ECO:0000244|PDB:1T6N}.; HELIX 70 80 {ECO:0000244|PDB:1T6N}.; HELIX 95 106 {ECO:0000244|PDB:1T6N}.; HELIX 123 136 {ECO:0000244|PDB:1T6N}.; HELIX 154 163 {ECO:0000244|PDB:1T6N}.; HELIX 173 181 {ECO:0000244|PDB:1T6N}.; HELIX 198 202 {ECO:0000244|PDB:1T6N}.; HELIX 205 216 {ECO:0000244|PDB:1T6N}.; HELIX 236 240 {ECO:0000244|PDB:1T6N}.; HELIX 271 273 {ECO:0000244|PDB:1T5I}.; HELIX 274 284 {ECO:0000244|PDB:1T5I}.; HELIX 297 309 {ECO:0000244|PDB:1T5I}.; HELIX 323 334 {ECO:0000244|PDB:1T5I}.; HELIX 353 355 {ECO:0000244|PDB:1T5I}.; HELIX 368 378 {ECO:0000244|PDB:1T5I}.; HELIX 380 382 {ECO:0000244|PDB:1T5I}.; HELIX 394 407 {ECO:0000244|PDB:1T5I}.; HELIX 420 422 {ECO:0000244|PDB:1XTI}.,STRAND 85 88 {ECO:0000244|PDB:1T6N}.; STRAND 116 119 {ECO:0000244|PDB:1T6N}.; STRAND 145 149 {ECO:0000244|PDB:1T6N}.; STRAND 167 171 {ECO:0000244|PDB:1T6N}.; STRAND 183 185 {ECO:0000244|PDB:1XTJ}.; STRAND 192 197 {ECO:0000244|PDB:1T6N}.; STRAND 220 229 {ECO:0000244|PDB:1T6N}.; STRAND 247 250 {ECO:0000244|PDB:1T6N}.; STRAND 263 268 {ECO:0000244|PDB:1T5I}.; STRAND 288 293 {ECO:0000244|PDB:1T5I}.; STRAND 314 317 {ECO:0000244|PDB:1T5I}.; STRAND 319 321 {ECO:0000244|PDB:1XTK}.; STRAND 335 337 {ECO:0000244|PDB:1XTJ}.; STRAND 339 345 {ECO:0000244|PDB:1T5I}.; STRAND 357 363 {ECO:0000244|PDB:1T5I}.; STRAND 386 391 {ECO:0000244|PDB:1T5I}.; STRAND 411 413 {ECO:0000244|PDB:1T5I}.; STRAND 417 419 {ECO:0000244|PDB:1XTJ}.,TURN 137 139 {ECO:0000244|PDB:1T6N}.; TURN 233 235 {ECO:0000244|PDB:1T6N}.,DOMAIN 76 249 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 261 422 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.,,,,,1.869158879,-0.274,49,24,25Q9Y520,PRC2C_HUMAN,reviewed,Protein PRRC2C (BAT2 domain-containing protein 1) (HBV X-transactivated gene 2 protein) (HBV XAg-transactivated protein 2) (HLA-B-associated transcript 2-like 2) (Proline-rich and coiled-coil-containing protein 2C),PRRC2C BAT2D1 BAT2L2 KIAA1096 XTP2,Homo sapiens (Human),2896,GO:0002244; GO:0016020; GO:0044822; GO:0008022,23215;,MSEKSGQSTKAKDGKKYATLSLFNTYKGKSLETQKTTARHGLQSLGKVGISRRMPPPANLPSLKAENKGNDPNVNIVPKDGTGWASKQEQHEEEKTPEVPPAQPKPGVAAPPEVAPAPKSWASNKQGGQGDGIQVNSQFQQEFPSLQAAGDQEKKEKETNDDNYGPGPSLRPPNVACWRDGGKAAGSPSSSDQDEKLPGQDESTAGTSEQNDILKVVEKRIACGPPQAKLNGQQAALASQYRAMMPPYMFQQYPRMTYPPLHGPMRFPPSLSETNKGLRGRGPPPSWASEPERPSILSASELKELDKFDNLDAEADEGWAGAQMEVDYTEQLNFSDDDEQGSNSPKENNSEDQGSKASENNENKKETDEVSNTKSSSQIPAQPSVAKVPYGKGPSFNQERGTSSHLPPPPKLLAQQHPPPDRQAVPGRPGPFPSKQQVADEDEIWKQRRRQQSEISAAVERARKRREEEERRMEEQRKAACAEKLKRLDEKLGILEKQPSPEEIREREREKEREREKELEKEQEQEREKEREKDRERQQEKEKELEKEQEKQREMEKERKQEKEKELERQKEKEKELQKMKEQEKECELEKEREKLEEKIEPREPNLEPMVEKQESENSCNKEEEPVFTRQDSNRSEKEATPVVHETEPESGSQPRPAVLSGYFKQFQKSLPPRFQRQQEQMKQQQWQQQQQQGVLPQTVPSQPSSSTVPPPPHRPLYQPMQPHPQHLASMGFDPRWLMMQSYMDPRMMSGRPAMDIPPIHPGMIPPKPLMRRDQMEGSPNSSESFEHIARSARDHAISLSEPRMLWGSDPYPHAEPQQATTPKATEEPEDVRSEAALDQEQITAAYSVEHNQLEAHPKADFIRESSEAQVQKFLSRSVEDVRPHHTDANNQSACFEAPDQKTLSAPQEERISAVESQPSRKRSVSHGSNHTQKPDEQRSEPSAGIPKVTSRCIDSKEPIERPEEKPKKEGFIRSSEGPKPEKVYKSKSETRWGPRPSSNRREEVNDRPVRRSGPIKKPVLRDMKEEREQRKEKEGEKAEKVTEKVVVKPEKTEKKDLPPPPPPPQPPAPIQPQSVPPPIQPEAEKFPSTETATLAQKPSQDTEKPLEPVSTVQVEPAVKTVNQQTMAAPVVKEEKQPEKVISKDLVIERPRPDSRPAVKKESTLPPRTYWKEARERDWFPDQGYRGRGRGEYYSRGRSYRGSYGGRGRGGRGHTRDYPQYRDNKPRAEHIPSGPLRQREESETRSESSDFEVVPKRRRQRGSETDTDSEIHESASDKDSLSKGKLPKREERPENKKPVKPHSSFKPDNHVRIDNRLLEKPYVRDDDKAKPGFLPKGEPTRRGRGGTFRRGGRDPGGRPSRPSTLRRPAYRDNQWNPRQSEVPKPEDGEPPRRHEQFIPIAADKRPPKFERKFDPARERPRRQRPTRPPRQDKPPRFRRLREREAASKSNEVVAVPTNGTVNNVAQEPVNTLGDISGNKTPDLSNQNSSDQANEEWETASESSDFNERRERDEKKNADLNAQTVVKVGENVLPPKREIAKRSFSSQRPVDRQNRRGNNGPPKSGRNFSGPRNERRSGPPSKSGKRGPFDDQPAGTTGVDLINGSSAHHQEGVPNGTGQKNSKDSTGKKREDPKPGPKKPKEKVDALSQFDLNNYASVVIIDDHPEVTVIEDPQSNLNDDGFTEVVSKKQQKRLQDEERRKKEEQVIQVWNKKNANEKGRSQTSKLPPRFAKKQATGIQQAQSSASVPPLASAPLPPSTSASVPASTSAPLPATLTPVPASTSAPVPASTLAPVLASTSAPVPASPLAPVSASASVSASVPASTSAAAITSSSAPASAPAPTPILASVSTPASVTILASASIPILASALASTSAPTPAPAASSPAAPVITAPTIPASAPTASVPLAPASASAPAPAPTPVSAPNPAPPAPAQTQAQTHKPVQNPLQTTSQSSKQPPPSIRLPSAQTPNGTDYVASGKSIQTPQSHGTLTAELWDNKVAPPAVLNDISKKLGPISPPQPPSVSAWNKPLTSFGSAPSSEGAKNGQESGLEIGTDTIQFGAPASNGNENEVVPVLSEKSADKIPEPKEQRQKQPRAGPIKAQKLPDLSPVENKEHKPGPIGKERSLKNRKVKDAQQVEPEGQEKPSPATVRSTDPVTTKETKAVSEMSTEIGTMISVSSAEYGTNAKESVTDYTTPSSSLPNTVATNNTKMEDTLVNNVPLPNTLPLPKRETIQQSSSLTSVPPTTFSLTFKMESARKAWENSPNVREKGSPVTSTAPPIATGVSSSASGPSTANYNSFSSASMPQIPVASVTPTASLSGAGTYTTSSLSTKSTTTSDPPNICKVKPQQLQTSSLPSASHFSQLSCMPSLIAQQQQNPQVYVSQSAAAQIPAFYMDTSHLFNTQHARLAPPSLAQQQGFQPGLSQPTSVQQIPIPIYAPLQGQHQAQLSLGAGPAVSQAQELFSSSLQPYRSQPAFMQSSLSQPSVVLSGTAIHNFPTVQHQELAKAQSGLAFQQTSNTQPIPILYEHQLGQASGLGGSQLIDTHLLQARANLTQASNLYSGQVQQPGQTNFYNTAQSPSALQQVTVPLPASQLSLPNFGSTGQPLIALPQTLQPPLQHTTPQAQAQSLSRPAQVSQPFRGLIPAGTQHSMIATTGKMSEMELKAFGSGIDIKPGTPPIAGRSTTPTSSPFRATSTSPNSQSSKMNSIVYQKQFQSAPATVRMTQPFPTQFAPQILSQPNLVPPLVRAPHTNTFPAPVQRPPMALASQMPPPLTTGLMSHARLPHVARGPCGSLSGVRGNQAQAALKAEQDMKAKQRAEVLQSTQRFFSEQQQSKQIGGGKAQKVDSDSSKPPETLTDPPGVCQEKVEEKPPPAPSIATKPVRTGPIKPQAIKTEETKS,,,,PF07001;,hsa:23215;,,,,,,,,,,,,0.379834254,-1.027,316.99,7.68,8.68Q9HB71,CYBP_HUMAN,reviewed,Calcyclin-binding protein (CacyBP) (hCacyBP) (S100A6-binding protein) (Siah-interacting protein),CACYBP S100A6BP SIP PNAS-107,Homo sapiens (Human),228,GO:0007568; GO:0030877; GO:0055007; GO:0044297; GO:0071277; GO:0005737; GO:0070062; GO:0060548; GO:0043005; GO:0005641; GO:0005654; GO:0045740; GO:0042803; GO:0060416,27101;,MASEELQKDLEEVKVLLEKATRKRVRDALTAEKSKIETEIKNKMQQKSQKKAELLDNEKPAAVVAPITTGYTVKISNYGWDQSDKFVKIYITLTGVHQVPTENVQVHFTERSFDLLVKNLNGKSYSMIVNNLLKPISVEGSSKKVKTDTVLILCRKKVENTRWDYLTQVEKECKEKEKPSYDTETDPSEGLMNVLKKIYEDGDDDMKRTINKAWVESREKQAKGDTEF,,,,PF04969;PF05002;PF09032;,hsa:27101;,,,"SUBUNIT: Homodimer. Interacts with proteins of the S100 family S100A1, S100A6, S100B, S100P and S100A12 in a calcium-dependent manner (By similarity). Component of some large E3 complex at least composed of UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X. Interacts directly with SIAH1, SIAH2 and SKP1. {ECO:0000250, ECO:0000269|PubMed:11389839, ECO:0000269|PubMed:16085652}.",HELIX 3 19 {ECO:0000244|PDB:2A26}.; HELIX 23 46 {ECO:0000244|PDB:2A26}.; HELIX 168 174 {ECO:0000244|PDB:1X5M}.,STRAND 61 64 {ECO:0000244|PDB:2A25}.; STRAND 79 83 {ECO:0000244|PDB:1X5M}.; STRAND 86 92 {ECO:0000244|PDB:1X5M}.; STRAND 103 108 {ECO:0000244|PDB:1X5M}.; STRAND 110 117 {ECO:0000244|PDB:1X5M}.; STRAND 121 123 {ECO:0000244|PDB:1X5M}.; STRAND 125 130 {ECO:0000244|PDB:1X5M}.; STRAND 132 134 {ECO:0000244|PDB:1X5M}.; STRAND 142 146 {ECO:0000244|PDB:1X5M}.; STRAND 149 155 {ECO:0000244|PDB:1X5M}.; STRAND 157 160 {ECO:0000244|PDB:1X5M}.; STRAND 164 167 {ECO:0000244|PDB:1X5M}.,TURN 94 98 {ECO:0000244|PDB:1X5M}.; TURN 138 140 {ECO:0000244|PDB:1X5M}.,DOMAIN 73 167 CS. {ECO:0000255|PROSITE-ProRule:PRU00547}.; DOMAIN 168 228 SGS. {ECO:0000255|PROSITE-ProRule:PRU00386}.,,,,,0.877192982,-0.791,26.21,287,288P27708,PYR1_HUMAN,reviewed,CAD protein [Includes: Glutamine-dependent carbamoyl-phosphate synthase (EC 6.3.5.5); Aspartate carbamoyltransferase (EC 2.1.3.2); Dihydroorotase (EC 3.5.2.3)],CAD,Homo sapiens (Human),2225,GO:0044205; GO:0006207; GO:0005524; GO:0006228; GO:0006526; GO:0070335; GO:0004070; GO:0070409; GO:0004087; GO:0004088; GO:0042995; GO:0035690; GO:0071364; GO:0005829; GO:0004151; GO:0017144; GO:0019899; GO:0070062; GO:0007565; GO:0006543; GO:0006541; GO:0007507; GO:0042802; GO:0007595; GO:0001889; GO:0016020; GO:0043025; GO:0016363; GO:0055086; GO:0005654; GO:0005634; GO:0031100; GO:0018107; GO:0005886; GO:0046777; GO:0043234; GO:0004672; GO:0006206; GO:0046134; GO:0014075; GO:0031000; GO:0051414; GO:0033574; GO:0044281; GO:0043195; GO:0000050; GO:0008270,790;,MAALVLEDGSVLRGQPFGAAVSTAGEVVFQTGMVGYPEALTDPSYKAQILVLTYPLIGNYGIPPDEMDEFGLCKWFESSGIHVAALVVGECCPTPSHWSATRTLHEWLQQHGIPGLQGVDTRELTKKLREQGSLLGKLVQNGTEPSSLPFLDPNARPLVPEVSIKTPRVFNTGGAPRILALDCGLKYNQIRCLCQRGAEVTVVPWDHALDSQEYEGLFLSNGPGDPASYPSVVSTLSRVLSEPNPRPVFGICLGHQLLALAIGAKTYKMRYGNRGHNQPCLLVGSGRCFLTSQNHGFAVETDSLPADWAPLFTNANDGSNEGIVHNSLPFFSVQFHPEHQAGPSDMELLFDIFLETVKEATAGNPGGQTVRERLTERLCPPGIPTPGSGLPPPRKVLILGSGGLSIGQAGEFDYSGSQAIKALKEENIQTLLINPNIATVQTSQGLADKVYFLPITPHYVTQVIRNERPDGVLLTFGGQTALNCGVELTKAGVLARYGVRVLGTPVETIELTEDRRAFAARMAEIGEHVAPSEAANSLEQAQAAAERLGYPVLVRAAFALGGLGSGFASNREELSALVAPAFAHTSQVLVDKSLKGWKEIEYEVVRDAYGNCVTVCNMENLDPLGIHTGESIVVAPSQTLNDREYQLLRQTAIKVTQHLGIVGECNVQYALNPESEQYYIIEVNARLSRSSALASKATGYPLAYVAAKLALGIPLPELRNSVTGGTAAFEPSVDYCVVKIPRWDLSKFLRVSTKIGSCMKSVGEVMGIGRSFEEAFQKALRMVDENCVGFDHTVKPVSDMELETPTDKRIFVVAAALWAGYSVDRLYELTRIDRWFLHRMKRIIAHAQLLEQHRGQPLPPDLLQQAKCLGFSDKQIALAVLSTELAVRKLRQELGICPAVKQIDTVAAEWPAQTNYLYLTYWGTTHDLTFRTPHVLVLGSGVYRIGSSVEFDWCAVGCIQQLRKMGYKTIMVNYNPETVSTDYDMCDRLYFDEISFEVVMDIYELENPEGVILSMGGQLPNNMAMALHRQQCRVLGTSPEAIDSAENRFKFSRLLDTIGISQPQWRELSDLESARQFCQTVGYPCVVRPSYVLSGAAMNVAYTDGDLERFLSSAAAVSKEHPVVISKFIQEAKEIDVDAVASDGVVAAIAISEHVENAGVHSGDATLVTPPQDITAKTLERIKAIVHAVGQELQVTGPFNLQLIAKDDQLKVIECNVRVSRSFPFVSKTLGVDLVALATRVIMGEEVEPVGLMTGSGVVGVKVPQFSFSRLAGADVVLGVEMTSTGEVAGFGESRCEAYLKAMLSTGFKIPKKNILLTIGSYKNKSELLPTVRLLESLGYSLYASLGTADFYTEHGVKVTAVDWHFEEAVDGECPPQRSILEQLAEKNFELVINLSMRGAGGRRLSSFVTKGYRTRRLAADFSVPLIIDIKCTKLFVEALGQIGPAPPLKVHVDCMTSQKLVRLPGLIDVHVHLREPGGTHKEDFASGTAAALAGGITMVCAMPNTRPPIIDAPALALAQKLAEAGARCDFALFLGASSENAGTLGTVAGSAAGLKLYLNETFSELRLDSVVQWMEHFETWPSHLPIVAHAEQQTVAAVLMVAQLTQRSVHICHVARKEEILLIKAAKARGLPVTCEVAPHHLFLSHDDLERLGPGKGEVRPELGSRQDVEALWENMAVIDCFASDHAPHTLEEKCGSRPPPGFPGLETMLPLLLTAVSEGRLSLDDLLQRLHHNPRRIFHLPPQEDTYVEVDLEHEWTIPSHMPFSKAHWTPFEGQKVKGTVRRVVLRGEVAYIDGQVLVPPGYGQDVRKWPQGAVPQLPPSAPATSEMTTTPERPRRGIPGLPDGRFHLPPRIHRASDPGLPAEEPKEKSSRKVAEPELMGTPDGTCYPPPPVPRQASPQNLGTPGLLHPQTSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF,,,,PF00289;PF02786;PF02787;PF00988;PF00117;PF02142;PF00185;PF02729;,hsa:790;,,,SUBUNIT: Homohexamer. {ECO:0000269|PubMed:24332717}.,HELIX 1485 1494 {ECO:0000244|PDB:4C6F}.; HELIX 1513 1526 {ECO:0000244|PDB:4C6F}.; HELIX 1549 1551 {ECO:0000244|PDB:4C6F}.; HELIX 1571 1580 {ECO:0000244|PDB:4C6F}.; HELIX 1594 1605 {ECO:0000244|PDB:4C6F}.; HELIX 1618 1629 {ECO:0000244|PDB:4C6F}.; HELIX 1640 1644 {ECO:0000244|PDB:4C6F}.; HELIX 1647 1649 {ECO:0000244|PDB:4C6F}.; HELIX 1650 1657 {ECO:0000244|PDB:4C6F}.; HELIX 1667 1675 {ECO:0000244|PDB:4C6F}.; HELIX 1677 1679 {ECO:0000244|PDB:4C6F}.; HELIX 1692 1695 {ECO:0000244|PDB:4C6F}.; HELIX 1707 1719 {ECO:0000244|PDB:4C6F}.; HELIX 1725 1732 {ECO:0000244|PDB:4C6F}.; HELIX 1734 1740 {ECO:0000244|PDB:4C6F}.; HELIX 1809 1811 {ECO:0000244|PDB:4C6F}.; HELIX 1813 1815 {ECO:0000244|PDB:4C6F}.,STRAND 1462 1465 {ECO:0000244|PDB:4C6F}.; STRAND 1467 1472 {ECO:0000244|PDB:4C6F}.; STRAND 1497 1502 {ECO:0000244|PDB:4C6F}.; STRAND 1506 1508 {ECO:0000244|PDB:4C6F}.; STRAND 1528 1533 {ECO:0000244|PDB:4C6F}.; STRAND 1555 1558 {ECO:0000244|PDB:4C6F}.; STRAND 1560 1563 {ECO:0000244|PDB:4C6F}.; STRAND 1587 1590 {ECO:0000244|PDB:4C6F}.; STRAND 1610 1612 {ECO:0000244|PDB:4C6F}.; STRAND 1634 1638 {ECO:0000244|PDB:4C6F}.; STRAND 1697 1699 {ECO:0000244|PDB:4C6F}.; STRAND 1749 1759 {ECO:0000244|PDB:4C6F}.; STRAND 1778 1788 {ECO:0000244|PDB:4C6F}.; STRAND 1791 1795 {ECO:0000244|PDB:4C6F}.,TURN 1476 1478 {ECO:0000244|PDB:4C6F}.; TURN 1480 1482 {ECO:0000244|PDB:4C6F}.; TURN 1546 1548 {ECO:0000244|PDB:4C6F}.; TURN 1564 1566 {ECO:0000244|PDB:4C6C}.; TURN 1773 1776 {ECO:0000244|PDB:4C6F}.,DOMAIN 177 363 Glutamine amidotransferase type-1.; DOMAIN 519 711 ATP-grasp 1.; DOMAIN 1052 1243 ATP-grasp 2.,,,,,1.842696629,-0.08,243.02,1.8,2.8Q86VP6,CAND1_HUMAN,reviewed,Cullin-associated NEDD8-dissociated protein 1 (Cullin-associated and neddylation-dissociated protein 1) (TBP-interacting protein of 120 kDa A) (TBP-interacting protein 120A) (p120 CAND1),CAND1 KIAA0829 TIP120 TIP120A,Homo sapiens (Human),1230,GO:0010265; GO:0030154; GO:0031461; GO:0005737; GO:0070062; GO:0016020; GO:0043086; GO:0005654; GO:0005634; GO:0045899; GO:0016567; GO:0000151,55832;,MASASYHISNLLEKMTSSDKDFRFMATNDLMTELQKDSIKLDDDSERKVVKMILKLLEDKNGEVQNLAVKCLGPLVSKVKEYQVETIVDTLCTNMLSDKEQLRDISSIGLKTVIGELPPASSGSALAANVCKKITGRLTSAIAKQEDVSVQLEALDIMADMLSRQGGLLVNFHPSILTCLLPQLTSPRLAVRKRTIIALGHLVMSCGNIVFVDLIEHLLSELSKNDSMSTTRTYIQCIAAISRQAGHRIGEYLEKIIPLVVKFCNVDDDELREYCIQAFESFVRRCPKEVYPHVSTIINICLKYLTYDPNYNYDDEDEDENAMDADGGDDDDQGSDDEYSDDDDMSWKVRRAAAKCLDAVVSTRHEMLPEFYKTVSPALISRFKEREENVKADVFHAYLSLLKQTRPVQSWLCDPDAMEQGETPLTMLQSQVPNIVKALHKQMKEKSVKTRQCCFNMLTELVNVLPGALTQHIPVLVPGIIFSLNDKSSSSNLKIDALSCLYVILCNHSPQVFHPHVQALVPPVVACVGDPFYKITSEALLVTQQLVKVIRPLDQPSSFDATPYIKDLFTCTIKRLKAADIDQEVKERAISCMGQIICNLGDNLGSDLPNTLQIFLERLKNEITRLTTVKALTLIAGSPLKIDLRPVLGEGVPILASFLRKNQRALKLGTLSALDILIKNYSDSLTAAMIDAVLDELPPLISESDMHVSQMAISFLTTLAKVYPSSLSKISGSILNELIGLVRSPLLQGGALSAMLDFFQALVVTGTNNLGYMDLLRMLTGPVYSQSTALTHKQSYYSIAKCVAALTRACPKEGPAVVGQFIQDVKNSRSTDSIRLLALLSLGEVGHHIDLSGQLELKSVILEAFSSPSEEVKSAASYALGSISVGNLPEYLPFVLQEITSQPKRQYLLLHSLKEIISSASVVGLKPYVENIWALLLKHCECAEEGTRNVVAECLGKLTLIDPETLLPRLKGYLISGSSYARSSVVTAVKFTISDHPQPIDPLLKNCIGDFLKTLEDPDLNVRRVALVTFNSAAHNKPSLIRDLLDTVLPHLYNETKVRKELIREVEMGPFKHTVDDGLDIRKAAFECMYTLLDSCLDRLDIFEFLNHVEDGLKDHYDIKMLTFLMLVRLSTLCPSAVLQRLDRLVEPLRATCTTKVKANSVKQEFEKQDELKRSAMRAVAALLTIPEAEKSPLMSEFQSQISSNPELAAIFESIQKDSSSTNLESMDTS,,,,PF08623;,hsa:55832;,,,"SUBUNIT: Interacts with TBP (By similarity). Part of a complex that contains CUL1 and RBX1. Interacts with unneddylated cullins: interacts with CUL1, CUL2, CUL3, CUL4A, CUL4B and CUL5. Does not bind neddylated CUL1. Interaction with cullins is abolished in presence of COMMD1, which antagonizes with CAND1 for interacting with cullins. {ECO:0000250, ECO:0000269|PubMed:12504025, ECO:0000269|PubMed:12504026, ECO:0000269|PubMed:12609982, ECO:0000269|PubMed:15537541, ECO:0000269|PubMed:16449638, ECO:0000269|PubMed:21249194, ECO:0000269|PubMed:21778237, ECO:0000269|PubMed:22118460}.",HELIX 6 14 {ECO:0000244|PDB:1U6G}.; HELIX 20 33 {ECO:0000244|PDB:1U6G}.; HELIX 45 56 {ECO:0000244|PDB:1U6G}.; HELIX 62 76 {ECO:0000244|PDB:1U6G}.; HELIX 81 94 {ECO:0000244|PDB:1U6G}.; HELIX 101 116 {ECO:0000244|PDB:1U6G}.; HELIX 127 142 {ECO:0000244|PDB:1U6G}.; HELIX 148 164 {ECO:0000244|PDB:1U6G}.; HELIX 173 180 {ECO:0000244|PDB:1U6G}.; HELIX 181 185 {ECO:0000244|PDB:1U6G}.; HELIX 189 202 {ECO:0000244|PDB:1U6G}.; HELIX 214 224 {ECO:0000244|PDB:1U6G}.; HELIX 234 244 {ECO:0000244|PDB:1U6G}.; HELIX 247 249 {ECO:0000244|PDB:1U6G}.; HELIX 256 264 {ECO:0000244|PDB:1U6G}.; HELIX 272 284 {ECO:0000244|PDB:1U6G}.; HELIX 291 301 {ECO:0000244|PDB:1U6G}.; HELIX 348 361 {ECO:0000244|PDB:1U6G}.; HELIX 368 372 {ECO:0000244|PDB:1U6G}.; HELIX 376 380 {ECO:0000244|PDB:1U6G}.; HELIX 389 405 {ECO:0000244|PDB:1U6G}.; HELIX 424 431 {ECO:0000244|PDB:1U6G}.; HELIX 434 442 {ECO:0000244|PDB:1U6G}.; HELIX 448 464 {ECO:0000244|PDB:1U6G}.; HELIX 470 472 {ECO:0000244|PDB:1U6G}.; HELIX 473 483 {ECO:0000244|PDB:1U6G}.; HELIX 491 506 {ECO:0000244|PDB:1U6G}.; HELIX 510 513 {ECO:0000244|PDB:1U6G}.; HELIX 514 517 {ECO:0000244|PDB:1U6G}.; HELIX 521 528 {ECO:0000244|PDB:1U6G}.; HELIX 533 550 {ECO:0000244|PDB:1U6G}.; HELIX 562 576 {ECO:0000244|PDB:1U6G}.; HELIX 583 599 {ECO:0000244|PDB:1U6G}.; HELIX 601 603 {ECO:0000244|PDB:1U6G}.; HELIX 607 618 {ECO:0000244|PDB:1U6G}.; HELIX 624 635 {ECO:0000244|PDB:1U6G}.; HELIX 645 658 {ECO:0000244|PDB:1U6G}.; HELIX 664 680 {ECO:0000244|PDB:1U6G}.; HELIX 687 694 {ECO:0000244|PDB:1U6G}.; HELIX 698 700 {ECO:0000244|PDB:1U6G}.; HELIX 706 719 {ECO:0000244|PDB:1U6G}.; HELIX 724 729 {ECO:0000244|PDB:1U6G}.; HELIX 735 742 {ECO:0000244|PDB:1U6G}.; HELIX 749 763 {ECO:0000244|PDB:1U6G}.; HELIX 772 779 {ECO:0000244|PDB:1U6G}.; HELIX 793 809 {ECO:0000244|PDB:1U6G}.; HELIX 815 818 {ECO:0000244|PDB:1U6G}.; HELIX 832 848 {ECO:0000244|PDB:1U6G}.; HELIX 856 863 {ECO:0000244|PDB:1U6G}.; HELIX 864 866 {ECO:0000244|PDB:1U6G}.; HELIX 870 886 {ECO:0000244|PDB:1U6G}.; HELIX 888 900 {ECO:0000244|PDB:1U6G}.; HELIX 903 905 {ECO:0000244|PDB:1U6G}.; HELIX 906 918 {ECO:0000244|PDB:1U6G}.; HELIX 926 936 {ECO:0000244|PDB:1U6G}.; HELIX 947 960 {ECO:0000244|PDB:1U6G}.; HELIX 963 965 {ECO:0000244|PDB:1U6G}.; HELIX 967 970 {ECO:0000244|PDB:1U6G}.; HELIX 979 988 {ECO:0000244|PDB:1U6G}.; HELIX 990 992 {ECO:0000244|PDB:1U6G}.; HELIX 1001 1007 {ECO:0000244|PDB:1U6G}.; HELIX 1021 1036 {ECO:0000244|PDB:1U6G}.; HELIX 1038 1040 {ECO:0000244|PDB:1U6G}.; HELIX 1042 1044 {ECO:0000244|PDB:1U6G}.; HELIX 1045 1054 {ECO:0000244|PDB:1U6G}.; HELIX 1060 1062 {ECO:0000244|PDB:1U6G}.; HELIX 1079 1094 {ECO:0000244|PDB:1U6G}.; HELIX 1102 1111 {ECO:0000244|PDB:1U6G}.; HELIX 1117 1132 {ECO:0000244|PDB:1U6G}.; HELIX 1136 1139 {ECO:0000244|PDB:1U6G}.; HELIX 1146 1154 {ECO:0000244|PDB:1U6G}.; HELIX 1163 1182 {ECO:0000244|PDB:1U6G}.; HELIX 1200 1208 {ECO:0000244|PDB:1U6G}.,STRAND 35 37 {ECO:0000244|PDB:1U6G}.; STRAND 98 100 {ECO:0000244|PDB:1U6G}.; STRAND 386 388 {ECO:0000244|PDB:1U6G}.; STRAND 487 489 {ECO:0000244|PDB:1U6G}.; STRAND 553 555 {ECO:0000244|PDB:1U6G}.; STRAND 579 581 {ECO:0000244|PDB:1U6G}.; STRAND 621 623 {ECO:0000244|PDB:1U6G}.; STRAND 974 977 {ECO:0000244|PDB:1U6G}.; STRAND 1015 1019 {ECO:0000244|PDB:1U6G}.; STRAND 1063 1068 {ECO:0000244|PDB:1U6G}.; STRAND 1071 1076 {ECO:0000244|PDB:1U6G}.; STRAND 1098 1100 {ECO:0000244|PDB:1U6G}.; STRAND 1190 1194 {ECO:0000244|PDB:1U6G}.,TURN 170 172 {ECO:0000244|PDB:1U6G}.; TURN 203 205 {ECO:0000244|PDB:1U6G}.; TURN 269 271 {ECO:0000244|PDB:1U6G}.; TURN 373 375 {ECO:0000244|PDB:1U6G}.; TURN 466 469 {ECO:0000244|PDB:1U6G}.; TURN 518 520 {ECO:0000244|PDB:1U6G}.; TURN 730 734 {ECO:0000244|PDB:1U6G}.; TURN 781 785 {ECO:0000244|PDB:1U6G}.; TURN 819 824 {ECO:0000244|PDB:1U6G}.; TURN 826 829 {ECO:0000244|PDB:1U6G}.; TURN 923 925 {ECO:0000244|PDB:1U6G}.; TURN 971 973 {ECO:0000244|PDB:1U6G}.; TURN 1009 1014 {ECO:0000244|PDB:1U6G}.; TURN 1140 1145 {ECO:0000244|PDB:1U6G}.,,,,,,2.43902439,-0.019,136.4,52.4,53.4Q3V6T2,GRDN_HUMAN,reviewed,Girdin (Akt phosphorylation enhancer) (APE) (Coiled-coil domain-containing protein 88A) (G alpha-interacting vesicle-associated protein) (GIV) (Girders of actin filament) (Hook-related protein 1) (HkRP1),CCDC88A APE GRDN KIAA1212,Homo sapiens (Human),1871,GO:0006260; GO:0005794; GO:0031929; GO:0003779; GO:0032148; GO:0016477; GO:0016023; GO:0031410; GO:0005829; GO:0005783; GO:0030027; GO:0030032; GO:0016020; GO:0061024; GO:0008017; GO:0035091; GO:0005886; GO:0042803; GO:0043422; GO:0006275; GO:0032956; GO:0042127; GO:0010975; GO:0001932,55704;,MENEIFTPLLEQFMTSPLVTWVKTFGPLAAGNGTNLDEYVALVDGVFLNQVMLQINPKLESQRVNKKVNNDASLRMHNLSILVRQIKFYYQETLQQLIMMSLPNVLIIGKNPFSEQGTEEVKKLLLLLLGCAVQCQKKEEFIERIQGLDFDTKAAVAAHIQEVTHNQENVFDLQWMEVTDMSQEDIEPLLKNMALHLKRLIDERDEHSETIIELSEERDGLHFLPHASSSAQSPCGSPGMKRTESRQHLSVELADAKAKIRRLRQELEEKTEQLLDCKQELEQMEIELKRLQQENMNLLSDARSARMYRDELDALREKAVRVDKLESEVSRYKERLHDIEFYKARVEELKEDNQVLLETKTMLEDQLEGTRARSDKLHELEKENLQLKAKLHDMEMERDMDRKKIEELMEENMTLEMAQKQSMDESLHLGWELEQISRTSELSEAPQKSLGHEVNELTSSRLLKLEMENQSLTKTVEELRTTVDSVEGNASKILKMEKENQRLSKKVEILENEIVQEKQSLQNCQNLSKDLMKEKAQLEKTIETLRENSERQIKILEQENEHLNQTVSSLRQRSQISAEARVKDIEKENKILHESIKETSSKLSKIEFEKRQIKKELEHYKEKGERAEELENELHHLEKENELLQKKITNLKITCEKIEALEQENSELERENRKLKKTLDSFKNLTFQLESLEKENSQLDEENLELRRNVESLKCASMKMAQLQLENKELESEKEQLKKGLELLKASFKKTERLEVSYQGLDIENQRLQKTLENSNKKIQQLESELQDLEMENQTLQKNLEELKISSKRLEQLEKENKSLEQETSQLEKDKKQLEKENKRLRQQAEIKDTTLEENNVKIGNLEKENKTLSKEIGIYKESCVRLKELEKENKELVKRATIDIKTLVTLREDLVSEKLKTQQMNNDLEKLTHELEKIGLNKERLLHDEQSTDDSRYKLLESKLESTLKKSLEIKEEKIAALEARLEESTNYNQQLRQELKTVKKNYEALKQRQDEERMVQSSPPISGEDNKWERESQETTRELLKVKDRLIEVERNNATLQAEKQALKTQLKQLETQNNNLQAQILALQRQTVSLQEQNTTLQTQNAKLQVENSTLNSQSTSLMNQNAQLLIQQSSLENENESVIKEREDLKSLYDSLIKDHEKLELLHERQASEYESLISKHGTLKSAHKNLEVEHRDLEDRYNQLLKQKGQLEDLEKMLKVEQEKMLLENKNHETVAAEYKKLCGENDRLNHTYSQLLKETEVLQTDHKNLKSLLNNSKLEQTRLEAEFSKLKEQYQQLDITSTKLNNQCELLSQLKGNLEEENRHLLDQIQTLMLQNRTLLEQNMESKDLFHVEQRQYIDKLNELRRQKEKLEEKIMDQYKFYDPSPPRRRGNWITLKMRKLIKSKKDINRERQKSLTLTPTRSDSSEGFLQLPHQDSQDSSSVGSNSLEDGQTLGTKKSSMVALKRLPFLRNRPKDKDKMKACYRRSMSMNDLVQSMVLAGQWTGSTENLEVPDDISTGKRRKELGAMAFSTTAINFSTVNSSAGFRSKQLVNNKDTTSFEDISPQGVSDDSSTGSRVHASRPASLDSGRTSTSNSNNNASLHEVKAGAVNNQSRPQSHSSGEFSLLHDHEAWSSSGSSPIQYLKRQTRSSPVLQHKISETLESRHHKIKTGSPGSEVVTLQQFLEESNKLTSVQIKSSSQENLLDEVMKSLSVSSDFLGKDKPVSCGLARSVSGKTPGDFYDRRTTKPEFLRPGPRKTEDTYFISSAGKPTPGTQGKIKLVKESSLSRQSKDSNPYATLPRASSVISTAEGTTRRTSIHDFLTKDSRLPISVDSPPAAADSNTTAASNVDKVQESRNSKSRSREQQSS,,,,PF05622;,hsa:55704;,,,"SUBUNIT: Interacts (via C-terminus) with DISC1; the interaction is direct. Interacts with AKT proteins; the interaction is inhibited in presence of DISC1 (By similarity). Homodimer. The non-phosphorylated form interacts with phosphatidylinositol 4-phosphate [PI(4)P] and weakly with phosphatidylinositol 3-phosphate [PI(3)P]. Interacts with microtubules. Interacts with actin through its C-terminal domain. Interacts with the C-terminus of AKT1/PKB. {ECO:0000250, ECO:0000269|PubMed:16139227}.",,,,,,,,,0.641368252,-0.949,216.09,0.57,1.57Q9NX63,MIC19_HUMAN,reviewed,MICOS complex subunit MIC19 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 3),CHCHD3 MIC19 MINOS3,Homo sapiens (Human),227,GO:0001227; GO:0005737; GO:0070062; GO:0007007; GO:0008053; GO:0005743; GO:0005739; GO:0000122; GO:0005634; GO:0019902; GO:0032947,54927;,MGGTTSTRRVTFEADENENITVVKGIRLSENVIDRMKESSPSGSKSQRYSGAYGASVSDEELKRRVAEELALEQAKKESEDQKRLKQAKELDRERAAANEQLTRAILRERICSEEERAKAKHLARQLEEKDRVLKKQDAFYKEQLARLEERSSEFYRVTTEQYQKAAEEVEAKFKRYESHPVCADLQAKILQCYRENTHQTLKCSALATQYMHCVNHAKQSMLEKGG,,,,PF05300;,hsa:54927;,,,"SUBUNIT: Interacts with HSPA1A/HSPA1B and OPA1, preferentially with the soluble OPA1 form (By similarity). Component of the mitochondrial contact site and cristae organizing system (MICOS) complex, composed of at least MINOS1/MIC10, CHCHD3/MIC19, CHCHD6/MIC25, APOOL/MIC27 and IMMT/MIC60. The complex associates with mitochondrial outer membrane proteins SAMM50, MTX1 and MTX2, and with HSPA9. {ECO:0000250, ECO:0000269|PubMed:21081504, ECO:0000269|PubMed:22114354, ECO:0000269|PubMed:22228767}.",,,,DOMAIN 176 217 CHCH.,,,,,2.202643172,-1.021,26.16,127,128Q14839,CHD4_HUMAN,reviewed,Chromodomain-helicase-DNA-binding protein 4 (CHD-4) (EC 3.6.4.12) (ATP-dependent helicase CHD4) (Mi-2 autoantigen 218 kDa protein) (Mi2-beta),CHD4,Homo sapiens (Human),1912,GO:0005524; GO:0004003; GO:0043044; GO:0003677; GO:0032508; GO:0016581; GO:0001103; GO:0005813; GO:0005737; GO:0016020; GO:0000790; GO:0005654; GO:0005634; GO:0043234; GO:0006357; GO:0051225; GO:0006351; GO:0008270,1108;,MASGLGSPSPCSAGSEEEDMDALLNNSLPPPHPENEEDPEEDLSETETPKLKKKKKPKKPRDPKIPKSKRQKKERMLLCRQLGDSSGEGPEFVEEEEEVALRSDSEGSDYTPGKKKKKKLGPKKEKKSKSKRKEEEEEEDDDDDSKEPKSSAQLLEDWGMEDIDHVFSEEDYRTLTNYKAFSQFVRPLIAAKNPKIAVSKMMMVLGAKWREFSTNNPFKGSSGASVAAAAAAAVAVVESMVTATEVAPPPPPVEVPIRKAKTKEGKGPNARRKPKGSPRVPDAKKPKPKKVAPLKIKLGGFGSKRKRSSSEDDDLDVESDFDDASINSYSVSDGSTSRSSRSRKKLRTTKKKKKGEEEVTAVDGYETDHQDYCEVCQQGGEIILCDTCPRAYHMVCLDPDMEKAPEGKWSCPHCEKEGIQWEAKEDNSEGEEILEEVGGDLEEEDDHHMEFCRVCKDGGELLCCDTCPSSYHIHCLNPPLPEIPNGEWLCPRCTCPALKGKVQKILIWKWGQPPSPTPVPRPPDADPNTPSPKPLEGRPERQFFVKWQGMSYWHCSWVSELQLELHCQVMFRNYQRKNDMDEPPSGDFGGDEEKSRKRKNKDPKFAEMEERFYRYGIKPEWMMIHRILNHSVDKKGHVHYLIKWRDLPYDQASWESEDVEIQDYDLFKQSYWNHRELMRGEEGRPGKKLKKVKLRKLERPPETPTVDPTVKYERQPEYLDATGGTLHPYQMEGLNWLRFSWAQGTDTILADEMGLGKTVQTAVFLYSLYKEGHSKGPFLVSAPLSTIINWEREFEMWAPDMYVVTYVGDKDSRAIIRENEFSFEDNAIRGGKKASRMKKEASVKFHVLLTSYELITIDMAILGSIDWACLIVDEAHRLKNNQSKFFRVLNGYSLQHKLLLTGTPLQNNLEELFHLLNFLTPERFHNLEGFLEEFADIAKEDQIKKLHDMLGPHMLRRLKADVFKNMPSKTELIVRVELSPMQKKYYKYILTRNFEALNARGGGNQVSLLNVVMDLKKCCNHPYLFPVAAMEAPKMPNGMYDGSALIRASGKLLLLQKMLKNLKEGGHRVLIFSQMTKMLDLLEDFLEHEGYKYERIDGGITGNMRQEAIDRFNAPGAQQFCFLLSTRAGGLGINLATADTVIIYDSDWNPHNDIQAFSRAHRIGQNKKVMIYRFVTRASVEERITQVAKKKMMLTHLVVRPGLGSKTGSMSKQELDDILKFGTEELFKDEATDGGGDNKEGEDSSVIHYDDKAIERLLDRNQDETEDTELQGMNEYLSSFKVAQYVVREEEMGEEEEVEREIIKQEESVDPDYWEKLLRHHYEQQQEDLARNLGKGKRIRKQVNYNDGSQEDRDWQDDQSDNQSDYSVASEEGDEDFDERSEAPRRPSRKGLRNDKDKPLPPLLARVGGNIEVLGFNARQRKAFLNAIMRYGMPPQDAFTTQWLVRDLRGKSEKEFKAYVSLFMRHLCEPGADGAETFADGVPREGLSRQHVLTRIGVMSLIRKKVQEFEHVNGRWSMPELAEVEENKKMSQPGSPSPKTPTPSTPGDTQPNTPAPVPPAEDGIKIEENSLKEEESIEGEKEVKSTAPETAIECTQAPAPASEDEKVVVEPPEGEEKVEKAEVKERTEEPMETEPKGAADVEKVEEKSAIDLTPIVVEDKEEKKEEEEKKEVMLQNGETPKDLNDEKQKKNIKQRFMFNIADGGFTELHSLWQNEERAATVTKKTYEIWHRRHDYWLLAGIINHGYARWQDIQNDPRYAILNEPFKGEMNRGNFLEIKNKFLARRFKLLEQALVIEEQLRRAAYLNMSEDPSHPSMALNTRFAEVECLAESHQHLSKESMAGNKPANAVLHKVLKQLEELLSDMKADVTRLPATIARIPPVAVRLQMSERNILSRLANRAPEPTPQQVAQQQ,,,,PF08074;PF08073;PF00385;PF06461;PF06465;PF00271;PF00628;PF00176;,hsa:1108;,,,"SUBUNIT: Central component of the nucleosome remodeling and histone deacetylase (NuRD) repressor complex. Interacts directly with IKFZ1 in the NuRD complex. Interacts with TRIM27. Part of a complex containing ATR and HDAC2. Interacts with KLF1; the interaction depends on sumoylation of KLF1, and leads to its transcriptional repression. Interacts with ZGPAT; the interaction is direct. Interacts with BCL6, BRD4 and PCNT. {ECO:0000269|PubMed:10204490, ECO:0000269|PubMed:10545197, ECO:0000269|PubMed:14530259, ECO:0000269|PubMed:15454082, ECO:0000269|PubMed:17626165, ECO:0000269|PubMed:19644445, ECO:0000269|PubMed:21555454}.",HELIX 394 397 {ECO:0000244|PDB:2L5U}.; HELIX 414 417 {ECO:0000244|PDB:2L5U}.; HELIX 664 673 {ECO:0000244|PDB:2EE1}.,STRAND 386 389 {ECO:0000244|PDB:2L5U}.; STRAND 450 452 {ECO:0000244|PDB:1MM3}.; STRAND 459 463 {ECO:0000244|PDB:2L75}.; STRAND 465 467 {ECO:0000244|PDB:1MM2}.; STRAND 473 478 {ECO:0000244|PDB:1MM2}.; STRAND 629 632 {ECO:0000244|PDB:2EE1}.; STRAND 638 642 {ECO:0000244|PDB:2EE1}.; STRAND 653 656 {ECO:0000244|PDB:2EE1}.,TURN 374 376 {ECO:0000244|PDB:2L5U}.; TURN 453 455 {ECO:0000244|PDB:1MM2}.; TURN 491 496 {ECO:0000244|PDB:1MM2}.; TURN 649 651 {ECO:0000244|PDB:2EE1}.,DOMAIN 494 594 Chromo 1. {ECO:0000255|PROSITE-ProRule:PRU00053}.; DOMAIN 622 697 Chromo 2. {ECO:0000255|PROSITE-ProRule:PRU00053}.; DOMAIN 738 922 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 1054 1203 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.,,,,,1.412133891,-0.834,218.04,13.8,14.8Q8IWX8,CHERP_HUMAN,reviewed,Calcium homeostasis endoplasmic reticulum protein (ERPROT 213-21) (SR-related CTD-associated factor 6),CHERP DAN26 SCAF6,Homo sapiens (Human),916,GO:0006396; GO:0006874; GO:0005737; GO:0044325; GO:0016020; GO:0008285; GO:0007399; GO:0048471; GO:0044822; GO:0051533; GO:0051209; GO:0033017,10523;,MEMPLPPDDQELRNVIDKLAQFVARNGPEFEKMTMEKQKDNPKFSFLFGGEFYSYYKCKLALEQQQLICKQQTPELEPAATMPPLPQPPLAPAAPIPPAQGAPSMDELIQQSQWNLQQQEQHLLALRQEQVTAAVAHAVEQQMQKLLEETQLDMNEFDNLLQPIIDTCTKDAISAGKNWMFSNAKSPPHCELMAGHLRNRITADGAHFELRLHLIYLINDVLHHCQRKQARELLAALQKVVVPIYCTSFLAVEEDKQQKIARLLQLWEKNGYFDDSIIQQLQSPALGLGQYQATLINEYSSVVQPVQLAFQQQIQTLKTQHEEFVTSLAQQQQQQQQQQQQLQMPQMEAEVKATPPPPAPPPAPAPAPAIPPTTQPDDSKPPIQMPGSSEYEAPGGVQDPAAAGPRGPGPHDQIPPNKPPWFDQPHPVAPWGQQQPPEQPPYPHHQGGPPHCPPWNNSHEGMWGEQRGDPGWNGQRDAPWNNQPDAAWNSQFEGPWNSQHEQPPWGGGQREPPFRMQRPPHFRGPFPPHQQHPQFNQPPHPHNFNRFPPRFMQDDFPPRHPFERPPYPHRFDYPQGDFPAEMGPPHHHPGHRMPHPGINEHPPWAGPQHPDFGPPPHGFNGQPPHMRRQGPPHINHDDPSLVPNVPYFDLPAGLMAPLVKLEDHEYKPLDPKDIRLPPPMPPSERLLAAVEAFYSPPSHDRPRNSEGWEQNGLYEFFRAKMRARRRKGQEKRNSGPSRSRSRSKSRGRSSSRSNSRSSKSSGSYSRSRSRSCSRSYSRSRSRSRSRSRSSRSRSRSQSRSRSKSYSPGRRRRSRSRSPTPPSSAGLGSNSAPPIPDSRLGEENKGHQMLVKMGWSGSGGLGAKEQGIQDPIKGGDVRDKWDQYKGVGVALDDPYENYRRNKSYSFIARMKARDECK,,,,PF04818;PF01585;PF01805;,hsa:10523;,,,,,,,DOMAIN 149 289 CID. {ECO:0000255|PROSITE-ProRule:PRU00724}.; DOMAIN 841 891 G-patch. {ECO:0000255|PROSITE-ProRule:PRU00092}.,,,,,0.982532751,-1.066,103.73,4.67,5.67Q9UHD1,CHRD1_HUMAN,reviewed,Cysteine and histidine-rich domain-containing protein 1 (CHORD domain-containing protein 1) (CHORD-containing protein 1) (CHP-1) (Protein morgana),CHORDC1 CHP1,Homo sapiens (Human),332,GO:0051879; GO:0061077; GO:2000299; GO:1900034; GO:0010824; GO:0008270,26973;,MALLCYNRGCGQRFDPETNSDDACTYHPGVPVFHDALKGWSCCKRRTTDFSDFLSIVGCTKGRHNSEKPPEPVKPEVKTTEKKELCELKPKFQEHIIQAPKPVEAIKRPSPDEPMTNLELKISASLKQALDKLKLSSGNEENKKEEDNDEIKIGTSCKNGGCSKTYQGLESLEEVCVYHSGVPIFHEGMKYWSCCRRKTSDFNTFLAQEGCTKGKHMWTKKDAGKKVVPCRHDWHQTGGEVTISVYAKNSLPELSRVEANSTLLNVHIVFEGEKEFDQNVKLWGVIDVKRSYVTMTATKIEITMRKAEPMQWASLELPAAKKQEKQKDATTD,,,,PF04968;PF04969;,hsa:26973;,,,"SUBUNIT: Interacts with HSP90AA1, ROCK1 and ROCK2. Interacts with HSP90AB1 and PPP5C (By similarity). {ECO:0000250}.",HELIX 50 53 {ECO:0000244|PDB:2YRT}.,STRAND 31 34 {ECO:0000244|PDB:2YRT}.; STRAND 37 44 {ECO:0000244|PDB:2YRT}.; STRAND 46 49 {ECO:0000244|PDB:2YRT}.,TURN 8 10 {ECO:0000244|PDB:2YRT}.; TURN 16 18 {ECO:0000244|PDB:2YRT}.; TURN 21 23 {ECO:0000244|PDB:2YRT}.,DOMAIN 5 64 CHORD 1. {ECO:0000255|PROSITE-ProRule:PRU00734}.; DOMAIN 157 216 CHORD 2. {ECO:0000255|PROSITE-ProRule:PRU00734}.; DOMAIN 227 316 CS. {ECO:0000255|PROSITE-ProRule:PRU00547}.,,,,,4.21686747,-0.729,37.49,102,103Q00610,CLH1_HUMAN,reviewed,Clathrin heavy chain 1 (Clathrin heavy chain on chromosome 17) (CLH-17),CLTC CLH17 CLTCL2 KIAA0034,Homo sapiens (Human),1675,GO:0019886; GO:0030118; GO:0030132; GO:0030130; GO:0071439; GO:0032051; GO:0030669; GO:0030136; GO:0005737; GO:0005829; GO:0003725; GO:0070062; GO:0005925; GO:0043231; GO:0006886; GO:0042470; GO:0016020; GO:0061024; GO:0007067; GO:1900126; GO:1903077; GO:0001649; GO:0005886; GO:0044822; GO:0006892; GO:0043234; GO:0019901; GO:0031623; GO:0006898; GO:0005819; GO:0005198; GO:0032588; GO:0033572; GO:0031982,1213;,MAQILPIRFQEHLQLQNLGINPANIGFSTLTMESDKFICIREKVGEQAQVVIIDMNDPSNPIRRPISADSAIMNPASKVIALKAGKTLQIFNIEMKSKMKAHTMTDDVTFWKWISLNTVALVTDNAVYHWSMEGESQPVKMFDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNAEESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGYIHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRMAVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGILLDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQCFAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQQCTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHFTDLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIELFESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQLPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQFSTDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCEKRDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALSETQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNYDAPDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVWSQLAKAQLQKGMVKEAIDSYIKADDPSSYMEVVQAANTSGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFINGPNNAHIQQVGDRCYDEKMYDAAKLLYNNVSNFGRLASTLVHLGEYQAAVDGARKANSTRTWKEVCFACVDGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQKMREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVANVELYYRAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNLFITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQYASESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVDKLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM,,,"DOMAIN: The N-terminal seven-bladed beta-propeller is formed by WD40-like repeats, and projects inward from the polyhedral outer clathrin coat. It consitutes a major protein-protein interaction node.",PF00637;PF09268;PF01394;,hsa:1213;,,,"SUBUNIT: Clathrin triskelions, composed of 3 heavy chains and 3 light chains, are the basic subunits of the clathrin coat. In the presence of light chains, hub assembly is influenced by both the pH and the concentration of calcium. Interacts with HIP1. Interacts with DENND1A, DENND1B and DENND1C (By similarity). May interact with OCRL. Interacts with ERBB2 (By similarity). Interacts with FKBP6. {ECO:0000250, ECO:0000269|PubMed:11532990, ECO:0000269|PubMed:16314522, ECO:0000269|PubMed:18529014, ECO:0000269|PubMed:21816279}.",HELIX 15 18 {ECO:0000244|PDB:4G55}.; HELIX 22 24 {ECO:0000244|PDB:4G55}.; HELIX 146 148 {ECO:0000244|PDB:4G55}.; HELIX 310 312 {ECO:0000244|PDB:4G55}.; HELIX 334 340 {ECO:0000244|PDB:4G55}.; HELIX 345 354 {ECO:0000244|PDB:4G55}.,STRAND 6 14 {ECO:0000244|PDB:4G55}.; STRAND 30 34 {ECO:0000244|PDB:4G55}.; STRAND 37 44 {ECO:0000244|PDB:4G55}.; STRAND 47 54 {ECO:0000244|PDB:4G55}.; STRAND 62 65 {ECO:0000244|PDB:4G55}.; STRAND 69 73 {ECO:0000244|PDB:4G55}.; STRAND 75 84 {ECO:0000244|PDB:4G55}.; STRAND 87 92 {ECO:0000244|PDB:4G55}.; STRAND 97 103 {ECO:0000244|PDB:4G55}.; STRAND 108 113 {ECO:0000244|PDB:4G55}.; STRAND 115 133 {ECO:0000244|PDB:4G55}.; STRAND 139 143 {ECO:0000244|PDB:4G55}.; STRAND 152 158 {ECO:0000244|PDB:4G55}.; STRAND 164 173 {ECO:0000244|PDB:4G55}.; STRAND 176 185 {ECO:0000244|PDB:4G55}.; STRAND 190 194 {ECO:0000244|PDB:4G55}.; STRAND 197 204 {ECO:0000244|PDB:4G55}.; STRAND 213 222 {ECO:0000244|PDB:4G55}.; STRAND 225 232 {ECO:0000244|PDB:4G55}.; STRAND 246 250 {ECO:0000244|PDB:4G55}.; STRAND 261 267 {ECO:0000244|PDB:4G55}.; STRAND 272 277 {ECO:0000244|PDB:4G55}.; STRAND 280 286 {ECO:0000244|PDB:4G55}.; STRAND 292 297 {ECO:0000244|PDB:4G55}.; STRAND 303 309 {ECO:0000244|PDB:4G55}.; STRAND 314 319 {ECO:0000244|PDB:4G55}.; STRAND 323 329 {ECO:0000244|PDB:4G55}.,TURN 27 29 {ECO:0000244|PDB:4G55}.; TURN 93 96 {ECO:0000244|PDB:4G55}.; TURN 186 189 {ECO:0000244|PDB:4G55}.; TURN 268 271 {ECO:0000244|PDB:4G55}.; TURN 287 289 {ECO:0000244|PDB:4G55}.; TURN 331 333 {ECO:0000244|PDB:4G55}.,,,,,,1.850746269,-0.243,191.65,221,222A5YKK6,CNOT1_HUMAN,reviewed,CCR4-NOT transcription complex subunit 1 (CCR4-associated factor 1) (Negative regulator of transcription subunit 1 homolog) (NOT1H) (hNOT1),CNOT1 CDC39 KIAA1007 NOT1 AD-005,Homo sapiens (Human),2376,GO:0030014; GO:0016070; GO:0090503; GO:0000932; GO:0005829; GO:0030331; GO:0005615; GO:0010467; GO:0031047; GO:0016071; GO:0016020; GO:0033147; GO:0048387; GO:0000122; GO:0000288; GO:0000289; GO:0005654; GO:0005778; GO:0044822; GO:0010606; GO:1900153; GO:0060213; GO:2000036; GO:0006417; GO:0042974; GO:0006351; GO:0001829,23019;,MNLDSLSLALSQISYLVDNLTKKNYRASQQEIQHIVNRHGPEADRHLLRCLFSHVDFSGDGKSSGKDFHQTQFLIQECALLITKPNFISTLSYAIDNPLHYQKSLKPAPHLFAQLSKVLKLSKVQEVIFGLALLNSSSSDLRGFAAQFIKQKLPDLLRSYIDADVSGNQEGGFQDIAIEVLHLLLSHLLFGQKGAFGVGQEQIDAFLKTLRRDFPQERCPVVLAPLLYPEKRDILMDRILPDSGGVAKTMMESSLADFMQEVGYGFCASIEECRNIIVQFGVREVTAAQVARVLGMMARTHSGLTDGIPLQSISAPGSGIWSDGKDKSDGAQAHTWNVEVLIDVLKELNPSLNFKEVTYELDHPGFQIRDSKGLHNVVYGIQRGLGMEVFPVDLIYRPWKHAEGQLSFIQHSLINPEIFCFADYPCHTVATDILKAPPEDDNREIATWKSLDLIESLLRLAEVGQYEQVKQLFSFPIKHCPDMLVLALLQINTSWHTLRHELISTLMPIFLGNHPNSAIILHYAWHGQGQSPSIRQLIMHAMAEWYMRGEQYDQAKLSRILDVAQDLKALSMLLNGTPFAFVIDLAALASRREYLKLDKWLTDKIREHGEPFIQACMTFLKRRCPSILGGLAPEKDQPKSAQLPPETLATMLACLQACAGSVSQELSETILTMVANCSNVMNKARQPPPGVMPKGRPPSASSLDAISPVQIDPLAGMTSLSIGGSAAPHTQSMQGFPPNLGSAFSTPQSPAKAFPPLSTPNQTTAFSGIGGLSSQLPVGGLGTGSLTGIGTGALGLPAVNNDPFVQRKLGTSGLNQPTFQQSKMKPSDLSQVWPEANQHFSKEIDDEANSYFQRIYNHPPHPTMSVDEVLEMLQRFKDSTIKREREVFNCMLRNLFEEYRFFPQYPDKELHITACLFGGIIEKGLVTYMALGLALRYVLEALRKPFGSKMYYFGIAALDRFKNRLKDYPQYCQHLASISHFMQFPHHLQEYIEYGQQSRDPPVKMQGSITTPGSIALAQAQAQAQVPAKAPLAGQVSTMVTTSTTTTVAKTVTVTRPTGVSFKKDVPPSINTTNIDTLLVATDQTERIVEPPENIQEKIAFIFNNLSQSNMTQKVEELKETVKEEFMPWVSQYLVMKRVSIEPNFHSLYSNFLDTLKNPEFNKMVLNETYRNIKVLLTSDKAAANFSDRSLLKNLGHWLGMITLAKNKPILHTDLDVKSLLLEAYVKGQQELLYVVPFVAKVLESSIRSVVFRPPNPWTMAIMNVLAELHQEHDLKLNLKFEIEVLCKNLALDINELKPGNLLKDKDRLKNLDEQLSAPKKDVKQPEELPPITTTTTSTTPATNTTCTATVPPQPQYSYHDINVYSLAGLAPHITLNPTIPLFQAHPQLKQCVRQAIERAVQELVHPVVDRSIKIAMTTCEQIVRKDFALDSEESRMRIAAHHMMRNLTAGMAMITCREPLLMSISTNLKNSFASALRTASPQQREMMDQAAAQLAQDNCELACCFIQKTAVEKAGPEMDKRLATEFELRKHARQEGRRYCDPVVLTYQAERMPEQIRLKVGGVDPKQLAVYEEFARNVPGFLPTNDLSQPTGFLAQPMKQAWATDDVAQIYDKCITELEQHLHAIPPTLAMNPQAQALRSLLEVVVLSRNSRDAIAALGLLQKAVEGLLDATSGADADLLLRYRECHLLVLKALQDGRAYGSPWCNKQITRCLIECRDEYKYNVEAVELLIRNHLVNMQQYDLHLAQSMENGLNYMAVAFAMQLVKILLVDERSVAHVTEADLFHTIETLMRINAHSRGNAPEGLPQLMEVVRSNYEAMIDRAHGGPNFMMHSGISQASEYDDPPGLREKAEYLLREWVNLYHSAAAGRDSTKAFSAFVGQMHQQGILKTDDLITRFFRLCTEMCVEISYRAQAEQQHNPAANPTMIRAKCYHNLDAFVRLIALLVKHSGEATNTVTKINLLNKVLGIVVGVLLQDHDVRQSEFQQLPYHRIFIMLLLELNAPEHVLETINFQTLTAFCNTFHILRPTKAPGFVYAWLELISHRIFIARMLAHTPQQKGWPMYAQLLIDLFKYLAPFLRNVELTKPMQILYKGTLRVLLVLLHDFPEFLCDYHYGFCDVIPPNCIQLRNLILSAFPRNMRLPDPFTPNLKVDMLSEINIAPRILTNFTGVMPPQFKKDLDSYLKTRSPVTFLSDLRSNLQVSNEPGNRYNLQLINALVLYVGTQAIAHIHNKGSTPSMSTITHSAHMDIFQNLAVDLDTEGRYLFLNAIANQLRYPNSHTHYFSCTMLYLFAEANTEAIQEQITRVLLERLIVNRPHPWGLLITFIELIKNPAFKFWNHEFVHCAPEIEKLFQSVAQCCMGQKQAQQVMEGTGAS,,,"DOMAIN: Contains Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs, a motif known to be important for the association with nuclear receptors. {ECO:0000269|PubMed:16778766}.",PF12842;PF04054;,hsa:23019;,,,"SUBUNIT: Component of the CCR4-NOT complex; distinct complexes seem to exist that differ in the participation of probably mutually exclusive catalytic subunits. In the complex, interacts directly with CNOT6, CNOT6L, CNOT7 or CNOT8. Interacts in a ligand-dependent fashion with ESR1 and RXRA. Interacts with NANOS2, TOB1 and ZFP36. Interacts with TNRC6A, TNRC6B or TNRC6C; the interactions are direct. {ECO:0000269|PubMed:10637334, ECO:0000269|PubMed:16778766, ECO:0000269|PubMed:18377426, ECO:0000269|PubMed:19558367, ECO:0000269|PubMed:21278420, ECO:0000269|PubMed:21981923, ECO:0000269|PubMed:21984185, ECO:0000269|PubMed:22977175, ECO:0000269|PubMed:23644599}.",HELIX 841 856 {ECO:0000244|PDB:4J8S}.; HELIX 866 877 {ECO:0000244|PDB:4J8S}.; HELIX 882 897 {ECO:0000244|PDB:4J8S}.; HELIX 899 904 {ECO:0000244|PDB:4J8S}.; HELIX 907 922 {ECO:0000244|PDB:4J8S}.; HELIX 929 942 {ECO:0000244|PDB:4J8S}.; HELIX 949 961 {ECO:0000244|PDB:4J8S}.; HELIX 962 967 {ECO:0000244|PDB:4J8S}.; HELIX 969 976 {ECO:0000244|PDB:4J8S}.; HELIX 981 983 {ECO:0000244|PDB:4J8S}.; HELIX 986 996 {ECO:0000244|PDB:4J8S}.; HELIX 1076 1082 {ECO:0000244|PDB:4CT4}.; HELIX 1093 1104 {ECO:0000244|PDB:4CRW}.; HELIX 1111 1121 {ECO:0000244|PDB:4CRW}.; HELIX 1124 1126 {ECO:0000244|PDB:4CRW}.; HELIX 1127 1137 {ECO:0000244|PDB:4CRW}.; HELIX 1143 1145 {ECO:0000244|PDB:4CRW}.; HELIX 1146 1156 {ECO:0000244|PDB:4CRW}.; HELIX 1159 1177 {ECO:0000244|PDB:4CRW}.; HELIX 1186 1202 {ECO:0000244|PDB:4CRW}.; HELIX 1204 1206 {ECO:0000244|PDB:4CRW}.; HELIX 1217 1227 {ECO:0000244|PDB:4CRW}.; HELIX 1229 1243 {ECO:0000244|PDB:4CRW}.; HELIX 1244 1248 {ECO:0000244|PDB:4CRW}.; HELIX 1257 1271 {ECO:0000244|PDB:4CRW}.; HELIX 1277 1289 {ECO:0000244|PDB:4CRW}.; HELIX 1294 1296 {ECO:0000244|PDB:4CRW}.; HELIX 1302 1304 {ECO:0000244|PDB:4CRW}.; HELIX 1306 1310 {ECO:0000244|PDB:4CRW}.; HELIX 1359 1361 {ECO:0000244|PDB:4CRU}.; HELIX 1367 1369 {ECO:0000244|PDB:4CRU}.; HELIX 1371 1373 {ECO:0000244|PDB:4CRU}.; HELIX 1381 1385 {ECO:0000244|PDB:4CRU}.; HELIX 1387 1392 {ECO:0000244|PDB:4CRU}.; HELIX 1393 1427 {ECO:0000244|PDB:4CRU}.; HELIX 1434 1476 {ECO:0000244|PDB:4CRU}.; HELIX 1482 1522 {ECO:0000244|PDB:4CRU}.; HELIX 1524 1535 {ECO:0000244|PDB:4CRU}.; HELIX 1543 1552 {ECO:0000244|PDB:4CRU}.; HELIX 1555 1557 {ECO:0000244|PDB:4CRU}.; HELIX 1566 1569 {ECO:0000244|PDB:4CRU}.; HELIX 1570 1577 {ECO:0000244|PDB:4CRU}.; HELIX 1848 1865 {ECO:0000244|PDB:4CQO}.; HELIX 1870 1885 {ECO:0000244|PDB:4CQO}.; HELIX 1892 1915 {ECO:0000244|PDB:4CQO}.; HELIX 1926 1948 {ECO:0000244|PDB:4CQO}.; HELIX 1957 1981 {ECO:0000244|PDB:4CQO}.; HELIX 1982 1984 {ECO:0000244|PDB:4CQO}.; HELIX 1988 2000 {ECO:0000244|PDB:4CQO}.; HELIX 2006 2009 {ECO:0000244|PDB:4CQO}.; HELIX 2012 2025 {ECO:0000244|PDB:4CQO}.; HELIX 2032 2034 {ECO:0000244|PDB:4CQO}.; HELIX 2035 2042 {ECO:0000244|PDB:4CQO}.; HELIX 2045 2052 {ECO:0000244|PDB:4CQO}.; HELIX 2056 2058 {ECO:0000244|PDB:4CQO}.; HELIX 2061 2080 {ECO:0000244|PDB:4CQO}.; HELIX 2086 2105 {ECO:0000244|PDB:4CQO}.; HELIX 2107 2112 {ECO:0000244|PDB:4CQO}.; HELIX 2114 2120 {ECO:0000244|PDB:4CQO}.; HELIX 2126 2133 {ECO:0000244|PDB:4CQO}.; HELIX 2152 2154 {ECO:0000244|PDB:4CQO}.; HELIX 2157 2159 {ECO:0000244|PDB:4CQO}.; HELIX 2168 2171 {ECO:0000244|PDB:4CQO}.; HELIX 2174 2186 {ECO:0000244|PDB:4CQO}.; HELIX 2191 2200 {ECO:0000244|PDB:4CQO}.; HELIX 2212 2232 {ECO:0000244|PDB:4CQO}.; HELIX 2246 2257 {ECO:0000244|PDB:4CQO}.; HELIX 2260 2271 {ECO:0000244|PDB:4CQO}.; HELIX 2279 2293 {ECO:0000244|PDB:4CQO}.; HELIX 2299 2312 {ECO:0000244|PDB:4CQO}.; HELIX 2320 2331 {ECO:0000244|PDB:4CQO}.; HELIX 2337 2339 {ECO:0000244|PDB:4CQO}.; HELIX 2348 2360 {ECO:0000244|PDB:4CQO}.,STRAND 1561 1563 {ECO:0000244|PDB:4CRU}.; STRAND 1888 1891 {ECO:0000244|PDB:4CQO}.; STRAND 1950 1954 {ECO:0000244|PDB:4CQO}.; STRAND 2145 2147 {ECO:0000244|PDB:4C0D}.; STRAND 2205 2207 {ECO:0000244|PDB:4C0D}.; STRAND 2208 2210 {ECO:0000244|PDB:4CQO}.; STRAND 2242 2245 {ECO:0000244|PDB:4CQO}.; STRAND 2276 2278 {ECO:0000244|PDB:4CQO}.; STRAND 2296 2298 {ECO:0000244|PDB:4CQO}.; STRAND 2313 2316 {ECO:0000244|PDB:4CQO}.,TURN 830 832 {ECO:0000244|PDB:4J8S}.; TURN 838 840 {ECO:0000244|PDB:4J8S}.; TURN 1108 1110 {ECO:0000244|PDB:4CRW}.; TURN 1138 1141 {ECO:0000244|PDB:4CRW}.; TURN 1212 1214 {ECO:0000244|PDB:4CRW}.; TURN 1250 1252 {ECO:0000244|PDB:4CRW}.; TURN 1428 1430 {ECO:0000244|PDB:4CRU}.; TURN 2028 2030 {ECO:0000244|PDB:4CQO}.; TURN 2239 2241 {ECO:0000244|PDB:4CQO}.; TURN 2342 2344 {ECO:0000244|PDB:4CQO}.,,,,,,1.725589226,-0.157,266.99,3.89,4.89O60610,DIAP1_HUMAN,reviewed,Protein diaphanous homolog 1 (Diaphanous-related formin-1) (DRF1),DIAPH1 DIAP1,Homo sapiens (Human),1272,GO:0030041; GO:0071420; GO:0005737; GO:0007010; GO:0044325; GO:0072686; GO:0044822; GO:0030335; GO:0035372; GO:0005102; GO:0008360; GO:0032886; GO:0051279; GO:0032587; GO:0007605,1729;,MEPPGGSLGPGRGTRDKKKGRSPDELPSAGGDGGKSKKFTLKRLMADELERFTSMRIKKEKEKPNSAHRNSSASYGDDPTAQSLQDVSDEQVLVLFEQMLLDMNLNEEKQQPLREKDIIIKREMVSQYLYTSKAGMSQKESSKSAMMYIQELRSGLRDMPLLSCLESLRVSLNNNPVSWVQTFGAEGLASLLDILKRLHDEKEETAGSYDSRNKHEIIRCLKAFMNNKFGIKTMLETEEGILLLVRAMDPAVPNMMIDAAKLLSALCILPQPEDMNERVLEAMTERAEMDEVERFQPLLDGLKSGTTIALKVGCLQLINALITPAEELDFRVHIRSELMRLGLHQVLQDLREIENEDMRVQLNVFDEQGEEDSYDLKGRLDDIRMEMDDFNEVFQILLNTVKDSKAEPHFLSILQHLLLVRNDYEARPQYYKLIEECISQIVLHKNGADPDFKCRHLQIEIEGLIDQMIDKTKVEKSEAKAAELEKKLDSELTARHELQVEMKKMESDFEQKLQDLQGEKDALHSEKQQIATEKQDLEAEVSQLTGEVAKLTKELEDAKKEMASLSAAAITVPPSVPSRAPVPPAPPLPGDSGTIIPPPPAPGDSTTPPPPPPPPPPPPPLPGGVCISSPPSLPGGTAISPPPPLSGDATIPPPPPLPEGVGIPSPSSLPGGTAIPPPPPLPGSARIPPPPPPLPGSAGIPPPPPPLPGEAGMPPPPPPLPGGPGIPPPPPFPGGPGIPPPPPGMGMPPPPPFGFGVPAAPVLPFGLTPKKLYKPEVQLRRPNWSKLVAEDLSQDCFWTKVKEDRFENNELFAKLTLTFSAQTKTSKAKKDQEGGEEKKSVQKKKVKELKVLDSKTAQNLSIFLGSFRMPYQEIKNVILEVNEAVLTESMIQNLIKQMPEPEQLKMLSELKDEYDDLAESEQFGVVMGTVPRLRPRLNAILFKLQFSEQVENIKPEIVSVTAACEELRKSESFSNLLEITLLVGNYMNAGSRNAGAFGFNISFLCKLRDTKSTDQKMTLLHFLAELCENDYPDVLKFPDELAHVEKASRVSAENLQKNLDQMKKQISDVERDVQNFPAATDEKDKFVEKMTSFVKDAQEQYNKLRMMHSNMETLYKELGEYFLFDPKKLSVEEFFMDLHNFRNMFLQAVKENQKRRETEEKMRRAKLAKEKAEKERLEKQQKREQLIDMNAEGDETGVMDSLLEALQSGAAFRRKRGPRQANRKAGCAVTSLLASELTKDDAMAAVPAKVSKNSETFPTILEEAKELVGRAS,"DISEASE: Deafness, autosomal dominant, 1 (DFNA1) [MIM:124900]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. Note=The disease is caused by mutations affecting the gene represented in this entry.",,DOMAIN: The DAD domain regulates activation via by an autoinhibitory interaction with the GBD/FH3 domain. This autoinhibition is released upon competitive binding of an activated GTPase. The release of DAD allows the FH2 domain to then nucleate and elongate nonbranched actin filaments (By similarity). {ECO:0000250}.,PF06345;PF06346;PF06367;PF06371;PF02181;,hsa:1729;,,,"SUBUNIT: Homodimer. Interacts with the GTP-bound form of RHOA. Interacts with RHOC, PFY1, MAPRE1, BAIAP2 and APC. Interacts with SCAI (By similarity). Interacts with DCAF7, via FH2 domain. Interacts with NCDN (By similarity). {ECO:0000250}.",,,,DOMAIN 84 449 GBD/FH3. {ECO:0000255|PROSITE-ProRule:PRU00579}.; DOMAIN 583 764 FH1.; DOMAIN 769 1171 FH2. {ECO:0000255|PROSITE-ProRule:PRU00774}.; DOMAIN 1194 1222 DAD. {ECO:0000255|PROSITE-ProRule:PRU00577}.,,,,,0.943396226,-0.542,141.37,73,74Q9UNQ2,DIM1_HUMAN,reviewed,"Probable dimethyladenosine transferase (EC 2.1.1.183) (DIM1 dimethyladenosine transferase 1 homolog) (DIM1 dimethyladenosine transferase 1-like) (Probable 18S rRNA (adenine(1779)-N(6)/adenine(1780)-N(6))-dimethyltransferase) (Probable 18S rRNA dimethylase) (Probable S-adenosylmethionine-6-N',N'-adenosyl(rRNA) dimethyltransferase)",DIMT1 DIMT1L HUSSY-05,Homo sapiens (Human),313,GO:0052909; GO:0005737; GO:0005730; GO:0005634; GO:0044822; GO:0000179,27292;,MPKVKSGAIGRRRGRQEQRRELKSAGGLMFNTGIGQHILKNPLIINSIIDKAALRPTDVVLEVGPGTGNMTVKLLEKAKKVVACELDPRLVAELHKRVQGTPVASKLQVLVGDVLKTDLPFFDTCVANLPYQISSPFVFKLLLHRPFFRCAILMFQREFALRLVAKPGDKLYCRLSINTQLLARVDHLMKVGKNNFRPPPKVESSVVRIEPKNPPPPINFQEWDGLVRITFVRKNKTLSAAFKSSAVQQLLEKNYRIHCSVHNIIIPEDFSIADKIQQILTSTGFSDKRARSMDIDDFIRLLHGFNAEGIHFS,,,,PF00398;,hsa:27292;,,,,HELIX 42 51 {ECO:0000244|PDB:1ZQ9}.; HELIX 71 77 {ECO:0000244|PDB:1ZQ9}.; HELIX 88 98 {ECO:0000244|PDB:1ZQ9}.; HELIX 104 106 {ECO:0000244|PDB:1ZQ9}.; HELIX 131 133 {ECO:0000244|PDB:1ZQ9}.; HELIX 134 143 {ECO:0000244|PDB:1ZQ9}.; HELIX 157 164 {ECO:0000244|PDB:1ZQ9}.; HELIX 174 182 {ECO:0000244|PDB:1ZQ9}.; HELIX 193 195 {ECO:0000244|PDB:1ZQ9}.; HELIX 220 231 {ECO:0000244|PDB:1ZQ9}.; HELIX 238 241 {ECO:0000244|PDB:1ZQ9}.; HELIX 245 262 {ECO:0000244|PDB:1ZQ9}.; HELIX 272 282 {ECO:0000244|PDB:1ZQ9}.; HELIX 290 292 {ECO:0000244|PDB:1ZQ9}.; HELIX 295 306 {ECO:0000244|PDB:1ZQ9}.,STRAND 59 63 {ECO:0000244|PDB:1ZQ9}.; STRAND 78 86 {ECO:0000244|PDB:1ZQ9}.; STRAND 107 112 {ECO:0000244|PDB:1ZQ9}.; STRAND 123 128 {ECO:0000244|PDB:1ZQ9}.; STRAND 149 156 {ECO:0000244|PDB:1ZQ9}.; STRAND 183 191 {ECO:0000244|PDB:1ZQ9}.; STRAND 196 198 {ECO:0000244|PDB:1ZQ9}.; STRAND 204 211 {ECO:0000244|PDB:1ZQ9}.,TURN 114 116 {ECO:0000244|PDB:1ZQ9}.; TURN 232 235 {ECO:0000244|PDB:1ZQ9}.; TURN 307 309 {ECO:0000244|PDB:1ZQ9}.,,,,,,1.597444089,-0.127,35.24,3.51,4.51P31689,DNJA1_HUMAN,reviewed,DnaJ homolog subfamily A member 1 (DnaJ protein homolog 2) (HSDJ) (Heat shock 40 kDa protein 4) (Heat shock protein J2) (HSJ-2) (Human DnaJ protein 2) (hDj-2),DNAJA1 DNAJ2 HDJ2 HSJ2 HSPF4,Homo sapiens (Human),397,GO:0005524; GO:0042769; GO:0001664; GO:0030544; GO:0030521; GO:0051087; GO:0098554; GO:0005829; GO:0070062; GO:0050750; GO:0016020; GO:0046872; GO:0005739; GO:0043508; GO:0043066; GO:0031397; GO:0005634; GO:0048471; GO:0043065; GO:0006457; GO:0070585; GO:0042026; GO:0051223; GO:0009408; GO:0006986; GO:0030317; GO:0007283; GO:0031625; GO:0051082,3301;,MVKETTYYDVLGVKPNATQEELKKAYRKLALKYHPDKNPNEGEKFKQISQAYEVLSDAKKRELYDKGGEQAIKEGGAGGGFGSPMDIFDMFFGGGGRMQRERRGKNVVHQLSVTLEDLYNGATRKLALQKNVICDKCEGRGGKKGAVECCPNCRGTGMQIRIHQIGPGMVQQIQSVCMECQGHGERISPKDRCKSCNGRKIVREKKILEVHIDKGMKDGQKITFHGEGDQEPGLEPGDIIIVLDQKDHAVFTRRGEDLFMCMDIQLVEALCGFQKPISTLDNRTIVITSHPGQIVKHGDIKCVLNEGMPIYRRPYEKGRLIIEFKVNFPENGFLSPDKLSLLEKLLPERKEVEETDEMDQVELVDFDPNQERRRHYNGEAYEDDEHHPRGGVQCQTS,,,,PF01556;PF00226;PF00684;,hsa:3301;,,,SUBUNIT: Identified in a complex with HSPA1B and BAX. {ECO:0000269|PubMed:14752510}.,HELIX 7 10 {ECO:0000244|PDB:2LO1}.; HELIX 19 33 {ECO:0000244|PDB:2LO1}.; HELIX 35 37 {ECO:0000244|PDB:2LO1}.; HELIX 42 54 {ECO:0000244|PDB:2LO1}.; HELIX 58 64 {ECO:0000244|PDB:2LO1}.,STRAND 39 41 {ECO:0000244|PDB:2LO1}.,TURN 65 67 {ECO:0000244|PDB:2LO1}.,DOMAIN 6 68 J.,,,,,3.274559194,-0.729,44.88,62.6,63.6P25685,DNJB1_HUMAN,reviewed,DnaJ homolog subfamily B member 1 (DnaJ protein homolog 1) (Heat shock 40 kDa protein 1) (HSP40) (Heat shock protein 40) (Human DnaJ protein 1) (hDj-1),DNAJB1 DNAJ1 HDJ1 HSPF1,Homo sapiens (Human),340,GO:0001671; GO:0051117; GO:0030544; GO:0051087; GO:0070389; GO:0051085; GO:0005829; GO:0070062; GO:0090084; GO:0005730; GO:0005634; GO:0032781; GO:0006986; GO:0051082,3337;,MGKDYYQTLGLARGASDEEIKRAYRRQALRYHPDKNKEPGAEEKFKEIAEAYDVLSDPRKREIFDRYGEEGLKGSGPSGGSGGGANGTSFSYTFHGDPHAMFAEFFGGRNPFDTFFGQRNGEEGMDIDDPFSGFPMGMGGFTNVNFGRSRSAQEPARKKQDPPVTHDLRVSLEEIYSGCTKKMKISHKRLNPDGKSIRNEDKILTIEVKKGWKEGTKITFPKEGDQTSNNIPADIVFVLKDKPHNIFKRDGSDVIYPARISLREALCGCTVNVPTLDGRTIPVVFKDVIRPGMRRKVPGEGLPLPKTPEKRGDLIIEFEVIFPERIPQTSRTVLEQVLPI,,,,PF01556;PF00226;,hsa:3337;,,,"SUBUNIT: Interacts with DNAJC3. Interacts with SRPK1. {ECO:0000269|PubMed:19240134, ECO:0000269|PubMed:9920933}.",HELIX 172 177 {ECO:0000244|PDB:3AGX}.; HELIX 262 267 {ECO:0000244|PDB:3AGX}.; HELIX 328 337 {ECO:0000244|PDB:3AGX}.,STRAND 166 170 {ECO:0000244|PDB:3AGX}.; STRAND 179 190 {ECO:0000244|PDB:3AGX}.; STRAND 197 208 {ECO:0000244|PDB:3AGX}.; STRAND 217 220 {ECO:0000244|PDB:3AGX}.; STRAND 228 230 {ECO:0000244|PDB:3AGX}.; STRAND 235 241 {ECO:0000244|PDB:3AGX}.; STRAND 248 250 {ECO:0000244|PDB:3AGX}.; STRAND 253 261 {ECO:0000244|PDB:3AGX}.; STRAND 269 274 {ECO:0000244|PDB:3AGX}.; STRAND 280 285 {ECO:0000244|PDB:3AGX}.; STRAND 294 297 {ECO:0000244|PDB:3AGX}.; STRAND 305 307 {ECO:0000244|PDB:3AGX}.; STRAND 314 321 {ECO:0000244|PDB:3AGX}.,TURN 191 193 {ECO:0000244|PDB:2QLD}.,DOMAIN 2 70 J. {ECO:0000255|PROSITE-ProRule:PRU00286}.,,,,,0.882352941,-0.715,38.05,12.6,13.6P68104,EF1A1_HUMAN,reviewed,Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor Tu) (EF-Tu) (Eukaryotic elongation factor 1 A-1) (eEF1A-1) (Leukocyte receptor cluster member 7),EEF1A1 EEF1A EF1A LENG7,Homo sapiens (Human),462,GO:0005525; GO:0003924; GO:0044267; GO:0071364; GO:0005737; GO:0005829; GO:0005853; GO:0005615; GO:0070062; GO:0010467; GO:0016020; GO:0005730; GO:0005634; GO:0005886; GO:0044822; GO:0019901; GO:0006355; GO:0006351; GO:0006412; GO:0003746; GO:0006414,1915;,MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKKIGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPVLDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPPLGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK,,,,PF00009;PF03144;PF03143;,hsa:1915;,,,"SUBUNIT: Found in a nuclear export complex with XPO5, EEF1A1, Ran and aminoacylated tRNA. Interacts with PARP1, TXK, XPO5 and KARS. May interact with ERGIC2. Interacts with IFIT1 (via TPR repeats 4-7) (By similarity). Interacts with DLC1, facilitating distribution to the membrane periphery and ruffles upon growth factor stimulation. Interacts with ZPR1; the interaction occurs in a epidermal growth factor (EGF)-dependent manner. {ECO:0000250, ECO:0000269|PubMed:12426392, ECO:0000269|PubMed:12426393, ECO:0000269|PubMed:17177976, ECO:0000269|PubMed:17980171, ECO:0000269|PubMed:18029264, ECO:0000269|PubMed:19158340, ECO:0000269|PubMed:8650580}.",,,,DOMAIN 5 242 tr-type G.,,,,,1.298701299,-0.257,50.15,517,518Q14152,EIF3A_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit A (eIF3a) (Eukaryotic translation initiation factor 3 subunit 10) (eIF-3-theta) (eIF3 p167) (eIF3 p180) (eIF3 p185),EIF3A EIF3S10 KIAA0139,Homo sapiens (Human),1382,GO:0044267; GO:0005737; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0071541; GO:0001732; GO:0001731; GO:0010467; GO:0016020; GO:0005730; GO:0005634; GO:0044822; GO:0006446; GO:0005198; GO:0006412; GO:0003743; GO:0006413,8661;,MPAYFQRPENALKRANEFLEVGKKQPALDVLYDVMKSKKHRTWQKIHEPIMLKYLELCVDLRKSHLAKEGLYQYKNICQQVNIKSLEDVVRAYLKMAEEKTEAAKEESQQMVLDIEDLDNIQTPESVLLSAVSGEDTQDRTDRLLLTPWVKFLWESYRQCLDLLRNNSRVERLYHDIAQQAFKFCLQYTRKAEFRKLCDNLRMHLSQIQRHHNQSTAINLNNPESQSMHLETRLVQLDSAISMELWQEAFKAVEDIHGLFSLSKKPPKPQLMANYYNKVSTVFWKSGNALFHASTLHRLYHLSREMRKNLTQDEMQRMSTRVLLATLSIPITPERTDIARLLDMDGIIVEKQRRLATLLGLQAPPTRIGLINDMVRFNVLQYVVPEVKDLYNWLEVEFNPLKLCERVTKVLNWVREQPEKEPELQQYVPQLQNNTILRLLQQVSQIYQSIEFSRLTSLVPFVDAFQLERAIVDAARHCDLQVRIDHTSRTLSFGSDLNYATREDAPIGPHLQSMPSEQIRNQLTAMSSVLAKALEVIKPAHILQEKEEQHQLAVTAYLKNSRKEHQRILARRQTIEERKERLESLNIQREKEELEQREAELQKVRKAEEERLRQEAKEREKERILQEHEQIKKKTVRERLEQIKKTELGAKAFKDIDIEDLEELDPDFIMAKQVEQLEKEKKELQERLKNQEKKIDYFERAKRLEEIPLIKSAYEEQRIKDMDLWEQQEEERITTMQLEREKALEHKNRMSRMLEDRDLFVMRLKAARQSVYEEKLKQFEERLAEERHNRLEERKRQRKEERRITYYREKEEEEQRRAEEQMLKEREERERAERAKREEELREYQERVKKLEEVERKKRQRELEIEERERRREEERRLGDSSLSRKDSRWGDRDSEGTWRKGPEADSEWRRGPPEKEWRRGEGRDEDRSHRRDEERPRRLGDDEDREPSLRPDDDRVPRRGMDDDRGPRRGPEEDRFSRRGADDDRPSWRNTDDDRPPRRIADEDRGNWRHADDDRPPRRGLDEDRGSWRTADEDRGPRRGMDDDRGPRRGGADDERSSWRNADDDRGPRRGLDDDRGPRRGMDDDRGPRRGMDDDRGPRRGMDDDRGPRRGLDDDRGPWRNADDDRIPRRGAEDDRGPWRNMDDDRLSRRADDDRFPRRGDDSRPGPWRPLVKPGGWREKEKAREESWGPPRESRPSEEREWDREKERDRDNQDREENDKDPERERDRERDVDREDRFRRPRDEGGWRRGPAEESSSWRDSSRRDDRDRDDRRRERDDRRDLRERRDLRDDRDRRGPPLRSEREEVSSWRRADDRKDDRVEERDPPRRVPPPALSRDRERDRDREREGEKEKASWRAEKDRESLRRTKNETDEDGWTTVRR,,,,PF01399;,hsa:8661;,,,"SUBUNIT: Interacts with EIF4G1 (By similarity). Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3L and EIF3K. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Also interacts with KRT7 and PIWIL2. {ECO:0000250, ECO:0000269|PubMed:11169732, ECO:0000269|PubMed:14519125, ECO:0000269|PubMed:14688252, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:18599441}.",,,,DOMAIN 366 494 PCI. {ECO:0000255|HAMAP-Rule:MF_03000}.,,,,,0.506512301,-1.489,166.6,63.9,64.9Q99613,EIF3C_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit C (eIF3c) (Eukaryotic translation initiation factor 3 subunit 8) (eIF3 p110),EIF3C EIF3S8,Homo sapiens (Human),913,GO:0044267; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0001731; GO:0010467; GO:0044822; GO:0006446; GO:0006412; GO:0003743; GO:0006413,8663;,MSRFFTTGSDSESESSLSGEELVTKPVGGNYGKQPLLLSEDEEDTKRVVRSAKDKRFEELTNLIRTIRNAMKIRDVTKCLEEFELLGKAYGKAKSIVDKEGVPRFYIRILADLEDYLNELWEDKEGKKKMNKNNAKALSTLRQKIRKYNRDFESHITSYKQNPEQSADEDAEKNEEDSEGSSDEDEDEDGVSAATFLKKKSEAPSGESRKFLKKMDDEDEDSEDSEDDEDWDTGSTSSDSDSEEEEGKQTALASRFLKKAPTTDEDKKAAEKKREDKAKKKHDRKSKRLDEEEEDNEGGEWERVRGGVPLVKEKPKMFAKGTEITHAVVIKKLNEILQARGKKGTDRAAQIELLQLLVQIAAENNLGEGVIVKIKFNIIASLYDYNPNLATYMKPEMWGKCLDCINELMDILFANPNIFVGENILEESENLHNADQPLRVRGCILTLVERMDEEFTKIMQNTDPHSQEYVEHLKDEAQVCAIIERVQRYLEEKGTTEEVCRIYLLRILHTYYKFDYKAHQRQLTPPEGSSKSEQDQAENEGEDSAVLMERLCKYIYAKDRTDRIRTCAILCHIYHHALHSRWYQARDLMLMSHLQDNIQHADPPVQILYNRTMVQLGICAFRQGLTKDAHNALLDIQSSGRAKELLGQGLLLRSLQERNQEQEKVERRRQVPFHLHINLELLECVYLVSAMLLEIPYMAAHESDARRRMISKQFHHQLRVGERQPLLGPPESMREHVVAASKAMKMGDWKTCHSFIINEKMNGKVWDLFPEADKVRTMLVRKIQEESLRTYLFTYSSVYDSISMETLSDMFELDLPTVHSIISKMIINEELMASLDQPTQTVVMHRTEPTAQQNLALQLAEKLGSLVENNERVFDHKQGTYGGYFRDQKDGYRKNEGYMRRGGYRQQQSQTAY,,,,PF05470;PF01399;,hsa:8663;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Identified in a HCV IRES-mediated translation complex, at least composed of EIF3C, IGF2BP1, RPS3 and HCV RNA-replicon. Interacts with ALKBH4, IFIT1 and IFIT2. {ECO:0000255|HAMAP-Rule:MF_03002, ECO:0000269|PubMed:14519125, ECO:0000269|PubMed:16023166, ECO:0000269|PubMed:16286006, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:16973618, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:18599441, ECO:0000269|PubMed:19541769, ECO:0000269|PubMed:23145062}.",,,,DOMAIN 712 846 PCI. {ECO:0000255|HAMAP-Rule:MF_03002}.,,,,,1.314348302,-0.793,105.36,12.7,13.7O15371,EIF3D_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit D (eIF3d) (Eukaryotic translation initiation factor 3 subunit 7) (eIF-3-zeta) (eIF3 p66),EIF3D EIF3S7,Homo sapiens (Human),548,GO:0044267; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0071541; GO:0001732; GO:0001731; GO:0010467; GO:0016020; GO:0044822; GO:0006446; GO:0006412; GO:0003743; GO:0006413,8664;,MAKFMTPVIQDNPSGWGPCAVPEQFRDMPYQPFSKGDRLGKVADWTGATYQDKRYTNKYSSQFGGGSQYAYFHEEDESSFQLVDTARTQKTAYQRNRMRFAQRNLRRDKDRRNMLQFNLQILPKSAKQKERERIRLQKKFQKQFGVRQKWDQKSQKPRDSSVEVRSDWEVKEEMDFPQLMKMRYLEVSEPQDIECCGALEYYDKAFDRITTRSEKPLRSIKRIFHTVTTTDDPVIRKLAKTQGNVFATDAILATLMSCTRSVYSWDIVVQRVGSKLFFDKRDNSDFDLLTVSETANEPPQDEGNSFNSPRNLAMEATYINHNFSQQCLRMGKERYNFPNPNPFVEDDMDKNEIASVAYRYRRWKLGDDIDLIVRCEHDGVMTGANGEVSFINIKTLNEWDSRHCNGVDWRQKLDSQRGAVIATELKNNSYKLARWTCCALLAGSEYLKLGYVSRYHVKDSSRHVILGTQQFKPNEFASQINLSVENAWGILRCVIDICMKLEEGKYLILKDPNKQVIRVYSLPDGTFSSDEDEEEEEEEEEEEEEEET,,,,PF05091;,hsa:8664;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. {ECO:0000255|HAMAP-Rule:MF_03003, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:18599441}.",,,,,,,,,2.00729927,-0.842,63.98,31.2,32.2P60228,EIF3E_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit E (eIF3e) (Eukaryotic translation initiation factor 3 subunit 6) (Viral integration site protein INT-6 homolog) (eIF-3 p48),EIF3E EIF3S6 INT6,Homo sapiens (Human),445,GO:0016605; GO:0044267; GO:0005737; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0070062; GO:0001731; GO:0010467; GO:0016020; GO:0045947; GO:0000184; GO:0005654; GO:0005634; GO:0044822; GO:0047485; GO:0006446; GO:0006412; GO:0003743; GO:0006413,3646;,MAEYDLTTRIAHFLDRHLVFPLLEFLSVKEIYNEKELLQGKLDLLSDTNMVDFAMDVYKNLYSDDIPHALREKRTTVVAQLKQLQAETEPIVKMFEDPETTRQMQSTRDGRMLFDYLADKHGFRQEYLDTLYRYAKFQYECGNYSGAAEYLYFFRVLVPATDRNALSSLWGKLASEILMQNWDAAMEDLTRLKETIDNNSVSSPLQSLQQRTWLIHWSLFVFFNHPKGRDNIIDLFLYQPQYLNAIQTMCPHILRYLTTAVITNKDVRKRRQVLKDLVKVIQQESYTYKDPITEFVECLYVNFDFDGAQKKLRECESVLVNDFFLVACLEDFIENARLFIFETFCRIHQCISINMLADKLNMTPEEAERWIVNLIRNARLDAKIDSKLGHVVMGNNAVSPYQQVIEKTKSLSFRSQMLAMNIEKKLNQNSRSEAPNWATQDSGFY,,,,PF09440;PF01399;,hsa:3646;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Interacts with COPS3, COPS6, COPS7 (COPS7A or COPS7B), EIF4G1, EPAS1, MCM7, NCBP1, PSMC6, TRIM27 and UPF2. Interacts with the HTLV-1 protein Tax-1. Interacts with IFIT1 and IFIT2. {ECO:0000255|HAMAP-Rule:MF_03004, ECO:0000269|PubMed:10504338, ECO:0000269|PubMed:11457827, ECO:0000269|PubMed:11590142, ECO:0000269|PubMed:12220626, ECO:0000269|PubMed:12386384, ECO:0000269|PubMed:16023166, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:16973618, ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:17324924, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:18599441, ECO:0000269|PubMed:8688078, ECO:0000269|PubMed:9295280}.",,,,DOMAIN 290 395 PCI. {ECO:0000255|HAMAP-Rule:MF_03004}.,,,,,1.573033708,-0.327,52.23,23.8,24.8O00303,EIF3F_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit F (eIF3f) (Deubiquitinating enzyme eIF3f) (EC 3.4.19.12) (Eukaryotic translation initiation factor 3 subunit 5) (eIF-3-epsilon) (eIF3 p47),EIF3F EIF3S5,Homo sapiens (Human),357,GO:0044267; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0071541; GO:0001731; GO:0010467; GO:0016020; GO:0016579; GO:0006446; GO:0006412; GO:0003743; GO:0006413; GO:0004843,8665;,MATPAVPVSAPPATPTPVPAAAPASVPAPTPAPAAAPVPAAAPASSSDPAAAAAATAAPGQTPASAQAPAQTPAPALPGPALPGPFPGGRVVRLHPVILASIVDSYERRNEGAARVIGTLLGTVDKHSVEVTNCFSVPHNESEDEVAVDMEFAKNMYELHKKVSPNELILGWYATGHDITEHSVLIHEYYSREAPNPIHLTVDTSLQNGRMSIKAYVSTLMGVPGRTMGVMFTPLTVKYAYYDTERIGVDLIMKTCFSPNRVIGLSSDLQQVGGASARIQDALSTVLQYAEDVLSGKVSADNTVGRFLMSLVNQVPKIVPDDFETMLNSNINDLLMVTYLANLTQSQIALNEKLVNL,,,DOMAIN: The MPN domain mediates deubiquitinating activity.,PF01398;PF13012;,hsa:8665;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Interacts with RNF139; the interaction leads to protein translation inhibitions in a ubiquitination-dependent manner. Interacts with DTX1, the interaction is required for deubiquitinating activity towards NOTCH1. {ECO:0000255|HAMAP-Rule:MF_03005, ECO:0000269|PubMed:16286006, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:18599441, ECO:0000269|PubMed:20068067, ECO:0000269|PubMed:21124883}.",,,,DOMAIN 87 196 MPN. {ECO:0000255|HAMAP-Rule:MF_03005}.,,,,,0.56022409,0.043,37.57,90.2,91.2O75821,EIF3G_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit G (eIF3g) (Eukaryotic translation initiation factor 3 RNA-binding subunit) (eIF-3 RNA-binding subunit) (Eukaryotic translation initiation factor 3 subunit 4) (eIF-3-delta) (eIF3 p42) (eIF3 p44),EIF3G EIF3S4,Homo sapiens (Human),320,GO:0044267; GO:0005737; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0001731; GO:0010467; GO:0000166; GO:0005634; GO:0048471; GO:0044822; GO:0006446; GO:0006412; GO:0003743; GO:0006413,8666;,MPTGDFDSKPSWADQVEEEGEDDKCVTSELLKGIPLATGDTSPEPELLPGAPLPPPKEVINGNIKTVTEYKIDEDGKKFKIVRTFRIETRKASKAVARRKNWKKFGNSEFDPPGPNVATTTVSDDVSMTFITSKEDLNCQEEEDPMNKLKGQKIVSCRICKGDHWTTRCPYKDTLGPMQKELAEQLGLSTGEKEKLPGELEPVQATQNKTGKYVPPSLRDGASRRGESMQPNRRADDNATIRVTNLSEDTRETDLQELFRPFGSISRIYLAKDKTTGQSKGFAFISFHRREDAARAIAGVSGFGYDHLILNVEWAKPSTN,,,,PF12353;PF00076;,hsa:8666;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Interacts (via C-terminus) with AIFM1 (via N-terminus). {ECO:0000255|HAMAP-Rule:MF_03006, ECO:0000269|PubMed:14519125, ECO:0000269|PubMed:14688252, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:18599441, ECO:0000269|PubMed:9822659, ECO:0000269|PubMed:9973622}.",HELIX 252 256 {ECO:0000244|PDB:2CQ0}.; HELIX 290 299 {ECO:0000244|PDB:2CQ0}.,STRAND 236 245 {ECO:0000244|PDB:2CQ0}.; STRAND 265 272 {ECO:0000244|PDB:2CQ0}.; STRAND 274 276 {ECO:0000244|PDB:2CQ0}.; STRAND 278 289 {ECO:0000244|PDB:2CQ0}.; STRAND 311 316 {ECO:0000244|PDB:2CQ0}.,TURN 260 262 {ECO:0000244|PDB:2CQ0}.; TURN 300 302 {ECO:0000244|PDB:2CQ0}.,DOMAIN 239 317 RRM. {ECO:0000255|HAMAP-Rule:MF_03006}.,,,,,1.5625,-0.808,35.62,68.3,69.3Q13347,EIF3I_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit I (eIF3i) (Eukaryotic translation initiation factor 3 subunit 2) (TGF-beta receptor-interacting protein 1) (TRIP-1) (eIF-3-beta) (eIF3 p36),EIF3I EIF3S2 TRIP1,Homo sapiens (Human),325,GO:0044267; GO:0005829; GO:0016282; GO:0033290; GO:0005852; GO:0071541; GO:0070062; GO:0001731; GO:0010467; GO:0006446; GO:0006412; GO:0003743; GO:0006413,8668;,MKPILLQGHERSITQIKYNREGDLLFTVAKDPIVNVWYSVNGERLGTYMGHTGAVWCVDADWDTKHVLTGSADNSCRLWDCETGKQLALLKTNSAVRTCGFDFGGNIIMFSTDKQMGYQCFVSFFDLRDPSQIDNNEPYMKIPCNDSKITSAVWGPLGECIIAGHESGELNQYSAKSGEVLVNVKEHSRQINDIQLSRDMTMFVTASKDNTAKLFDSTTLEHQKTFRTERPVNSAALSPNYDHVVLGGGQEAMDVTTTSTRIGKFEARFFHLAFEEEFGRVKGHFGPINSVAFHPDGKSYSSGGEDGYVRIHYFDPQYFEFEFEA,,,,PF00400;,hsa:8668;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. {ECO:0000255|HAMAP-Rule:MF_03008, ECO:0000269|PubMed:14519125, ECO:0000269|PubMed:14688252, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:18599441}.",,,,,,,,,2.153846154,-0.416,36.51,117,118Q9Y262,EIF3L_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit L (eIF3l) (Eukaryotic translation initiation factor 3 subunit 6-interacting protein) (Eukaryotic translation initiation factor 3 subunit E-interacting protein),EIF3L EIF3EIP EIF3S6IP HSPC021 HSPC025 MSTP005,Homo sapiens (Human),564,GO:0016282; GO:0033290; GO:0005852; GO:0001731; GO:0016020; GO:0044822; GO:0006446; GO:0003743; GO:0006413,51386;,MSYPADDYESEAAYDPYAYPSDYDMHTGDPKQDLAYERQYEQQTYQVIPEVIKNFIQYFHKTVSDLIDQKVYELQASRVSSDVIDQKVYEIQDIYENSWTKLTERFFKNTPWPEAEAIAPQVGNDAVFLILYKELYYRHIYAKVSGGPSLEQRFESYYNYCNLFNYILNADGPAPLELPNQWLWDIIDEFIYQFQSFSQYRCKTAKKSEEEIDFLRSNPKIWNVHSVLNVLHSLVDKSNINRQLEVYTSGGDPESVAGEYGRHSLYKMLGYFSLVGLLRLHSLLGDYYQAIKVLENIELNKKSMYSRVPECQVTTYYYVGFAYLMMRRYQDAIRVFANILLYIQRTKSMFQRTTYKYEMINKQNEQMHALLAIALTMYPMRIDESIHLQLREKYGDKMLRMQKGDPQVYEELFSYSCPKFLSPVVPNYDNVHPNYHKEPFLQQLKVFSDEVQQQAQLSTIRSFLKLYTTMPVAKLAGFLDLTEQEFRIQLLVFKHKMKNLVWTSGISALDGEFQSASEVDFYIDKDMIHIADTKVARRYGDFFIRQIHKFEELNRTLKKMGQRP,,,,PF10255;,hsa:51386;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. Interacts with RRN3. {ECO:0000255|HAMAP-Rule:MF_03011}.",,,,,,,,,0.709219858,-0.472,66.74,36,37Q7L2H7,EIF3M_HUMAN,reviewed,Eukaryotic translation initiation factor 3 subunit M (eIF3m) (Fetal lung protein B5) (hFL-B5) (PCI domain-containing protein 1),EIF3M HFLB5 PCID1 GA17 PNAS-125,Homo sapiens (Human),374,GO:0002183; GO:0016282; GO:0033290; GO:0005852; GO:0071541; GO:0001731; GO:0006446; GO:0003743; GO:0006413,10480;,MSVPAFIDISEEDQAAELRAYLKSKGAEISEENSEGGLHVDLAQIIEACDVCLKEDDKDVESVMNSVVSLLLILEPDKQEALIESLCEKLVKFREGERPSLRLQLLSNLFHGMDKNTPVRYTVYCSLIKVAASCGAIQYIPTELDQVRKWISDWNLTTEKKHTLLRLLYEALVDCKKSDAASKVMVELLGSYTEDNASQARVDAHRCIVRALKDPNAFLFDHLLTLKPVKFLEGELIHDLLTIFVSAKLASYVKFYQNNKDFIDSLGLLHEQNMAKMRLLTFMGMAVENKEISFDTMQQELQIGADDVEAFVIDAVRTKMVYCKIDQTQRKVVVSHSTHRTFGKQQWQQLYDTLNAWKQNLNKVKNSLLSLSDT,,,,PF01399;,hsa:10480;,,,"SUBUNIT: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and EIF3M. The eIF-3 complex appears to include 3 stable modules: module A is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D, EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and EIF3H of module B, thereby linking the three modules. EIF3J is a labile subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex interacts with RPS6KB1 under conditions of nutrient depletion. Mitogenic stimulation leads to binding and activation of a complex composed of MTOR and RPTOR, leading to phosphorylation and release of RPS6KB1 and binding of EIF4B to eIF-3. {ECO:0000255|HAMAP-Rule:MF_03012, ECO:0000269|PubMed:15601822, ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:17322308, ECO:0000269|PubMed:17403899, ECO:0000269|PubMed:18599441}.",,,,DOMAIN 235 336 PCI. {ECO:0000255|HAMAP-Rule:MF_03012}.,,,,,2.139037433,-0.184,42.51,41.8,42.8P60842,IF4A1_HUMAN,reviewed,Eukaryotic initiation factor 4A-I (eIF-4A-I) (eIF4A-I) (EC 3.6.4.13) (ATP-dependent RNA helicase eIF4A-1),EIF4A1 DDX2A EIF4A,Homo sapiens (Human),406,GO:0005524; GO:0008026; GO:0000339; GO:0016070; GO:0044267; GO:0019221; GO:0005829; GO:0003725; GO:0016281; GO:0070062; GO:0010467; GO:0004386; GO:0003729; GO:0016071; GO:0016020; GO:0000288; GO:0000289; GO:0031100; GO:0044822; GO:0006412; GO:0008135; GO:0003743; GO:0006413; GO:0016032,1973;,MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI,,,,PF00270;PF00271;,hsa:1973;,,,"SUBUNIT: eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with PAIP1, EIF4E and UPF2. Found in a complex with XPO7, EIF4A1, ARHGAP1, VPS26A, VPS29, VPS35 and SFN. May interact with NOM1. Interacts with PDCD4; this interferes with the interaction between EIF4A and EIF4G. Interacts with RBM4. Interacts with human cytomegalovirus/HHV-5 protein UL69. {ECO:0000269|PubMed:11073994, ECO:0000269|PubMed:11408474, ECO:0000269|PubMed:15282546, ECO:0000269|PubMed:17284590, ECO:0000269|PubMed:19153607, ECO:0000269|PubMed:19204291, ECO:0000269|PubMed:20133758, ECO:0000269|PubMed:9548260}.",HELIX 34 36 {ECO:0000244|PDB:2G9N}.; HELIX 41 50 {ECO:0000244|PDB:2G9N}.; HELIX 57 68 {ECO:0000244|PDB:2G9N}.; HELIX 82 93 {ECO:0000244|PDB:2G9N}.; HELIX 110 123 {ECO:0000244|PDB:2G9N}.; HELIX 141 148 {ECO:0000244|PDB:2G9N}.; HELIX 159 167 {ECO:0000244|PDB:2G9N}.; HELIX 184 189 {ECO:0000244|PDB:2G9N}.; HELIX 193 202 {ECO:0000244|PDB:2G9N}.; HELIX 218 227 {ECO:0000244|PDB:2G9N}.; HELIX 256 269 {ECO:0000244|PDB:2ZU6}.; HELIX 282 290 {ECO:0000244|PDB:2ZU6}.; HELIX 312 316 {ECO:0000244|PDB:2ZU6}.; HELIX 318 320 {ECO:0000244|PDB:2ZU6}.; HELIX 330 333 {ECO:0000244|PDB:2ZU6}.; HELIX 338 340 {ECO:0000244|PDB:3EIQ}.; HELIX 355 360 {ECO:0000244|PDB:2ZU6}.; HELIX 378 391 {ECO:0000244|PDB:2ZU6}.,STRAND 23 25 {ECO:0000244|PDB:2ZU6}.; STRAND 72 75 {ECO:0000244|PDB:2G9N}.; STRAND 103 106 {ECO:0000244|PDB:2G9N}.; STRAND 131 134 {ECO:0000244|PDB:2G9N}.; STRAND 153 157 {ECO:0000244|PDB:2G9N}.; STRAND 178 182 {ECO:0000244|PDB:2G9N}.; STRAND 208 214 {ECO:0000244|PDB:2G9N}.; STRAND 232 235 {ECO:0000244|PDB:2G9N}.; STRAND 241 243 {ECO:0000244|PDB:2ZU6}.; STRAND 246 251 {ECO:0000244|PDB:2ZU6}.; STRAND 273 278 {ECO:0000244|PDB:2ZU6}.; STRAND 300 302 {ECO:0000244|PDB:3EIQ}.; STRAND 321 323 {ECO:0000244|PDB:2ZU6}.; STRAND 325 328 {ECO:0000244|PDB:2ZU6}.; STRAND 342 348 {ECO:0000244|PDB:2ZU6}.; STRAND 370 375 {ECO:0000244|PDB:2ZU6}.,TURN 124 128 {ECO:0000244|PDB:2G9N}.; TURN 190 192 {ECO:0000244|PDB:3EIQ}.; TURN 291 296 {ECO:0000244|PDB:2ZU6}.; TURN 364 366 {ECO:0000244|PDB:2ZU6}.,DOMAIN 63 234 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 245 406 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.,,,,,0.985221675,-0.261,46.16,188,189P38919,IF4A3_HUMAN,reviewed,"Eukaryotic initiation factor 4A-III (eIF-4A-III) (eIF4A-III) (EC 3.6.4.13) (ATP-dependent RNA helicase DDX48) (ATP-dependent RNA helicase eIF4A-3) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Eukaryotic translation initiation factor 4A isoform 3) (Nuclear matrix protein 265) (NMP 265) (hNMP 265) [Cleaved into: Eukaryotic initiation factor 4A-III, N-terminally processed]",EIF4A3 DDX48 KIAA0111,Homo sapiens (Human),411,GO:0005524; GO:0006200; GO:0004004; GO:0016070; GO:0071013; GO:0019221; GO:0005737; GO:0005829; GO:0048701; GO:0035145; GO:0010467; GO:0003729; GO:0016071; GO:0000398; GO:0051028; GO:0016020; GO:0017148; GO:0016607; GO:0000288; GO:0000184; GO:0000289; GO:0005654; GO:0044822; GO:0008143; GO:0045727; GO:0006364,9775;,MATTATMATSGSARKRLLKEEDMTKVEFETSEEVDVTPTFDTMGLREDLLRGIYAYGFEKPSAIQQRAIKQIIKGRDVIAQSQSGTGKTATFSISVLQCLDIQVRETQALILAPTRELAVQIQKGLLALGDYMNVQCHACIGGTNVGEDIRKLDYGQHVVAGTPGRVFDMIRRRSLRTRAIKMLVLDEADEMLNKGFKEQIYDVYRYLPPATQVVLISATLPHEILEMTNKFMTDPIRILVKRDELTLEGIKQFFVAVEREEWKFDTLCDLYDTLTITQAVIFCNTKRKVDWLTEKMREANFTVSSMHGDMPQKERESIMKEFRSGASRVLISTDVWARGLDVPQVSLIINYDLPNNRELYIHRIGRSGRYGRKGVAINFVKNDDIRILRDIEQYYSTQIDEMPMNVADLI,"DISEASE: Richieri-Costa-Pereira syndrome (RCPS) [MIM:268305]: A syndrome characterized by a unique pattern of anomalies consisting of microstomia, micrognathia, abnormal fusion of mandible, cleft palate/Robin sequence, absence of central lower incisors, minor ears anomalies, hypoplastic first ray, abnormal tibiae, hypoplastic halluces, and clubfeet. Learning disability is also a common finding. {ECO:0000269|PubMed:24360810}. Note=The disease is caused by mutations affecting the gene represented in this entry. EIF4A3 mutations resulting in Richieri-Costa-Pereira syndrome include a repeat expansion of 18 or 20 nucleotides in the 5' untranslated region. Affected individuals have 14 to 16 repeats, while healthy individuals have 3 to 12 repeats (PubMed:24360810). {ECO:0000269|PubMed:24360810}.",,,PF00270;PF00271;,hsa:9775;,,,"SUBUNIT: Part of the mRNA splicing-dependent exon junction complex (EJC) complex; the core complex contains CASC3, EIF4A3, MAGOH and RBM8A. Interacts with CASC3, MAGOH, NXF1, RBM8A and ALYREF/THOC4. Identified in the spliceosome C complex. May interact with NOM1. Interacts with POLDIP3. Interacts with CWC22 and PRPF19 in an RNA-independent manner. Direct interaction with CWC22 is mediated by the helicase C-terminal domain. Full interaction with CWC22 occurs only when EIF4A3 is not part of the EJC and prevents EIF4A3 binding to RNA. {ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:14730019, ECO:0000269|PubMed:15034551, ECO:0000269|PubMed:16170325, ECO:0000269|PubMed:16314458, ECO:0000269|PubMed:16495234, ECO:0000269|PubMed:18423201, ECO:0000269|PubMed:22959432, ECO:0000269|PubMed:22961380, ECO:0000269|PubMed:23236153}.",HELIX 23 25 {ECO:0000244|PDB:4C9B}.; HELIX 40 42 {ECO:0000244|PDB:4C9B}.; HELIX 47 56 {ECO:0000244|PDB:4C9B}.; HELIX 65 73 {ECO:0000244|PDB:4C9B}.; HELIX 88 98 {ECO:0000244|PDB:4C9B}.; HELIX 116 129 {ECO:0000244|PDB:4C9B}.; HELIX 143 145 {ECO:0000244|PDB:4C9B}.; HELIX 146 155 {ECO:0000244|PDB:4C9B}.; HELIX 164 172 {ECO:0000244|PDB:4C9B}.; HELIX 189 195 {ECO:0000244|PDB:4C9B}.; HELIX 198 206 {ECO:0000244|PDB:4C9B}.; HELIX 223 232 {ECO:0000244|PDB:4C9B}.; HELIX 243 245 {ECO:0000244|PDB:2J0S}.; HELIX 261 263 {ECO:0000244|PDB:4C9B}.; HELIX 264 274 {ECO:0000244|PDB:4C9B}.; HELIX 287 299 {ECO:0000244|PDB:4C9B}.; HELIX 313 324 {ECO:0000244|PDB:4C9B}.; HELIX 335 337 {ECO:0000244|PDB:2J0S}.; HELIX 360 365 {ECO:0000244|PDB:4C9B}.; HELIX 370 372 {ECO:0000244|PDB:2J0S}.; HELIX 383 385 {ECO:0000244|PDB:4C9B}.; HELIX 386 396 {ECO:0000244|PDB:4C9B}.; HELIX 405 410 {ECO:0000244|PDB:4C9B}.,STRAND 28 32 {ECO:0000244|PDB:4C9B}.; STRAND 78 81 {ECO:0000244|PDB:4C9B}.; STRAND 84 86 {ECO:0000244|PDB:2HXY}.; STRAND 102 104 {ECO:0000244|PDB:2J0U}.; STRAND 109 112 {ECO:0000244|PDB:4C9B}.; STRAND 137 139 {ECO:0000244|PDB:4C9B}.; STRAND 158 162 {ECO:0000244|PDB:4C9B}.; STRAND 183 186 {ECO:0000244|PDB:4C9B}.; STRAND 213 219 {ECO:0000244|PDB:4C9B}.; STRAND 237 241 {ECO:0000244|PDB:4C9B}.; STRAND 251 260 {ECO:0000244|PDB:4C9B}.; STRAND 278 283 {ECO:0000244|PDB:4C9B}.; STRAND 304 307 {ECO:0000244|PDB:4C9B}.; STRAND 309 311 {ECO:0000244|PDB:2J0U}.; STRAND 329 333 {ECO:0000244|PDB:4C9B}.; STRAND 338 340 {ECO:0000244|PDB:2J0S}.; STRAND 346 353 {ECO:0000244|PDB:4C9B}.; STRAND 356 358 {ECO:0000244|PDB:4C9B}.; STRAND 367 369 {ECO:0000244|PDB:4C9B}.; STRAND 375 382 {ECO:0000244|PDB:4C9B}.; STRAND 400 402 {ECO:0000244|PDB:2HYI}.,TURN 130 134 {ECO:0000244|PDB:4C9B}.,DOMAIN 69 239 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 250 411 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.,,,,,1.216545012,-0.258,46.88,33.3,34.3O43432,IF4G3_HUMAN,reviewed,Eukaryotic translation initiation factor 4 gamma 3 (eIF-4-gamma 3) (eIF-4G 3) (eIF4G 3) (eIF-4-gamma II) (eIF4GII),EIF4G3,Homo sapiens (Human),1585,GO:0000339; GO:0019221; GO:0005829; GO:0016281; GO:0044822; GO:0060903; GO:0001934; GO:0045727; GO:0006446; GO:0007283; GO:0008135; GO:0003743; GO:0016032,8672;,MNSQPQTRSPFFQRPQIQPPRATIPNSSPSIRPGAQTPTAVYQANQHIMMVNHLPMPYPVPQGPQYCIPQYRHSGPPYVGPPQQYPVQPPGPGPFYPGPGPGDFPNAYGTPFYPSQPVYQSAPIIVPTQQQPPPAKREKKTIRIRDPNQGGKDITEEIMSGGGSRNPTPPIGRPTSTPTPPQQLPSQVPEHSPVVYGTVESAHLAASTPVTAASDQKQEEKPKPDPVLKSPSPVLRLVLSGEKKEQEGQTSETTAIVSIAELPLPPSPTTVSSVARSTIAAPTSSALSSQPIFTTAIDDRCELSSPREDTIPIPSLTSCTETSDPLPTNENDDDICKKPCSVAPNDIPLVSSTNLINEINGVSEKLSATESIVEIVKQEVLPLTLELEILENPPEEMKLECIPAPITPSTVPSFPPTPPTPPASPPHTPVIVPAAATTVSSPSAAITVQRVLEEDESIRTCLSEDAKEIQNKIEVEADGQTEEILDSQNLNSRRSPVPAQIAITVPKTWKKPKDRTRTTEEMLEAELELKAEEELSIDKVLESEQDKMSQGFHPERDPSDLKKVKAVEENGEEAEPVRNGAESVSEGEGIDANSGSTDSSGDGVTFPFKPESWKPTDTEGKKQYDREFLLDFQFMPACIQKPEGLPPISDVVLDKINQPKLPMRTLDPRILPRGPDFTPAFADFGRQTPGGRGVPLLNVGSRRSQPGQRREPRKIITVSVKEDVHLKKAENAWKPSQKRDSQADDPENIKTQELFRKVRSILNKLTPQMFNQLMKQVSGLTVDTEERLKGVIDLVFEKAIDEPSFSVAYANMCRCLVTLKVPMADKPGNTVNFRKLLLNRCQKEFEKDKADDDVFEKKQKELEAASAPEERTRLHDELEEAKDKARRRSIGNIKFIGELFKLKMLTEAIMHDCVVKLLKNHDEESLECLCRLLTTIGKDLDFEKAKPRMDQYFNQMEKIVKERKTSSRIRFMLQDVIDLRLCNWVSRRADQGPKTIEQIHKEAKIEEQEEQRKVQQLMTKEKRRPGVQRVDEGGWNTVQGAKNSRVLDPSKFLKITKPTIDEKIQLVPKAQLGSWGKGSSGGAKASETDALRSSASSLNRFSALQPPAPSGSTPSTPVEFDSRRTLTSRGSMGREKNDKPLPSATARPNTFMRGGSSKDLLDNQSQEEQRREMLETVKQLTGGVDVERNSTEAERNKTRESAKPEISAMSAHDKAALSEEELERKSKSIIDEFLHINDFKEAMQCVEELNAQGLLHVFVRVGVESTLERSQITRDHMGQLLYQLVQSEKLSKQDFFKGFSETLELADDMAIDIPHIWLYLAELVTPMLKEGGISMRELTIEFSKPLLPVGRAGVLLSEILHLLCKQMSHKKVGALWREADLSWKDFLPEGEDVHNFLLEQKLDFIESDSPCSSEALSKKELSAEELYKRLEKLIIEDKANDEQIFDWVEANLDEIQMSSPTFLRALMTAVCKAAIIADSSTFRVDTAVIKQRVPILLKYLDSDTEKELQALYALQASIVKLDQPANLLRMFFDCLYDEEVISEDAFYKWESSKDPAEQNGKGVALKSVTAFFTWLREAEEESEDN,,,,PF02847;PF02854;PF02020;,hsa:8672;,,,"SUBUNIT: Interacts with EIF4A, EIF4E, eIF3 and PABPC1. Part of a complex with EIF4E. eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. EIF4G1/EIF4G3 interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate eIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIFG3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA (By similarity). {ECO:0000250}.",HELIX 746 762 {ECO:0000244|PDB:1HU3}.; HELIX 770 777 {ECO:0000244|PDB:1HU3}.; HELIX 785 801 {ECO:0000244|PDB:1HU3}.; HELIX 803 805 {ECO:0000244|PDB:1HU3}.; HELIX 806 816 {ECO:0000244|PDB:1HU3}.; HELIX 833 848 {ECO:0000244|PDB:1HU3}.; HELIX 885 900 {ECO:0000244|PDB:1HU3}.; HELIX 907 919 {ECO:0000244|PDB:1HU3}.; HELIX 923 940 {ECO:0000244|PDB:1HU3}.; HELIX 946 961 {ECO:0000244|PDB:1HU3}.; HELIX 967 981 {ECO:0000244|PDB:1HU3}.,,TURN 901 903 {ECO:0000244|PDB:1HU3}.; TURN 943 945 {ECO:0000244|PDB:1HU3}.; TURN 982 984 {ECO:0000244|PDB:1HU3}.,DOMAIN 755 983 MIF4G. {ECO:0000255|PROSITE-ProRule:PRU00698}.; DOMAIN 1221 1343 MI. {ECO:0000255|PROSITE-ProRule:PRU00698}.; DOMAIN 1416 1585 W2. {ECO:0000255|PROSITE-ProRule:PRU00695}.,,,,,1.261829653,-0.613,176.68,3.6,4.6P07814,SYEP_HUMAN,reviewed,Bifunctional glutamate/proline--tRNA ligase (Bifunctional aminoacyl-tRNA synthetase) (Cell proliferation-inducing gene 32 protein) (Glutamatyl-prolyl-tRNA synthetase) [Includes: Glutamate--tRNA ligase (EC 6.1.1.17) (Glutamyl-tRNA synthetase) (GluRS); Proline--tRNA ligase (EC 6.1.1.15) (Prolyl-tRNA synthetase)],EPRS GLNS PARS QARS QPRS PIG32,Homo sapiens (Human),1512,GO:0005524; GO:0097452; GO:0035613; GO:0071346; GO:0005737; GO:0005829; GO:0010467; GO:0004818; GO:0006424; GO:0016020; GO:0017148; GO:0004827; GO:0006433; GO:0006461; GO:0030529; GO:0006418,2058;,MATLSLTVNSGDPPLGALLAVEHVKDDVSISVEEGKENILHVSENVIFTDVNSILRYLARVATTAGLYGSNLMEHTEIDHWLEFSATKLSSCDSFTSTINELNHCLSLRTYLVGNSLSLADLCVWATLKGNAAWQEQLKQKKAPVHVKRWFGFLEAQQAFQSVGTKWDVSTTKARVAPEKKQDVGKFVELPGAEMGKVTVRFPPEASGYLHIGHAKAALLNQHYQVNFKGKLIMRFDDTNPEKEKEDFEKVILEDVAMLHIKPDQFTYTSDHFETIMKYAEKLIQEGKAYVDDTPAEQMKAEREQRIDSKHRKNPIEKNLQMWEEMKKGSQFGQSCCLRAKIDMSSNNGCMRDPTLYRCKIQPHPRTGNKYNVYPTYDFACPIVDSIEGVTHALRTTEYHDRDEQFYWIIEALGIRKPYIWEYSRLNLNNTVLSKRKLTWFVNEGLVDGWDDPRFPTVRGVLRRGMTVEGLKQFIAAQGSSRSVVNMEWDKIWAFNKKVIDPVAPRYVALLKKEVIPVNVPEAQEEMKEVAKHPKNPEVGLKPVWYSPKVFIEGADAETFSEGEMVTFINWGNLNITKIHKNADGKIISLDAKLNLENKDYKKTTKVTWLAETTHALPIPVICVTYEHLITKPVLGKDEDFKQYVNKNSKHEELMLGDPCLKDLKKGDIIQLQRRGFFICDQPYEPVSPYSCKEAPCVLIYIPDGHTKEMPTSGSKEKTKVEATKNETSAPFKERPTPSLNNNCTTSEDSLVLYNRVAVQGDVVRELKAKKAPKEDVDAAVKQLLSLKAEYKEKTGQEYKPGNPPAEIGQNISSNSSASILESKSLYDEVAAQGEVVRKLKAEKSPKAKINEAVECLLSLKAQYKEKTGKEYIPGQPPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQGEVVRKLKTEKAPKDQVDIAVQELLQLKAQYKSLIGVEYKPVSATGAEDKDKKKKEKENKSEKQNKPQKQNDGQRKDPSKNQGGGLSSSGAGEGQGPKKQTRLGLEAKKEENLADWYSQVITKSEMIEYHDISGCYILRPWAYAIWEAIKDFFDAEIKKLGVENCYFPMFVSQSALEKEKTHVADFAPEVAWVTRSGKTELAEPIAIRPTSETVMYPAYAKWVQSHRDLPIKLNQWCNVVRWEFKHPQPFLRTREFLWQEGHSAFATMEEAAEEVLQILDLYAQVYEELLAIPVVKGRKTEKEKFAGGDYTTTIEAFISASGRAIQGGTSHHLGQNFSKMFEIVFEDPKIPGEKQFAYQNSWGLTTRTIGVMTMVHGDNMGLVLPPRVACVQVVIIPCGITNALSEEDKEALIAKCNDYRRRLLSVNIRVRADLRDNYSPGWKFNHWELKGVPIRLEVGPRDMKSCQFVAVRRDTGEKLTVAENEAETKLQAILEDIQVTLFTRASEDLKTHMVVANTMEDFQKILDSGKIVQIPFCGEIDCEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCVCGKNPAKYYTLFGRSY,,,DOMAIN: The WHEP-TRS domain is involved in RNA binding.,PF14497;PF03129;PF09180;PF00749;PF03950;PF00587;PF00458;,hsa:2058;,,,"SUBUNIT: Component of the multisynthetase complex which is comprised of a bifunctional glutamyl-prolyl-tRNA synthetase, the monospecific isoleucyl, leucyl, glutaminyl, methionyl, lysyl, arginyl, and aspartyl-tRNA synthetases as well as three auxiliary proteins, p18, p48 and p43. Interacts with DUS2L. Component of the GAIT complex; in humans the complex assembly seems to be a two-step process in which EPRS first associates with SYNCRIP to form a pre-GAIT complex which is deficient in GAIT element binding. {ECO:0000269|PubMed:15479637, ECO:0000269|PubMed:15994936, ECO:0000269|PubMed:19647514}.",HELIX 750 769 {ECO:0000244|PDB:1FYJ}.; HELIX 774 795 {ECO:0000244|PDB:1FYJ}.; HELIX 1024 1034 {ECO:0000244|PDB:4HVC}.; HELIX 1051 1070 {ECO:0000244|PDB:4HVC}.; HELIX 1084 1087 {ECO:0000244|PDB:4HVC}.; HELIX 1095 1100 {ECO:0000244|PDB:4HVC}.; HELIX 1123 1133 {ECO:0000244|PDB:4HVC}.; HELIX 1137 1139 {ECO:0000244|PDB:4HVC}.; HELIX 1179 1198 {ECO:0000244|PDB:4HVC}.; HELIX 1247 1252 {ECO:0000244|PDB:4HVC}.; HELIX 1278 1287 {ECO:0000244|PDB:4HVC}.; HELIX 1317 1336 {ECO:0000244|PDB:4HVC}.; HELIX 1351 1360 {ECO:0000244|PDB:4HVC}.; HELIX 1371 1376 {ECO:0000244|PDB:4HVC}.; HELIX 1394 1396 {ECO:0000244|PDB:4HVC}.; HELIX 1397 1423 {ECO:0000244|PDB:4HVC}.; HELIX 1430 1438 {ECO:0000244|PDB:4HVC}.; HELIX 1451 1462 {ECO:0000244|PDB:4HVC}.,STRAND 1038 1040 {ECO:0000244|PDB:4HVC}.; STRAND 1042 1045 {ECO:0000244|PDB:4K86}.; STRAND 1047 1049 {ECO:0000244|PDB:4HVC}.; STRAND 1080 1083 {ECO:0000244|PDB:4HVC}.; STRAND 1102 1107 {ECO:0000244|PDB:4HVC}.; STRAND 1110 1118 {ECO:0000244|PDB:4HVC}.; STRAND 1120 1122 {ECO:0000244|PDB:4HVC}.; STRAND 1142 1151 {ECO:0000244|PDB:4HVC}.; STRAND 1165 1178 {ECO:0000244|PDB:4HVC}.; STRAND 1206 1209 {ECO:0000244|PDB:4HVC}.; STRAND 1219 1229 {ECO:0000244|PDB:4HVC}.; STRAND 1234 1245 {ECO:0000244|PDB:4HVC}.; STRAND 1255 1257 {ECO:0000244|PDB:4HVC}.; STRAND 1261 1264 {ECO:0000244|PDB:4K86}.; STRAND 1265 1267 {ECO:0000244|PDB:4HVC}.; STRAND 1269 1276 {ECO:0000244|PDB:4HVC}.; STRAND 1303 1308 {ECO:0000244|PDB:4HVC}.; STRAND 1313 1315 {ECO:0000244|PDB:4K87}.; STRAND 1341 1343 {ECO:0000244|PDB:4HVC}.; STRAND 1347 1349 {ECO:0000244|PDB:4HVC}.; STRAND 1364 1369 {ECO:0000244|PDB:4HVC}.; STRAND 1378 1383 {ECO:0000244|PDB:4HVC}.; STRAND 1389 1393 {ECO:0000244|PDB:4HVC}.; STRAND 1424 1426 {ECO:0000244|PDB:4HVC}.; STRAND 1442 1447 {ECO:0000244|PDB:4HVC}.; STRAND 1477 1484 {ECO:0000244|PDB:4HVC}.; STRAND 1498 1501 {ECO:0000244|PDB:4K87}.; STRAND 1504 1509 {ECO:0000244|PDB:4HVC}.,TURN 1020 1022 {ECO:0000244|PDB:4HVC}.; TURN 1088 1090 {ECO:0000244|PDB:4K86}.; TURN 1160 1162 {ECO:0000244|PDB:4HVC}.; TURN 1212 1214 {ECO:0000244|PDB:4HVC}.; TURN 1230 1233 {ECO:0000244|PDB:4HVC}.; TURN 1297 1299 {ECO:0000244|PDB:4HVC}.; TURN 1384 1386 {ECO:0000244|PDB:4HVC}.,DOMAIN 749 805 WHEP-TRS 1.; DOMAIN 822 878 WHEP-TRS 2.; DOMAIN 900 956 WHEP-TRS 3.,,,,,1.851851852,-0.517,170.62,87.7,88.7O94905,ERLN2_HUMAN,reviewed,Erlin-2 (Endoplasmic reticulum lipid raft-associated protein 2) (Stomatin-prohibitin-flotillin-HflC/K domain-containing protein 2) (SPFH domain-containing protein 2),ERLIN2 C8orf2 SPFH2 UNQ2441/PRO5003/PRO9924,Homo sapiens (Human),339,GO:0030433; GO:0005737; GO:0005783; GO:0005789; GO:0070062; GO:0016021; GO:0005886; GO:0043234,11160;,MAQLGAVVAVASSFFCASLFSAVHKIEEGHIGVYYRGGALLTSTSGPGFHLMLPFITSYKSVQTTLQTDEVKNVPCGTSGGVMIYFDRIEVVNFLVPNAVYDIVKNYTADYDKALIFNKIHHELNQFCSVHTLQEVYIELFDQIDENLKLALQQDLTSMAPGLVIQAVRVTKPNIPEAIRRNYELMESEKTKLLIAAQKQKVVEKEAETERKKALIEAEKVAQVAEITYGQKVMEKETEKKISEIEDAAFLAREKAKADAECYTAMKIAEANKLKLTPEYLQLMKYKAIASNSKIYFGKDIPNMFMDSAGSVSKQFEGLADKLSFGLEDEPLETATKEN,"DISEASE: Spastic paraplegia 18, autosomal recessive (SPG18) [MIM:611225]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG18 is a severe form with onset in early childhood. Most affected individuals have severe psychomotor retardation. Some may develop significant joint contractures. {ECO:0000269|PubMed:21330303}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF01145;,hsa:11160;,,,"SUBUNIT: Interacts with activated ITPR1, independently of the degree of ITPR1 polyubiquitination (By similarity). Forms a heteromeric complex with ERLIN1. In complex with ERLIN1, interacts with RNF170. {ECO:0000250, ECO:0000269|PubMed:19240031, ECO:0000269|PubMed:21610068}.",,,,,,,,,1.179941003,-0.163,37.85,11.5,12.5Q9NZB2,F120A_HUMAN,reviewed,Constitutive coactivator of PPAR-gamma-like protein 1 (Oxidative stress-associated Src activator) (Protein FAM120A),FAM120A C9orf10 KIAA0183 OSSA,Homo sapiens (Human),1118,GO:0005737; GO:0016020; GO:0005886; GO:0044822,23196;,MGVQGFQDYIEKHCPSAVVPVELQKLARGSLVGGGRQRPPQTPLRLLVDADNCLHRLYGGFYTDWVSGGQWNHMLGYLAALAKACFGGNIELFVFFNGALEKARLHEWVKRQGNERQTAQQIVSHVQNKGTPPPKVWFLPPVCMAHCIRLALIRFHVKVAQSIEDHHQEVIGFCRENGFHGLVAYDSDYALCNIPYYFSAHALKLSRNGKSLTTSQYLMHEVAKQLDLNPNRFPIFAALLGNHILPDEDLASFHWSLLGPEHPLASLKVRAHQLVLPPCDVVIKAVADYVRNIQDTSDLDAIAKDVFQHSQSRTDDKVIRFKRAIGYYSATSKPMSFHPPHYLAARPGPFGMPGMVPPHVPPQMLNIPQTSLQAKPVAPQVPSPGGAPGQGPYPYSLSEPAPLTLDTSGKNLTEQNSYSNIPHEGKHTPLYERSSPINPAQSGSPNHVDSAYFPGSSTSSSSDNDEGSGGATNHISGNKIGWEKTGSHSEPQARGDPGDQTKAEGSSTASSGSQLAEGKGSQMGTVQPIPCLLSMPTRNHMDITTPPLPPVAPEVLRVAEHRHKKGLMYPYIFHVLTKGEIKIAVSIEDEANKDLPPAALLYRPVRQYVYGVLFSLAESRKKTERLAFRKNRLPPEFSPVIIKEWAAYKGKSPQTPELVEALAFREWTCPNLKRLWLGKAVEDKNRRMRAFLACMRSDTPAMLNPANVPTHLMVLCCVLRYMVQWPGARILRRQELDAFLAQALSPKLYEPDQLQELKIENLDPRGIQLSALFMSGVDMALFANDACGQPIPWEHCCPWMYFDGKLFQSKLLKASREKTPLIDLCDGQADQAAKVEKMRQSVLEGLSFSRQSHTLPFPPPPALPFYPASAYPRHFGPVPPSQGRGRGFAGVCGFGGPYGETVATGPYRAFRVAAASGHCGAFSGSDSSRTSKSQGGVQPIPSQGGKLEIAGTVVGHWAGSRRGRGGRGPFPLQVVSVGGPARGRPRGVISTPVIRTFGRGGRYYGRGYKNQAAIQGRPPYAASAEEVAKELKSKSGESKSSAMSSDGSLAENGVMAEEKPAPQMNGSTGDARAPSHSESALNNDSKTCNTNPHLNALSTDSACRREAALEAAVLNKEE,,,,,hsa:23196;,,,"SUBUNIT: Interacts with PURA (By similarity). Interacts with YES1, SRC, FYN. Upon tyrosine phosphorylation, interacts with PIK3R1. {ECO:0000250, ECO:0000269|PubMed:19015244}.",,,,,,,,,1.878354204,-0.406,121.91,0.36,1.36P21333,FLNA_HUMAN,reviewed,Filamin-A (FLN-A) (Actin-binding protein 280) (ABP-280) (Alpha-filamin) (Endothelial actin-binding protein) (Filamin-1) (Non-muscle filamin),FLNA FLN FLN1,Homo sapiens (Human),2647,GO:0034988; GO:0031523; GO:0048365; GO:0017160; GO:0017048; GO:0051764; GO:0015629; GO:0031532; GO:0005884; GO:0051015; GO:0007195; GO:0097440; GO:0007596; GO:0034329; GO:0042384; GO:0030863; GO:0005737; GO:0051220; GO:0005829; GO:0043198; GO:0045022; GO:0001837; GO:0045184; GO:0005576; GO:0070062; GO:0005925; GO:0001948; GO:0042789; GO:0016020; GO:0042177; GO:0043433; GO:0043025; GO:0005634; GO:0048471; GO:0005886; GO:0030168; GO:0070527; GO:0002576; GO:0044822; GO:0043123; GO:0042993; GO:0042803; GO:0034394; GO:0050821; GO:0043113; GO:0004871; GO:0031267; GO:0090307; GO:0005802; GO:0008134,2316;,MSSSHSRAGQSAAGAAPGGGVDTRDAEMPATEKDLAEDAPWKKIQQNTFTRWCNEHLKCVSKRIANLQTDLSDGLRLIALLEVLSQKKMHRKHNQRPTFRQMQLENVSVALEFLDRESIKLVSIDSKAIVDGNLKLILGLIWTLILHYSISMPMWDEEEDEEAKKQTPKQRLLGWIQNKLPQLPITNFSRDWQSGRALGALVDSCAPGLCPDWDSWDASKPVTNAREAMQQADDWLGIPQVITPEEIVDPNVDEHSVMTYLSQFPKAKLKPGAPLRPKLNPKKARAYGPGIEPTGNMVKKRAEFTVETRSAGQGEVLVYVEDPAGHQEEAKVTANNDKNRTFSVWYVPEVTGTHKVTVLFAGQHIAKSPFEVYVDKSQGDASKVTAQGPGLEPSGNIANKTTYFEIFTAGAGTGEVEVVIQDPMGQKGTVEPQLEARGDSTYRCSYQPTMEGVHTVHVTFAGVPIPRSPYTVTVGQACNPSACRAVGRGLQPKGVRVKETADFKVYTKGAGSGELKVTVKGPKGEERVKQKDLGDGVYGFEYYPMVPGTYIVTITWGGQNIGRSPFEVKVGTECGNQKVRAWGPGLEGGVVGKSADFVVEAIGDDVGTLGFSVEGPSQAKIECDDKGDGSCDVRYWPQEAGEYAVHVLCNSEDIRLSPFMADIRDAPQDFHPDRVKARGPGLEKTGVAVNKPAEFTVDAKHGGKAPLRVQVQDNEGCPVEALVKDNGNGTYSCSYVPRKPVKHTAMVSWGGVSIPNSPFRVNVGAGSHPNKVKVYGPGVAKTGLKAHEPTYFTVDCAEAGQGDVSIGIKCAPGVVGPAEADIDFDIIRNDNDTFTVKYTPRGAGSYTIMVLFADQATPTSPIRVKVEPSHDASKVKAEGPGLSRTGVELGKPTHFTVNAKAAGKGKLDVQFSGLTKGDAVRDVDIIDHHDNTYTVKYTPVQQGPVGVNVTYGGDPIPKSPFSVAVSPSLDLSKIKVSGLGEKVDVGKDQEFTVKSKGAGGQGKVASKIVGPSGAAVPCKVEPGLGADNSVVRFLPREEGPYEVEVTYDGVPVPGSPFPLEAVAPTKPSKVKAFGPGLQGGSAGSPARFTIDTKGAGTGGLGLTVEGPCEAQLECLDNGDGTCSVSYVPTEPGDYNINILFADTHIPGSPFKAHVVPCFDASKVKCSGPGLERATAGEVGQFQVDCSSAGSAELTIEICSEAGLPAEVYIQDHGDGTHTITYIPLCPGAYTVTIKYGGQPVPNFPSKLQVEPAVDTSGVQCYGPGIEGQGVFREATTEFSVDARALTQTGGPHVKARVANPSGNLTETYVQDRGDGMYKVEYTPYEEGLHSVDVTYDGSPVPSSPFQVPVTEGCDPSRVRVHGPGIQSGTTNKPNKFTVETRGAGTGGLGLAVEGPSEAKMSCMDNKDGSCSVEYIPYEAGTYSLNVTYGGHQVPGSPFKVPVHDVTDASKVKCSGPGLSPGMVRANLPQSFQVDTSKAGVAPLQVKVQGPKGLVEPVDVVDNADGTQTVNYVPSREGPYSISVLYGDEEVPRSPFKVKVLPTHDASKVKASGPGLNTTGVPASLPVEFTIDAKDAGEGLLAVQITDPEGKPKKTHIQDNHDGTYTVAYVPDVTGRYTILIKYGGDEIPFSPYRVRAVPTGDASKCTVTVSIGGHGLGAGIGPTIQIGEETVITVDTKAAGKGKVTCTVCTPDGSEVDVDVVENEDGTFDIFYTAPQPGKYVICVRFGGEHVPNSPFQVTALAGDQPSVQPPLRSQQLAPQYTYAQGGQQTWAPERPLVGVNGLDVTSLRPFDLVIPFTIKKGEITGEVRMPSGKVAQPTITDNKDGTVTVRYAPSEAGLHEMDIRYDNMHIPGSPLQFYVDYVNCGHVTAYGPGLTHGVVNKPATFTVNTKDAGEGGLSLAIEGPSKAEISCTDNQDGTCSVSYLPVLPGDYSILVKYNEQHVPGSPFTARVTGDDSMRMSHLKVGSAADIPINISETDLSLLTATVVPPSGREEPCLLKRLRNGHVGISFVPKETGEHLVHVKKNGQHVASSPIPVVISQSEIGDASRVRVSGQGLHEGHTFEPAEFIIDTRDAGYGGLSLSIEGPSKVDINTEDLEDGTCRVTYCPTEPGNYIINIKFADQHVPGSPFSVKVTGEGRVKESITRRRRAPSVANVGSHCDLSLKIPEISIQDMTAQVTSPSGKTHEAEIVEGENHTYCIRFVPAEMGTHTVSVKYKGQHVPGSPFQFTVGPLGEGGAHKVRAGGPGLERAEAGVPAEFSIWTREAGAGGLAIAVEGPSKAEISFEDRKDGSCGVAYVVQEPGDYEVSVKFNEEHIPDSPFVVPVASPSGDARRLTVSSLQESGLKVNQPASFAVSLNGAKGAIDAKVHSPSGALEECYVTEIDQDKYAVRFIPRENGVYLIDVKFNGTHIPGSPFKIRVGEPGHGGDPGLVSAYGAGLEGGVTGNPAEFVVNTSNAGAGALSVTIDGPSKVKMDCQECPEGYRVTYTPMAPGSYLISIKYGGPYHIGGSPFKAKVTGPRLVSNHSLHETSSVFVDSLTKATCAPQHGAPGPGPADASKVVAKGLGLSKAYVGQKSSFTVDCSKAGNNMLLVGVHGPRTPCEEILVKHVGSRLYSVSYLLKDKGEYTLVVKWGDEHIPGSPYRVVVP,"DISEASE: Periventricular nodular heterotopia 1 (PVNH1) [MIM:300049]: A developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period. {ECO:0000269|PubMed:11532987, ECO:0000269|PubMed:11914408, ECO:0000269|PubMed:12410386, ECO:0000269|PubMed:15249610, ECO:0000269|PubMed:16299064}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Periventricular nodular heterotopia 4 (PVNH4) [MIM:300537]: A disorder characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood. {ECO:0000269|PubMed:15668422, ECO:0000269|PubMed:15994863}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Otopalatodigital syndrome 1 (OPD1) [MIM:311300]: X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum. {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:15940695}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Otopalatodigital syndrome 2 (OPD2) [MIM:304120]: Congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects. {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:17431908}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Frontometaphyseal dysplasia (FMD) [MIM:305620]: Congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies. {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:16596676}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Melnick-Needles syndrome (MNS) [MIM:309350]: Severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull. {ECO:0000269|PubMed:12612583}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Intestinal pseudoobstruction, neuronal, chronic idiopathic, X-linked (IPOX) [MIM:300048]: A disease characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion. {ECO:0000269|PubMed:17357080}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: FG syndrome 2 (FGS2) [MIM:300321]: FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation. {ECO:0000269|PubMed:17632775}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Terminal osseous dysplasia (TOD) [MIM:300244]: A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females. {ECO:0000269|PubMed:20598277}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]: A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets. {ECO:0000269|PubMed:17190868}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in FLNA may be a cause of macrothrombocytopenia, a disorder characterized by subnormal levels of blood platelets. Blood platelets are abnormally enlarged.; DISEASE: Congenital short bowel syndrome, X-linked (CSBSX) [MIM:300048]: A disease characterized by a shortened small intestine, and malabsorption. The mean length of the small intestine in affected individuals is approximately 50 cm, compared with a normal length at birth of 190-280 cm. It is associated with significant mortality and morbidity. Infants usually present with failure to thrive, recurrent vomiting, and diarrhea. {ECO:0000269|PubMed:23037936}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,"DOMAIN: Comprised of a NH2-terminal actin-binding domain, 24 immunoglobulin-like internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.",PF00307;PF00630;,hsa:2316;,,,"SUBUNIT: Homodimer. Interacts with PDLIM2 (By similarity). Interacts with FAM101A and FAM101B (By similarity). Interacts with FCGR1A, FLNB, FURIN, HSPB7, INPPL1, KCND2, MYOT, MYOZ1, ARHGAP24, PSEN1, PSEN2 and ECSCR. Interacts also with various other binding partners in addition to filamentous actin. Interacts (via N-terminus) with MIS18BP1 (via N-terminus). Interacts (via N-terminus) with TAF1B. Interacts with TMEM67 (via C-terminus) and MKS1. Interacts (via actin-binding domain) with MICALL2 (via CH domain). {ECO:0000250, ECO:0000250|UniProtKB:Q8BTM8, ECO:0000269|PubMed:11102480, ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:12393796, ECO:0000269|PubMed:16076904, ECO:0000269|PubMed:16862148, ECO:0000269|PubMed:18322202, ECO:0000269|PubMed:18556573, ECO:0000269|PubMed:19923718, ECO:0000269|PubMed:21228480, ECO:0000269|PubMed:22121117, ECO:0000269|PubMed:23890175, ECO:0000269|PubMed:9437013}.",HELIX 40 43 {ECO:0000244|PDB:3HOC}.; HELIX 44 57 {ECO:0000244|PDB:3HOC}.; HELIX 58 60 {ECO:0000244|PDB:3HOC}.; HELIX 75 85 {ECO:0000244|PDB:3HOC}.; HELIX 100 116 {ECO:0000244|PDB:3HOC}.; HELIX 126 130 {ECO:0000244|PDB:3HOC}.; HELIX 134 149 {ECO:0000244|PDB:3HOC}.; HELIX 168 179 {ECO:0000244|PDB:3HOC}.; HELIX 190 192 {ECO:0000244|PDB:3HOC}.; HELIX 196 205 {ECO:0000244|PDB:3HOC}.; HELIX 213 215 {ECO:0000244|PDB:3HOC}.; HELIX 221 236 {ECO:0000244|PDB:3HOC}.; HELIX 244 247 {ECO:0000244|PDB:3HOC}.; HELIX 254 261 {ECO:0000244|PDB:3HOC}.; HELIX 263 266 {ECO:0000244|PDB:3HOP}.; HELIX 480 482 {ECO:0000244|PDB:4M9P}.; HELIX 488 490 {ECO:0000244|PDB:4M9P}.; HELIX 584 586 {ECO:0000244|PDB:4M9P}.; HELIX 672 674 {ECO:0000244|PDB:4M9P}.; HELIX 680 682 {ECO:0000244|PDB:4M9P}.; HELIX 1160 1162 {ECO:0000244|PDB:3RGH}.; HELIX 1168 1170 {ECO:0000244|PDB:3RGH}.; HELIX 1873 1875 {ECO:0000244|PDB:2BP3}.; HELIX 2041 2043 {ECO:0000244|PDB:2K7Q}.; HELIX 2047 2049 {ECO:0000244|PDB:2J3S}.; HELIX 2055 2057 {ECO:0000244|PDB:2J3S}.; HELIX 2238 2240 {ECO:0000244|PDB:2W0P}.; HELIX 2246 2248 {ECO:0000244|PDB:2W0P}.; HELIX 2264 2266 {ECO:0000244|PDB:2W0P}.; HELIX 2437 2439 {ECO:0000244|PDB:2K3T}.; HELIX 2565 2567 {ECO:0000244|PDB:3CNK}.,STRAND 181 183 {ECO:0000244|PDB:3HOR}.; STRAND 193 195 {ECO:0000244|PDB:3HOR}.; STRAND 484 487 {ECO:0000244|PDB:4M9P}.; STRAND 501 506 {ECO:0000244|PDB:4M9P}.; STRAND 515 521 {ECO:0000244|PDB:4M9P}.; STRAND 529 534 {ECO:0000244|PDB:4M9P}.; STRAND 537 542 {ECO:0000244|PDB:4M9P}.; STRAND 548 556 {ECO:0000244|PDB:4M9P}.; STRAND 565 571 {ECO:0000244|PDB:4M9P}.; STRAND 579 583 {ECO:0000244|PDB:4M9P}.; STRAND 588 590 {ECO:0000244|PDB:4M9P}.; STRAND 595 604 {ECO:0000244|PDB:4M9P}.; STRAND 609 617 {ECO:0000244|PDB:4M9P}.; STRAND 620 625 {ECO:0000244|PDB:4M9P}.; STRAND 627 636 {ECO:0000244|PDB:4M9P}.; STRAND 639 649 {ECO:0000244|PDB:4M9P}.; STRAND 658 664 {ECO:0000244|PDB:4M9P}.; STRAND 676 679 {ECO:0000244|PDB:4M9P}.; STRAND 683 685 {ECO:0000244|PDB:4M9P}.; STRAND 693 698 {ECO:0000244|PDB:4M9P}.; STRAND 707 712 {ECO:0000244|PDB:4M9P}.; STRAND 714 716 {ECO:0000244|PDB:4M9P}.; STRAND 721 725 {ECO:0000244|PDB:4M9P}.; STRAND 727 735 {ECO:0000244|PDB:4M9P}.; STRAND 739 749 {ECO:0000244|PDB:4M9P}.; STRAND 758 762 {ECO:0000244|PDB:4M9P}.; STRAND 1164 1167 {ECO:0000244|PDB:3RGH}.; STRAND 1172 1174 {ECO:0000244|PDB:3RGH}.; STRAND 1179 1184 {ECO:0000244|PDB:3RGH}.; STRAND 1193 1198 {ECO:0000244|PDB:3RGH}.; STRAND 1206 1211 {ECO:0000244|PDB:3RGH}.; STRAND 1213 1222 {ECO:0000244|PDB:3RGH}.; STRAND 1225 1235 {ECO:0000244|PDB:3RGH}.; STRAND 1244 1250 {ECO:0000244|PDB:3RGH}.; STRAND 1791 1796 {ECO:0000244|PDB:2K7P}.; STRAND 1804 1809 {ECO:0000244|PDB:2K7P}.; STRAND 1819 1822 {ECO:0000244|PDB:2K7P}.; STRAND 1824 1832 {ECO:0000244|PDB:2K7P}.; STRAND 1838 1846 {ECO:0000244|PDB:2K7P}.; STRAND 1855 1860 {ECO:0000244|PDB:2K7P}.; STRAND 1865 1867 {ECO:0000244|PDB:2K7P}.; STRAND 1869 1872 {ECO:0000244|PDB:2BP3}.; STRAND 1877 1879 {ECO:0000244|PDB:2BP3}.; STRAND 1884 1889 {ECO:0000244|PDB:2BP3}.; STRAND 1895 1906 {ECO:0000244|PDB:2BP3}.; STRAND 1909 1914 {ECO:0000244|PDB:2BP3}.; STRAND 1916 1925 {ECO:0000244|PDB:2BP3}.; STRAND 1930 1938 {ECO:0000244|PDB:2BP3}.; STRAND 1947 1953 {ECO:0000244|PDB:2BP3}.; STRAND 1959 1967 {ECO:0000244|PDB:2K7Q}.; STRAND 1980 1988 {ECO:0000244|PDB:2K7Q}.; STRAND 1998 2001 {ECO:0000244|PDB:2K7Q}.; STRAND 2007 2010 {ECO:0000244|PDB:2K7Q}.; STRAND 2014 2025 {ECO:0000244|PDB:2K7Q}.; STRAND 2034 2039 {ECO:0000244|PDB:2K7Q}.; STRAND 2051 2054 {ECO:0000244|PDB:2J3S}.; STRAND 2059 2061 {ECO:0000244|PDB:2J3S}.; STRAND 2066 2071 {ECO:0000244|PDB:2J3S}.; STRAND 2075 2077 {ECO:0000244|PDB:2J3S}.; STRAND 2080 2088 {ECO:0000244|PDB:2J3S}.; STRAND 2091 2096 {ECO:0000244|PDB:2J3S}.; STRAND 2100 2107 {ECO:0000244|PDB:2J3S}.; STRAND 2112 2120 {ECO:0000244|PDB:2J3S}.; STRAND 2129 2136 {ECO:0000244|PDB:2J3S}.; STRAND 2139 2148 {ECO:0000244|PDB:2J3S}.; STRAND 2174 2179 {ECO:0000244|PDB:2J3S}.; STRAND 2185 2189 {ECO:0000244|PDB:2J3S}.; STRAND 2208 2216 {ECO:0000244|PDB:2J3S}.; STRAND 2225 2231 {ECO:0000244|PDB:2J3S}.; STRAND 2242 2245 {ECO:0000244|PDB:2W0P}.; STRAND 2257 2262 {ECO:0000244|PDB:2W0P}.; STRAND 2271 2279 {ECO:0000244|PDB:2W0P}.; STRAND 2282 2287 {ECO:0000244|PDB:2W0P}.; STRAND 2293 2298 {ECO:0000244|PDB:2W0P}.; STRAND 2303 2311 {ECO:0000244|PDB:2W0P}.; STRAND 2320 2326 {ECO:0000244|PDB:2W0P}.; STRAND 2433 2436 {ECO:0000244|PDB:2K3T}.; STRAND 2441 2443 {ECO:0000244|PDB:2K3T}.; STRAND 2448 2453 {ECO:0000244|PDB:2K3T}.; STRAND 2462 2470 {ECO:0000244|PDB:2K3T}.; STRAND 2472 2479 {ECO:0000244|PDB:2K3T}.; STRAND 2482 2489 {ECO:0000244|PDB:2K3T}.; STRAND 2491 2506 {ECO:0000244|PDB:2K3T}.; STRAND 2511 2518 {ECO:0000244|PDB:2K3T}.; STRAND 2561 2564 {ECO:0000244|PDB:3CNK}.; STRAND 2576 2581 {ECO:0000244|PDB:3CNK}.; STRAND 2590 2595 {ECO:0000244|PDB:3CNK}.; STRAND 2597 2599 {ECO:0000244|PDB:3CNK}.; STRAND 2602 2610 {ECO:0000244|PDB:3CNK}.; STRAND 2613 2619 {ECO:0000244|PDB:3CNK}.; STRAND 2624 2632 {ECO:0000244|PDB:3CNK}.; STRAND 2641 2646 {ECO:0000244|PDB:3CNK}.,TURN 67 73 {ECO:0000244|PDB:3HOC}.; TURN 1785 1787 {ECO:0000244|PDB:2K7P}.; TURN 1891 1893 {ECO:0000244|PDB:2AAV}.; TURN 2429 2431 {ECO:0000244|PDB:2K3T}.; TURN 2455 2457 {ECO:0000244|PDB:2K3T}.,DOMAIN 2 274 Actin-binding.; DOMAIN 43 149 CH 1. {ECO:0000255|PROSITE-ProRule:PRU00044}.; DOMAIN 166 266 CH 2. {ECO:0000255|PROSITE-ProRule:PRU00044}.,,,,,1.813373631,-0.317,280.78,892,893O75369,FLNB_HUMAN,reviewed,Filamin-B (FLN-B) (ABP-278) (ABP-280 homolog) (Actin-binding-like protein) (Beta-filamin) (Filamin homolog 1) (Fh1) (Filamin-3) (Thyroid autoantigen) (Truncated actin-binding protein) (Truncated ABP),FLNB FLN1L FLN3 TABP TAP,Homo sapiens (Human),2602,GO:0030018; GO:0003779; GO:0015629; GO:0030036; GO:0005938; GO:0030154; GO:0019221; GO:0005737; GO:0007016; GO:0005829; GO:0070062; GO:0005925; GO:0042802; GO:0016021; GO:0005886; GO:0044822; GO:0007165; GO:0007519; GO:0001725,2317;,MPVTEKDLAEDAPWKKIQQNTFTRWCNEHLKCVNKRIGNLQTDLSDGLRLIALLEVLSQKRMYRKYHQRPTFRQMQLENVSVALEFLDRESIKLVSIDSKAIVDGNLKLILGLVWTLILHYSISMPVWEDEGDDDAKKQTPKQRLLGWIQNKIPYLPITNFNQNWQDGKALGALVDSCAPGLCPDWESWDPQKPVDNAREAMQQADDWLGVPQVITPEEIIHPDVDEHSVMTYLSQFPKAKLKPGAPLKPKLNPKKARAYGRGIEPTGNMVKQPAKFTVDTISAGQGDVMVFVEDPEGNKEEAQVTPDSDKNKTYSVEYLPKVTGLHKVTVLFAGQHISKSPFEVSVDKAQGDASKVTAKGPGLEAVGNIANKPTYFDIYTAGAGVGDIGVEVEDPQGKNTVELLVEDKGNQVYRCVYKPMQPGPHVVKIFFAGDTIPKSPFVVQVGEACNPNACRASGRGLQPKGVRIRETTDFKVDTKAAGSGELGVTMKGPKGLEELVKQKDFLDGVYAFEYYPSTPGRYSIAITWGGHHIPKSPFEVQVGPEAGMQKVRAWGPGLHGGIVGRSADFVVESIGSEVGSLGFAIEGPSQAKIEYNDQNDGSCDVKYWPKEPGEYAVHIMCDDEDIKDSPYMAFIHPATGGYNPDLVRAYGPGLEKSGCIVNNLAEFTVDPKDAGKAPLKIFAQDGEGQRIDIQMKNRMDGTYACSYTPVKAIKHTIAVVWGGVNIPHSPYRVNIGQGSHPQKVKVFGPGVERSGLKANEPTHFTVDCTEAGEGDVSVGIKCDARVLSEDEEDVDFDIIHNANDTFTVKYVPPAAGRYTIKVLFASQEIPASPFRVKVDPSHDASKVKAEGPGLSKAGVENGKPTHFTVYTKGAGKAPLNVQFNSPLPGDAVKDLDIIDNYDYSHTVKYTPTQQGNMQVLVTYGGDPIPKSPFTVGVAAPLDLSKIKLNGLENRVEVGKDQEFTVDTRGAGGQGKLDVTILSPSRKVVPCLVTPVTGRENSTAKFIPREEGLYAVDVTYDGHPVPGSPYTVEASLPPDPSKVKAHGPGLEGGLVGKPAEFTIDTKGAGTGGLGLTVEGPCEAKIECSDNGDGTCSVSYLPTKPGEYFVNILFEEVHIPGSPFKADIEMPFDPSKVVASGPGLEHGKVGEAGLLSVDCSEAGPGALGLEAVSDSGTKAEVSIQNNKDGTYAVTYVPLTAGMYTLTMKYGGELVPHFPARVKVEPAVDTSRIKVFGPGIEGKDVFREATTDFTVDSRPLTQVGGDHIKAHIANPSGASTECFVTDNADGTYQVEYTPFEKGLHVVEVTYDDVPIPNSPFKVAVTEGCQPSRVQAQGPGLKEAFTNKPNVFTVVTRGAGIGGLGITVEGPSESKINCRDNKDGSCSAEYIPFAPGDYDVNITYGGAHIPGSPFRVPVKDVVDPSKVKIAGPGLGSGVRARVLQSFTVDSSKAGLAPLEVRVLGPRGLVEPVNVVDNGDGTHTVTYTPSQEGPYMVSVKYADEEIPRSPFKVKVLPTYDASKVTASGPGLSSYGVPASLPVDFAIDARDAGEGLLAVQITDQEGKPKRAIVHDNKDGTYAVTYIPDKTGRYMIGVTYGGDDIPLSPYRIRATQTGDASKCLATGPGIASTVKTGEEVGFVVDAKTAGKGKVTCTVLTPDGTEAEADVIENEDGTYDIFYTAAKPGTYVIYVRFGGVDIPNSPFTVMATDGEVTAVEEAPVNACPPGFRPWVTEEAYVPVSDMNGLGFKPFDLVIPFAVRKGEITGEVHMPSGKTATPEIVDNKDGTVTVRYAPTEVGLHEMHIKYMGSHIPESPLQFYVNYPNSGSVSAYGPGLVYGVANKTATFTIVTEDAGEGGLDLAIEGPSKAEISCIDNKDGTCTVTYLPTLPGDYSILVKYNDKHIPGSPFTAKITDDSRRCSQVKLGSAADFLLDISETDLSSLTASIKAPSGRDEPCLLKRLPNNHIGISFIPREVGEHLVSIKKNGNHVANSPVSIMVVQSEIGDARRAKVYGRGLSEGRTFEMSDFIVDTRDAGYGGISLAVEGPSKVDIQTEDLEDGTCKVSYFPTVPGVYIVSTKFADEHVPGSPFTVKISGEGRVKESITRTSRAPSVATVGSICDLNLKIPEINSSDMSAHVTSPSGRVTEAEIVPMGKNSHCVRFVPQEMGVHTVSVKYRGQHVTGSPFQFTVGPLGEGGAHKVRAGGPGLERGEAGVPAEFSIWTREAGAGGLSIAVEGPSKAEITFDDHKNGSCGVSYIAQEPGNYEVSIKFNDEHIPESPYLVPVIAPSDDARRLTVMSLQESGLKVNQPASFAIRLNGAKGKIDAKVHSPSGAVEECHVSELEPDKYAVRFIPHENGVHTIDVKFNGSHVVGSPFKVRVGEPGQAGNPALVSAYGTGLEGGTTGIQSEFFINTTRAGPGTLSVTIEGPSKVKMDCQETPEGYKVMYTPMAPGNYLISVKYGGPNHIVGSPFKAKVTGQRLVSPGSANETSSILVESVTRSSTETCYSAIPKASSDASKVTSKGAGLSKAFVGQKSSFLVDCSKAGSNMLLIGVHGPTTPCEEVSMKHVGNQQYNVTYVVKERGDYVLAVKWGEEHIPGSPFHVTVP,"DISEASE: Note=Interaction with FLNA may compensate for dysfunctional FLNA homodimer in the periventricular nodular heterotopia (PVNH) disorder.; DISEASE: Atelosteogenesis 1 (AO1) [MIM:108720]: A lethal chondrodysplasia characterized by distal hypoplasia of the humeri and femurs, hypoplasia of the mid-thoracic spine, occasionally complete lack of ossification of single hand bones, and the finding in cartilage of multiple degenerated chondrocytes which are encapsulated in fibrous tissue. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Atelosteogenesis 3 (AO3) [MIM:108721]: A short-limb lethal skeletal dysplasia with vertebral abnormalities, disharmonious skeletal maturation, poorly modeled long bones and joint dislocations. Recurrent respiratory insufficiency and/or infections usually result in early death. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Boomerang dysplasia (BOOMD) [MIM:112310]: A perinatal lethal osteochondrodysplasia characterized by absence or underossification of the limb bones and vertebrae. Patients manifest dwarfism with short, bowed, rigid limbs and characteristic facies. Boomerang dysplasia is distinguished from atelosteogenesis on the basis of a more severe defect in mineralization, with complete absence of ossification in some limb elements and vertebral segments. {ECO:0000269|PubMed:15994868}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Larsen syndrome (LRS) [MIM:150250]: An osteochondrodysplasia characterized by large-joint dislocations and characteristic craniofacial abnormalities. The cardinal features of the condition are dislocations of the hip, knee and elbow joints, with equinovarus or equinovalgus foot deformities. Spatula-shaped fingers, most marked in the thumb, are also present. Craniofacial anomalies include hypertelorism, prominence of the forehead, a depressed nasal bridge, and a flattened midface. Cleft palate and short stature are often associated features. Spinal anomalies include scoliosis and cervical kyphosis. Hearing loss is a well-recognized complication. {ECO:0000269|PubMed:14991055, ECO:0000269|PubMed:16801345}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spondylocarpotarsal synostosis syndrome (SCT) [MIM:272460]: Disorder characterized by short stature and vertebral, carpal and tarsal fusions. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,"DOMAIN: Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation. The first hinge region prevents binding to ITGA and ITGB subunits.",PF00307;PF00630;,hsa:2317;,,,"SUBUNIT: Homodimer. Interacts with MICALL2 (By similarity). Interacts with FAM101A and FAM101B (By similarity). Isoform 1 interacts with FBLP1, FLNA, FLNC, GP1BA, INPPL1, ITGB1A, PSEN1 and PSEN2. Isoform 3 interacts with ITGB1A, ITGB1D, ITGB3 and ITGB6. Interacts with MYOT and MYOZ1. Interacts with HBV capsid protein. {ECO:0000250, ECO:0000250|UniProtKB:Q80X90, ECO:0000269|PubMed:10754391, ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:11807098, ECO:0000269|PubMed:12393796, ECO:0000269|PubMed:12496242, ECO:0000269|PubMed:12525170, ECO:0000269|PubMed:16076904, ECO:0000269|PubMed:9437013, ECO:0000269|PubMed:9651345, ECO:0000269|PubMed:9694715}.",HELIX 5 10 {ECO:0000244|PDB:2WA5}.; HELIX 13 16 {ECO:0000244|PDB:2WA7}.; HELIX 17 30 {ECO:0000244|PDB:2WA7}.; HELIX 31 33 {ECO:0000244|PDB:2WA7}.; HELIX 48 58 {ECO:0000244|PDB:2WA7}.; HELIX 73 89 {ECO:0000244|PDB:2WA7}.; HELIX 99 103 {ECO:0000244|PDB:2WA7}.; HELIX 107 122 {ECO:0000244|PDB:2WA7}.; HELIX 141 152 {ECO:0000244|PDB:2WA7}.; HELIX 163 165 {ECO:0000244|PDB:2WA7}.; HELIX 169 178 {ECO:0000244|PDB:2WA7}.; HELIX 186 188 {ECO:0000244|PDB:2WA7}.; HELIX 194 208 {ECO:0000244|PDB:2WA7}.; HELIX 217 220 {ECO:0000244|PDB:2WA7}.; HELIX 227 234 {ECO:0000244|PDB:2WA7}.; HELIX 236 239 {ECO:0000244|PDB:2WA7}.; HELIX 254 256 {ECO:0000244|PDB:4B7L}.; HELIX 262 264 {ECO:0000244|PDB:4B7L}.; HELIX 1133 1135 {ECO:0000244|PDB:2DIA}.; HELIX 1141 1143 {ECO:0000244|PDB:2DIA}.; HELIX 1236 1239 {ECO:0000244|PDB:2DIB}.; HELIX 1517 1519 {ECO:0000244|PDB:2E9J}.; HELIX 1525 1527 {ECO:0000244|PDB:2E9J}.; HELIX 1622 1624 {ECO:0000244|PDB:2DMB}.; HELIX 1829 1832 {ECO:0000244|PDB:2EEA}.; HELIX 2002 2004 {ECO:0000244|PDB:2DI8}.; HELIX 2126 2128 {ECO:0000244|PDB:2DLG}.; HELIX 2193 2195 {ECO:0000244|PDB:2EE6}.; HELIX 2520 2523 {ECO:0000244|PDB:2EED}.,STRAND 258 261 {ECO:0000244|PDB:4B7L}.; STRAND 265 267 {ECO:0000244|PDB:4B7L}.; STRAND 275 280 {ECO:0000244|PDB:4B7L}.; STRAND 289 294 {ECO:0000244|PDB:4B7L}.; STRAND 300 302 {ECO:0000244|PDB:4B7L}.; STRAND 304 309 {ECO:0000244|PDB:4B7L}.; STRAND 313 319 {ECO:0000244|PDB:4B7L}.; STRAND 323 333 {ECO:0000244|PDB:4B7L}.; STRAND 342 347 {ECO:0000244|PDB:4B7L}.; STRAND 1136 1140 {ECO:0000244|PDB:2DIA}.; STRAND 1154 1160 {ECO:0000244|PDB:2DIA}.; STRAND 1166 1172 {ECO:0000244|PDB:2DIA}.; STRAND 1179 1184 {ECO:0000244|PDB:2DIA}.; STRAND 1188 1195 {ECO:0000244|PDB:2DIA}.; STRAND 1200 1208 {ECO:0000244|PDB:2DIA}.; STRAND 1217 1223 {ECO:0000244|PDB:2DIA}.; STRAND 1232 1235 {ECO:0000244|PDB:2DIB}.; STRAND 1249 1254 {ECO:0000244|PDB:2DIB}.; STRAND 1256 1258 {ECO:0000244|PDB:2DIB}.; STRAND 1273 1275 {ECO:0000244|PDB:2DIB}.; STRAND 1281 1284 {ECO:0000244|PDB:2DIB}.; STRAND 1286 1294 {ECO:0000244|PDB:2DIB}.; STRAND 1300 1310 {ECO:0000244|PDB:2DIB}.; STRAND 1317 1321 {ECO:0000244|PDB:2DIB}.; STRAND 1425 1428 {ECO:0000244|PDB:2DJ4}.; STRAND 1441 1446 {ECO:0000244|PDB:2DJ4}.; STRAND 1455 1460 {ECO:0000244|PDB:2DJ4}.; STRAND 1462 1464 {ECO:0000244|PDB:2DJ4}.; STRAND 1475 1483 {ECO:0000244|PDB:2DJ4}.; STRAND 1489 1501 {ECO:0000244|PDB:2DJ4}.; STRAND 1506 1512 {ECO:0000244|PDB:2DJ4}.; STRAND 1520 1524 {ECO:0000244|PDB:2E9J}.; STRAND 1538 1546 {ECO:0000244|PDB:2E9J}.; STRAND 1566 1570 {ECO:0000244|PDB:2E9J}.; STRAND 1573 1580 {ECO:0000244|PDB:2E9J}.; STRAND 1586 1590 {ECO:0000244|PDB:2E9J}.; STRAND 1593 1596 {ECO:0000244|PDB:2E9J}.; STRAND 1603 1609 {ECO:0000244|PDB:2E9J}.; STRAND 1618 1621 {ECO:0000244|PDB:2DMB}.; STRAND 1625 1639 {ECO:0000244|PDB:2DMB}.; STRAND 1641 1643 {ECO:0000244|PDB:2DMB}.; STRAND 1648 1653 {ECO:0000244|PDB:2DMB}.; STRAND 1663 1666 {ECO:0000244|PDB:2DMB}.; STRAND 1672 1677 {ECO:0000244|PDB:2DMB}.; STRAND 1682 1692 {ECO:0000244|PDB:2DMB}.; STRAND 1699 1705 {ECO:0000244|PDB:2DMB}.; STRAND 1748 1750 {ECO:0000244|PDB:2EE9}.; STRAND 1759 1765 {ECO:0000244|PDB:2EE9}.; STRAND 1775 1778 {ECO:0000244|PDB:2EE9}.; STRAND 1780 1782 {ECO:0000244|PDB:2EE9}.; STRAND 1784 1787 {ECO:0000244|PDB:2EE9}.; STRAND 1792 1804 {ECO:0000244|PDB:2EE9}.; STRAND 1811 1816 {ECO:0000244|PDB:2EE9}.; STRAND 1825 1828 {ECO:0000244|PDB:2EEA}.; STRAND 1833 1835 {ECO:0000244|PDB:2EEA}.; STRAND 1840 1845 {ECO:0000244|PDB:2EEA}.; STRAND 1854 1862 {ECO:0000244|PDB:2EEA}.; STRAND 1872 1881 {ECO:0000244|PDB:2EEA}.; STRAND 1888 1898 {ECO:0000244|PDB:2EEA}.; STRAND 1903 1909 {ECO:0000244|PDB:2EEA}.; STRAND 1924 1927 {ECO:0000244|PDB:2DMC}.; STRAND 1941 1943 {ECO:0000244|PDB:2DMC}.; STRAND 1952 1957 {ECO:0000244|PDB:2DMC}.; STRAND 1961 1966 {ECO:0000244|PDB:2DMC}.; STRAND 1972 1977 {ECO:0000244|PDB:2DMC}.; STRAND 1979 1984 {ECO:0000244|PDB:2DMC}.; STRAND 1989 1994 {ECO:0000244|PDB:2DMC}.; STRAND 1997 1999 {ECO:0000244|PDB:2DMC}.; STRAND 2006 2010 {ECO:0000244|PDB:2DI8}.; STRAND 2014 2016 {ECO:0000244|PDB:2DI8}.; STRAND 2021 2026 {ECO:0000244|PDB:2DI8}.; STRAND 2035 2043 {ECO:0000244|PDB:2DI8}.; STRAND 2057 2061 {ECO:0000244|PDB:2DI8}.; STRAND 2067 2077 {ECO:0000244|PDB:2DI8}.; STRAND 2084 2090 {ECO:0000244|PDB:2DI8}.; STRAND 2111 2113 {ECO:0000244|PDB:2DLG}.; STRAND 2118 2120 {ECO:0000244|PDB:2DLG}.; STRAND 2130 2134 {ECO:0000244|PDB:2DLG}.; STRAND 2140 2142 {ECO:0000244|PDB:2DLG}.; STRAND 2144 2147 {ECO:0000244|PDB:2DLG}.; STRAND 2149 2157 {ECO:0000244|PDB:2DLG}.; STRAND 2164 2175 {ECO:0000244|PDB:2DLG}.; STRAND 2180 2185 {ECO:0000244|PDB:2DLG}.; STRAND 2206 2208 {ECO:0000244|PDB:2EE6}.; STRAND 2210 2214 {ECO:0000244|PDB:2EE6}.; STRAND 2219 2221 {ECO:0000244|PDB:2EE6}.; STRAND 2226 2234 {ECO:0000244|PDB:2EE6}.; STRAND 2236 2240 {ECO:0000244|PDB:2EE6}.; STRAND 2250 2256 {ECO:0000244|PDB:2EE6}.; STRAND 2258 2266 {ECO:0000244|PDB:2EE6}.; STRAND 2275 2281 {ECO:0000244|PDB:2EE6}.; STRAND 2288 2294 {ECO:0000244|PDB:2EEB}.; STRAND 2306 2314 {ECO:0000244|PDB:2EEB}.; STRAND 2320 2324 {ECO:0000244|PDB:2EEB}.; STRAND 2330 2332 {ECO:0000244|PDB:2EEB}.; STRAND 2334 2337 {ECO:0000244|PDB:2EEB}.; STRAND 2340 2347 {ECO:0000244|PDB:2EEB}.; STRAND 2352 2365 {ECO:0000244|PDB:2EEB}.; STRAND 2370 2375 {ECO:0000244|PDB:2EEB}.; STRAND 2388 2392 {ECO:0000244|PDB:2EEC}.; STRAND 2403 2408 {ECO:0000244|PDB:2EEC}.; STRAND 2417 2425 {ECO:0000244|PDB:2EEC}.; STRAND 2430 2433 {ECO:0000244|PDB:2EEC}.; STRAND 2435 2442 {ECO:0000244|PDB:2EEC}.; STRAND 2448 2459 {ECO:0000244|PDB:2EEC}.; STRAND 2466 2473 {ECO:0000244|PDB:2EEC}.; STRAND 2516 2519 {ECO:0000244|PDB:2EED}.; STRAND 2531 2536 {ECO:0000244|PDB:2EED}.; STRAND 2545 2547 {ECO:0000244|PDB:2EED}.; STRAND 2557 2565 {ECO:0000244|PDB:2EED}.; STRAND 2568 2574 {ECO:0000244|PDB:2EED}.; STRAND 2579 2583 {ECO:0000244|PDB:2EED}.; STRAND 2585 2591 {ECO:0000244|PDB:2EED}.; STRAND 2596 2601 {ECO:0000244|PDB:2EED}.,TURN 40 46 {ECO:0000244|PDB:2WA7}.; TURN 282 284 {ECO:0000244|PDB:4B7L}.; TURN 1173 1175 {ECO:0000244|PDB:2DIA}.; TURN 1429 1431 {ECO:0000244|PDB:2DJ4}.; TURN 1448 1450 {ECO:0000244|PDB:2DJ4}.; TURN 1958 1960 {ECO:0000244|PDB:2DMC}.; TURN 2011 2013 {ECO:0000244|PDB:2DI8}.; TURN 2028 2030 {ECO:0000244|PDB:2DI8}.; TURN 2201 2203 {ECO:0000244|PDB:2EE6}.; TURN 2384 2386 {ECO:0000244|PDB:2EEC}.; TURN 2393 2395 {ECO:0000244|PDB:2EEC}.; TURN 2410 2412 {ECO:0000244|PDB:2EEC}.; TURN 2512 2514 {ECO:0000244|PDB:2EED}.; TURN 2538 2540 {ECO:0000244|PDB:2EED}.,DOMAIN 1 239 Actin-binding.; DOMAIN 16 122 CH 1. {ECO:0000255|PROSITE-ProRule:PRU00044}.; DOMAIN 139 239 CH 2. {ECO:0000255|PROSITE-ProRule:PRU00044}.,,,,,1.460415065,-0.293,278.2,75.5,76.5Q14315,FLNC_HUMAN,reviewed,Filamin-C (FLN-C) (FLNc) (ABP-280-like protein) (ABP-L) (Actin-binding-like protein) (Filamin-2) (Gamma-filamin),FLNC ABPL FLN2,Homo sapiens (Human),2725,GO:0030018; GO:0030506; GO:0034329; GO:0043034; GO:0005737; GO:0008092; GO:0005856; GO:0005829; GO:0005925; GO:0005886; GO:0042383; GO:0016528,2318;,MMNNSGYSDAGLGLGDETDEMPSTEKDLAEDAPWKKIQQNTFTRWCNEHLKCVGKRLTDLQRDLSDGLRLIALLEVLSQKRMYRKFHPRPNFRQMKLENVSVALEFLEREHIKLVSIDSKAIVDGNLKLILGLIWTLILHYSISMPMWEDEDDEDARKQTPKQRLLGWIQNKVPQLPITNFNRDWQDGKALGALVDNCAPGLCPDWEAWDPNQPVENAREAMQQADDWLGVPQVIAPEEIVDPNVDEHSVMTYLSQFPKAKLKPGAPVRSKQLNPKKAIAYGPGIEPQGNTVLQPAHFTVQTVDAGVGEVLVYIEDPEGHTEEAKVVPNNDKDRTYAVSYVPKVAGLHKVTVLFAGQNIERSPFEVNVGMALGDANKVSARGPGLEPVGNVANKPTYFDIYTAGAGTGDVAVVIVDPQGRRDTVEVALEDKGDSTFRCTYRPAMEGPHTVHVAFAGAPITRSPFPVHVSEACNPNACRASGRGLQPKGVRVKEVADFKVFTKGAGSGELKVTVKGPKGTEEPVKVREAGDGVFECEYYPVVPGKYVVTITWGGYAIPRSPFEVQVSPEAGVQKVRAWGPGLETGQVGKSADFVVEAIGTEVGTLGFSIEGPSQAKIECDDKGDGSCDVRYWPTEPGEYAVHVICDDEDIRDSPFIAHILPAPPDCFPDKVKAFGPGLEPTGCIVDKPAEFTIDARAAGKGDLKLYAQDADGCPIDIKVIPNGDGTFRCSYVPTKPIKHTIIISWGGVNVPKSPFRVNVGEGSHPERVKVYGPGVEKTGLKANEPTYFTVDCSEAGQGDVSIGIKCAPGVVGPAEADIDFDIIKNDNDTFTVKYTPPGAGRYTIMVLFANQEIPASPFHIKVDPSHDASKVKAEGPGLNRTGVEVGKPTHFTVLTKGAGKAKLDVQFAGTAKGEVVRDFEIIDNHDYSYTVKYTAVQQGNMAVTVTYGGDPVPKSPFVVNVAPPLDLSKIKVQGLNSKVAVGQEQAFSVNTRGAGGQGQLDVRMTSPSRRPIPCKLEPGGGAEAQAVRYMPPEEGPYKVDITYDGHPVPGSPFAVEGVLPPDPSKVCAYGPGLKGGLVGTPAPFSIDTKGAGTGGLGLTVEGPCEAKIECQDNGDGSCAVSYLPTEPGEYTINILFAEAHIPGSPFKATIRPVFDPSKVRASGPGLERGKVGEAATFTVDCSEAGEAELTIEILSDAGVKAEVLIHNNADGTYHITYSPAFPGTYTITIKYGGHPVPKFPTRVHVQPAVDTSGVKVSGPGVEPHGVLREVTTEFTVDARSLTATGGNHVTARVLNPSGAKTDTYVTDNGDGTYRVQYTAYEEGVHLVEVLYDEVAVPKSPFRVGVTEGCDPTRVRAFGPGLEGGLVNKANRFTVETRGAGTGGLGLAIEGPSEAKMSCKDNKDGSCTVEYIPFTPGDYDVNITFGGRPIPGSPFRVPVKDVVDPGKVKCSGPGLGAGVRARVPQTFTVDCSQAGRAPLQVAVLGPTGVAEPVEVRDNGDGTHTVHYTPATDGPYTVAVKYADQEVPRSPFKIKVLPAHDASKVRASGPGLNASGIPASLPVEFTIDARDAGEGLLTVQILDPEGKPKKANIRDNGDGTYTVSYLPDMSGRYTITIKYGGDEIPYSPFRIHALPTGDASKCLVTVSIGGHGLGACLGPRIQIGQETVITVDAKAAGEGKVTCTVSTPDGAELDVDVVENHDGTFDIYYTAPEPGKYVITIRFGGEHIPNSPFHVLACDPLPHEEEPSEVPQLRQPYAPPRPGARPTHWATEEPVVPVEPMESMLRPFNLVIPFAVQKGELTGEVRMPSGKTARPNITDNKDGTITVRYAPTEKGLHQMGIKYDGNHIPGSPLQFYVDAINSRHVSAYGPGLSHGMVNKPATFTIVTKDAGEGGLSLAVEGPSKAEITCKDNKDGTCTVSYLPTAPGDYSIIVRFDDKHIPGSPFTAKITGDDSMRTSQLNVGTSTDVSLKITESDLSQLTASIRAPSGNEEPCLLKRLPNRHIGISFTPKEVGEHVVSVRKSGKHVTNSPFKILVGPSEIGDASKVRVWGKGLSEGHTFQVAEFIVDTRNAGYGGLGLSIEGPSKVDINCEDMEDGTCKVTYCPTEPGTYIINIKFADKHVPGSPFTVKVTGEGRMKESITRRRQAPSIATIGSTCDLNLKIPGNWFQMVSAQERLTRTFTRSSHTYTRTERTEISKTRGGETKREVRVEESTQVGGDPFPAVFGDFLGRERLGSFGSITRQQEGEASSQDMTAQVTSPSGKVEAAEIVEGEDSAYSVRFVPQEMGPHTVAVKYRGQHVPGSPFQFTVGPLGEGGAHKVRAGGTGLERGVAGVPAEFSIWTREAGAGGLSIAVEGPSKAEIAFEDRKDGSCGVSYVVQEPGDYEVSIKFNDEHIPDSPFVVPVASLSDDARRLTVTSLQETGLKVNQPASFAVQLNGARGVIDARVHTPSGAVEECYVSELDSDKHTIRFIPHENGVHSIDVKFNGAHIPGSPFKIRVGEQSQAGDPGLVSAYGPGLEGGTTGVSSEFIVNTLNAGSGALSVTIDGPSKVQLDCRECPEGHVVTYTPMAPGNYLIAIKYGGPQHIVGSPFKAKVTGPRLSGGHSLHETSTVLVETVTKSSSSRGSSYSSIPKFSSDASKVVTRGPGLSQAFVGQKNSFTVDCSKAGTNMMMVGVHGPKTPCEEVYVKHMGNRVYNVTYTVKEKGDYILIVKWGDESVPGSPFKVKVP,"DISEASE: Myopathy, myofibrillar, 5 (MFM5) [MIM:609524]: A neuromuscular disorder, usually with an adult onset, characterized by focal myofibrillar destruction, pathological cytoplasmic protein aggregations, and clinical features of a limb-girdle myopathy. {ECO:0000269|PubMed:15929027}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, distal, 4 (MPD4) [MIM:614065]: A slowly progressive muscular disorder characterized by distal muscle weakness and atrophy affecting the upper and lower limbs. Onset occurs around the third to fourth decades of life, and patients remain ambulatory even after long disease duration. Muscle biopsy shows non-specific changes with no evidence of rods, necrosis, or inflammation. {ECO:0000269|PubMed:21620354}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF00307;PF00630;,hsa:2318;,,,"SUBUNIT: Homodimer; the filamin repeat 24 and the second hinge domain are important for dimer formation. Interacts with FLNB, INPPL1, ITGB1A, KCND2, MYOT, MYOZ1 and MYOZ3. Interacts with sarcoglycans SGCD and SGCG. Interacts (via filament repeats 17-18, 20-21 and 24) with USP25 (isoform USP25m only). Interacts with FBLIM1. Interacts with XIRP1; this interaction is mediated by filamin 20 repeat. Interacts with KY. Interacts with IGFN1 (By similarity). Interacts with MICALL2 (By similarity). Interacts with ANK3. {ECO:0000250, ECO:0000269|PubMed:10629222, ECO:0000269|PubMed:10984498, ECO:0000269|PubMed:11038172, ECO:0000269|PubMed:11102480, ECO:0000269|PubMed:11171996, ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:11842093, ECO:0000269|PubMed:12525170, ECO:0000269|PubMed:16076904, ECO:0000269|PubMed:16501887, ECO:0000269|PubMed:16631741, ECO:0000269|PubMed:17379241, ECO:0000269|PubMed:19074766, ECO:0000269|PubMed:21223964}.",HELIX 579 581 {ECO:0000244|PDB:3V8O}.; HELIX 601 603 {ECO:0000244|PDB:3V8O}.; HELIX 667 669 {ECO:0000244|PDB:3V8O}.; HELIX 675 677 {ECO:0000244|PDB:3V8O}.; HELIX 1539 1541 {ECO:0000244|PDB:2D7M}.; HELIX 1867 1870 {ECO:0000244|PDB:2D7O}.; HELIX 2407 2410 {ECO:0000244|PDB:2D7P}.; HELIX 2505 2507 {ECO:0000244|PDB:2NQC}.; HELIX 2513 2515 {ECO:0000244|PDB:2NQC}.; HELIX 2635 2637 {ECO:0000244|PDB:1V05}.; HELIX 2643 2645 {ECO:0000244|PDB:1V05}.,STRAND 574 578 {ECO:0000244|PDB:3V8O}.; STRAND 583 585 {ECO:0000244|PDB:3V8O}.; STRAND 590 599 {ECO:0000244|PDB:3V8O}.; STRAND 604 612 {ECO:0000244|PDB:3V8O}.; STRAND 617 620 {ECO:0000244|PDB:3V8O}.; STRAND 622 630 {ECO:0000244|PDB:3V8O}.; STRAND 636 644 {ECO:0000244|PDB:3V8O}.; STRAND 653 659 {ECO:0000244|PDB:3V8O}.; STRAND 671 674 {ECO:0000244|PDB:3V8O}.; STRAND 678 680 {ECO:0000244|PDB:3V8O}.; STRAND 688 693 {ECO:0000244|PDB:3V8O}.; STRAND 697 699 {ECO:0000244|PDB:3V8O}.; STRAND 702 708 {ECO:0000244|PDB:3V8O}.; STRAND 717 720 {ECO:0000244|PDB:3V8O}.; STRAND 722 730 {ECO:0000244|PDB:3V8O}.; STRAND 734 744 {ECO:0000244|PDB:3V8O}.; STRAND 753 759 {ECO:0000244|PDB:3V8O}.; STRAND 1542 1547 {ECO:0000244|PDB:2D7M}.; STRAND 1554 1558 {ECO:0000244|PDB:2D7M}.; STRAND 1560 1569 {ECO:0000244|PDB:2D7M}.; STRAND 1574 1579 {ECO:0000244|PDB:2D7M}.; STRAND 1588 1592 {ECO:0000244|PDB:2D7M}.; STRAND 1594 1596 {ECO:0000244|PDB:2D7M}.; STRAND 1598 1602 {ECO:0000244|PDB:2D7M}.; STRAND 1608 1618 {ECO:0000244|PDB:2D7M}.; STRAND 1625 1631 {ECO:0000244|PDB:2D7M}.; STRAND 1785 1789 {ECO:0000244|PDB:2D7N}.; STRAND 1794 1796 {ECO:0000244|PDB:2D7N}.; STRAND 1798 1803 {ECO:0000244|PDB:2D7N}.; STRAND 1813 1816 {ECO:0000244|PDB:2D7N}.; STRAND 1818 1820 {ECO:0000244|PDB:2D7N}.; STRAND 1822 1826 {ECO:0000244|PDB:2D7N}.; STRAND 1832 1843 {ECO:0000244|PDB:2D7N}.; STRAND 1849 1854 {ECO:0000244|PDB:2D7N}.; STRAND 1863 1866 {ECO:0000244|PDB:2D7O}.; STRAND 1871 1873 {ECO:0000244|PDB:2D7O}.; STRAND 1878 1883 {ECO:0000244|PDB:2D7O}.; STRAND 1895 1900 {ECO:0000244|PDB:2D7O}.; STRAND 1910 1918 {ECO:0000244|PDB:2D7O}.; STRAND 1924 1929 {ECO:0000244|PDB:2D7O}.; STRAND 1931 1934 {ECO:0000244|PDB:2D7O}.; STRAND 1941 1947 {ECO:0000244|PDB:2D7O}.; STRAND 2303 2308 {ECO:0000244|PDB:2K9U}.; STRAND 2318 2322 {ECO:0000244|PDB:2K9U}.; STRAND 2332 2338 {ECO:0000244|PDB:2K9U}.; STRAND 2344 2355 {ECO:0000244|PDB:2K9U}.; STRAND 2358 2362 {ECO:0000244|PDB:2K9U}.; STRAND 2365 2374 {ECO:0000244|PDB:2K9U}.; STRAND 2377 2389 {ECO:0000244|PDB:2K9U}.; STRAND 2396 2404 {ECO:0000244|PDB:2K9U}.; STRAND 2427 2432 {ECO:0000244|PDB:2D7P}.; STRAND 2440 2445 {ECO:0000244|PDB:2D7P}.; STRAND 2447 2449 {ECO:0000244|PDB:2D7P}.; STRAND 2463 2468 {ECO:0000244|PDB:2D7P}.; STRAND 2474 2484 {ECO:0000244|PDB:2D7P}.; STRAND 2491 2496 {ECO:0000244|PDB:2D7P}.; STRAND 2509 2512 {ECO:0000244|PDB:2NQC}.; STRAND 2517 2519 {ECO:0000244|PDB:2NQC}.; STRAND 2524 2529 {ECO:0000244|PDB:2NQC}.; STRAND 2538 2546 {ECO:0000244|PDB:2NQC}.; STRAND 2549 2555 {ECO:0000244|PDB:2NQC}.; STRAND 2558 2564 {ECO:0000244|PDB:2NQC}.; STRAND 2569 2580 {ECO:0000244|PDB:2NQC}.; STRAND 2587 2594 {ECO:0000244|PDB:2NQC}.; STRAND 2639 2642 {ECO:0000244|PDB:1V05}.; STRAND 2654 2659 {ECO:0000244|PDB:1V05}.; STRAND 2663 2665 {ECO:0000244|PDB:1V05}.; STRAND 2668 2673 {ECO:0000244|PDB:1V05}.; STRAND 2675 2677 {ECO:0000244|PDB:1V05}.; STRAND 2680 2686 {ECO:0000244|PDB:1V05}.; STRAND 2691 2697 {ECO:0000244|PDB:1V05}.; STRAND 2702 2710 {ECO:0000244|PDB:1V05}.; STRAND 2719 2724 {ECO:0000244|PDB:1V05}.,TURN 1885 1887 {ECO:0000244|PDB:2D7O}.; TURN 2313 2316 {ECO:0000244|PDB:2K9U}.; TURN 2323 2325 {ECO:0000244|PDB:2K9U}.; TURN 2531 2533 {ECO:0000244|PDB:2D7Q}.,DOMAIN 1 259 Actin-binding.; DOMAIN 36 142 CH 1. {ECO:0000255|PROSITE-ProRule:PRU00044}.; DOMAIN 159 259 CH 2. {ECO:0000255|PROSITE-ProRule:PRU00044}.,,,,,1.651376147,-0.32,291.06,35.7,36.7P57678,GEMI4_HUMAN,reviewed,Gem-associated protein 4 (Gemin-4) (Component of gems 4) (p97),GEMIN4,Homo sapiens (Human),1058,GO:0097504; GO:0016070; GO:0032797; GO:0034719; GO:0005737; GO:0005829; GO:0070062; GO:0010467; GO:0016020; GO:0034660; GO:0005730; GO:0005654; GO:0006364; GO:0030532; GO:0000387,50628;,MDLGPLNICEEMTILHGGFLLAEQLFHPKALAELTKSDWERVGRPIVEALREISSAAAHSQPFAWKKKALIIIWAKVLQPHPVTPSDTETRWQEDLFFSVGNMIPTINHTILFELLKSLEASGLFIQLLMALPTTICHAELERFLEHVTVDTSAEDVAFFLDVWWEVMKHKGHPQDPLLSQFSAMAHKYLPALDEFPHPPKRLRSDPDACPTMPLLAMLLRGLTQIQSRILGPGRKCCALANLADMLTVFALTEDDPQEVSATVYLDKLATVISVWNSDTQNPYHQQALAEKVKEAERDVSLTSLAKLPSETIFVGCEFLHHLLREWGEELQAVLRSSQGTSYDSYRLCDSLTSFSQNATLYLNRTSLSKEDRQVVSELAECVRDFLRKTSTVLKNRALEDITASIAMAVIQQKMDRHMEVCYIFASEKKWAFSDEWVACLGSNRALFRQPDLVLRLLETVIDVSTADRAIPESQIRQVIHLILECYADLSLPGKNKVLAGILRSWGRKGLSEKLLAYVEGFQEDLNTTFNQLTQSASEQGLAKAVASVARLVIVHPEVTVKKMCSLAVVNLGTHKFLAQILTAFPALRFVEEQGPNSSATFMVSCLKETVWMKFSTPKEEKQFLELLNCLMSPVKPQGIPVAALLEPDEVLKEFVLPFLRLDVEEVDLSLRIFIQTLEANACREEYWLQTCSPFPLLFSLCQLLDRFSKYWQLPKEKRCLSLDRKDLAIHILELLCEIVSANAETFSPDVWIKSLSWLHRKLEQLDWTVGLRLKSFFEGHFKCEVPATLFEICKLSEDEWTSQAHPGYGAGTGLLAWMECCCVSSGISERMLSLLVVDVGNPEEVRLFSKGFLVALVQVMPWCSPQEWQRLHQLTRRLLEKQLLHVPYSLEYIQFVPLLNLKPFAQELQLSVLFLRTFQFLCSHSCRDWLPLEGWNHVVKLLCGSLTRLLDSVRAIQAAGPWVQGPEQDLTQEALFVYTQVFCHALHIMAMLHPEVCEPLYVLALETLTCYETLSKTNPSVSSLLQRAHEQRFLKSIAEGIGPEERRQTLLQKMSSF,,,,,hsa:50628;,,,"SUBUNIT: Part of the core SMN complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8 and STRAP/UNRIP. Part of the SMN-Sm complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8, STRAP/UNRIP and the Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG. Interacts directly with GEMIN3 and with several snRNP SM core proteins, including SNRPB, SNRPD1, SNRPD2, SNRPD3 and SNRPE. Interacts with PPP4R2. {ECO:0000269|PubMed:12668731, ECO:0000269|PubMed:18984161}.",,,,,,,,,2.930056711,0.026,120.06,1.79,2.79Q8TEQ6,GEMI5_HUMAN,reviewed,Gem-associated protein 5 (Gemin5),GEMIN5,Homo sapiens (Human),1508,GO:0097504; GO:0016070; GO:0032797; GO:0034719; GO:0005737; GO:0005829; GO:0010467; GO:0000398; GO:0016020; GO:0034660; GO:0016604; GO:0005654; GO:0005634; GO:0044822; GO:0006461; GO:0017069; GO:0000387,25929;,MGQEPRTLPPSPNWYCARCSDAVPGGLFGFAARTSVFLVRVGPGAGESPGTPPFRVIGELVGHTERVSGFTFSHHPGQYNLCATSSDDGTVKIWDVETKTVVTEHALHQHTISTLHWSPRVKDLIVSGDEKGVVFCYWFNRNDSQHLFIEPRTIFCLTCSPHHEDLVAIGYKDGIVVIIDISKKGEVIHRLRGHDDEIHSIAWCPLPGEDCLSINQEETSEEAEITNGNAVAQAPVTKGCYLATGSKDQTIRIWSCSRGRGVMILKLPFLKRRGGGIDPTVKERLWLTLHWPSNQPTQLVSSCFGGELLQWDLTQSWRRKYTLFSASSEGQNHSRIVFNLCPLQTEDDKQLLLSTSMDRDVKCWDIATLECSWTLPSLGGFAYSLAFSSVDIGSLAIGVGDGMIRVWNTLSIKNNYDVKNFWQGVKSKVTALCWHPTKEGCLAFGTDDGKVGLYDTYSNKPPQISSTYHKKTVYTLAWGPPVPPMSLGGEGDRPSLALYSCGGEGIVLQHNPWKLSGEAFDINKLIRDTNSIKYKLPVHTEISWKADGKIMALGNEDGSIEIFQIPNLKLICTIQQHHKLVNTISWHHEHGSQPELSYLMASGSNNAVIYVHNLKTVIESSPESPVTITEPYRTLSGHTAKITSVAWSPHHDGRLVSASYDGTAQVWDALREEPLCNFRGHRGRLLCVAWSPLDPDCIYSGADDFCVHKWLTSMQDHSRPPQGKKSIELEKKRLSQPKAKPKKKKKPTLRTPVKLESIDGNEEESMKENSGPVENGVSDQEGEEQAREPELPCGLAPAVSREPVICTPVSSGFEKSKVTINNKVILLKKEPPKEKPETLIKKRKARSLLPLSTSLDHRSKEELHQDCLVLATAKHSRELNEDVSADVEERFHLGLFTDRATLYRMIDIEGKGHLENGHPELFHQLMLWKGDLKGVLQTAAERGELTDNLVAMAPAAGYHVWLWAVEAFAKQLCFQDQYVKAASHLLSIHKVYEAVELLKSNHFYREAIAIAKARLRPEDPVLKDLYLSWGTVLERDGHYAVAAKCYLGATCAYDAAKVLAKKGDAASLRTAAELAAIVGEDELSASLALRCAQELLLANNWVGAQEALQLHESLQGQRLVFCLLELLSRHLEEKQLSEGKSSSSYHTWNTGTEGPFVERVTAVWKSIFSLDTPEQYQEAFQKLQNIKYPSATNNTPAKQLLLHICHDLTLAVLSQQMASWDEAVQALLRAVVRSYDSGSFTIMQEVYSAFLPDGCDHLRDKLGDHQSPATPAFKSLEAFFLYGRLYEFWWSLSRPCPNSSVWVRAGHRTLSVEPSQQLDTASTEETDPETSQPEPNRPSELDLRLTEEGERMLSTFKELFSEKHASLQNSQRTVAEVQETLAEMIRQHQKSQLCKSTANGPDKNEPEVEAEQPLCSSQSQCKEEKNEPLSLPELTKRLTEANQRMAKFPESIKAWPFPDVLECCLVLLLIRSHFPGCLAQEMQQQAQELLQKYGNTKTYRRHCQTFCM,,,,PF00400;,hsa:25929;,,,"SUBUNIT: Part of the core SMN complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8 and STRAP/UNRIP. Part of the SMN-Sm complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8, STRAP/UNRIP and the Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG. Interacts directly with SMN1, SNRPB, SNRPD1, SNRPD2, SNRPD3 and SNRPE. {ECO:0000269|PubMed:11714716, ECO:0000269|PubMed:18984161}.",,,,,,,,,2.718832891,-0.399,168.62,6.07,7.07P78347,GTF2I_HUMAN,reviewed,General transcription factor II-I (GTFII-I) (TFII-I) (Bruton tyrosine kinase-associated protein 135) (BAP-135) (BTK-associated protein 135) (SRF-Phox1-interacting protein) (SPIN) (Williams-Beuren syndrome chromosomal region 6 protein),GTF2I BAP135 WBSCR6,Homo sapiens (Human),998,GO:0003677; GO:0005737; GO:0016020; GO:0016525; GO:0005654; GO:0005634; GO:0003700; GO:0007165; GO:0006366; GO:0006367,2969;,MAQVAMSTLPVEDEESSESRMVVTFLMSALESMCKELAKSKAEVACIAVYETDVFVVGTERGRAFVNTRKDFQKDFVKYCVEEEEKAAEMHKMKSTTQANRMSVDAVEIETLRKTVEDYFCFCYGKALGKSTVVPVPYEKMLRDQSAVVVQGLPEGVAFKHPENYDLATLKWILENKAGISFIIKRPFLEPKKHVGGRVMVTDADRSILSPGGSCGPIKVKTEPTEDSGISLEMAAVTVKEESEDPDYYQYNIQAGPSETDDVDEKQPLSKPLQGSHHSSEGNEGTEMEVPAEDSTQHVPSETSEDPEVEVTIEDDDYSPPSKRPKANELPQPPVPEPANAGKRKVREFNFEKWNARITDLRKQVEELFERKYAQAIKAKGPVTIPYPLFQSHVEDLYVEGLPEGIPFRRPSTYGIPRLERILLAKERIRFVIKKHELLNSTREDLQLDKPASGVKEEWYARITKLRKMVDQLFCKKFAEALGSTEAKAVPYQKFEAHPNDLYVEGLPENIPFRSPSWYGIPRLEKIIQVGNRIKFVIKRPELLTHSTTEVTQPRTNTPVKEDWNVRITKLRKQVEEIFNLKFAQALGLTEAVKVPYPVFESNPEFLYVEGLPEGIPFRSPTWFGIPRLERIVRGSNKIKFVVKKPELVISYLPPGMASKINTKALQSPKRPRSPGSNSKVPEIEVTVEGPNNNNPQTSAVRTPTQTNGSNVPFKPRGREFSFEAWNAKITDLKQKVENLFNEKCGEALGLKQAVKVPFALFESFPEDFYVEGLPEGVPFRRPSTFGIPRLEKILRNKAKIKFIIKKPEMFETAIKESTSSKSPPRKINSSPNVNTTASGVEDLNIIQVTIPDDDNERLSKVEKARQLREQVNDLFSRKFGEAIGMGFPVKVPYRKITINPGCVVVDGMPPGVSFKAPSYLEISSMRRILDSAEFIKFTVIRPFPGLVINNQLVDQSESEGPVIQESAEPSQLEVPATEEIKETDGSSQIKQEPDPTW,"DISEASE: Note=GTF2I is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region. Haploinsufficiency of GTF2I may be the cause of certain cardiovascular and musculo-skeletal abnormalities observed in the disease.",,,PF02946;,hsa:2969;,,,"SUBUNIT: Homodimer (Potential). Interacts with SRF and PHOX1. Binds a pyrimidine-rich initiator (Inr) and a recognition site (E-box) for upstream stimulatory factor 1 (USF1). Associates with the PH domain of Bruton's tyrosine kinase (BTK). May be a component of a BHC histone deacetylase complex that contains HDAC1, HDAC2, HMG20B/BRAF35, KDM1A, RCOR1/CoREST, PHF21A/BHC80, ZMYM2, ZNF217, ZMYM3, GSE1 and GTF2I. Interacts with BTK and ARID3A. Interacts with isoform beta of PRKG1. {ECO:0000269|PubMed:10373551, ECO:0000269|PubMed:11373296, ECO:0000269|PubMed:12082086, ECO:0000269|PubMed:16738337, ECO:0000305}.",HELIX 106 128 {ECO:0000244|PDB:2D9B}.; HELIX 138 143 {ECO:0000244|PDB:2D9B}.; HELIX 167 175 {ECO:0000244|PDB:2D9B}.; HELIX 361 376 {ECO:0000244|PDB:2DN4}.; HELIX 387 392 {ECO:0000244|PDB:2DN4}.; HELIX 416 424 {ECO:0000244|PDB:2DN4}.; HELIX 466 482 {ECO:0000244|PDB:2ED2}.; HELIX 492 497 {ECO:0000244|PDB:2ED2}.; HELIX 521 529 {ECO:0000244|PDB:2ED2}.; HELIX 541 544 {ECO:0000244|PDB:2ED2}.; HELIX 861 883 {ECO:0000244|PDB:2EJE}.; HELIX 894 899 {ECO:0000244|PDB:2EJE}.; HELIX 923 931 {ECO:0000244|PDB:2EJE}.,STRAND 146 152 {ECO:0000244|PDB:2D9B}.; STRAND 181 185 {ECO:0000244|PDB:2D9B}.; STRAND 397 401 {ECO:0000244|PDB:2DN4}.; STRAND 430 434 {ECO:0000244|PDB:2DN4}.; STRAND 502 506 {ECO:0000244|PDB:2ED2}.; STRAND 535 539 {ECO:0000244|PDB:2ED2}.; STRAND 901 907 {ECO:0000244|PDB:2EJE}.; STRAND 937 942 {ECO:0000244|PDB:2EJE}.,TURN 176 179 {ECO:0000244|PDB:2D9B}.; TURN 393 396 {ECO:0000244|PDB:2DN4}.; TURN 411 413 {ECO:0000244|PDB:2DN4}.; TURN 426 428 {ECO:0000244|PDB:2DN4}.; TURN 437 439 {ECO:0000244|PDB:2DN4}.; TURN 499 501 {ECO:0000244|PDB:2ED2}.; TURN 516 518 {ECO:0000244|PDB:2ED2}.; TURN 530 533 {ECO:0000244|PDB:2ED2}.; TURN 856 858 {ECO:0000244|PDB:2EJE}.; TURN 918 920 {ECO:0000244|PDB:2EJE}.; TURN 932 935 {ECO:0000244|PDB:2EJE}.,,,,,,0.901803607,-0.526,112.43,43.7,44.7P07305,H10_HUMAN,reviewed,"Histone H1.0 (Histone H1') (Histone H1(0)) [Cleaved into: Histone H1.0, N-terminally processed]",H1F0 H1FV,Homo sapiens (Human),194,GO:0005794; GO:0015629; GO:0006309; GO:0006915; GO:0006921; GO:0031490; GO:0000790; GO:0005719; GO:0005654; GO:0000786; GO:0006334; GO:0005634; GO:0044822,3005;,MTENSTSAPAAKPKRAKASKKSTDHPKYSDMIVAAIQAEKNRAGSSRQSIQKYIKSHYKVGENADSQIKLSIKRLVTTGVLKQTKGVGASGSFRLAKSDEPKKSVAFKKTKKEIKKVATPKKASKPKKAASKAPTKKPKATPVKKAKKKLAATPKKAKKPKTVKAKPVKASKPKKAKPVKPKAKSSAKRAGKKK,,,,PF00538;,hsa:3005;,,,,,,,DOMAIN 24 97 H15. {ECO:0000255|PROSITE-ProRule:PRU00837}.,,,,,0,-1.073,20.87,74.2,75.2P51610,HCFC1_HUMAN,reviewed,Host cell factor 1 (HCF) (HCF-1) (C1 factor) (CFF) (VCAF) (VP16 accessory protein) [Cleaved into: HCF N-terminal chain 1; HCF N-terminal chain 2; HCF N-terminal chain 3; HCF N-terminal chain 4; HCF N-terminal chain 5; HCF N-terminal chain 6; HCF C-terminal chain 1; HCF C-terminal chain 2; HCF C-terminal chain 3; HCF C-terminal chain 4; HCF C-terminal chain 5; HCF C-terminal chain 6],HCFC1 HCF1 HFC1,Homo sapiens (Human),2035,GO:0071339; GO:0070688; GO:0001205; GO:0048188; GO:0007049; GO:0003682; GO:0006325; GO:0005737; GO:0043984; GO:0043981; GO:0043982; GO:0000123; GO:0042802; GO:0016020; GO:0005739; GO:0000122; GO:0043025; GO:0005654; GO:0005634; GO:0045787; GO:0010628; GO:0050821; GO:0043254; GO:0006355; GO:0019046; GO:0003700; GO:0003713; GO:0006366,3054;,MASAVSPANLPAVLLQPRWKRVVGWSGPVPRPRHGHRAVAIKELIVVFGGGNEGIVDELHVYNTATNQWFIPAVRGDIPPGCAAYGFVCDGTRLLVFGGMVEYGKYSNDLYELQASRWEWKRLKAKTPKNGPPPCPRLGHSFSLVGNKCYLFGGLANDSEDPKNNIPRYLNDLYILELRPGSGVVAWDIPITYGVLPPPRESHTAVVYTEKDNKKSKLVIYGGMSGCRLGDLWTLDIDTLTWNKPSLSGVAPLPRSLHSATTIGNKMYVFGGWVPLVMDDVKVATHEKEWKCTNTLACLNLDTMAWETILMDTLEDNIPRARAGHCAVAINTRLYIWSGRDGYRKAWNNQVCCKDLWYLETEKPPPPARVQLVRANTNSLEVSWGAVATADSYLLQLQKYDIPATAATATSPTPNPVPSVPANPPKSPAPAAAAPAVQPLTQVGITLLPQAAPAPPTTTTIQVLPTVPGSSISVPTAARTQGVPAVLKVTGPQATTGTPLVTMRPASQAGKAPVTVTSLPAGVRMVVPTQSAQGTVIGSSPQMSGMAALAAAAAATQKIPPSSAPTVLSVPAGTTIVKTMAVTPGTTTLPATVKVASSPVMVSNPATRMLKTAAAQVGTSVSSATNTSTRPIITVHKSGTVTVAQQAQVVTTVVGGVTKTITLVKSPISVPGGSALISNLGKVMSVVQTKPVQTSAVTGQASTGPVTQIIQTKGPLPAGTILKLVTSADGKPTTIITTTQASGAGTKPTILGISSVSPSTTKPGTTTIIKTIPMSAIITQAGATGVTSSPGIKSPITIITTKVMTSGTGAPAKIITAVPKIATGHGQQGVTQVVLKGAPGQPGTILRTVPMGGVRLVTPVTVSAVKPAVTTLVVKGTTGVTTLGTVTGTVSTSLAGAGGHSTSASLATPITTLGTIATLSSQVINPTAITVSAAQTTLTAAGGLTTPTITMQPVSQPTQVTLITAPSGVEAQPVHDLPVSILASPTTEQPTATVTIADSGQGDVQPGTVTLVCSNPPCETHETGTTNTATTTVVANLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSVVRVCSNPPCETHETGTTNTATTATSNMAGQHGCSNPPCETHETGTTNTATTAMSSVGANHQRDARRACAAGTPAVIRISVATGALEAAQGSKSQCQTRQTSATSTTMTVMATGAPCSAGPLLGPSMAREPGGRSPAFVQLAPLSSKVRLSSPSIKDLPAGRHSHAVSTAAMTRSSVGAGEPRMAPVCESLQGGSPSTTVTVTALEALLCPSATVTQVCSNPPCETHETGTTNTATTSNAGSAQRVCSNPPCETHETGTTHTATTATSNGGTGQPEGGQQPPAGRPCETHQTTSTGTTMSVSVGALLPDATSSHRTVESGLEVAAAPSVTPQAGTALLAPFPTQRVCSNPPCETHETGTTHTATTVTSNMSSNQDPPPAASDQGEVESTQGDSVNITSSSAITTTVSSTLTRAVTTVTQSTPVPGPSVPPPEELQVSPGPRQQLPPRQLLQSASTALMGESAEVLSASQTPELPAAVDLSSTGEPSSGQESAGSAVVATVVVQPPPPTQSEVDQLSLPQELMAEAQAGTTTLMVTGLTPEELAVTAAAEAAAQAAATEEAQALAIQAVLQAAQQAVMGTGEPMDTSEAAATVTQAELGHLSAEGQEGQATTIPIVLTQQELAALVQQQQLQEAQAQQQHHHLPTEALAPADSLNDPAIESNCLNELAGTVPSTVALLPSTATESLAPSNTFVAPQPVVVASPAKLQAAATLTEVANGIESLGVKPDLPPPPSKAPMKKENQWFDVGVIKGTNVMVTHYFLPPDDAVPSDDDLGTVPDYNQLKKQELQPGTAYKFRVAGINACGRGPFSEISAFKTCLPGFPGAPCAIKISKSPDGAHLTWEPPSVTSGKIIEYSVYLAIQSSQAGGELKSSTPAQLAFMRVYCGPSPSCLVQSSSLSNAHIDYTTKPAIIFRIAARNEKGYGPATQVRWLQETSKDSSGTKPANKRPMSSPEMKSAPKKSKADGQ,"DISEASE: Mental retardation, X-linked 3 (MRX3) [MIM:309541]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:23000143}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,DOMAIN: The HCF repeat is a highly specific proteolytic cleavage signal. {ECO:0000269|PubMed:12235138}.; DOMAIN: The kelch repeats fold into a 6-bladed kelch beta-propeller called the beta-propeller domain which mediates interaction with HCFC1R1. {ECO:0000269|PubMed:12235138}.,PF01344;,hsa:3054;,,,"SUBUNIT: Composed predominantly of six polypeptides ranging from 110 to 150 kDa and a minor 300 kDa polypeptide. The majority of N- and C-terminal cleavage products remain tightly, albeit non-covalently, associated. Interacts with POU2F1, CREB3, ZBTB17, EGR2, E2F4, CREBZF, SP1, GABP2, Sin3 HDAC complex (SIN3A, HDAC1, HDAC2, SUDS3), SAP30, SIN3B and FHL2. Component of a MLL1 complex, composed of at least the core components KMT2A/MLL1, ASH2L, HCFC1, WDR5 and RBBP5, as well as the facultative components BAP18, CHD8, DPY30, E2F6, HCFC2, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MEN1, MGA, KAT8, PELP1, PHF20, PRP31, RING2, RUVBL1, RUVBL2, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Component of the MLL5-L complex, composed of at least KMT2E/MLL5, STK38, PPP1CA, PPP1CB, PPP1CC, HCFC1, ACTB and OGT. Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1. Interacts directly with OGT; the interaction, which requires the HCFC1 cleavage site domain, glycosylates and promotes the proteolytic processing of HCFC1, retains OGT in the nucleus and impacts the expression of herpes simplex virus immediate early viral genes. Interacts with TET2 and TET3. Interacts directly with THAP3 (via its HBM). Interacts (via the Kelch-repeat domain) with THAP1 (via the HBM); the interaction recruits HCHC1 to the RRM1. Interacts with HCFC1R1 and THAP11. Associates with the VP16-induced complex; binding to HCFC1 activates the viral transcriptional activator VP16 for association with POU2F1, to form a multiprotein-DNA complex responsible for activating transcription of the viral immediate early genes. Component of the SET1 complex, at least composed of the catalytic subunit (SETD1A or SETD1B), WDR5, WDR82, RBBP5, ASH2L, CXXC1, HCFC1 and DPY30. Component of the NSL complex at least composed of MOF/KAT8, KANSL1, KANSL2, KANSL3, MCRS1, PHF20, OGT1/OGT, WDR5 and HCFC1. Interacts with the viral transactivator protein VP16. Part of a complex composed at least of ASCL2, C11orf30/EMSY, HCFC1, HSPA8, CCAR2, MATR3, MKI67, RBBP5, TUBB2A, WDR5 and ZNF335; this complex may have a histone H3-specific methyltransferase activity (By similarity). {ECO:0000250}.",HELIX 1963 1966 {ECO:0000244|PDB:4GO6}.,STRAND 368 375 {ECO:0000244|PDB:4GO6}.; STRAND 380 385 {ECO:0000244|PDB:4GO6}.; STRAND 391 399 {ECO:0000244|PDB:4GO6}.; STRAND 1813 1825 {ECO:0000244|PDB:4GO6}.; STRAND 1827 1829 {ECO:0000244|PDB:4GO6}.; STRAND 1853 1855 {ECO:0000244|PDB:4GO6}.; STRAND 1861 1870 {ECO:0000244|PDB:4GO6}.; STRAND 1873 1877 {ECO:0000244|PDB:4GO6}.; STRAND 1881 1884 {ECO:0000244|PDB:4GO6}.; STRAND 1895 1902 {ECO:0000244|PDB:4GO6}.; STRAND 1905 1911 {ECO:0000244|PDB:4GO6}.; STRAND 1922 1929 {ECO:0000244|PDB:4GO6}.; STRAND 1946 1962 {ECO:0000244|PDB:4GO6}.; STRAND 1971 1986 {ECO:0000244|PDB:4GO6}.; STRAND 1995 2000 {ECO:0000244|PDB:4GO6}.,,DOMAIN 366 466 Fibronectin type-III 1. {ECO:0000255|PROSITE-ProRule:PRU00316}.; DOMAIN 1797 1888 Fibronectin type-III 2. {ECO:0000255|PROSITE-ProRule:PRU00316}.; DOMAIN 1890 2006 Fibronectin type-III 3. {ECO:0000255|PROSITE-ProRule:PRU00316}.,,,,,1.71990172,-0.09,208.77,10.5,11.5Q00341,VIGLN_HUMAN,reviewed,Vigilin (High density lipoprotein-binding protein) (HDL-binding protein),HDLBP HBP VGL,Homo sapiens (Human),1268,GO:0008203; GO:0005737; GO:0034364; GO:0008289; GO:0006869; GO:0005634; GO:0005886; GO:0044822,3069;,MSSVAVLTQESFAEHRSGLVPQQIKVATLNSEEESDPPTYKDAFPPLPEKAACLESAQEPSGAWGNKIRPIKASVITQVFHVPLEERKYKDMNQFGEGEQAKICLEIMQRTGAHLELSLAKDQGLSIMVSGKLDAVMKARKDIVARLQTQASATVAIPKEHHRFVIGKNGEKLQDLELKTATKIQIPRPDDPSNQIKITGTKEGIEKARHEVLLISAEQDKRAVERLEVEKAFHPFIAGPYNRLVGEIMQETGTRINIPPPSVNRTEIVFTGEKEQLAQAVARIKKIYEEKKKKTTTIAVEVKKSQHKYVIGPKGNSLQEILERTGVSVEIPPSDSISETVILRGEPEKLGQALTEVYAKANSFTVSSVAAPSWLHRFIIGKKGQNLAKITQQMPKVHIEFTEGEDKITLEGPTEDVNVAQEQIEGMVKDLINRMDYVEINIDHKFHRHLIGKSGANINRIKDQYKVSVRIPPDSEKSNLIRIEGDPQGVQQAKRELLELASRMENERTKDLIIEQRFHRTIIGQKGERIREIRDKFPEVIINFPDPAQKSDIVQLRGPKNEVEKCTKYMQKMVADLVENSYSISVPIFKQFHKNIIGKGGANIKKIREESNTKIDLPAENSNSETIIITGKRANCEAARSRILSIQKDLANIAEVEVSIPAKLHNSLIGTKGRLIRSIMEECGGVHIHFPVEGSGSDTVVIRGPSSDVEKAKKQLLHLAEEKQTKSFTVDIRAKPEYHKFLIGKGGGKIRKVRDSTGARVIFPAAEDKDQDLITIIGKEDAVREAQKELEALIQNLDNVVEDSMLVDPKHHRHFVIRRGQVLREIAEEYGGVMVSFPRSGTQSDKVTLKGAKDCVEAAKKRIQEIIEDLEAQVTLECAIPQKFHRSVMGPKGSRIQQITRDFSVQIKFPDREENAVHSTEPVVQENGDEAGEGREAKDCDPGSPRRCDIIIISGRKEKCEAAKEALEALVPVTIEVEVPFDLHRYVIGQKGSGIRKMMDEFEVNIHVPAPELQSDIIAITGLAANLDRAKAGLLERVKELQAEQEDRALRSFKLSVTVDPKYHPKIIGRKGAVITQIRLEHDVNIQFPDKDDGNQPQDQITITGYEKNTEAARDAILRIVGELEQMVSEDVPLDHRVHARIIGARGKAIRKIMDEFKVDIRFPQSGAPDPNCVTVTGLPENVEEAIDHILNLEEEYLADVVDSEALQVYMKPPAHEEAKAPSRGFVVRDAPWTASSSEKAPDMSSSEEFPSFGAQVAPKTLPWGPKR,,,,PF00013;,hsa:3069;,,,,HELIX 162 166 {ECO:0000244|PDB:2CTE}.; HELIX 172 179 {ECO:0000244|PDB:2CTE}.; HELIX 202 220 {ECO:0000244|PDB:2CTE}.; HELIX 376 380 {ECO:0000244|PDB:2CTF}.; HELIX 386 393 {ECO:0000244|PDB:2CTF}.; HELIX 414 434 {ECO:0000244|PDB:2CTF}.; HELIX 446 450 {ECO:0000244|PDB:1VIG}.; HELIX 457 464 {ECO:0000244|PDB:1VIG}.; HELIX 488 499 {ECO:0000244|PDB:1VIG}.; HELIX 662 669 {ECO:0000244|PDB:2CTJ}.; HELIX 674 683 {ECO:0000244|PDB:2CTJ}.; HELIX 706 723 {ECO:0000244|PDB:2CTJ}.; HELIX 981 988 {ECO:0000244|PDB:2CTK}.; HELIX 993 1001 {ECO:0000244|PDB:2CTK}.; HELIX 1024 1050 {ECO:0000244|PDB:2CTK}.; HELIX 1064 1067 {ECO:0000244|PDB:2CTL}.; HELIX 1074 1082 {ECO:0000244|PDB:2CTL}.; HELIX 1107 1126 {ECO:0000244|PDB:2CTL}.; HELIX 1139 1143 {ECO:0000244|PDB:2CTM}.; HELIX 1149 1157 {ECO:0000244|PDB:2CTM}.; HELIX 1180 1198 {ECO:0000244|PDB:2CTM}.,STRAND 151 156 {ECO:0000244|PDB:2CTE}.; STRAND 168 170 {ECO:0000244|PDB:2CTE}.; STRAND 195 200 {ECO:0000244|PDB:2CTE}.; STRAND 365 370 {ECO:0000244|PDB:2CTF}.; STRAND 395 401 {ECO:0000244|PDB:2CTF}.; STRAND 403 405 {ECO:0000244|PDB:2CTF}.; STRAND 407 412 {ECO:0000244|PDB:2CTF}.; STRAND 436 442 {ECO:0000244|PDB:1VIG}.; STRAND 468 470 {ECO:0000244|PDB:1VIG}.; STRAND 476 487 {ECO:0000244|PDB:1VIG}.; STRAND 656 659 {ECO:0000244|PDB:2CTJ}.; STRAND 671 673 {ECO:0000244|PDB:2CTJ}.; STRAND 687 689 {ECO:0000244|PDB:2CTJ}.; STRAND 699 704 {ECO:0000244|PDB:2CTJ}.; STRAND 973 978 {ECO:0000244|PDB:2CTK}.; STRAND 990 992 {ECO:0000244|PDB:2CTK}.; STRAND 1005 1007 {ECO:0000244|PDB:2CTK}.; STRAND 1017 1022 {ECO:0000244|PDB:2CTK}.; STRAND 1054 1058 {ECO:0000244|PDB:2CTL}.; STRAND 1070 1072 {ECO:0000244|PDB:2CTL}.; STRAND 1085 1087 {ECO:0000244|PDB:2CTL}.; STRAND 1098 1105 {ECO:0000244|PDB:2CTL}.; STRAND 1130 1133 {ECO:0000244|PDB:2CTM}.; STRAND 1145 1147 {ECO:0000244|PDB:2CTM}.; STRAND 1160 1162 {ECO:0000244|PDB:2CTM}.; STRAND 1173 1178 {ECO:0000244|PDB:2CTM}.,TURN 159 161 {ECO:0000244|PDB:2CTE}.; TURN 381 384 {ECO:0000244|PDB:2CTF}.; TURN 452 454 {ECO:0000244|PDB:1VIH}.; TURN 693 696 {ECO:0000244|PDB:2CTJ}.; TURN 1011 1013 {ECO:0000244|PDB:2CTK}.; TURN 1061 1063 {ECO:0000244|PDB:2CTL}.; TURN 1091 1093 {ECO:0000244|PDB:2CTL}.; TURN 1136 1138 {ECO:0000244|PDB:2CTM}.,DOMAIN 158 229 KH 1. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 230 302 KH 2. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 303 371 KH 3. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 372 442 KH 4. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 443 514 KH 5. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 515 588 KH 6. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 589 660 KH 7. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 661 734 KH 8. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 735 807 KH 9. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 808 880 KH 10. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 881 979 KH 11. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 980 1059 KH 12. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 1060 1134 KH 13. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 1135 1209 KH 14. {ECO:0000255|PROSITE-ProRule:PRU00117}.,,,,,0.867507886,-0.499,141.48,24,25P11142,HSP7C_HUMAN,reviewed,Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) (Lipopolysaccharide-associated protein 1) (LAP-1) (LPS-associated protein 1),HSPA8 HSC70 HSP73 HSPA10,Homo sapiens (Human),646,GO:0005524; GO:0006200; GO:0016887; GO:0042623; GO:0001664; GO:0023026; GO:0000974; GO:0016070; GO:0008380; GO:0007411; GO:0072562; GO:0051085; GO:0072318; GO:0061202; GO:0005829; GO:0019899; GO:0005615; GO:0070062; GO:0005925; GO:0010467; GO:0031072; GO:0005622; GO:0016071; GO:0006397; GO:0042470; GO:0016020; GO:0061024; GO:1902904; GO:0045892; GO:0007269; GO:0005730; GO:0005634; GO:0005886; GO:0044822; GO:0006892; GO:0006457; GO:0042026; GO:0051726; GO:0006986; GO:0030529; GO:0005681; GO:0007268; GO:0006351; GO:0031625; GO:0051082; GO:0016032,3312;,MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD,,,"DOMAIN: The N-terminal 1-386 residues constitute the ATPase domain, while residues 387-646 form the peptide-binding domain. {ECO:0000269|PubMed:9305631}.",PF00012;,hsa:3312;,,,"SUBUNIT: Identified in a IGF2BP1-dependent mRNP granule complex containing untranslated mRNAs. Interacts with PACRG. Interacts with HSPH1/HSP105. Interacts with IRAK1BP1 and BAG1. Interacts with DNAJC7 and DNAJB14 (via J domain). Interacts (via C-terminus) with the E3 ligase CHIP forming a 210 kDa complex of one CHIP and two HSPA8 molecules. Interacts with CITED1 (via N-terminus); the interaction suppresses the association of CITED1 to p300/CBP and Smad-mediated transcription transactivation. Component of the PRP19-CDC5L splicing complex composed of a core complex comprising a homotetramer of PRPF19, CDC5L, PLRG1 and BCAS2, and at least three less stably associated proteins CTNNBL1, CWC15 and HSPA8. Interacts with SV40 VP1. Interacts with TRIM5. Part of a complex composed at least of ASCL2, C11orf30/EMSY, HCFC1, HSPA8, CCAR2, MATR3, MKI67, RBBP5, TUBB2A, WDR5 and ZNF335; this complex may have a histone H3-specific methyltransferase activity. Interacts with METTL21A. Following LPS binding, may form a complex with CXCR4, GDF5 and HSP90AA1. Interacts with PARK2. {ECO:0000269|PubMed:10722728, ECO:0000269|PubMed:11147964, ECO:0000269|PubMed:11276205, ECO:0000269|PubMed:14532270, ECO:0000269|PubMed:15963462, ECO:0000269|PubMed:16815975, ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:19131338, ECO:0000269|PubMed:20053985, ECO:0000269|PubMed:23865999, ECO:0000269|PubMed:23921388, ECO:0000269|PubMed:23990462, ECO:0000269|PubMed:24270810, ECO:0000269|PubMed:9305631, ECO:0000269|PubMed:9679980}.",HELIX 53 57 {ECO:0000244|PDB:4H5R}.; HELIX 63 65 {ECO:0000244|PDB:4H5R}.; HELIX 70 73 {ECO:0000244|PDB:4H5R}.; HELIX 81 86 {ECO:0000244|PDB:4H5R}.; HELIX 87 89 {ECO:0000244|PDB:4H5R}.; HELIX 116 135 {ECO:0000244|PDB:4H5R}.; HELIX 152 164 {ECO:0000244|PDB:4H5R}.; HELIX 175 182 {ECO:0000244|PDB:4H5R}.; HELIX 185 187 {ECO:0000244|PDB:4H5R}.; HELIX 230 249 {ECO:0000244|PDB:4H5R}.; HELIX 253 255 {ECO:0000244|PDB:3LDQ}.; HELIX 257 274 {ECO:0000244|PDB:4H5R}.; HELIX 299 305 {ECO:0000244|PDB:4H5R}.; HELIX 307 312 {ECO:0000244|PDB:4H5R}.; HELIX 314 323 {ECO:0000244|PDB:4H5R}.; HELIX 328 330 {ECO:0000244|PDB:4H5R}.; HELIX 339 342 {ECO:0000244|PDB:4H5R}.; HELIX 344 353 {ECO:0000244|PDB:4H5R}.; HELIX 368 380 {ECO:0000244|PDB:4H5R}.,STRAND 7 10 {ECO:0000244|PDB:4H5R}.; STRAND 13 22 {ECO:0000244|PDB:4H5R}.; STRAND 25 28 {ECO:0000244|PDB:4H5R}.; STRAND 36 40 {ECO:0000244|PDB:4H5R}.; STRAND 42 44 {ECO:0000244|PDB:4H5R}.; STRAND 49 52 {ECO:0000244|PDB:4H5R}.; STRAND 91 97 {ECO:0000244|PDB:4H5R}.; STRAND 100 107 {ECO:0000244|PDB:4H5R}.; STRAND 110 114 {ECO:0000244|PDB:4H5R}.; STRAND 141 146 {ECO:0000244|PDB:4H5R}.; STRAND 168 174 {ECO:0000244|PDB:4H5R}.; STRAND 193 200 {ECO:0000244|PDB:4H5R}.; STRAND 205 213 {ECO:0000244|PDB:4H5R}.; STRAND 216 225 {ECO:0000244|PDB:4H5R}.; STRAND 277 288 {ECO:0000244|PDB:4H5R}.; STRAND 291 298 {ECO:0000244|PDB:4H5R}.; STRAND 333 338 {ECO:0000244|PDB:4H5R}.; STRAND 357 360 {ECO:0000244|PDB:3FZF}.; STRAND 641 644 {ECO:0000244|PDB:3AGY}.,TURN 58 61 {ECO:0000244|PDB:4H5R}.; TURN 354 356 {ECO:0000244|PDB:4H5R}.; TURN 365 367 {ECO:0000244|PDB:4H5R}.,,,,,,0.619195046,-0.456,70.91,1362,1363Q92598,HS105_HUMAN,reviewed,Heat shock protein 105 kDa (Antigen NY-CO-25) (Heat shock 110 kDa protein),HSPH1 HSP105 HSP110 KIAA0201,Homo sapiens (Human),858,GO:0005524; GO:0051085; GO:0005737; GO:0005829; GO:0071682; GO:0005576; GO:0070062; GO:0005874; GO:0005654; GO:0045345; GO:0051135; GO:0006986,10808;,MSVVGLDVGSQSCYIAVARAGGIETIANEFSDRCTPSVISFGSKNRTIGVAAKNQQITHANNTVSNFKRFHGRAFNDPFIQKEKENLSYDLVPLKNGGVGIKVMYMGEEHLFSVEQITAMLLTKLKETAENSLKKPVTDCVISVPSFFTDAERRSVLDAAQIVGLNCLRLMNDMTAVALNYGIYKQDLPSLDEKPRIVVFVDMGHSAFQVSACAFNKGKLKVLGTAFDPFLGGKNFDEKLVEHFCAEFKTKYKLDAKSKIRALLRLYQECEKLKKLMSSNSTDLPLNIECFMNDKDVSGKMNRSQFEELCAELLQKIEVPLYSLLEQTHLKVEDVSAVEIVGGATRIPAVKERIAKFFGKDISTTLNADEAVARGCALQCAILSPAFKVREFSVTDAVPFPISLIWNHDSEDTEGVHEVFSRNHAAPFSKVLTFLRRGPFELEAFYSDPQGVPYPEAKIGRFVVQNVSAQKDGEKSRVKVKVRVNTHGIFTISTASMVEKVPTEENEMSSEADMECLNQRPPENPDTDKNVQQDNSEAGTQPQVQTDAQQTSQSPPSPELTSEENKIPDADKANEKKVDQPPEAKKPKIKVVNVELPIEANLVWQLGKDLLNMYIETEGKMIMQDKLEKERNDAKNAVEEYVYEFRDKLCGPYEKFICEQDHQNFLRLLTETEDWLYEEGEDQAKQAYVDKLEELMKIGTPVKVRFQEAEERPKMFEELGQRLQHYAKIAADFRNKDEKYNHIDESEMKKVEKSVNEVMEWMNNVMNAQAKKSLDQDPVVRAQEIKTKIKELNNTCEPVVTQPKPKIESPKLERTPNGPNIDKKEEDLEDKNNFGAEPPHQNGECYPNEKNSVNMDLD,,,,PF00012;,hsa:10808;,,,SUBUNIT: Interacts with HSPA8/HSC70. {ECO:0000250}.,,,,,,,,,1.864801865,-0.572,96.88,57.9,58.9O00425,IF2B3_HUMAN,reviewed,Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2 mRNA-binding protein 3) (IMP-3) (IGF-II mRNA-binding protein 3) (KH domain-containing protein overexpressed in cancer) (hKOC) (VICKZ family member 3),IGF2BP3 IMP3 KOC1 VICKZ3,Homo sapiens (Human),579,GO:0003723; GO:0009653; GO:0005737; GO:0005829; GO:0010467; GO:0003730; GO:0048027; GO:0051028; GO:0017148; GO:0000166; GO:0005634; GO:0044822; GO:0042035; GO:0006412; GO:0045182,10643;,MNKLYIGNLSENAAPSDLESIFKDAKIPVSGPFLVKTGYAFVDCPDESWALKAIEALSGKIELHGKPIEVEHSVPKRQRIRKLQIRNIPPHLQWEVLDSLLVQYGVVESCEQVNTDSETAVVNVTYSSKDQARQALDKLNGFQLENFTLKVAYIPDEMAAQQNPLQQPRGRRGLGQRGSSRQGSPGSVSKQKPCDLPLRLLVPTQFVGAIIGKEGATIRNITKQTQSKIDVHRKENAGAAEKSITILSTPEGTSAACKSILEIMHKEAQDIKFTEEIPLKILAHNNFVGRLIGKEGRNLKKIEQDTDTKITISPLQELTLYNPERTITVKGNVETCAKAEEEIMKKIRESYENDIASMNLQAHLIPGLNLNALGLFPPTSGMPPPTSGPPSAMTPPYPQFEQSETETVHLFIPALSVGAIIGKQGQHIKQLSRFAGASIKIAPAEAPDAKVRMVIITGPPEAQFKAQGRIYGKIKEENFVSPKEEVKLEAHIRVPSFAAGRVIGKGGKTVNELQNLSSAEVVVPRDQTPDENDQVVVKITGHFYACQVAQRKIQEILTQVKQHQQQKALQSGPPQSRRK,,,"DOMAIN: All KH domains contribute binding to target mRNA. They are also required for RNA-dependent homo- and heterooligomerization. The integrity of KH domains seems not to be required for localization to stress granules. {ECO:0000269|PubMed:20080952, ECO:0000269|PubMed:23640942}.",PF00013;PF00076;,hsa:10643;,,,"SUBUNIT: Can form homooligomers and heterooligomers with IGF2BP1 and IGF2BP3 in an RNA-dependent manner. Interacts with IGF2BP1. Interacts with ELAVL1, DHX9 and HNRNPU. {ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:23640942}.",HELIX 94 104 {ECO:0000244|PDB:2E44}.; HELIX 129 139 {ECO:0000244|PDB:2E44}.,STRAND 83 88 {ECO:0000244|PDB:2E44}.; STRAND 90 92 {ECO:0000244|PDB:2E44}.; STRAND 107 113 {ECO:0000244|PDB:2E44}.; STRAND 116 128 {ECO:0000244|PDB:2E44}.; STRAND 150 153 {ECO:0000244|PDB:2E44}.,,DOMAIN 2 75 RRM 1. {ECO:0000255|PROSITE-ProRule:PRU00176}.; DOMAIN 81 156 RRM 2. {ECO:0000255|PROSITE-ProRule:PRU00176}.; DOMAIN 195 260 KH 1. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 276 343 KH 2. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 405 470 KH 3. {ECO:0000255|PROSITE-ProRule:PRU00117}.; DOMAIN 487 553 KH 4. {ECO:0000255|PROSITE-ProRule:PRU00117}.,,,,,1.03626943,-0.427,63.72,27,28Q16891,MIC60_HUMAN,reviewed,MICOS complex subunit MIC60 (Cell proliferation-inducing gene 4/52 protein) (Mitochondrial inner membrane protein) (Mitofilin) (p87/89),IMMT HMP MIC60 MINOS2 PIG4 PIG52,Homo sapiens (Human),758,GO:0016021; GO:0016020; GO:0051560; GO:0005743; GO:0005739; GO:0044822; GO:0009409,10989;,MLRACQLSGVTAAAQSCLCGKFVLRPLRPCRRYSTSGSSGLTTGKIAGAGLLFVGGGIGGTILYAKWDSHFRESVEKTIPYSDKLFEMVLGPAAYNVPLPKKSIQSGPLKISSVSEVMKESKQPASQLQKQKGDTPASATAPTEAAQIISAAGDTLSVPAPAVQPEESLKTDHPEIGEGKPTPALSEEASSSSIRERPPEEVAARLAQQEKQEQVKIESLAKSLEDALRQTASVTLQAIAAQNAAVQAVNAHSNILKAAMDNSEIAGEKKSAQWRTVEGALKERRKAVDEAADALLKAKEELEKMKSVIENAKKKEVAGAKPHITAAEGKLHNMIVDLDNVVKKVQAAQSEAKVVSQYHELVVQARDDFKRELDSITPEVLPGWKGMSVSDLADKLSTDDLNSLIAHAHRRIDQLNRELAEQKATEKQHITLALEKQKLEEKRAFDSAVAKALEHHRSEIQAEQDRKIEEVRDAMENEMRTQLRRQAAAHTDHLRDVLRVQEQELKSEFEQNLSEKLSEQELQFRRLSQEQVDNFTLDINTAYARLRGIEQAVQSHAVAEEEARKAHQLWLSVEALKYSMKTSSAETPTIPLGSAVEAIKANCSDNEFTQALTAAIPPESLTRGVYSEETLRARFYAVQKLARRVAMIDETRNSLYQYFLSYLQSLLLFPPQQLKPPPELCPEDINTFKLLSYASYCIEHGDLELAAKFVNQLKGESRRVAQDWLKEARMTLETKQIVEILTAYASAVGIGTTQVQPE,,,,PF09731;,hsa:10989;,,,"SUBUNIT: Interacts with HSPA1A/HSPA1B and OPA1, preferentially with the soluble OPA1 form (By similarity). Component of the mitochondrial contact site and cristae organizing system (MICOS) complex, composed of at least MINOS1/MIC10, CHCHD3/MIC19, CHCHD6/MIC25, APOOL/MIC27 and IMMT/MIC60. The complex associates with mitochondrial outer membrane proteins SAMM50, MTX1 and MTX2, and with HSPA9. {ECO:0000250, ECO:0000269|PubMed:21081504, ECO:0000269|PubMed:22114354, ECO:0000269|PubMed:22228767}.",,,,,,,,,0.92348285,-0.465,83.7,85.6,86.6P33176,KINH_HUMAN,reviewed,Kinesin-1 heavy chain (Conventional kinesin heavy chain) (Ubiquitous kinesin heavy chain) (UKHC),KIF5B KNS KNS1,Homo sapiens (Human),963,GO:0005524; GO:0006200; GO:0016887; GO:0007411; GO:0044267; GO:0035253; GO:0005737; GO:0007028; GO:0030705; GO:0030139; GO:0005871; GO:0016020; GO:0005874; GO:0008017; GO:0003777; GO:0005815; GO:0007018; GO:0043005; GO:0048471; GO:0008574; GO:0072383; GO:0090004; GO:0043268; GO:0042391; GO:0035617; GO:0031982; GO:0047496,3799;,MADLAECNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDCAKKIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGCTERFVCSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNCRTTIVICCSPSSYNESETKSTLLFGQRAKTIKNTVCVNVELTAEQWKKKYEKEKEKNKILRNTIQWLENELNRWRNGETVPIDEQFDKEKANLEAFTVDKDITLTNDKPATAIGVIGNFTDAERRKCEEEIAKLYKQLDDKDEEINQQSQLVEKLKTQMLDQEELLASTRRDQDNMQAELNRLQAENDASKEEVKEVLQALEELAVNYDQKSQEVEDKTKEYELLSDELNQKSATLASIDAELQKLKEMTNHQKKRAAEMMASLLKDLAEIGIAVGNNDVKQPEGTGMIDEEFTVARLYISKMKSEVKTMVKRCKQLESTQTESNKKMEENEKELAACQLRISQHEAKIKSLTEYLQNVEQKKRQLEESVDALSEELVQLRAQEKVHEMEKEHLNKVQTANEVKQAVEQQIQSHRETHQKQISSLRDEVEAKAKLITDLQDQNQKMMLEQERLRVEHEKLKATDQEKSRKLHELTVMQDRREQARQDLKGLEETVAKELQTLHNLRKLFVQDLATRVKKSAEIDSDDTGGSAAQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALESALKEAKENASRDRKRYQQEVDRIKEAVRSKNMARRGHSAQIAKPIRPGQHPAASPTHPSAIRGGGAFVQNSQPVAVRGGGGKQV,,,"DOMAIN: Composed of three structural domains: a large globular N-terminal domain which is responsible for the motor activity of kinesin (it hydrolyzes ATP and binds microtubule), a central alpha-helical coiled coil domain that mediates the heavy chain dimerization; and a small globular C-terminal domain which interacts with other proteins (such as the kinesin light chains), vesicles and membranous organelles.",PF00225;,hsa:3799;,,,"SUBUNIT: Oligomer composed of two heavy chains and two light chains. Interacts with GRIP1 and PPP1R42 (By similarity). Interacts with SYBU. Interacts with JAKMIP1. Interacts with PLEKHM2. Interacts with ECM29. {ECO:0000250, ECO:0000269|PubMed:12368902, ECO:0000269|PubMed:15459722, ECO:0000269|PubMed:15905402, ECO:0000269|PubMed:17532644, ECO:0000269|PubMed:20682791, ECO:0000269|PubMed:8606779}.",HELIX 20 25 {ECO:0000244|PDB:1BG2}.; HELIX 58 65 {ECO:0000244|PDB:1BG2}.; HELIX 67 74 {ECO:0000244|PDB:1BG2}.; HELIX 91 95 {ECO:0000244|PDB:1BG2}.; HELIX 107 122 {ECO:0000244|PDB:1BG2}.; HELIX 176 189 {ECO:0000244|PDB:1BG2}.; HELIX 197 203 {ECO:0000244|PDB:1BG2}.; HELIX 238 241 {ECO:0000244|PDB:4HNA}.; HELIX 256 269 {ECO:0000244|PDB:1BG2}.; HELIX 277 279 {ECO:0000244|PDB:1BG2}.; HELIX 281 285 {ECO:0000244|PDB:1BG2}.; HELIX 286 288 {ECO:0000244|PDB:1BG2}.; HELIX 306 308 {ECO:0000244|PDB:1BG2}.; HELIX 309 320 {ECO:0000244|PDB:1BG2}.; HELIX 337 348 {ECO:0000244|PDB:1MKJ}.,STRAND 8 15 {ECO:0000244|PDB:1BG2}.; STRAND 32 34 {ECO:0000244|PDB:1BG2}.; STRAND 38 41 {ECO:0000244|PDB:1BG2}.; STRAND 44 47 {ECO:0000244|PDB:1BG2}.; STRAND 49 52 {ECO:0000244|PDB:1BG2}.; STRAND 79 84 {ECO:0000244|PDB:1BG2}.; STRAND 124 138 {ECO:0000244|PDB:1BG2}.; STRAND 141 146 {ECO:0000244|PDB:1BG2}.; STRAND 155 157 {ECO:0000244|PDB:1BG2}.; STRAND 163 165 {ECO:0000244|PDB:1BG2}.; STRAND 171 173 {ECO:0000244|PDB:1BG2}.; STRAND 204 216 {ECO:0000244|PDB:1BG2}.; STRAND 222 231 {ECO:0000244|PDB:1BG2}.; STRAND 242 244 {ECO:0000244|PDB:1BG2}.; STRAND 290 293 {ECO:0000244|PDB:1BG2}.; STRAND 295 302 {ECO:0000244|PDB:1BG2}.; STRAND 326 329 {ECO:0000244|PDB:1MKJ}.,TURN 35 37 {ECO:0000244|PDB:1BG2}.; TURN 102 104 {ECO:0000244|PDB:1BG2}.; TURN 190 193 {ECO:0000244|PDB:1BG2}.; TURN 217 219 {ECO:0000244|PDB:1BG2}.,DOMAIN 8 325 Kinesin motor. {ECO:0000255|PROSITE-ProRule:PRU00283}.,,,,,1.349948079,-0.81,109.71,26.6,27.6P52292,IMA1_HUMAN,reviewed,Importin subunit alpha-1 (Karyopherin subunit alpha-2) (RAG cohort protein 1) (SRP1-alpha),KPNA2 RCH1 SRP1,Homo sapiens (Human),529,GO:0006259; GO:0006607; GO:0019221; GO:0005737; GO:0005829; GO:0042826; GO:0016020; GO:0008139; GO:0005654; GO:0044822; GO:0008565; GO:0000018; GO:0016032,3838;,MSTNENANTPAARLHRFKNKGKDSTEMRRRRIEVNVELRKAKKDDQMLKRRNVSSFPDDATSPLQENRNNQGTVNWSVDDIVKGINSSNVENQLQATQAARKLLSREKQPPIDNIIRAGLIPKFVSFLGRTDCSPIQFESAWALTNIASGTSEQTKAVVDGGAIPAFISLLASPHAHISEQAVWALGNIAGDGSVFRDLVIKYGAVDPLLALLAVPDMSSLACGYLRNLTWTLSNLCRNKNPAPPIDAVEQILPTLVRLLHHDDPEVLADTCWAISYLTDGPNERIGMVVKTGVVPQLVKLLGASELPIVTPALRAIGNIVTGTDEQTQVVIDAGALAVFPSLLTNPKTNIQKEATWTMSNITAGRQDQIQQVVNHGLVPFLVSVLSKADFKTQKEAVWAVTNYTSGGTVEQIVYLVHCGIIEPLMNLLTAKDTKIILVILDAISNIFQAAEKLGETEKLSIMIEECGGLDKIEALQNHENESVYKASLSLIEKYFSVEEEEDQNVVPETTSEGYTFQVQDGAPGTFNF,,,"DOMAIN: Consists of an N-terminal hydrophilic region, a hydrophobic central region composed of 10 repeats, and a short hydrophilic C-terminus. The N-terminal hydrophilic region contains the importin beta binding domain (IBB domain), which is sufficient for binding importin beta and essential for nuclear protein import. {ECO:0000269|PubMed:8617227}.; DOMAIN: The IBB domain is thought to act as an intrasteric autoregulatory sequence by interacting with the internal autoinhibitory NLS. Binding of KPNB1 probably overlaps the internal NLS and contributes to a high affinity for cytoplasmic NLS-containing cargo substrates. After dissociation of the importin/substrate complex in the nucleus the internal autohibitory NLS contributes to a low affinity for nuclear NLS-containing proteins (By similarity). {ECO:0000250}.; DOMAIN: The major and minor NLS binding sites are mainly involved in recognition of simple or bipartite NLS motifs. Structurally located within in a helical surface groove they contain several conserved Trp and Asn residues of the corresponding third helices (H3) of ARM repeats which mainly contribute to binding (By similarity). {ECO:0000250}.",PF00514;PF01749;,hsa:3838;,,,"SUBUNIT: Heterodimer; with KPNB1. Interacts with ANP32E (By similarity). Component of a complex containing CSE1L, RAN and KPNA2. Interacts directly with CSE1L. Interacts with HIV-1 Vpr and PLAG1. Interacts with APEX1 (via N-terminus). Interacts with FRG1 (via N-terminus). Interacts with ARL4A, CTNNBL1 and NBN. Interacts with SNAI1 (via zinc fingers) and SNAI2 (via zinc fingers). {ECO:0000250, ECO:0000269|PubMed:10980193, ECO:0000269|PubMed:11882654, ECO:0000269|PubMed:15942031, ECO:0000269|PubMed:16188882, ECO:0000269|PubMed:19386897, ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:21454664, ECO:0000269|PubMed:21699900, ECO:0000269|PubMed:7604027, ECO:0000269|PubMed:9323134, ECO:0000269|PubMed:9463369, ECO:0000269|PubMed:9786944}.",HELIX 14 16 {ECO:0000244|PDB:1QGK}.; HELIX 30 48 {ECO:0000244|PDB:1QGR}.; HELIX 78 85 {ECO:0000244|PDB:3FEY}.; HELIX 90 104 {ECO:0000244|PDB:3FEY}.; HELIX 112 117 {ECO:0000244|PDB:3FEY}.; HELIX 120 129 {ECO:0000244|PDB:3FEY}.; HELIX 134 147 {ECO:0000244|PDB:3FEY}.; HELIX 152 160 {ECO:0000244|PDB:3FEY}.; HELIX 163 170 {ECO:0000244|PDB:3FEY}.; HELIX 176 190 {ECO:0000244|PDB:3FEY}.; HELIX 194 202 {ECO:0000244|PDB:3FEY}.; HELIX 206 211 {ECO:0000244|PDB:3FEY}.; HELIX 218 220 {ECO:0000244|PDB:4E4V}.; HELIX 223 236 {ECO:0000244|PDB:3FEY}.; HELIX 246 259 {ECO:0000244|PDB:3FEY}.; HELIX 265 279 {ECO:0000244|PDB:3FEY}.; HELIX 283 291 {ECO:0000244|PDB:3FEY}.; HELIX 295 301 {ECO:0000244|PDB:3FEY}.; HELIX 307 320 {ECO:0000244|PDB:3FEY}.; HELIX 325 333 {ECO:0000244|PDB:3FEY}.; HELIX 336 344 {ECO:0000244|PDB:3FEY}.; HELIX 349 362 {ECO:0000244|PDB:3FEY}.; HELIX 367 375 {ECO:0000244|PDB:3FEY}.; HELIX 379 388 {ECO:0000244|PDB:3FEY}.; HELIX 391 407 {ECO:0000244|PDB:3FEY}.; HELIX 410 418 {ECO:0000244|PDB:3FEY}.; HELIX 422 427 {ECO:0000244|PDB:3FEY}.; HELIX 428 430 {ECO:0000244|PDB:3FEY}.; HELIX 434 453 {ECO:0000244|PDB:3FEY}.; HELIX 457 466 {ECO:0000244|PDB:3FEY}.; HELIX 469 475 {ECO:0000244|PDB:3FEY}.; HELIX 476 478 {ECO:0000244|PDB:3FEY}.; HELIX 482 495 {ECO:0000244|PDB:3FEY}.,STRAND 106 108 {ECO:0000244|PDB:3FEY}.,TURN 18 21 {ECO:0000244|PDB:1QGK}.,DOMAIN 2 60 IBB. {ECO:0000255|PROSITE-ProRule:PRU00561}.,,,,,1.134215501,-0.138,57.87,0.47,1.47P20700,LMNB1_HUMAN,reviewed,Lamin-B1,LMNB1 LMN2 LMNB,Homo sapiens (Human),586,GO:0006915; GO:0006921; GO:0005638; GO:0016020; GO:0005635; GO:0005637; GO:0031965; GO:0005654; GO:0005198,4001;,MATATPVPPRMGSRAGGPTTPLSPTRLSRLQEKEELRELNDRLAVYIDKVRSLETENSALQLQVTEREEVRGRELTGLKALYETELADARRALDDTARERAKLQIELGKCKAEHDQLLLNYAKKESDLNGAQIKLREYEAALNSKDAALATALGDKKSLEGDLEDLKDQIAQLEASLAAAKKQLADETLLKVDLENRCQSLTEDLEFRKSMYEEEINETRRKHETRLVEVDSGRQIEYEYKLAQALHEMREQHDAQVRLYKEELEQTYHAKLENARLSSEMNTSTVNSAREELMESRMRIESLSSQLSNLQKESRACLERIQELEDLLAKEKDNSRRMLTDKEREMAEIRDQMQQQLNDYEQLLDVKLALDMEISAYRKLLEGEEERLKLSPSPSSRVTVSRASSSRSVRTTRGKRKRVDVEESEASSSVSISHSASATGNVCIEEIDVDGKFIRLKNTSEQDQPMGGWEMIRKIGDTSVSYKYTSRYVLKAGQTVTIWAANAGVTASPPTDLIWKNQNSWGTGEDVKVILKNSQGEEVAQRSTVFKTTIPEEEEEEEEAAGVVVEEELFHQQGTPRASNRSCAIM,"DISEASE: Leukodystrophy, demyelinating, autosomal dominant, adult-onset (ADLD) [MIM:169500]: A slowly progressive and fatal demyelinating leukodystrophy, presenting in the fourth or fifth decade of life. Clinically characterized by early autonomic abnormalities, pyramidal and cerebellar dysfunction, and symmetric demyelination of the CNS. It differs from multiple sclerosis and other demyelinating disorders in that neuropathology shows preservation of oligodendroglia in the presence of subtotal demyelination and lack of astrogliosis. {ECO:0000269|PubMed:16951681}. Note=The disease is caused by mutations affecting the gene represented in this entry.",DISULFID 317 317 Interchain. {ECO:0000269|PubMed:22265972}.,,PF00038;PF00932;,hsa:4001;,,,"SUBUNIT: Homodimer. Interacts with lamin-associated polypeptides IA, IB and 2. {ECO:0000269|PubMed:22265972}.",HELIX 315 381 {ECO:0000244|PDB:3TYY}.,STRAND 432 447 {ECO:0000244|PDB:3UMN}.; STRAND 451 458 {ECO:0000244|PDB:3UMN}.; STRAND 460 462 {ECO:0000244|PDB:3UMN}.; STRAND 470 475 {ECO:0000244|PDB:3UMN}.; STRAND 478 483 {ECO:0000244|PDB:3UMN}.; STRAND 495 500 {ECO:0000244|PDB:3UMN}.; STRAND 512 515 {ECO:0000244|PDB:3UMN}.; STRAND 523 525 {ECO:0000244|PDB:3UMN}.; STRAND 527 532 {ECO:0000244|PDB:3UMN}.; STRAND 538 546 {ECO:0000244|PDB:3UMN}.,TURN 509 511 {ECO:0000244|PDB:3UMN}.,DOMAIN 434 546 LTD.,,,,,0.853242321,-0.788,66.42,105,106P29966,MARCS_HUMAN,reviewed,"Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein kinase C substrate, 80 kDa protein, light chain) (80K-L protein) (PKCSL)",MARCKS MACS PRKCSL,Homo sapiens (Human),332,GO:0015629; GO:0051015; GO:0005516; GO:0005938; GO:0005813; GO:0006112; GO:0070062; GO:0005925; GO:0042585; GO:0005886; GO:0050796; GO:0044281,4082;,MGAQFSKTAAKGEAAAERPGEAAVASSPSKANGQENGHVKVNGDASPAAAESGAKEELQANGSAPAADKEEPAAAGSGAASPSAAEKGEPAAAAAPEAGASPVEKEAPAEGEAAEPGSPTAAEGEAASAASSTSSPKAEDGATPSPSNETPKKKKKRFSFKKSFKLSGFSFKKNKKEAGEGGEAEAPAAEGGKDEAAGGAAAAAAEAGAASGEQAAAPGEEAAAGEEGAAGGDPQEAKPQEAAVAPEKPPASDETKAAEEPSKVEEKKAEEAGASAAACEAPSAAGPGAPPEQEAAPAEEPAAAAASSACAAPSQEAQPECSPEAPPAEAAE,,,,PF02063;,hsa:4082;,,,,,,,,,,,,0.903614458,-0.714,31.56,171,172E9PAV3,NACAM_HUMAN,reviewed,"Nascent polypeptide-associated complex subunit alpha, muscle-specific form (Alpha-NAC, muscle-specific form) (skNAC)",NACA,Homo sapiens (Human),2078,GO:0003677; GO:0005737; GO:0005634; GO:0006355; GO:0006351,4666;,MPGEATETVPATEQELPQPQAETAVLPMSSALSVTAALGQPGPTLPPPCSPAPQQCPLSAANQASPFPSPSTIASTPLEVPFPQSSSGTALPLGTAPEAPTFLPNLIGPPISPAALALASPMIAPTLKGTPSSSAPLALVALAPHSVQKSSAFPPNLLTSPPSVAVAESGSVITLSAPIAPSEPKTNLNKVPSEVVPNPKGTPSPPCIVSTVPYHCVTPMASIQSGVASLPQTTPTTTLAIASPQVKDTTISSVLISPQNPGSLSLKGPVSPPAALSLSTQSLPVVTSSQKTAGPNTPPDFPISLGSHLAPLHQSSFGSVQLLGQTGPSALSDPTVKTISVDHSSTGASYPSQRSVIPPLPSRNEVVPATVAAFPVVAPSVDKGPSTISSITCSPSGSLNVATSFSLSPTTSLILKSSPNATYHYPLVAQMPVSSVGTTPLVVTNPCTIAAAPTTTFEVATCVSPPMSSGPISNIEPTSPAALVMAPVAPKEPSTQVATTLRIPVSPPLPDPEDLKNLPSSVLVKFPTQKDLQTVPASLEGAPFSPAQAGLTTKKDPTVLPLVQAAPKNSPSFQSTSSSPEIPLSPEATLAKKSLGEPLPIGKPASSMTSPLGVNSSASVIKTDSYAGPDSAGPLLKSSLITPTVAAFPLESADPAGVAPTTAKGTSTYTTTASPFLEGTVSLAPKNHPVKEGTLTTLPLVPTASENCPVAPSPQNTCAPLATLVLAPEIPKSVPSPSLPPAGTPPGTKKVDGISHTSALAPVASSPKECPTEDSGASATASSKGTLTYLADSPSPLGVSVSPQTKRPPTKKGSAGPDTPIGNLSSPVSPVEASFLPENSLSFQGSKDSPATTHSPTPPSPKGAPTPSAVTPLSPKGVTLPPKETPTPSVVNLPFPKEGPATPAPKQAPALSMTSSSPKKARATPAPKGIPASPSPKGAPTPPAATPPSPKGGPATPSPKWAPTPPAATPPSPKGGPATPSPKGAPTPPAATPPSPKGGPATPSPKGAPTPPAVTPPSPKGSPAATPFPKGASTPPAATPPSPKGSPAATPLPKGAPTTPAATLPSPKGGPATPSLKGAPTPPAATPPSPKGGPATPSPKGAPMPPAATPPSPKGGLATPPHKGAPTTPAATPPSPKGGLATPPPKGAPTTPAATPPSPKGGLATPPPKGAPTTPAATPPSPKGGLATPSPKGAPTTPAATPPSPKGGLATPSPKGAPTTPAATPPSPKGGLATPSPKGAPTTPAATPPSPKGGPATPPPKGAPTPPAATPPSLKGGLATPPHKGAPNPAVVTPPSPKGGPATSPPKGAPTPPAATPPSPKGSPGTPPPKGAPTPPAVTPPSPKGTPTLPATTPSSKGGPTTPSSKEGPTPPAATPSHKGGPAMTPPSPKRGPAIPSPKGDPTSPAVIPLSPKKAPATPVTREGAATPSKGDLTPPAVTPVSLKKAPATSAPKGGPATPSSKGDPTLPAVTPPSPKEPPAPKQVATSSSPKKAPATPAPMGAPTLPAVIPSSPKEVPATPSSRRDPIAPTATLLSKKTPATLAPKEALIPPAMTVPSPKKTPAIPTPKEAPATPSSKEASSPPAVTPSTYKGAPSPKELLIPPAVTSPSPKEAPTPPAVTPPSPEKGPATPAPKGTPTSPPVTPSSLKDSPTSPASVTCKMGATVPQASKGLPAKKGPTALKEVLVAPAPESTPIITAPTRKGPQTKKSSATSPPICPDPSAKNGSKGPLSTVAPAPLLPVQKDSSKTAKGKDASHSPKGPLAPPESKASTPLTAAAFEKVLPKPESASVSAAPSPPVSLPLAPSPVPTLPPKQQFLPSSPGLVLESPSKPLAPADEDELLPLIPPEPISGGVPFQSVLVNMPTPKSAGIPVPTPSAKQPVTKNNKGSGTESDSDESVPELEEQDSTQATTQQAQLAAAAEIDEEPVSKAKQSRSEKKARKAMSKLGLRQVTGVTRVTIRKSKNILFVITKPDVYKSPASDTYIVFGEAKIEDLSQQAQLAAAEKFKVQGEAVSNIQENTQTPTVQEESEEEEVDETGVEVKDIELVMSQANVSRAKAVRALKNNSNDIVNAIMELTM,,,DOMAIN: The proline-rich muscle-specific exon 3 contains eighteen approximate 23-AA repeats.,PF01849;,hsa:4666;,,,SUBUNIT: Interacts (via PXLXP motif) with the muscle-restricted histone methyltransferase SMYD1 (via MYND-type zinc finger). {ECO:0000250}.,,,,DOMAIN 1933 1998 NAC-A/B. {ECO:0000255|PROSITE-ProRule:PRU00507}.; DOMAIN 2039 2078 UBA.,,,,,0.577478345,-0.335,205.45,333,334P20290,BTF3_HUMAN,reviewed,Transcription factor BTF3 (Nascent polypeptide-associated complex subunit beta) (NAC-beta) (RNA polymerase B transcription factor 3),BTF3 NACB OK/SW-cl.8,Homo sapiens (Human),206,GO:0005737; GO:0001701; GO:0005634; GO:0044822; GO:0015031; GO:0006355; GO:0006366,689;,MRRTGAPAQADSRGRGRARGGCPGGEATLSQPPPRGGTRGQEPQMKETIMNQEKLAKLQAQVRIGGKGTARRKKKVVHRTATADDKKLQFSLKKLGVNNISGIEEVNMFTNQGTVIHFNNPKVQASLAANTFTITGHAETKQLTEMLPSILNQLGADSLTSLRRLAEALPKQSVDGKAPLATGEDDDDEVPDLVENFDEASKNEAN,,,,PF01849;,hsa:689;,,,"SUBUNIT: Part of the nascent polypeptide-associated complex (NAC), which is a heterodimer of NACA and BTF3 (via NAC-A/B domains). NAC associates with ribosomes through the BTF3/NACB subunit. Both subunits can contact nascent polypeptide chains. {ECO:0000269|PubMed:21203952}.",HELIX 143 146 {ECO:0000244|PDB:3MCB}.; HELIX 149 153 {ECO:0000244|PDB:3MCB}.; HELIX 158 161 {ECO:0000244|PDB:3LKX}.,STRAND 105 110 {ECO:0000244|PDB:3MCB}.; STRAND 113 120 {ECO:0000244|PDB:3MCB}.; STRAND 122 126 {ECO:0000244|PDB:3MCB}.; STRAND 131 136 {ECO:0000244|PDB:3MCB}.; STRAND 138 142 {ECO:0000244|PDB:3MCB}.,TURN 127 130 {ECO:0000244|PDB:3MCB}.,DOMAIN 82 147 NAC-A/B. {ECO:0000255|PROSITE-ProRule:PRU00507}.,,,,,0.485436893,-0.742,22.17,18.3,19.3Q14980,NUMA1_HUMAN,reviewed,Nuclear mitotic apparatus protein 1 (NuMA protein) (Nuclear matrix protein-22) (NMP-22) (SP-H antigen),NUMA1 NMP22 NUMA,Homo sapiens (Human),2115,GO:0000086; GO:0000139; GO:0045177; GO:0051301; GO:0005694; GO:0005737; GO:0005829; GO:0030425; GO:0000132; GO:0070062; GO:0060487; GO:0051321; GO:0000278; GO:0007067; GO:0043025; GO:0016363; GO:0005654; GO:0005634; GO:0006997; GO:0005819; GO:0005876; GO:0000922; GO:0005198,4926;,MTLHATRGAALLSWVNSLHVADPVEAVLQLQDCSIFIKIIDRIHGTEEGQQILKQPVSERLDFVCSFLQKNRKHPSSPECLVSAQKVLEGSELELAKMTMLLLYHSTMSSKSPRDWEQFEYKIQAELAVILKFVLDHEDGLNLNEDLENFLQKAPVPSTCSSTFPEELSPPSHQAKREIRFLELQKVASSSSGNNFLSGSPASPMGDILQTPQFQMRRLKKQLADERSNRDELELELAENRKLLTEKDAQIAMMQQRIDRLALLNEKQAASPLEPKELEELRDKNESLTMRLHETLKQCQDLKTEKSQMDRKINQLSEENGDLSFKLREFASHLQQLQDALNELTEEHSKATQEWLEKQAQLEKELSAALQDKKCLEEKNEILQGKLSQLEEHLSQLQDNPPQEKGEVLGDVLQLETLKQEAATLAANNTQLQARVEMLETERGQQEAKLLAERGHFEEEKQQLSSLITDLQSSISNLSQAKEELEQASQAHGARLTAQVASLTSELTTLNATIQQQDQELAGLKQQAKEKQAQLAQTLQQQEQASQGLRHQVEQLSSSLKQKEQQLKEVAEKQEATRQDHAQQLATAAEEREASLRERDAALKQLEALEKEKAAKLEILQQQLQVANEARDSAQTSVTQAQREKAELSRKVEELQACVETARQEQHEAQAQVAELELQLRSEQQKATEKERVAQEKDQLQEQLQALKESLKVTKGSLEEEKRRAADALEEQQRCISELKAETRSLVEQHKRERKELEEERAGRKGLEARLQQLGEAHQAETEVLRRELAEAMAAQHTAESECEQLVKEVAAWRERYEDSQQEEAQYGAMFQEQLMTLKEECEKARQELQEAKEKVAGIESHSELQISRQQNELAELHANLARALQQVQEKEVRAQKLADDLSTLQEKMAATSKEVARLETLVRKAGEQQETASRELVKEPARAGDRQPEWLEEQQGRQFCSTQAALQAMEREAEQMGNELERLRAALMESQGQQQEERGQQEREVARLTQERGRAQADLALEKAARAELEMRLQNALNEQRVEFATLQEALAHALTEKEGKDQELAKLRGLEAAQIKELEELRQTVKQLKEQLAKKEKEHASGSGAQSEAAGRTEPTGPKLEALRAEVSKLEQQCQKQQEQADSLERSLEAERASRAERDSALETLQGQLEEKAQELGHSQSALASAQRELAAFRTKVQDHSKAEDEWKAQVARGRQEAERKNSLISSLEEEVSILNRQVLEKEGESKELKRLVMAESEKSQKLEERLRLLQAETASNSARAAERSSALREEVQSLREEAEKQRVASENLRQELTSQAERAEELGQELKAWQEKFFQKEQALSTLQLEHTSTQALVSELLPAKHLCQQLQAEQAAAEKRHREELEQSKQAAGGLRAELLRAQRELGELIPLRQKVAEQERTAQQLRAEKASYAEQLSMLKKAHGLLAEENRGLGERANLGRQFLEVELDQAREKYVQELAAVRADAETRLAEVQREAQSTARELEVMTAKYEGAKVKVLEERQRFQEERQKLTAQVEQLEVFQREQTKQVEELSKKLADSDQASKVQQQKLKAVQAQGGESQQEAQRLQAQLNELQAQLSQKEQAAEHYKLQMEKAKTHYDAKKQQNQELQEQLRSLEQLQKENKELRAEAERLGHELQQAGLKTKEAEQTCRHLTAQVRSLEAQVAHADQQLRDLGKFQVATDALKSREPQAKPQLDLSIDSLDLSCEEGTPLSITSKLPRTQPDGTSVPGEPASPISQRLPPKVESLESLYFTPIPARSQAPLESSLDSLGDVFLDSGRKTRSARRRTTQIINITMTKKLDVEEPDSANSSFYSTRSAPASQASLRATSSTQSLARLGSPDYGNSALLSLPGYRPTTRSSARRSQAGVSSGAPPGRNSFYMGTCQDEPEQLDDWNRIAELQQRNRVCPPHLKTCYPLESRPSLSLGTITDEEMKTGDPQETLRRASMQPIQIAEGTGITTRQQRKRVSLEPHQGPGTPESKKATSCFPRPMTPRDRHEGRKQSTTEAQKKAAPASTKQADRRQSMAFSILNTPKKLGNSLLRRGASKKALSKASPNTRSGTRRSPRIATTTASAATAAAIGATPRAKGKAKH,,,"DOMAIN: The C-terminal tubulin-binding domain mediates direct binding to microtubules, independantly of dynein and dynactin, and induces their bundling and stabilization.",,hsa:4926;,,,"SUBUNIT: Homodimer. Also forms multiarm oligomers by association of C-terminal tail domains, oligomers may further assemble to form a hexagonal nuclear lattice-like network. Interacts with TNKS. {ECO:0000269|PubMed:10075938, ECO:0000269|PubMed:11956313, ECO:0000269|PubMed:16076287}.",HELIX 1920 1922 {ECO:0000244|PDB:3RO2}.,,TURN 1917 1919 {ECO:0000244|PDB:3RO2}.,,,,,,0.898345154,-0.916,238.34,0.77,1.77O15381,NVL_HUMAN,reviewed,Nuclear valosin-containing protein-like (NVLp) (Nuclear VCP-like protein),NVL,Homo sapiens (Human),856,GO:0005524; GO:0005737; GO:0016020; GO:0005739; GO:0005730; GO:0005634; GO:0005886; GO:0044822,4931;,MKPRPAGFVDNKLKQRVIQYLTSNKCGKYVDIGVLASDLQRVYSIDYGRRKRNAFRIQVEKVFSIISSEKELKNLTELEDEHLAKRARQGEEDNEYTESYSDDDSSMEDYPDPQSANHMNSSLLSLYRKGNPDSVSNTPEMEQRETTSSTPRISSKTGSIPLKTPAKDSEGGWFIDKTPSVKKDSFFLDLSCEKSNPKKPITEIQDSKDSSLLESDMKRKGKLKNKGSKRKKEDLQEVDGEIEAVLQKKAKARGLEFQISNVKFEDVGGNDMTLKEVCKMLIHMRHPEVYHHLGVVPPRGVLLHGPPGCGKTLLAHAIAGELDLPILKVAAPEIVSGVSGESEQKLRELFEQAVSNAPCIIFIDEIDAITPKREVASKDMERRIVAQLLTCMDDLNNVAATARVLVIGATNRPDSLDPALRRAGRFDREICLGIPDEASRERILQTLCRKLRLPQAFDFCHLAHLTPGFVGADLMALCREAAMCAVNRVLMKLQEQQKKNPEMEDLPSKGVQEERLGTEPTSETQDELQRLLGLLRDQDPLSEEQMQGLCIELNDFIVALSSVQPSAKREGFVTVPNVTWADIGALEDIREELTMAILAPVRNPDQFKALGLVTPAGVLLAGPPGCGKTLLAKAVANESGLNFISVKGPELLNMYVGESERAVRQVFQRAKNSAPCVIFFDEVDALCPRRSDRETGASVRVVNQLLTEMDGLEARQQVFIMAATNRPDIIDPAILRPGRLDKTLFVGLPPPADRLAILKTITKNGTKPPLDADVNLEAIAGDLRCDCYTGADLSALVREASICALRQEMARQKSGNEKGELKVSHKHFEEAFKKVRSSISKKDQIMYERLQESLSR,,,,PF00004;,hsa:4931;,,,"SUBUNIT: Interacts with NCL/nucleolin. {ECO:0000269|PubMed:21474449, ECO:0000269|Ref.11}.",HELIX 585 597 {ECO:0000244|PDB:2X8A}.; HELIX 599 602 {ECO:0000244|PDB:2X8A}.; HELIX 604 609 {ECO:0000244|PDB:2X8A}.; HELIX 628 638 {ECO:0000244|PDB:2X8A}.; HELIX 657 672 {ECO:0000244|PDB:2X8A}.; HELIX 701 710 {ECO:0000244|PDB:2X8A}.; HELIX 727 729 {ECO:0000244|PDB:2X8A}.; HELIX 732 735 {ECO:0000244|PDB:2X8A}.; HELIX 751 761 {ECO:0000244|PDB:2X8A}.; HELIX 776 780 {ECO:0000244|PDB:2X8A}.; HELIX 784 786 {ECO:0000244|PDB:2X8A}.; HELIX 790 808 {ECO:0000244|PDB:2X8A}.; HELIX 825 832 {ECO:0000244|PDB:2X8A}.,STRAND 616 623 {ECO:0000244|PDB:2X8A}.; STRAND 642 647 {ECO:0000244|PDB:2X8A}.; STRAND 675 681 {ECO:0000244|PDB:2X8A}.; STRAND 718 725 {ECO:0000244|PDB:2X8A}.; STRAND 742 745 {ECO:0000244|PDB:2X8A}.,TURN 648 651 {ECO:0000244|PDB:2X8A}.; TURN 684 686 {ECO:0000244|PDB:2X8A}.; TURN 762 769 {ECO:0000244|PDB:2X8A}.,,,,,,2.102803738,-0.428,95.07,1.93,2.93O15294,OGT1_HUMAN,reviewed,UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit (EC 2.4.1.255) (O-GlcNAc transferase subunit p110) (O-linked N-acetylglucosamine transferase 110 kDa subunit) (OGT),OGT,Homo sapiens (Human),1046,GO:0070688; GO:0008375; GO:0006915; GO:0071300; GO:0006325; GO:0032922; GO:0005737; GO:0005829; GO:0008047; GO:0080182; GO:0043984; GO:0043981; GO:0043982; GO:0000123; GO:0005815; GO:0005739; GO:0031397; GO:0005654; GO:0005634; GO:0005547; GO:0048015; GO:0005886; GO:0043085; GO:0030854; GO:0061087; GO:0051571; GO:0045862; GO:0045944; GO:0016262; GO:0097363; GO:0006493; GO:0035020; GO:0090526; GO:0006110; GO:0046626; GO:0032868; GO:0007584; GO:0007165,8473;,MASSVGNVADSTEPTKRMLSFQGLAELAHREYQAGDFEAAERHCMQLWRQEPDNTGVLLLLSSIHFQCRRLDRSAHFSTLAIKQNPLLAEAYSNLGNVYKERGQLQEAIEHYRHALRLKPDFIDGYINLAAALVAAGDMEGAVQAYVSALQYNPDLYCVRSDLGNLLKALGRLEEAKACYLKAIETQPNFAVAWSNLGCVFNAQGEIWLAIHHFEKAVTLDPNFLDAYINLGNVLKEARIFDRAVAAYLRALSLSPNHAVVHGNLACVYYEQGLIDLAIDTYRRAIELQPHFPDAYCNLANALKEKGSVAEAEDCYNTALRLCPTHADSLNNLANIKREQGNIEEAVRLYRKALEVFPEFAAAHSNLASVLQQQGKLQEALMHYKEAIRISPTFADAYSNMGNTLKEMQDVQGALQCYTRAIQINPAFADAHSNLASIHKDSGNIPEAIASYRTALKLKPDFPDAYCNLAHCLQIVCDWTDYDERMKKLVSIVADQLEKNRLPSVHPHHSMLYPLSHGFRKAIAERHGNLCLDKINVLHKPPYEHPKDLKLSDGRLRVGYVSSDFGNHPTSHLMQSIPGMHNPDKFEVFCYALSPDDGTNFRVKVMAEANHFIDLSQIPCNGKAADRIHQDGIHILVNMNGYTKGARNELFALRPAPIQAMWLGYPGTSGALFMDYIITDQETSPAEVAEQYSEKLAYMPHTFFIGDHANMFPHLKKKAVIDFKSNGHIYDNRIVLNGIDLKAFLDSLPDVKIVKMKCPDGGDNADSSNTALNMPVIPMNTIAEAVIEMINRGQIQITINGFSISNGLATTQINNKAATGEEVPRTIIVTTRSQYGLPEDAIVYCNFNQLYKIDPSTLQMWANILKRVPNSVLWLLRFPAVGEPNIQQYAQNMGLPQNRIIFSPVAPKEEHVRRGQLADVCLDTPLCNGHTTGMDVLWAGTPMVTMPGETLASRVAASQLTCLGCLELIAKNRQEYEDIAVKLGTDLEYLKKVRGKVWKQRISSPLFNTKQYTMELERLYLQMWEHYAAGNKPDHMIKPVEVTESA,"DISEASE: Note=Regulation of OGT activity and altered O-GlcNAcylations are implicated in diabetes and Alzheimer disease. O-GlcNAcylation of AKT1 affects insulin signaling and, possibly diabetes. Reduced O-GlcNAcylations and resulting increased phosphorylations of MAPT/TAU are observed in Alzheimer disease (AD) brain cerebrum.",,DOMAIN: The TPR repeat domain is required for substrate binding and oligomerization. {ECO:0000269|PubMed:15361863}.,PF13844;PF00515;,hsa:8473;,,,"SUBUNIT: Heterotrimer; consists of one 78 kDa subunit and two 110 kDa subunits dimerized via TPR repeats 6 and 7. Interacts (via TPR repeats 6 and 7) with ATXN10 (By similarity). Component of the MLL5-L complex, at least composed of KMT2E/MLL5, STK38, PPP1CA, PPP1CB, HCFC1, PPP1CC and ACTB. Component of a THAP1/THAP3-HCFC1-OGT complex. Component of the NSL complex at least composed of MOF/KAT8, KANSL1, KANSL2, KANSL3, MCRS1, PHF20, OGT1/OGT, WDR5 and HCFC1. Interacts directly with HCFC1; the interaction O-glycosylates HCFC1, regulates its proteolytic processing and transcriptional activity and, in turn, stabilizes OGT in the nucleus. Interacts (via TPRs 1-6) with SIN3A; the interaction mediates transcriptional repression in parallel with histone deacetylase. Interacts (via TPR 5-6) with TET1, TET2 and TET3. Interacts with ARNTL/BMAL1 (By similarity). {ECO:0000250}.",HELIX 27 34 {ECO:0000244|PDB:1W3B}.; HELIX 37 50 {ECO:0000244|PDB:1W3B}.; HELIX 55 67 {ECO:0000244|PDB:1W3B}.; HELIX 71 84 {ECO:0000244|PDB:1W3B}.; HELIX 89 102 {ECO:0000244|PDB:1W3B}.; HELIX 105 118 {ECO:0000244|PDB:1W3B}.; HELIX 123 136 {ECO:0000244|PDB:1W3B}.; HELIX 141 152 {ECO:0000244|PDB:1W3B}.; HELIX 158 168 {ECO:0000244|PDB:1W3B}.; HELIX 173 186 {ECO:0000244|PDB:1W3B}.; HELIX 191 202 {ECO:0000244|PDB:1W3B}.; HELIX 207 220 {ECO:0000244|PDB:1W3B}.; HELIX 225 236 {ECO:0000244|PDB:1W3B}.; HELIX 243 254 {ECO:0000244|PDB:1W3B}.; HELIX 259 271 {ECO:0000244|PDB:1W3B}.; HELIX 275 287 {ECO:0000244|PDB:1W3B}.; HELIX 293 306 {ECO:0000244|PDB:1W3B}.; HELIX 309 322 {ECO:0000244|PDB:1W3B}.; HELIX 325 339 {ECO:0000244|PDB:4GYW}.; HELIX 343 356 {ECO:0000244|PDB:4GYW}.; HELIX 361 373 {ECO:0000244|PDB:4GYW}.; HELIX 377 390 {ECO:0000244|PDB:4GYW}.; HELIX 395 407 {ECO:0000244|PDB:4GYW}.; HELIX 411 424 {ECO:0000244|PDB:4GYW}.; HELIX 429 441 {ECO:0000244|PDB:4GYW}.; HELIX 445 458 {ECO:0000244|PDB:4GYW}.; HELIX 463 475 {ECO:0000244|PDB:4GYW}.; HELIX 482 498 {ECO:0000244|PDB:4GYW}.; HELIX 509 512 {ECO:0000244|PDB:4GYW}.; HELIX 517 536 {ECO:0000244|PDB:4GYW}.; HELIX 569 574 {ECO:0000244|PDB:4GYW}.; HELIX 577 580 {ECO:0000244|PDB:4GYW}.; HELIX 600 608 {ECO:0000244|PDB:4GYW}.; HELIX 615 617 {ECO:0000244|PDB:4GYW}.; HELIX 621 630 {ECO:0000244|PDB:4GYW}.; HELIX 649 652 {ECO:0000244|PDB:4GYW}.; HELIX 686 691 {ECO:0000244|PDB:4GYW}.; HELIX 708 711 {ECO:0000244|PDB:4GYW}.; HELIX 713 715 {ECO:0000244|PDB:4GYW}.; HELIX 741 746 {ECO:0000244|PDB:4GYW}.; HELIX 781 792 {ECO:0000244|PDB:4GYW}.; HELIX 807 809 {ECO:0000244|PDB:4GYY}.; HELIX 810 813 {ECO:0000244|PDB:4GYW}.; HELIX 815 818 {ECO:0000244|PDB:4GYW}.; HELIX 832 835 {ECO:0000244|PDB:4GYW}.; HELIX 850 852 {ECO:0000244|PDB:4GYW}.; HELIX 855 867 {ECO:0000244|PDB:4GYW}.; HELIX 880 882 {ECO:0000244|PDB:4GYW}.; HELIX 883 892 {ECO:0000244|PDB:4GYW}.; HELIX 897 899 {ECO:0000244|PDB:4GYW}.; HELIX 908 914 {ECO:0000244|PDB:4GYW}.; HELIX 915 917 {ECO:0000244|PDB:4GYW}.; HELIX 931 938 {ECO:0000244|PDB:4GYW}.; HELIX 951 953 {ECO:0000244|PDB:4GYW}.; HELIX 955 963 {ECO:0000244|PDB:4GYW}.; HELIX 966 968 {ECO:0000244|PDB:4GYW}.; HELIX 973 985 {ECO:0000244|PDB:4GYW}.; HELIX 987 1003 {ECO:0000244|PDB:4GYW}.; HELIX 1005 1007 {ECO:0000244|PDB:4N3C}.; HELIX 1009 1028 {ECO:0000244|PDB:4GYW}.,STRAND 547 549 {ECO:0000244|PDB:4N39}.; STRAND 556 563 {ECO:0000244|PDB:4GYW}.; STRAND 565 568 {ECO:0000244|PDB:4GYW}.; STRAND 586 594 {ECO:0000244|PDB:4GYW}.; STRAND 609 614 {ECO:0000244|PDB:4GYW}.; STRAND 634 639 {ECO:0000244|PDB:4GYW}.; STRAND 641 643 {ECO:0000244|PDB:4GYW}.; STRAND 656 661 {ECO:0000244|PDB:4GYW}.; STRAND 676 679 {ECO:0000244|PDB:4GYW}.; STRAND 693 698 {ECO:0000244|PDB:4GYW}.; STRAND 719 721 {ECO:0000244|PDB:4GYW}.; STRAND 731 737 {ECO:0000244|PDB:4GYW}.; STRAND 748 750 {ECO:0000244|PDB:4GYW}.; STRAND 752 754 {ECO:0000244|PDB:4GYW}.; STRAND 774 777 {ECO:0000244|PDB:4GYW}.; STRAND 796 799 {ECO:0000244|PDB:4GYW}.; STRAND 802 806 {ECO:0000244|PDB:4GYW}.; STRAND 820 822 {ECO:0000244|PDB:4AY5}.; STRAND 826 831 {ECO:0000244|PDB:4GYW}.; STRAND 841 845 {ECO:0000244|PDB:4GYW}.; STRAND 869 877 {ECO:0000244|PDB:4GYW}.; STRAND 900 904 {ECO:0000244|PDB:4GYW}.; STRAND 919 922 {ECO:0000244|PDB:4GYW}.; STRAND 925 927 {ECO:0000244|PDB:4GYW}.; STRAND 943 945 {ECO:0000244|PDB:4GYW}.,TURN 203 205 {ECO:0000244|PDB:1W3B}.; TURN 237 239 {ECO:0000244|PDB:1W3B}.; TURN 537 539 {ECO:0000244|PDB:3TAX}.; TURN 550 554 {ECO:0000244|PDB:4GYW}.; TURN 583 585 {ECO:0000244|PDB:4GYW}.; TURN 681 683 {ECO:0000244|PDB:4GYW}.,,,,,,2.103250478,-0.242,116.94,45.6,46.6Q8WW12,PCNP_HUMAN,reviewed,PEST proteolytic signal-containing nuclear protein (PCNP) (PEST-containing nuclear protein),PCNP,Homo sapiens (Human),178,GO:0007049; GO:0005654; GO:0005634; GO:0043161; GO:0016567,57092;,MADGKAGDEKPEKSQRAGAAGGPEEEAEKPVKTKTVSSSNGGESSSRSAEKRSAEEEAADLPTKPTKISKFGFAIGSQTTKKASAISIKLGSSKPKETVPTLAPKTLSVAAAFNEDEDSEPEEMPPEAKMRMKNIGRDTPTSAGPNSFNKGKHGFSDNQKLWERNIKSHLGNVHDQDN,,,,PF15473;,hsa:57092;,,,"SUBUNIT: Interacts with UHRF2/NIRF. {ECO:0000269|PubMed:12176013, ECO:0000269|PubMed:14741369}.",,,,,,,,,0,-1.076,18.93,5.91,6.91Q14690,RRP5_HUMAN,reviewed,Protein RRP5 homolog (NF-kappa-B-binding protein) (NFBP) (Programmed cell death protein 11),PDCD11 KIAA0185,Homo sapiens (Human),1871,GO:0005829; GO:0006397; GO:0005730; GO:0005634; GO:0044822; GO:0006364; GO:0008134,22984;,MANLEESFPRGGTRKIHKPEKAFQQSVEQDNLFDISTEEGSTKRKKSQKGPAKTKKLKIEKRESSKSAREKFEILSVESLCEGMRILGCVKEVNELELVISLPNGLQGFVQVTEICDAYTKKLNEQVTQEQPLKDLLHLPELFSPGMLVRCVVSSLGITDRGKKSVKLSLNPKNVNRVLSAEALKPGMLLTGTVSSLEDHGYLVDIGVDGTRAFLPLLKAQEYIRQKNKGAKLKVGQYLNCIVEKVKGNGGVVSLSVGHSEVSTAIATEQQSWNLNNLLPGLVVKAQVQKVTPFGLTLNFLTFFTGVVDFMHLDPKKAGTYFSNQAVRACILCVHPRTRVVHLSLRPIFLQPGRPLTRLSCQNLGAVLDDVPVQGFFKKAGATFRLKDGVLAYARLSHLSDSKNVFNPEAFKPGNTHKCRIIDYSQMDELALLSLRTSIIEAQYLRYHDIEPGAVVKGTVLTIKSYGMLVKVGEQMRGLVPPMHLADILMKNPEKKYHIGDEVKCRVLLCDPEAKKLMMTLKKTLIESKLPVITCYADAKPGLQTHGFIIRVKDYGCIVKFYNNVQGLVPKHELSTEYIPDPERVFYTGQVVKVVVLNCEPSKERMLLSFKLSSDPEPKKEPAGHSQKKGKAINIGQLVDVKVLEKTKDGLEVAVLPHNIRAFLPTSHLSDHVANGPLLHHWLQAGDILHRVLCLSQSEGRVLLCRKPALVSTVEGGQDPKNFSEIHPGMLLIGFVKSIKDYGVFIQFPSGLSGLAPKAIMSDKFVTSTSDHFVEGQTVAAKVTNVDEEKQRMLLSLRLSDCGLGDLAITSLLLLNQCLEELQGVRSLMSNRDSVLIQTLAEMTPGMFLDLVVQEVLEDGSVVFSGGPVPDLVLKASRYHRAGQEVESGQKKKVVILNVDLLKLEVHVSLHQDLVNRKARKLRKGSEHQAIVQHLEKSFAIASLVETGHLAAFSLTSHLNDTFRFDSEKLQVGQGVSLTLKTTEPGVTGLLLAVEGPAAKRTMRPTQKDSETVDEDEEVDPALTVGTIKKHTLSIGDMVTGTVKSIKPTHVVVTLEDGIIGCIHASHILDDVPEGTSPTTKLKVGKTVTARVIGGRDMKTFKYLPISHPRFVRTIPELSVRPSELEDGHTALNTHSVSPMEKIKQYQAGQTVTCFLKKYNVVKKWLEVEIAPDIRGRIPLLLTSLSFKVLKHPDKKFRVGQALRATVVGPDSSKTLLCLSLTGPHKLEEGEVAMGRVVKVTPNEGLTVSFPFGKIGTVSIFHMSDSYSETPLEDFVPQKVVRCYILSTADNVLTLSLRSSRTNPETKSKVEDPEINSIQDIKEGQLLRGYVGSIQPHGVFFRLGPSVVGLARYSHVSQHSPSKKALYNKHLPEGKLLTARVLRLNHQKNLVELSFLPGDTGKPDVLSASLEGQLTKQEERKTEAEERDQKGEKKNQKRNEKKNQKGQEEVEMPSKEKQQPQKPQAQKRGGRECRESGSEQERVSKKPKKAGLSEEDDSLVDVYYREGKEEAEETNVLPKEKQTKPAEAPRLQLSSGFAWNVGLDSLTPALPPLAESSDSEEDEKPHQATIKKSKKERELEKQKAEKELSRIEEALMDPGRQPESADDFDRLVLSSPNSSILWLQYMAFHLQATEIEKARAVAERALKTISFREEQEKLNVWVALLNLENMYGSQESLTKVFERAVQYNEPLKVFLHLADIYAKSEKFQEAGELYNRMLKRFRQEKAVWIKYGAFLLRRSQAAASHRVLQRALECLPSKEHVDVIAKFAQLEFQLGDAERAKAIFENTLSTYPKRTDVWSVYIDMTIKHGSQKDVRDIFERVIHLSLAPKRMKFFFKRYLDYEKQHGTEKDVQAVKAKALEYVEAKSSVLED,,,,PF00575;PF05843;,hsa:22984;,,,SUBUNIT: Interacts with NF-kappa-B p50/NFKB1 and NF-kappa-B p65/RELA. {ECO:0000269|PubMed:14624448}.,HELIX 217 227 {ECO:0000244|PDB:1WI5}.,STRAND 189 197 {ECO:0000244|PDB:1WI5}.; STRAND 199 205 {ECO:0000244|PDB:1WI5}.; STRAND 212 216 {ECO:0000244|PDB:1WI5}.; STRAND 228 230 {ECO:0000244|PDB:1WI5}.; STRAND 238 245 {ECO:0000244|PDB:1WI5}.; STRAND 252 256 {ECO:0000244|PDB:1WI5}.,TURN 181 183 {ECO:0000244|PDB:1WI5}.,DOMAIN 83 171 S1 motif 1. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 187 258 S1 motif 2. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 281 346 S1 motif 3. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 365 436 S1 motif 4. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 453 522 S1 motif 5. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 542 611 S1 motif 6. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 636 707 S1 motif 7. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 729 798 S1 motif 8. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 1036 1109 S1 motif 9. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 1149 1222 S1 motif 10. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 1230 1298 S1 motif 11. {ECO:0000255|PROSITE-ProRule:PRU00180}.; DOMAIN 1324 1396 S1 motif 12. {ECO:0000255|PROSITE-ProRule:PRU00180}.,,,,,1.282736505,-0.349,208.74,34.7,35.7Q15149,PLEC_HUMAN,reviewed,Plectin (PCN) (PLTN) (Hemidesmosomal protein 1) (HD1) (Plectin-1),PLEC PLEC1,Homo sapiens (Human),4684,GO:0030506; GO:0006915; GO:0034329; GO:0006921; GO:0043034; GO:0005737; GO:0005829; GO:0030198; GO:0070062; GO:0005925; GO:0030056; GO:0031581; GO:0045111; GO:0005886; GO:0044822; GO:0042383; GO:0016528; GO:0008307,5339;,MVAGMLMPRDQLRAIYEVLFREGVMVAKKDRRPRSLHPHVPGVTNLQVMRAMASLRARGLVRETFAWCHFYWYLTNEGIAHLRQYLHLPPEIVPASLQRVRRPVAMVMPARRTPHVQAVQGPLGSPPKRGPLPTEEQRVYRRKELEEVSPETPVVPATTQRTLARPGPEPAPATDERDRVQKKTFTKWVNKHLIKAQRHISDLYEDLRDGHNLISLLEVLSGDSLPREKGRMRFHKLQNVQIALDYLRHRQVKLVNIRNDDIADGNPKLTLGLIWTIILHFQISDIQVSGQSEDMTAKEKLLLWSQRMVEGYQGLRCDNFTSSWRDGRLFNAIIHRHKPLLIDMNKVYRQTNLENLDQAFSVAERDLGVTRLLDPEDVDVPQPDEKSIITYVSSLYDAMPRVPDVQDGVRANELQLRWQEYRELVLLLLQWMRHHTAAFEERRFPSSFEEIEILWSQFLKFKEMELPAKEADKNRSKGIYQSLEGAVQAGQLKVPPGYHPLDVEKEWGKLHVAILEREKQLRSEFERLECLQRIVTKLQMEAGLCEEQLNQADALLQSDVRLLAAGKVPQRAGEVERDLDKADSMIRLLFNDVQTLKDGRHPQGEQMYRRVYRLHERLVAIRTEYNLRLKAGVAAPATQVAQVTLQSVQRRPELEDSTLRYLQDLLAWVEENQHRVDGAEWGVDLPSVEAQLGSHRGLHQSIEEFRAKIERARSDEGQLSPATRGAYRDCLGRLDLQYAKLLNSSKARLRSLESLHSFVAAATKELMWLNEKEEEEVGFDWSDRNTNMTAKKESYSALMRELELKEKKIKELQNAGDRLLREDHPARPTVESFQAALQTQWSWMLQLCCCIEAHLKENAAYFQFFSDVREAEGQLQKLQEALRRKYSCDRSATVTRLEDLLQDAQDEKEQLNEYKGHLSGLAKRAKAVVQLKPRHPAHPMRGRLPLLAVCDYKQVEVTVHKGDECQLVGPAQPSHWKVLSSSGSEAAVPSVCFLVPPPNQEAQEAVTRLEAQHQALVTLWHQLHVDMKSLLAWQSLRRDVQLIRSWSLATFRTLKPEEQRQALHSLELHYQAFLRDSQDAGGFGPEDRLMAEREYGSCSHHYQQLLQSLEQGAQEESRCQRCISELKDIRLQLEACETRTVHRLRLPLDKEPARECAQRIAEQQKAQAEVEGLGKGVARLSAEAEKVLALPEPSPAAPTLRSELELTLGKLEQVRSLSAIYLEKLKTISLVIRGTQGAEEVLRAHEEQLKEAQAVPATLPELEATKASLKKLRAQAEAQQPTFDALRDELRGAQEVGERLQQRHGERDVEVERWRERVAQLLERWQAVLAQTDVRQRELEQLGRQLRYYRESADPLGAWLQDARRRQEQIQAMPLADSQAVREQLRQEQALLEEIERHGEKVEECQRFAKQYINAIKDYELQLVTYKAQLEPVASPAKKPKVQSGSESVIQEYVDLRTHYSELTTLTSQYIKFISETLRRMEEEERLAEQQRAEERERLAEVEAALEKQRQLAEAHAQAKAQAEREAKELQQRMQEEVVRREEAAVDAQQQKRSIQEELQQLRQSSEAEIQAKARQAEAAERSRLRIEEEIRVVRLQLEATERQRGGAEGELQALRARAEEAEAQKRQAQEEAERLRRQVQDESQRKRQAEVELASRVKAEAEAAREKQRALQALEELRLQAEEAERRLRQAEVERARQVQVALETAQRSAEAELQSKRASFAEKTAQLERSLQEEHVAVAQLREEAERRAQQQAEAERAREEAERELERWQLKANEALRLRLQAEEVAQQKSLAQAEAEKQKEEAEREARRRGKAEEQAVRQRELAEQELEKQRQLAEGTAQQRLAAEQELIRLRAETEQGEQQRQLLEEELARLQREAAAATQKRQELEAELAKVRAEMEVLLASKARAEEESRSTSEKSKQRLEAEAGRFRELAEEAARLRALAEEAKRQRQLAEEDAARQRAEAERVLAEKLAAIGEATRLKTEAEIALKEKEAENERLRRLAEDEAFQRRRLEEQAAQHKADIEERLAQLRKASDSELERQKGLVEDTLRQRRQVEEEILALKASFEKAAAGKAELELELGRIRSNAEDTLRSKEQAELEAARQRQLAAEEERRRREAEERVQKSLAAEEEAARQRKAALEEVERLKAKVEEARRLRERAEQESARQLQLAQEAAQKRLQAEEKAHAFAVQQKEQELQQTLQQEQSVLDQLRGEAEAARRAAEEAEEARVQAEREAAQSRRQVEEAERLKQSAEEQAQARAQAQAAAEKLRKEAEQEAARRAQAEQAALRQKQAADAEMEKHKKFAEQTLRQKAQVEQELTTLRLQLEETDHQKNLLDEELQRLKAEATEAARQRSQVEEELFSVRVQMEELSKLKARIEAENRALILRDKDNTQRFLQEEAEKMKQVAEEAARLSVAAQEAARLRQLAEEDLAQQRALAEKMLKEKMQAVQEATRLKAEAELLQQQKELAQEQARRLQEDKEQMAQQLAEETQGFQRTLEAERQRQLEMSAEAERLKLRVAEMSRAQARAEEDAQRFRKQAEEIGEKLHRTELATQEKVTLVQTLEIQRQQSDHDAERLREAIAELEREKEKLQQEAKLLQLKSEEMQTVQQEQLLQETQALQQSFLSEKDSLLQRERFIEQEKAKLEQLFQDEVAKAQQLREEQQRQQQQMEQERQRLVASMEEARRRQHEAEEGVRRKQEELQQLEQQRRQQEELLAEENQRLREQLQLLEEQHRAALAHSEEVTASQVAATKTLPNGRDALDGPAAEAEPEHSFDGLRRKVSAQRLQEAGILSAEELQRLAQGHTTVDELARREDVRHYLQGRSSIAGLLLKATNEKLSVYAALQRQLLSPGTALILLEAQAASGFLLDPVRNRRLTVNEAVKEGVVGPELHHKLLSAERAVTGYKDPYTGQQISLFQAMQKGLIVREHGIRLLEAQIATGGVIDPVHSHRVPVDVAYRRGYFDEEMNRVLADPSDDTKGFFDPNTHENLTYLQLLERCVEDPETGLCLLPLTDKAAKGGELVYTDSEARDVFEKATVSAPFGKFQGKTVTIWEIINSEYFTAEQRRDLLRQFRTGRITVEKIIKIIITVVEEQEQKGRLCFEGLRSLVPAAELLESRVIDRELYQQLQRGERSVRDVAEVDTVRRALRGANVIAGVWLEEAGQKLSIYNALKKDLLPSDMAVALLEAQAGTGHIIDPATSARLTVDEAVRAGLVGPEFHEKLLSAEKAVTGYRDPYTGQSVSLFQALKKGLIPREQGLRLLDAQLSTGGIVDPSKSHRVPLDVACARGCLDEETSRALSAPRADAKAYSDPSTGEPATYGELQQRCRPDQLTGLSLLPLSEKAARARQEELYSELQARETFEKTPVEVPVGGFKGRTVTVWELISSEYFTAEQRQELLRQFRTGKVTVEKVIKILITIVEEVETLRQERLSFSGLRAPVPASELLASGVLSRAQFEQLKDGKTTVKDLSELGSVRTLLQGSGCLAGIYLEDTKEKVSIYEAMRRGLLRATTAALLLEAQAATGFLVDPVRNQRLYVHEAVKAGVVGPELHEQLLSAEKAVTGYRDPYSGSTISLFQAMQKGLVLRQHGIRLLEAQIATGGIIDPVHSHRVPVDVAYQRGYFSEEMNRVLADPSDDTKGFFDPNTHENLTYRQLLERCVEDPETGLRLLPLKGAEKAEVVETTQVYTEEETRRAFEETQIDIPGGGSHGGSTMSLWEVMQSDLIPEEQRAQLMADFQAGRVTKERMIIIIIEIIEKTEIIRQQGLASYDYVRRRLTAEDLFEARIISLETYNLLREGTRSLREALEAESAWCYLYGTGSVAGVYLPGSRQTLSIYQALKKGLLSAEVARLLLEAQAATGFLLDPVKGERLTVDEAVRKGLVGPELHDRLLSAERAVTGYRDPYTEQTISLFQAMKKELIPTEEALRLLDAQLATGGIVDPRLGFHLPLEVAYQRGYLNKDTHDQLSEPSEVRSYVDPSTDERLSYTQLLRRCRRDDGTGQLLLPLSDARKLTFRGLRKQITMEELVRSQVMDEATALQLREGLTSIEEVTKNLQKFLEGTSCIAGVFVDATKERLSVYQAMKKGIIRPGTAFELLEAQAATGYVIDPIKGLKLTVEEAVRMGIVGPEFKDKLLSAERAVTGYKDPYSGKLISLFQAMKKGLILKDHGIRLLEAQIATGGIIDPEESHRLPVEVAYKRGLFDEEMNEILTDPSDDTKGFFDPNTEENLTYLQLMERCITDPQTGLCLLPLKEKKRERKTSSKSSVRKRRVVIVDPETGKEMSVYEAYRKGLIDHQTYLELSEQECEWEEITISSSDGVVKSMIIDRRSGRQYDIDDAIAKNLIDRSALDQYRAGTLSITEFADMLSGNAGGFRSRSSSVGSSSSYPISPAVSRTQLASWSDPTEETGPVAGILDTETLEKVSITEAMHRNLVDNITGQRLLEAQACTGGIIDPSTGERFPVTDAVNKGLVDKIMVDRINLAQKAFCGFEDPRTKTKMSAAQALKKGWLYYEAGQRFLEVQYLTGGLIEPDTPGRVPLDEALQRGTVDARTAQKLRDVGAYSKYLTCPKTKLKISYKDALDRSMVEEGTGLRLLEAAAQSTKGYYSPYSVSGSGSTAGSRTGSRTGSRAGSRRGSFDATGSGFSMTFSSSSYSSSGYGRRYASGSSASLGGPESAVA,"DISEASE: Epidermolysis bullosa simplex with pyloric atresia (EBS-PA) [MIM:612138]: Autosomal recessive genodermatosis characterized by severe skin blistering at birth and congenital pyloric atresia. Death usually occurs in infancy. This disorder is allelic to MD-EBS. {ECO:0000269|PubMed:14675180, ECO:0000269|PubMed:20665883}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epidermolysis bullosa simplex, with muscular dystrophy (MD-EBS) [MIM:226670]: A form of epidermolysis bullosa characterized by the association of blister formation at the level of the hemidesmosome with late-onset muscular dystrophy. {ECO:0000269|PubMed:11159198, ECO:0000269|PubMed:8894687}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epidermolysis bullosa simplex, Ogna type (O-EBS) [MIM:131950]: A form of intraepidermal epidermolysis bullosa characterized by generalized skin bruising, skin fragility with non-scarring blistering and small hemorrhagic blisters on hands. At the ultrastructural level, it is differentiated from classical cases of K-EBS, WC-EBS and DM-EBS, by the occurrence of blisters originating in basal cells above hemidesmosomes, and abnormal hemidesmosome intracellular attachment plates. {ECO:0000269|PubMed:11851880}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Limb-girdle muscular dystrophy 2Q (LGMD2Q) [MIM:613723]: A form of limb-girdle muscular dystrophy characterized by early childhood onset of proximal muscle weakness. Limb-girdle muscular dystrophies are characterized by proximal weakness, weakness of the hip and shoulder girdles and prominent asymmetrical quadriceps femoris and biceps brachii atrophy. {ECO:0000269|PubMed:21109228}. Note=The disease is caused by mutations affecting the gene represented in this entry. A 9 bp deletion containing the initiation codon in exon 1f of PLEC have been found in limb-girdle muscular dystrophy patients. The mutation results in deficient expression of isoform 9 and disorganization of the myofibers, without any effect on the skin.",,"DOMAIN: The N-terminus interacts with actin, the C-terminus with vimentin, desmin, GFAP, cytokeratins, lamin B; whereas both the N- and the C-terminus can bind integrin beta-4.",PF00307;PF00681;PF03501;,hsa:5339;,,,"SUBUNIT: Homodimer or homotetramer. Interacts (via actin-binding domain) with SYNE3. Interacts (via CH 1 domain) with VIM (via rod region). Interacts (via N-terminus) with DST isoform 2 (via N-terminus). Interacts with FER. Interacts with TOR1A. Interacts with ANK3. {ECO:0000269|PubMed:12482924, ECO:0000269|PubMed:18827015, ECO:0000269|PubMed:19932097, ECO:0000269|PubMed:21223964}.",HELIX 175 193 {ECO:0000244|PDB:1MB8}.; HELIX 194 196 {ECO:0000244|PDB:4Q59}.; HELIX 211 221 {ECO:0000244|PDB:1MB8}.; HELIX 233 249 {ECO:0000244|PDB:1MB8}.; HELIX 260 263 {ECO:0000244|PDB:1MB8}.; HELIX 267 282 {ECO:0000244|PDB:1MB8}.; HELIX 297 308 {ECO:0000244|PDB:1MB8}.; HELIX 322 324 {ECO:0000244|PDB:1MB8}.; HELIX 328 337 {ECO:0000244|PDB:1MB8}.; HELIX 339 341 {ECO:0000244|PDB:1MB8}.; HELIX 344 347 {ECO:0000244|PDB:1MB8}.; HELIX 352 367 {ECO:0000244|PDB:1MB8}.; HELIX 375 378 {ECO:0000244|PDB:1MB8}.; HELIX 385 398 {ECO:0000244|PDB:1MB8}.; HELIX 414 440 {ECO:0000244|PDB:2ODV}.; HELIX 448 464 {ECO:0000244|PDB:2ODV}.; HELIX 466 488 {ECO:0000244|PDB:2ODV}.; HELIX 500 562 {ECO:0000244|PDB:2ODV}.; HELIX 572 598 {ECO:0000244|PDB:2ODV}.; HELIX 604 628 {ECO:0000244|PDB:2ODV}.; HELIX 656 678 {ECO:0000244|PDB:3PDY}.; HELIX 685 714 {ECO:0000244|PDB:3PDY}.; HELIX 715 718 {ECO:0000244|PDB:3PDY}.; HELIX 721 778 {ECO:0000244|PDB:3PDY}.; HELIX 788 821 {ECO:0000244|PDB:3PDY}.; HELIX 827 854 {ECO:0000244|PDB:3PDY}.; HELIX 893 900 {ECO:0000244|PDB:3PE0}.; HELIX 904 925 {ECO:0000244|PDB:3PE0}.; HELIX 932 934 {ECO:0000244|PDB:3PE0}.; HELIX 990 992 {ECO:0000244|PDB:3PE0}.; HELIX 1000 1024 {ECO:0000244|PDB:3PE0}.; HELIX 1493 1527 {ECO:0000244|PDB:4GDO}.,STRAND 380 382 {ECO:0000244|PDB:1MB8}.; STRAND 490 492 {ECO:0000244|PDB:2ODU}.; STRAND 944 948 {ECO:0000244|PDB:3PE0}.; STRAND 964 970 {ECO:0000244|PDB:3PE0}.; STRAND 975 979 {ECO:0000244|PDB:3PE0}.; STRAND 985 989 {ECO:0000244|PDB:3PE0}.,TURN 203 209 {ECO:0000244|PDB:1MB8}.; TURN 283 285 {ECO:0000244|PDB:4Q59}.; TURN 309 311 {ECO:0000244|PDB:1MB8}.; TURN 563 566 {ECO:0000244|PDB:2ODV}.,DOMAIN 175 400 Actin-binding.; DOMAIN 179 282 CH 1. {ECO:0000255|PROSITE-ProRule:PRU00044}.; DOMAIN 295 397 CH 2. {ECO:0000255|PROSITE-ProRule:PRU00044}.,,,,,0.747224594,-0.665,531.93,12.6,13.6Q9H307,PININ_HUMAN,reviewed,Pinin (140 kDa nuclear and cell adhesion-related phosphoprotein) (Desmosome-associated protein) (Domain-rich serine protein) (DRS protein) (DRSP) (Melanoma metastasis clone A protein) (Nuclear protein SDK3) (SR-like protein),PNN DRS MEMA,Homo sapiens (Human),717,GO:0003677; GO:0071013; GO:0007155; GO:0005911; GO:0005737; GO:0030057; GO:0005882; GO:0000398; GO:0016020; GO:0016607; GO:0005654; GO:0005886; GO:0044822; GO:0006355; GO:0005198; GO:0006351,5411;,MAVAVRTLQEQLEKAKESLKNVDENIRKLTGRDPNDVRPIQARLLALSGPGGGRGRGSLLLRRGFSDSGGGPPAKQRDLEGAVSRLGGERRTRRESRQESDPEDDDVKKPALQSSVVATSKERTRRDLIQDQNMDEKGKQRNRRIFGLLMGTLQKFKQESTVATERQKRRQEIEQKLEVQAEEERKQVENERRELFEERRAKQTELRLLEQKVELAQLQEEWNEHNAKIIKYIRTKTKPHLFYIPGRMCPATQKLIEESQRKMNALFEGRRIEFAEQINKMEARPRRQSMKEKEHQVVRNEEQKAEQEEGKVAQREEELEETGNQHNDVEIEEAGEEEEKEIAIVHSDAEKEQEEEEQKQEMEVKMEEETEVRESEKQQDSQPEEVMDVLEMVENVKHVIADQEVMETNRVESVEPSENEASKELEPEMEFEIEPDKECKSLSPGKENVSALDMEKESEEKEEKESEPQPEPVAQPQPQSQPQLQLQSQSQPVLQSQPPSQPEDLSLAVLQPTPQVTQEQGHLLPERKDFPVESVKLTEVPVEPVLTVHPESKSKTKTRSRSRGRARNKTSKSRSRSSSSSSSSSSSTSSSSGSSSSSGSSSSRSSSSSSSSTSGSSSRDSSSSTSSSSESRSRSRGRGHNRDRKHRRSVDRKRRDTSGLERSHKSSKGGSSRDTKGSKDKNSRSDRKRSISESSRSGKRSSRSERDRKSDRKDKRR,,,,PF04696;PF04697;,hsa:5411;,,,"SUBUNIT: Found in a mRNA splicing-dependent exon junction complex (EJC). Found in a complex with SR proteins. Found in a mRNP complex with RNPS1. Component of the PSAP complex consisting of RNPS1, SAP18 and PNN. Interacts with PNISR, CTBP1, CTBP2, KRT8, KRT18, KRT19, PS1D/PNO40, PPIG, RNPS1, SFRS4 and SRRM2. Identified in the spliceosome C complex. {ECO:0000269|PubMed:10809736, ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:12893261, ECO:0000269|PubMed:14517304, ECO:0000269|PubMed:14578391, ECO:0000269|PubMed:14729963, ECO:0000269|PubMed:15358154, ECO:0000269|PubMed:15542832, ECO:0000269|PubMed:16314458, ECO:0000269|PubMed:22388736}.",,,,,,,,,0.278940028,-1.414,81.63,52.9,53.9P78527,PRKDC_HUMAN,reviewed,DNA-dependent protein kinase catalytic subunit (DNA-PK catalytic subunit) (DNA-PKcs) (EC 2.7.11.1) (DNPK1) (p460),PRKDC HYRC HYRC1,Homo sapiens (Human),4128,GO:0005524; GO:0002326; GO:0003677; GO:0006281; GO:0004677; GO:0005958; GO:0033077; GO:0002360; GO:0033153; GO:0007420; GO:0006464; GO:0032869; GO:0005829; GO:0006302; GO:0000724; GO:0006303; GO:0035234; GO:0007507; GO:0033152; GO:0045087; GO:0008630; GO:0016020; GO:0001933; GO:0070419; GO:0005730; GO:0005654; GO:0018105; GO:0044822; GO:0043065; GO:0045944; GO:0032481; GO:0002328; GO:0031648; GO:0004672; GO:0004674; GO:0042752; GO:0010332; GO:0048511; GO:0072431; GO:0001756; GO:0000723; GO:0008134; GO:0005667,5591;,MAGSGAGVRCSLLRLQETLSAADRCGAALAGHQLIRGLGQECVLSSSPAVLALQTSLVFSRDFGLLVFVRKSLNSIEFRECREEILKFLCIFLEKMGQKIAPYSVEIKNTCTSVYTKDRAAKCKIPALDLLIKLLQTFRSSRLMDEFKIGELFSKFYGELALKKKIPDTVLEKVYELLGLLGEVHPSEMINNAENLFRAFLGELKTQMTSAVREPKLPVLAGCLKGLSSLLCNFTKSMEEDPQTSREIFNFVLKAIRPQIDLKRYAVPSAGLRLFALHASQFSTCLLDNYVSLFEVLLKWCAHTNVELKKAALSALESFLKQVSNMVAKNAEMHKNKLQYFMEQFYGIIRNVDSNNKELSIAIRGYGLFAGPCKVINAKDVDFMYVELIQRCKQMFLTQTDTGDDRVYQMPSFLQSVASVLLYLDTVPEVYTPVLEHLVVMQIDSFPQYSPKMQLVCCRAIVKVFLALAAKGPVLRNCISTVVHQGLIRICSKPVVLPKGPESESEDHRASGEVRTGKWKVPTYKDYVDLFRHLLSSDQMMDSILADEAFFSVNSSSESLNHLLYDEFVKSVLKIVEKLDLTLEIQTVGEQENGDEAPGVWMIPTSDPAANLHPAKPKDFSAFINLVEFCREILPEKQAEFFEPWVYSFSYELILQSTRLPLISGFYKLLSITVRNAKKIKYFEGVSPKSLKHSPEDPEKYSCFALFVKFGKEVAVKMKQYKDELLASCLTFLLSLPHNIIELDVRAYVPALQMAFKLGLSYTPLAEVGLNALEEWSIYIDRHVMQPYYKDILPCLDGYLKTSALSDETKNNWEVSALSRAAQKGFNKVVLKHLKKTKNLSSNEAISLEEIRIRVVQMLGSLGGQINKNLLTVTSSDEMMKSYVAWDREKRLSFAVPFREMKPVIFLDVFLPRVTELALTASDRQTKVAACELLHSMVMFMLGKATQMPEGGQGAPPMYQLYKRTFPVLLRLACDVDQVTRQLYEPLVMQLIHWFTNNKKFESQDTVALLEAILDGIVDPVDSTLRDFCGRCIREFLKWSIKQITPQQQEKSPVNTKSLFKRLYSLALHPNAFKRLGASLAFNNIYREFREEESLVEQFVFEALVIYMESLALAHADEKSLGTIQQCCDAIDHLCRIIEKKHVSLNKAKKRRLPRGFPPSASLCLLDLVKWLLAHCGRPQTECRHKSIELFYKFVPLLPGNRSPNLWLKDVLKEEGVSFLINTFEGGGCGQPSGILAQPTLLYLRGPFSLQATLCWLDLLLAALECYNTFIGERTVGALQVLGTEAQSSLLKAVAFFLESIAMHDIIAAEKCFGTGAAGNRTSPQEGERYNYSKCTVVVRIMEFTTTLLNTSPEGWKLLKKDLCNTHLMRVLVQTLCEPASIGFNIGDVQVMAHLPDVCVNLMKALKMSPYKDILETHLREKITAQSIEELCAVNLYGPDAQVDRSRLAAVVSACKQLHRAGLLHNILPSQSTDLHHSVGTELLSLVYKGIAPGDERQCLPSLDLSCKQLASGLLELAFAFGGLCERLVSLLLNPAVLSTASLGSSQGSVIHFSHGEYFYSLFSETINTELLKNLDLAVLELMQSSVDNTKMVSAVLNGMLDQSFRERANQKHQGLKLATTILQHWKKCDSWWAKDSPLETKMAVLALLAKILQIDSSVSFNTSHGSFPEVFTTYISLLADTKLDLHLKGQAVTLLPFFTSLTGGSLEELRRVLEQLIVAHFPMQSREFPPGTPRFNNYVDCMKKFLDALELSQSPMLLELMTEVLCREQQHVMEELFQSSFRRIARRGSCVTQVGLLESVYEMFRKDDPRLSFTRQSFVDRSLLTLLWHCSLDALREFFSTIVVDAIDVLKSRFTKLNESTFDTQITKKMGYYKILDVMYSRLPKDDVHAKESKINQVFHGSCITEGNELTKTLIKLCYDAFTENMAGENQLLERRRLYHCAAYNCAISVICCVFNELKFYQGFLFSEKPEKNLLIFENLIDLKRRYNFPVEVEVPMERKKKYIEIRKEAREAANGDSDGPSYMSSLSYLADSTLSEEMSQFDFSTGVQSYSYSSQDPRPATGRFRRREQRDPTVHDDVLELEMDELNRHECMAPLTALVKHMHRSLGPPQGEEDSVPRDLPSWMKFLHGKLGNPIVPLNIRLFLAKLVINTEEVFRPYAKHWLSPLLQLAASENNGGEGIHYMVVEIVATILSWTGLATPTGVPKDEVLANRLLNFLMKHVFHPKRAVFRHNLEIIKTLVECWKDCLSIPYRLIFEKFSGKDPNSKDNSVGIQLLGIVMANDLPPYDPQCGIQSSEYFQALVNNMSFVRYKEVYAAAAEVLGLILRYVMERKNILEESLCELVAKQLKQHQNTMEDKFIVCLNKVTKSFPPLADRFMNAVFFLLPKFHGVLKTLCLEVVLCRVEGMTELYFQLKSKDFVQVMRHRDDERQKVCLDIIYKMMPKLKPVELRELLNPVVEFVSHPSTTCREQMYNILMWIHDNYRDPESETDNDSQEIFKLAKDVLIQGLIDENPGLQLIIRNFWSHETRLPSNTLDRLLALNSLYSPKIEVHFLSLATNFLLEMTSMSPDYPNPMFEHPLSECEFQEYTIDSDWRFRSTVLTPMFVETQASQGTLQTRTQEGSLSARWPVAGQIRATQQQHDFTLTQTADGRSSFDWLTGSSTDPLVDHTSPSSDSLLFAHKRSERLQRAPLKSVGPDFGKKRLGLPGDEVDNKVKGAAGRTDLLRLRRRFMRDQEKLSLMYARKGVAEQKREKEIKSELKMKQDAQVVLYRSYRHGDLPDIQIKHSSLITPLQAVAQRDPIIAKQLFSSLFSGILKEMDKFKTLSEKNNITQKLLQDFNRFLNTTFSFFPPFVSCIQDISCQHAALLSLDPAAVSAGCLASLQQPVGIRLLEEALLRLLPAELPAKRVRGKARLPPDVLRWVELAKLYRSIGEYDVLRGIFTSEIGTKQITQSALLAEARSDYSEAAKQYDEALNKQDWVDGEPTEAEKDFWELASLDCYNHLAEWKSLEYCSTASIDSENPPDLNKIWSEPFYQETYLPYMIRSKLKLLLQGEADQSLLTFIDKAMHGELQKAILELHYSQELSLLYLLQDDVDRAKYYIQNGIQSFMQNYSSIDVLLHQSRLTKLQSVQALTEIQEFISFISKQGNLSSQVPLKRLLNTWTNRYPDAKMDPMNIWDDIITNRCFFLSKIEEKLTPLPEDNSMNVDQDGDPSDRMEVQEQEEDISSLIRSCKFSMKMKMIDSARKQNNFSLAMKLLKELHKESKTRDDWLVSWVQSYCRLSHCRSRSQGCSEQVLTVLKTVSLLDENNVSSYLSKNILAFRDQNILLGTTYRIIANALSSEPACLAEIEEDKARRILELSGSSSEDSEKVIAGLYQRAFQHLSEAVQAAEEEAQPPSWSCGPAAGVIDAYMTLADFCDQQLRKEEENASVIDSAELQAYPALVVEKMLKALKLNSNEARLKFPRLLQIIERYPEETLSLMTKEISSVPCWQFISWISHMVALLDKDQAVAVQHSVEEITDNYPQAIVYPFIISSESYSFKDTSTGHKNKEFVARIKSKLDQGGVIQDFINALDQLSNPELLFKDWSNDVRAELAKTPVNKKNIEKMYERMYAALGDPKAPGLGAFRRKFIQTFGKEFDKHFGKGGSKLLRMKLSDFNDITNMLLLKMNKDSKPPGNLKECSPWMSDFKVEFLRNELEIPGQYDGRGKPLPEYHVRIAGFDERVTVMASLRRPKRIIIRGHDEREHPFLVKGGEDLRQDQRVEQLFQVMNGILAQDSACSQRALQLRTYSVVPMTSRLGLIEWLENTVTLKDLLLNTMSQEEKAAYLSDPRAPPCEYKDWLTKMSGKHDVGAYMLMYKGANRTETVTSFRKRESKVPADLLKRAFVRMSTSPEAFLALRSHFASSHALICISHWILGIGDRHLNNFMVAMETGGVIGIDFGHAFGSATQFLPVPELMPFRLTRQFINLMLPMKETGLMYSIMVHALRAFRSDPGLLTNTMDVFVKEPSFDWKNFEQKMLKKGGSWIQEINVAEKNWYPRQKICYAKRKLAGANPAVITCDELLLGHEKAPAFRDYVAVARGSKDHNIRAQEPESGLSEETQVKCLMDQATDPNILGRTWEGWEPWM,,,,PF02259;PF02260;PF08163;PF00454;,hsa:5591;,,,"SUBUNIT: DNA-PK is a heterotrimer of PRKDC and the Ku p70-p86 (XRCC6-XRCC5) dimer. Formation of this complex may be promoted by interaction with ILF3. Associates with the DNA-bound Ku heterodimer, but it can also bind to and be activated by free DNA. Interacts with DNA-PKcs-interacting protein (KIP) with the region upstream the kinase domain. PRKDC alone also interacts with and phosphorylates DCLRE1C, thereby activating the latent endonuclease activity of this protein. Interacts with C1D. Interacts with TTI1 and TELO2. Interacts with CIB1. {ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:14744996, ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891, ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:15758953, ECO:0000269|PubMed:15811628, ECO:0000269|PubMed:15936993, ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:9372844, ECO:0000269|PubMed:9442054, ECO:0000269|PubMed:9679063}.",,,,"DOMAIN 2883 3539 FAT. {ECO:0000255|PROSITE-ProRule:PRU00534}.; DOMAIN 3747 4015 PI3K/PI4K. {ECO:0000255|PROSITE-ProRule:PRU00269}.; DOMAIN 4096 4128 FATC. {ECO:0000255|PROSITE-ProRule:PRU00534, ECO:0000255|PROSITE-ProRule:PRU00535}.",,,,,2.10755814,-0.198,469.17,36.2,37.2Q00577,PURA_HUMAN,reviewed,Transcriptional activator protein Pur-alpha (Purine-rich single-stranded DNA-binding protein alpha),PURA PUR1,Homo sapiens (Human),322,GO:0005662; GO:0006270; GO:0006268; GO:0003705; GO:0005737; GO:0030425; GO:0003691; GO:0045892; GO:0007399; GO:0043025; GO:0000784; GO:0005634; GO:0044822; GO:0008284; GO:0032422; GO:0006357; GO:0003697; GO:0008134; GO:0006366; GO:0000900,5813;,MADRDSGSEQGGAALGSGGSLGHPGSGSGSGGGGGGGGGGGGSGGGGGGAPGGLQHETQELASKRVDIQNKRFYLDVKQNAKGRFLKIAEVGAGGNKSRLTLSMSVAVEFRDYLGDFIEHYAQLGPSQPPDLAQAQDEPRRALKSEFLVRENRKYYMDLKENQRGRFLRIRQTVNRGPGLGSTQGQTIALPAQGLIEFRDALAKLIDDYGVEEEPAELPEGTSLTVDNKRFFFDVGSNKYGVFMRVSEVKPTYRNSITVPYKVWAKFGHTFCKYSEEMKKIQEKQREKRAACEQLHQQQQQQQEETAAATLLLQGEEEGEED,,,,PF04845;,hsa:5813;,,,"SUBUNIT: Homodimer, heterodimer with PURB and heterotrimer with PURB and YBX1/Y-box protein 1. {ECO:0000250}.",,,,,,,,,0.621118012,-0.752,34.92,1113,1114P43487,RANG_HUMAN,reviewed,Ran-specific GTPase-activating protein (Ran-binding protein 1) (RanBP1),RANBP1,Homo sapiens (Human),201,GO:0005092; GO:0005096; GO:0008536; GO:0005737; GO:0046907; GO:0005635; GO:0005634; GO:0050790; GO:0007165; GO:0016032,5902;,MAAAKDTHEDHDTSTENTDESNHDPQFEPIVSLPEQEIKTLEEDEEELFKMRAKLFRFASENDLPEWKERGTGDVKLLKHKEKGAIRLLMRRDKTLKICANHYITPMMELKPNAGSDRAWVWNTHADFADECPKPELLAIRFLNAENAQKFKTKFEECRKEIEEREKKAGSGKNDHAEKVAEKLEALSVKEETKEDAEEKQ,,,,PF00638;,hsa:5902;,,,,HELIX 145 165 {ECO:0000244|PDB:1K5D}.,STRAND 48 58 {ECO:0000244|PDB:1K5D}.; STRAND 67 79 {ECO:0000244|PDB:1K5D}.; STRAND 81 83 {ECO:0000244|PDB:1K5D}.; STRAND 86 92 {ECO:0000244|PDB:1K5D}.; STRAND 98 103 {ECO:0000244|PDB:1K5D}.; STRAND 117 127 {ECO:0000244|PDB:1K5D}.; STRAND 134 141 {ECO:0000244|PDB:1K5D}.,TURN 93 95 {ECO:0000244|PDB:1K5D}.,DOMAIN 26 164 RanBD1. {ECO:0000255|PROSITE-ProRule:PRU00164}.,,,,,1.492537313,-1.097,23.31,124,125Q09028,RBBP4_HUMAN,reviewed,Histone-binding protein RBBP4 (Chromatin assembly factor 1 subunit C) (CAF-1 subunit C) (Chromatin assembly factor I p48 subunit) (CAF-I 48 kDa subunit) (CAF-I p48) (Nucleosome-remodeling factor subunit RBAP48) (Retinoblastoma-binding protein 4) (RBBP-4) (Retinoblastoma-binding protein p48),RBBP4 RBAP48,Homo sapiens (Human),425,GO:0006200; GO:0043044; GO:0033186; GO:0034080; GO:0006260; GO:0006335; GO:0006336; GO:0035098; GO:0000086; GO:0016589; GO:0016581; GO:0016580; GO:0031497; GO:0006338; GO:0042393; GO:0042826; GO:0000278; GO:0008285; GO:0000790; GO:0005654; GO:0006334; GO:0005634; GO:0043234; GO:0051726; GO:0006355; GO:0006351,5928;,MADKEAAFDDAVEERVINEEYKIWKKNTPFLYDLVMTHALEWPSLTAQWLPDVTRPEGKDFSIHRLVLGTHTSDEQNHLVIASVQLPNDDAQFDASHYDSEKGEFGGFGSVSGKIEIEIKINHEGEVNRARYMPQNPCIIATKTPSSDVLVFDYTKHPSKPDPSGECNPDLRLRGHQKEGYGLSWNPNLSGHLLSASDDHTICLWDISAVPKEGKVVDAKTIFTGHTAVVEDVSWHLLHESLFGSVADDQKLMIWDTRSNNTSKPSHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLKLHSFESHKDEIFQVQWSPHNETILASSGTDRRLNVWDLSKIGEEQSPEDAEDGPPELLFIHGGHTAKISDFSWNPNEPWVICSVSEDNIMQVWQMAENIYNDEDPEGSVDPEGQGS,,,,PF12265;PF00400;,hsa:5928;,,,"SUBUNIT: Interacts with SUV39H1 and HDAC7 (By similarity). Binds directly to helix 1 of the histone fold of histone H4, a region that is not accessible when H4 is in chromatin. Subunit of the chromatin assembly factor 1 (CAF-1) complex, which is composed of RBBP4, CHAF1B and CHAF1A. Subunit of the core histone deacetylase (HDAC) complex, which is composed of HDAC1, HDAC2, RBBP4 and RBBP7. The core HDAC complex associates with SIN3A, ARID4B/SAP180, SAP18, SAP30, SAP130, SUDS3/SAP45 and possibly ARID4A/RBP1 and ING1 to form the SIN3 HDAC complex. The core HDAC complex may also associate with MTA2, MBD3, CHD3 and CHD4 to form the nucleosome remodeling and histone deacetylase complex (the NuRD complex). The NuRD complex may also interact with MBD3L1 and MBD3L2. Interacts with MTA1. Subunit of the PRC2/EED-EZH2 complex, which is composed of at least EED, EZH2, RBBP4, RBBP7 and SUZ12. The PRC2/EED-EZH2 complex may also associate with HDAC1. Component of the PRC2/EED-EZH1 complex, which includes EED, EZH1, SUZ12, RBBP4 and AEBP2. Part of the nucleosome remodeling factor (NURF) complex which consists of SMARCA1; BPTF; RBBP4 and RBBP7. Interacts with the viral protein-binding domain of the retinoblastoma protein (RB1). Interacts with SPEN/MINT. Interacts with BRCA1. Interacts with CREBBP, and this interaction may be enhanced by the binding of phosphorylated CREB1 to CREBBP. Component of the DREAM complex (also named LINC complex) at least composed of E2F4, E2F5, LIN9, LIN37, LIN52, LIN54, MYBL1, MYBL2, RBL1, RBL2, RBBP4, TFDP1 and TFDP2. The complex exists in quiescent cells where it represses cell cycle-dependent genes. It dissociates in S phase when LIN9, LIN37, LIN52 and LIN54 form a subcomplex that binds to MYBL2. Interacts with PHF6. {ECO:0000250, ECO:0000269|PubMed:10220405, ECO:0000269|PubMed:10444591, ECO:0000269|PubMed:10734134, ECO:0000269|PubMed:10866654, ECO:0000269|PubMed:11102443, ECO:0000269|PubMed:11118440, ECO:0000269|PubMed:11331609, ECO:0000269|PubMed:11784859, ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631, ECO:0000269|PubMed:12920132, ECO:0000269|PubMed:14609955, ECO:0000269|PubMed:15456747, ECO:0000269|PubMed:15701600, ECO:0000269|PubMed:17531812, ECO:0000269|PubMed:17671431, ECO:0000269|PubMed:24554700, ECO:0000269|PubMed:7503932, ECO:0000269|PubMed:8602529, ECO:0000269|PubMed:8858152, ECO:0000269|PubMed:9150135, ECO:0000269|PubMed:9427644, ECO:0000269|PubMed:9520398, ECO:0000269|PubMed:9651585, ECO:0000269|PubMed:9790534}.",HELIX 17 31 {ECO:0000244|PDB:2XU7}.; HELIX 154 156 {ECO:0000244|PDB:2XU7}.; HELIX 207 209 {ECO:0000244|PDB:3GFC}.; HELIX 347 349 {ECO:0000244|PDB:2XU7}.; HELIX 356 361 {ECO:0000244|PDB:4PBZ}.; HELIX 406 409 {ECO:0000244|PDB:2XU7}.,STRAND 32 39 {ECO:0000244|PDB:2XU7}.; STRAND 48 54 {ECO:0000244|PDB:2XU7}.; STRAND 62 69 {ECO:0000244|PDB:2XU7}.; STRAND 73 75 {ECO:0000244|PDB:2XU7}.; STRAND 78 86 {ECO:0000244|PDB:2XU7}.; STRAND 115 122 {ECO:0000244|PDB:2XU7}.; STRAND 128 133 {ECO:0000244|PDB:2XU7}.; STRAND 136 143 {ECO:0000244|PDB:2XU7}.; STRAND 145 147 {ECO:0000244|PDB:4PBZ}.; STRAND 149 153 {ECO:0000244|PDB:2XU7}.; STRAND 170 174 {ECO:0000244|PDB:2XU7}.; STRAND 180 185 {ECO:0000244|PDB:2XU7}.; STRAND 187 189 {ECO:0000244|PDB:4PBZ}.; STRAND 192 197 {ECO:0000244|PDB:2XU7}.; STRAND 202 206 {ECO:0000244|PDB:2XU7}.; STRAND 213 218 {ECO:0000244|PDB:2XU7}.; STRAND 220 223 {ECO:0000244|PDB:2XU7}.; STRAND 230 235 {ECO:0000244|PDB:2XU7}.; STRAND 242 247 {ECO:0000244|PDB:2XU7}.; STRAND 250 256 {ECO:0000244|PDB:2XU7}.; STRAND 262 264 {ECO:0000244|PDB:2XU7}.; STRAND 266 270 {ECO:0000244|PDB:2XU7}.; STRAND 276 281 {ECO:0000244|PDB:2XU7}.; STRAND 288 293 {ECO:0000244|PDB:2XU7}.; STRAND 296 302 {ECO:0000244|PDB:2XU7}.; STRAND 310 314 {ECO:0000244|PDB:2XU7}.; STRAND 320 325 {ECO:0000244|PDB:2XU7}.; STRAND 332 337 {ECO:0000244|PDB:2XU7}.; STRAND 342 346 {ECO:0000244|PDB:2XU7}.; STRAND 366 370 {ECO:0000244|PDB:2XU7}.; STRAND 377 382 {ECO:0000244|PDB:2XU7}.; STRAND 384 386 {ECO:0000244|PDB:2XU7}.; STRAND 389 394 {ECO:0000244|PDB:2XU7}.; STRAND 397 404 {ECO:0000244|PDB:2XU7}.,TURN 100 103 {ECO:0000244|PDB:4PC0}.,,,,,,1.176470588,-0.56,47.66,41.4,42.4Q9Y5S9,RBM8A_HUMAN,reviewed,RNA-binding protein 8A (Binder of OVCA1-1) (BOV-1) (RNA-binding motif protein 8A) (RNA-binding protein Y14) (Ribonucleoprotein RBM8A),RBM8A RBM8 HSPC114 MDS014,Homo sapiens (Human),174,GO:0003723; GO:0016070; GO:0008380; GO:0071013; GO:0005737; GO:0005829; GO:0035145; GO:0010467; GO:0031124; GO:0003729; GO:0006406; GO:0016071; GO:0000398; GO:0016607; GO:0000184; GO:0005654; GO:0000166; GO:0005634; GO:0044822; GO:0000381; GO:0006417; GO:0006369; GO:0006366,9939;,MADVLDLHEAGGEDFAMDEDGDESIHKLKEKAKKRKGRGFGSEEGSRARMREDYDSVEQDGDEPGPQRSVEGWILFVTGVHEEATEEDIHDKFAEYGEIKNIHLNLDRRTGYLKGYTLVEYETYKEAQAAMEGLNGQDLMGQPISVDWCFVRGPPKGKRRGGRRRSRSPDRRRR,,,,PF00076;,hsa:9939;,,,"SUBUNIT: Heterodimer with RBM8A. Part of the mRNA splicing-dependent exon junction complex (EJC) complex; the core complex contains CASC3, EIF4A3, MAGOH and RBM8A. Interacts with WIBG/PYM; the interaction is direct and dissociates the EJC from spliced mRNAs. Found in a post-splicing complex with NXF1, RBM8A, UPF1, UPF2, UPF3A, UPF3B and RNPS1. Interacts with BAT1, MAGOH, OVCA1, UPF3B, RNPS1, SRRM1 and ALYREF/THOC4. Interacts with IPO13; the interaction mediates the nuclear import of the MAGOH-RBM8A heterodimer. Identified in the spliceosome C complex. Associates with polysomes. {ECO:0000269|PubMed:10662555, ECO:0000269|PubMed:11013075, ECO:0000269|PubMed:11118221, ECO:0000269|PubMed:11447110, ECO:0000269|PubMed:11546873, ECO:0000269|PubMed:11546874, ECO:0000269|PubMed:11707413, ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:12718880, ECO:0000269|PubMed:12730685, ECO:0000269|PubMed:12781131, ECO:0000269|PubMed:12944400, ECO:0000269|PubMed:14625303, ECO:0000269|PubMed:14968132, ECO:0000269|PubMed:16170325, ECO:0000269|PubMed:16314458, ECO:0000269|PubMed:18026120, ECO:0000269|PubMed:19410547}.",HELIX 86 93 {ECO:0000244|PDB:1P27}.; HELIX 94 96 {ECO:0000244|PDB:1P27}.; HELIX 124 134 {ECO:0000244|PDB:1P27}.,STRAND 72 78 {ECO:0000244|PDB:1P27}.; STRAND 99 106 {ECO:0000244|PDB:1P27}.; STRAND 111 122 {ECO:0000244|PDB:1P27}.; STRAND 138 143 {ECO:0000244|PDB:1P27}.; STRAND 145 153 {ECO:0000244|PDB:1P27}.,TURN 108 110 {ECO:0000244|PDB:1P27}.,DOMAIN 73 151 RRM. {ECO:0000255|PROSITE-ProRule:PRU00176}.,,,,,0.574712644,-1.153,19.89,61.1,62.1Q9Y265,RUVB1_HUMAN,reviewed,RuvB-like 1 (EC 3.6.4.12) (49 kDa TATA box-binding protein-interacting protein) (49 kDa TBP-interacting protein) (54 kDa erythrocyte cytosolic protein) (ECP-54) (INO80 complex subunit H) (Nuclear matrix protein 238) (NMP 238) (Pontin 52) (TIP49a) (TIP60-associated protein 54-alpha) (TAP54-alpha),RUVBL1 INO80H NMP238 TIP49 TIP49A,Homo sapiens (Human),456,GO:0005524; GO:0034080; GO:0032508; GO:0003678; GO:0006310; GO:0006281; GO:0005794; GO:0031011; GO:0071339; GO:0035267; GO:0000812; GO:0051301; GO:0006325; GO:0005737; GO:0070062; GO:0043968; GO:0043967; GO:0043231; GO:0016020; GO:0005815; GO:0007067; GO:0016363; GO:0005654; GO:0006334; GO:0005634; GO:0040008; GO:0006357; GO:0030529; GO:0007283; GO:0006351,8607;,MKIEEVKSTTKTQRIASHSHVKGLGLDESGLAKQAASGLVGQENAREACGVIVELIKSKKMAGRAVLLAGPPGTGKTALALAIAQELGSKVPFCPMVGSEVYSTEIKKTEVLMENFRRAIGLRIKETKEVYEGEVTELTPCETENPMGGYGKTISHVIIGLKTAKGTKQLKLDPSIFESLQKERVEAGDVIYIEANSGAVKRQGRCDTYATEFDLEAEEYVPLPKGDVHKKKEIIQDVTLHDLDVANARPQGGQDILSMMGQLMKPKKTEITDKLRGEINKVVNKYIDQGIAELVPGVLFVDEVHMLDIECFTYLHRALESSIAPIVIFASNRGNCVIRGTEDITSPHGIPLDLLDRVMIIRTMLYTPQEMKQIIKIRAQTEGINISEEALNHLGEIGTKTTLRYSVQLLTPANLLAKINGKDSIEKEHVEEISELFYDAKSSAKILADQQDKYMK,,,DOMAIN: Binding to MYC is dependent on a Myc domain essential for oncogenic activity.,PF06068;,hsa:8607;,,,"SUBUNIT: Forms homohexameric rings. Can form a dodecamer with RUVBL2 made of two stacked hexameric rings; however, even though RUVBL1 and RUVBL2 are present in equimolar ratio, the oligomeric status of each hexamer is not known. Oligomerization may regulate binding to nucleic acids and conversely, binding to nucleic acids may affect the dodecameric assembly. Interacts with the transcriptional activation domain of MYC. Component of the RNA polymerase II holoenzyme complex. May also act to bridge the LEF1/TCF1-CTNNB1 complex and TBP. Component of the NuA4 histone acetyltransferase complex which contains the catalytic subunit KAT5/TIP60 and the subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. The NuA4 complex interacts with MYC and the adenovirus E1A protein. RUVBL1 interacts with EP400. Component of a NuA4-related complex which contains EP400, TRRAP/PAF400, SRCAP, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, actin, ACTL6A/BAF53A, VPS72 and YEATS4/GAS41. Component of the BAF53 complex, at least composed of ACTL6A/BAF53A, RUVBL1/TIP49, SMARCA2/BRM, and TRRAP/PAF400. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BAP18, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MYST1/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Associates with alpha and gamma tubulins, particularly during metaphase and early anaphase. Interacts with NPAT. Component of the chromatin-remodeling INO80 complex; specifically part of a complex module associated with the helicase ATP-binding and the helicase C-terminal domain of INO80. Interacts with IGHMBP2. Interacts with OFD1. Interacts with HINT1. Component of a complex with USP49 and PSMC5. Component of a SWR1-like complex. {ECO:0000269|PubMed:10428817, ECO:0000269|PubMed:10882073, ECO:0000269|PubMed:10966108, ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12963728, ECO:0000269|PubMed:14506706, ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:15960975, ECO:0000269|PubMed:16014379, ECO:0000269|PubMed:16230350, ECO:0000269|PubMed:17060327, ECO:0000269|PubMed:17157868, ECO:0000269|PubMed:17761535, ECO:0000269|PubMed:17967892, ECO:0000269|PubMed:18026119, ECO:0000269|PubMed:19299493, ECO:0000269|PubMed:21303910, ECO:0000269|PubMed:23824326, ECO:0000269|PubMed:24463511}.",HELIX 10 16 {ECO:0000244|PDB:2C9O}.; HELIX 43 57 {ECO:0000244|PDB:2C9O}.; HELIX 76 87 {ECO:0000244|PDB:2C9O}.; HELIX 98 101 {ECO:0000244|PDB:2C9O}.; HELIX 108 118 {ECO:0000244|PDB:2C9O}.; HELIX 174 182 {ECO:0000244|PDB:2C9O}.; HELIX 240 245 {ECO:0000244|PDB:2C9O}.; HELIX 278 288 {ECO:0000244|PDB:2C9O}.; HELIX 304 306 {ECO:0000244|PDB:2C9O}.; HELIX 309 318 {ECO:0000244|PDB:2C9O}.; HELIX 352 355 {ECO:0000244|PDB:2C9O}.; HELIX 368 382 {ECO:0000244|PDB:2C9O}.; HELIX 388 400 {ECO:0000244|PDB:2C9O}.; HELIX 403 408 {ECO:0000244|PDB:2C9O}.; HELIX 410 419 {ECO:0000244|PDB:2C9O}.; HELIX 427 436 {ECO:0000244|PDB:2C9O}.; HELIX 440 448 {ECO:0000244|PDB:2C9O}.,STRAND 28 30 {ECO:0000244|PDB:2XSZ}.; STRAND 34 36 {ECO:0000244|PDB:2C9O}.; STRAND 39 41 {ECO:0000244|PDB:2C9O}.; STRAND 65 69 {ECO:0000244|PDB:2C9O}.; STRAND 72 75 {ECO:0000244|PDB:2XSZ}.; STRAND 93 97 {ECO:0000244|PDB:2C9O}.; STRAND 104 106 {ECO:0000244|PDB:2C9O}.; STRAND 119 140 {ECO:0000244|PDB:2C9O}.; STRAND 157 163 {ECO:0000244|PDB:2C9O}.; STRAND 166 172 {ECO:0000244|PDB:2C9O}.; STRAND 189 194 {ECO:0000244|PDB:2C9O}.; STRAND 200 206 {ECO:0000244|PDB:2C9O}.; STRAND 216 221 {ECO:0000244|PDB:2C9O}.; STRAND 228 239 {ECO:0000244|PDB:2C9O}.; STRAND 291 296 {ECO:0000244|PDB:2C9O}.; STRAND 298 303 {ECO:0000244|PDB:2C9O}.; STRAND 326 331 {ECO:0000244|PDB:2C9O}.; STRAND 334 337 {ECO:0000244|PDB:2C9O}.; STRAND 345 347 {ECO:0000244|PDB:2C9O}.; STRAND 358 362 {ECO:0000244|PDB:2C9O}.; STRAND 423 425 {ECO:0000244|PDB:2C9O}.,TURN 17 20 {ECO:0000244|PDB:2C9O}.; TURN 195 197 {ECO:0000244|PDB:2C9O}.,,,,,,1.315789474,-0.251,50.24,35.8,36.8Q9Y230,RUVB2_HUMAN,reviewed,RuvB-like 2 (EC 3.6.4.12) (48 kDa TATA box-binding protein-interacting protein) (48 kDa TBP-interacting protein) (51 kDa erythrocyte cytosolic protein) (ECP-51) (INO80 complex subunit J) (Repressing pontin 52) (Reptin 52) (TIP49b) (TIP60-associated protein 54-beta) (TAP54-beta),RUVBL2 INO80J TIP48 TIP49B CGI-46,Homo sapiens (Human),463,GO:0005524; GO:0006200; GO:0043141; GO:0004003; GO:0032508; GO:0003678; GO:0006310; GO:0006281; GO:0031011; GO:0071339; GO:0035267; GO:0000979; GO:0000980; GO:0000812; GO:0034644; GO:0071392; GO:0031490; GO:0006325; GO:0006338; GO:0005737; GO:0003684; GO:0071169; GO:0070062; GO:0043968; GO:0043967; GO:0042802; GO:0005622; GO:0016020; GO:0071899; GO:0005719; GO:0016363; GO:0005654; GO:0005634; GO:0035066; GO:0045944; GO:0006457; GO:0040008; GO:0030529; GO:0006351; GO:0071733; GO:0051082,10856;,MATVTATTKVPEIRDVTRIERIGAHSHIRGLGLDDALEPRQASQGMVGQLAARRAAGVVLEMIREGKIAGRAVLIAGQPGTGKTAIAMGMAQALGPDTPFTAIAGSEIFSLEMSKTEALTQAFRRSIGVRIKEETEIIEGEVVEIQIDRPATGTGSKVGKLTLKTTEMETIYDLGTKMIESLTKDKVQAGDVITIDKATGKISKLGRSFTRARDYDAMGSQTKFVQCPDGELQKRKEVVHTVSLHEIDVINSRTQGFLALFSGDTGEIKSEVREQINAKVAEWREEGKAEIIPGVLFIDEVHMLDIESFSFLNRALESDMAPVLIMATNRGITRIRGTSYQSPHGIPIDLLDRLLIVSTTPYSEKDTKQILRIRCEEEDVEMSEDAYTVLTRIGLETSLRYAIQLITAASLVCRKRKGTEVQVDDIKRVYSLFLDESRSTQYMKEYQDAFLFNELKGETMDTS,,,DOMAIN: The C-terminal domain is required for association with ATF2.,PF06068;,hsa:10856;,,,"SUBUNIT: Forms homohexameric rings (Probable). Can form a dodecamer with RUVBL1 made of two stacked hexameric rings; however, even though RUVBL1 and RUVBL2 are present in equimolar ratio, the oligomeric status of each hexamer is not known. Oligomerization may regulate binding to nucleic acids and conversely, binding to nucleic acids may affect the dodecameric assembly. Interacts with the transcriptional activation domain of MYC. Interacts With ATF2. Component of the RNA polymerase II holoenzyme complex. May also act to bridge the LEF1/TCF1-CTNNB1 complex and TBP. Component of the NuA4 histone acetyltransferase complex which contains the catalytic subunit KAT5/TIP60 and the subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. The NuA4 complex interacts with MYC and the adenovirus E1A protein. RUVBL2 interacts with EP400. Component of a NuA4-related complex which contains EP400, TRRAP/PAF400, SRCAP, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, actin, ACTL6A/BAF53A, VPS72 and YEATS4/GAS41. Interacts with NPAT. Component of the chromatin-remodeling INO80 complex; specifically part of a complex module associated with the helicase ATP-binding and the helicase C-terminal domain of INO80. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BAP18, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MYST1/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Interacts with IGHMBP2. Interacts with TELO2. Interacts with HINT1. Component of a SWR1-like complex. {ECO:0000269|PubMed:10428817, ECO:0000269|PubMed:10882073, ECO:0000269|PubMed:10966108, ECO:0000269|PubMed:11713276, ECO:0000269|PubMed:12963728, ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:15960975, ECO:0000269|PubMed:16014379, ECO:0000269|PubMed:16230350, ECO:0000269|PubMed:17157868, ECO:0000269|PubMed:17967892, ECO:0000269|PubMed:18026119, ECO:0000269|PubMed:19299493, ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:21303910, ECO:0000269|PubMed:24463511, ECO:0000305}.",HELIX 50 64 {ECO:0000244|PDB:3UK6}.; HELIX 83 94 {ECO:0000244|PDB:3UK6}.; HELIX 105 108 {ECO:0000244|PDB:3UK6}.; HELIX 115 125 {ECO:0000244|PDB:3UK6}.; HELIX 177 184 {ECO:0000244|PDB:2CQA}.; HELIX 244 250 {ECO:0000244|PDB:3UK6}.; HELIX 270 286 {ECO:0000244|PDB:3UK6}.; HELIX 301 303 {ECO:0000244|PDB:3UK6}.; HELIX 306 315 {ECO:0000244|PDB:3UK6}.; HELIX 348 351 {ECO:0000244|PDB:3UK6}.; HELIX 364 377 {ECO:0000244|PDB:3UK6}.; HELIX 384 396 {ECO:0000244|PDB:3UK6}.; HELIX 399 415 {ECO:0000244|PDB:3UK6}.; HELIX 423 432 {ECO:0000244|PDB:3UK6}.; HELIX 436 443 {ECO:0000244|PDB:3UK6}.,STRAND 41 43 {ECO:0000244|PDB:3UK6}.; STRAND 46 48 {ECO:0000244|PDB:3UK6}.; STRAND 72 78 {ECO:0000244|PDB:3UK6}.; STRAND 100 104 {ECO:0000244|PDB:3UK6}.; STRAND 111 113 {ECO:0000244|PDB:3UK6}.; STRAND 126 129 {ECO:0000244|PDB:3UK6}.; STRAND 136 148 {ECO:0000244|PDB:2CQA}.; STRAND 152 156 {ECO:0000244|PDB:2CQA}.; STRAND 158 164 {ECO:0000244|PDB:2CQA}.; STRAND 166 174 {ECO:0000244|PDB:2CQA}.; STRAND 191 196 {ECO:0000244|PDB:2CQA}.; STRAND 201 206 {ECO:0000244|PDB:2CQA}.; STRAND 241 243 {ECO:0000244|PDB:2XSZ}.; STRAND 290 293 {ECO:0000244|PDB:2XSZ}.; STRAND 295 300 {ECO:0000244|PDB:3UK6}.; STRAND 323 329 {ECO:0000244|PDB:3UK6}.; STRAND 331 334 {ECO:0000244|PDB:3UK6}.; STRAND 341 343 {ECO:0000244|PDB:3UK6}.; STRAND 354 359 {ECO:0000244|PDB:3UK6}.; STRAND 419 421 {ECO:0000244|PDB:3UK6}.,TURN 24 27 {ECO:0000244|PDB:2XSZ}.; TURN 197 200 {ECO:0000244|PDB:2CQA}.,,,,,,0.647948164,-0.23,51.16,48.3,49.3Q9Y3A5,SBDS_HUMAN,reviewed,Ribosome maturation protein SBDS (Shwachman-Bodian-Diamond syndrome protein),SBDS CGI-97,Homo sapiens (Human),250,GO:0048539; GO:0030282; GO:0008283; GO:0005737; GO:0001833; GO:0030595; GO:0042256; GO:0008017; GO:0043148; GO:0005730; GO:0005654; GO:0005634; GO:0044822; GO:0019843; GO:0006364; GO:0042273; GO:0043022; GO:0000922,51119;,MSIFTPTNQIRLTNVAVVRMKRAGKRFEIACYKNKVVGWRSGVEKDLDEVLQTHSVFVNVSKGQVAKKEDLISAFGTDDQTEICKQILTKGEVQVSDKERHTQLEQMFRDIATIVADKCVNPETKRPYTVILIERAMKDIHYSVKTNKSTKQQALEVIKQLKEKMKIERAHMRLRFILPVNEGKKLKEKLKPLIKVIESEDYGQQLEIVCLIDPGCFREIDELIKKETKGKGSLEVLNLKDVEEGDEKFE,"DISEASE: Shwachman-Diamond syndrome (SDS) [MIM:260400]: Autosomal recessive disorder characterized by pancreatic exocrine insufficiency, hematologic dysfunction, and skeletal abnormalities. {ECO:0000269|PubMed:12496757, ECO:0000269|PubMed:24898207}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF01172;PF09377;,hsa:51119;,,,"SUBUNIT: Associates with the 60S ribosomal subunit. Interacts with NPM1, RPA1 and PRKDC. May interact with NIP7. {ECO:0000269|PubMed:17475909, ECO:0000269|PubMed:17643419, ECO:0000269|PubMed:19602484}.",HELIX 33 41 {ECO:0000244|PDB:2L9N}.; HELIX 47 50 {ECO:0000244|PDB:2L9N}.; HELIX 68 75 {ECO:0000244|PDB:2L9N}.; HELIX 80 89 {ECO:0000244|PDB:2L9N}.; HELIX 97 117 {ECO:0000244|PDB:2L9N}.; HELIX 130 139 {ECO:0000244|PDB:2L9N}.; HELIX 150 164 {ECO:0000244|PDB:2L9N}.; HELIX 182 193 {ECO:0000244|PDB:2L9N}.; HELIX 218 229 {ECO:0000244|PDB:2L9N}.,STRAND 16 22 {ECO:0000244|PDB:2L9N}.; STRAND 25 31 {ECO:0000244|PDB:2L9N}.; STRAND 51 55 {ECO:0000244|PDB:2L9N}.; STRAND 91 94 {ECO:0000244|PDB:2L9N}.; STRAND 171 178 {ECO:0000244|PDB:2L9N}.; STRAND 194 201 {ECO:0000244|PDB:2L9N}.; STRAND 207 214 {ECO:0000244|PDB:2L9N}.; STRAND 232 237 {ECO:0000244|PDB:2L9N}.,TURN 6 8 {ECO:0000244|PDB:2L9N}.; TURN 60 62 {ECO:0000244|PDB:2L9N}.; TURN 122 125 {ECO:0000244|PDB:2L9N}.; TURN 215 217 {ECO:0000244|PDB:2L9N}.,,,,,,2,-0.5,28.77,6.89,7.89O15027,SC16A_HUMAN,reviewed,Protein transport protein Sec16A (SEC16 homolog A),SEC16A KIAA0310 SEC16 SEC16L,Homo sapiens (Human),2179,GO:0048208; GO:0005794; GO:0000139; GO:0005737; GO:0005829; GO:0005789; GO:0007029; GO:0015031; GO:0021762,9919;,MPGLDRPLSRQNPHDGVVTPAASPSLPQPGLQMPGQWGPVQGGPQPSGQHRSPCPEGPVPSGVPCATSVPHFPTPSILHQGPGHEQHSPLVAPPAALPSDGRDEVSHLQSGSHLANNSDPESTFRQNPRIVNHWASPELRQNPGVKNEHRPASALVNPLARGDSPENRTHHPLGAGAGSGCAPLEADSGASGALAMFFQGGETENEENLSSEKAGLSGQADFDDFCSSPGLGRPPAPTHVGAGSLCQALLPGPSNEAAGDVWGDTASTGVPDASGSQYENVENLEFVQNQEVLPSEPLNLDPSSPSDQFRYGPLPGPAVPRHGAVCHTGAPDATLHTVHPDSVSSSYSSRSHGRLSGSARPQELVGTFIQQEVGKPEDEASGSFFKQIDSSPVGGETDETTVSQNYRGSVSQPSTPSPPKPTGIFQTSANSSFEPVKSHLVGVKPFEADRANVVGEVRETCVRQKQCRPAAALPDASPGNLEQPPDNMETLCAPQVCPLPLNSTTEAVHMLPHAGAPPLDTVYPAPEKRPSARTQGPVKCESPATTLWAQSELPDFGGNVLLAPAAPALYVCAKPQPPVVQPPEEAMSGQQSRNPSSAAPVQSRGGIGASENLENPPKMGEEEALQSQASSGYASLLSSPPTESLQNPPVLIAQPDHSYNLAQPINFSVSLSNSHEKNQSWREALVGDRPAVSSWALGGDSGENTSLSGIPTSSVLSLSLPSSVAQSNFPQGSGASEMVSNQPANLLVQPPSQPVPENLVPESQKDRKAGSALPGFANSPAGSTSVVLVPPAHGTLVPDGNKANHSSHQEDTYGALDFTLSRTLENPVNVYNPSHSDSLASQQSVASHPRQSGPGAPNLDRFYQQVTKDAQGQPGLERAQQELVPPQQQASPPQLPKAMFSELSNPESLPAQGQAQNSAQSPASLVLVDAGQQLPPRPPQSSSVSLVSSGSGQAAVPSEQPWPQPVPALAPGPPPQDLAAYYYYRPLYDAYQPQYSLPYPPEPGAASLYYQDVYSLYEPRYRPYDGAASAYAQNYRYPEPERPSSRASHSSERPPPRQGYPEGYYSSKSGWSSQSDYYASYYSSQYDYGDPGHWDRYHYSARVRDPRTYDRRYWCDAEYDAYRREHSAFGDRPEKRDNNWRYDPRFTGSFDDDPDPHRDPYGEEVDRRSVHSEHSARSLHSAHSLASRRSSLSSHSHQSQIYRSHNVAAGSYEAPLPPGSFHGDFAYGTYRSNFSSGPGFPEYGYPADTVWPAMEQVSSRPTSPEKFSVPHVCARFGPGGQLIKVIPNLPSEGQPALVEVHSMEALLQHTSEQEEMRAFPGPLAKDDTHKVDVINFAQNKAMKCLQNENLIDKESASLLWNFIVLLCRQNGTVVGTDIAELLLRDHRTVWLPGKSPNEANLIDFTNEAVEQVEEEESGEAQLSFLTGGPAAAASSLERETERFRELLLYGRKKDALESAMKNGLWGHALLLASKMDSRTHARVMTRFANSLPINDPLQTVYQLMSGRMPAASTCCGDEKWGDWRPHLAMVLSNLNNNMDVESRTMATMGDTLASRGLLDAAHFCYLMAQAGFGVYTKKTTKLVLIGSNHSLPFLKFATNEAIQRTEAYEYAQSLGAETCPLPSFQVFKFIYSCRLAEMGLATQAFHYCEAIAKSILTQPHLYSPVLISQLVQMASQLRLFDPQLKEKPEEESLAAPTWLVHLQQVERQIKEGAGVWHQDGALPQQCPGTPSSEMEQLDRPGLSQPGALGIANPLLAVPAPSPEHSSPSVRLLPSAPQTLPDGPLASPARVPMFPVPLPPGPLEPGPGCVTPGPALGFLEPSGPGLPPGVPPLQERRHLLQEARSPDPGIVPQEAPVGNSLSELSEENFDGKFANLTPSRTVPDSEAPPGWDRADSGPTQPPLSLSPAPETKRPGQAAKKETKEPKKGESWFFRWLPGKKKTEAYLPDDKNKSIVWDEKKNQWVNLNEPEEEKKAPPPPPTSMPKTVQAAPPALPGPPGAPVNMYSRRAAGTRARYVDVLNPSGTQRSEPALAPADFVAPLAPLPIPSNLFVPTPDAEEPQLPDGTGREGPAAARGLANPEPAPEPKVLSSAASLPGSELPSSRPEGSQGGELSRCSSMSSLSREVSQHFNQAPGDLPAAGGPPSGAMPFYNPAQLAQACATSGSSRLGRIGQRKHLVLN,,,,PF12932;,hsa:9919;,,,SUBUNIT: SEC16A and SEC16B are each present in multiple copies in a heteromeric complex. Interacts with SEC23A. {ECO:0000269|PubMed:17192411}.,,,,,,,,,1.193207894,-0.607,233.56,89.2,90.2Q15019,SEPT2_HUMAN,reviewed,Septin-2 (Neural precursor cell expressed developmentally down-regulated protein 5) (NEDD-5),SEPT2 DIFF6 KIAA0158 NEDD5,Homo sapiens (Human),361,GO:0005525; GO:0015629; GO:0051301; GO:0060170; GO:0042384; GO:0032154; GO:0000777; GO:0005737; GO:0070062; GO:0030496; GO:0007067; GO:0005730; GO:0005654; GO:0005634; GO:0031105; GO:0007224; GO:0005819,4735;,MSKQQPTQFINPETPGYVGFANLPNQVHRKSVKKGFEFTLMVVGESGLGKSTLINSLFLTDLYPERVIPGAAEKIERTVQIEASTVEIEERGVKLRLTVVDTPGYGDAINCRDCFKTIISYIDEQFERYLHDESGLNRRHIIDNRVHCCFYFISPFGHGLKPLDVAFMKAIHNKVNIVPVIAKADTLTLKERERLKKRILDEIEEHNIKIYHLPDAESDEDEDFKEQTRLLKASIPFSVVGSNQLIEAKGKKVRGRLYPWGVVEVENPEHNDFLKLRTMLITHMQDLQEVTQDLHYENFRSERLKRGGRKVENEDMNKDQILLEKEAELRRMQEMIARMQAQMQMQMQGGDGDGGALGHHV,,,,PF00735;,hsa:4735;,,,"SUBUNIT: Septins polymerize into heterooligomeric protein complexes that form filaments, and associate with cellular membranes, actin filaments and microtubules. GTPase activity is required for filament formation. Filaments are assembled from asymmetrical heterotrimers, composed of SEPT2, SEPT6 and SEPT7 that associate head-to-head to form a hexameric unit. Interaction between SEPT2 and SEPT7 seems indirect. Interacts with SEPT5 (By similarity). Interaction with SEPT4 not detected (By similarity). Interacts with SEPT9. Interacts with MAP4. {ECO:0000250, ECO:0000269|PubMed:16093351, ECO:0000269|PubMed:16914550, ECO:0000269|PubMed:17637674, ECO:0000269|PubMed:19145258, ECO:0000269|Ref.31}.",HELIX 23 34 {ECO:0000244|PDB:2QA5}.; HELIX 50 58 {ECO:0000244|PDB:2QNR}.; HELIX 118 133 {ECO:0000244|PDB:2QNR}.; HELIX 162 171 {ECO:0000244|PDB:2QNR}.; HELIX 184 186 {ECO:0000244|PDB:2QNR}.; HELIX 189 205 {ECO:0000244|PDB:2QNR}.; HELIX 225 232 {ECO:0000244|PDB:2QNR}.; HELIX 273 282 {ECO:0000244|PDB:2QNR}.; HELIX 284 293 {ECO:0000244|PDB:2QNR}.; HELIX 295 305 {ECO:0000244|PDB:2QNR}.,STRAND 38 45 {ECO:0000244|PDB:2QNR}.; STRAND 85 88 {ECO:0000244|PDB:2QNR}.; STRAND 95 102 {ECO:0000244|PDB:2QNR}.; STRAND 148 153 {ECO:0000244|PDB:2QNR}.; STRAND 155 159 {ECO:0000244|PDB:2QNR}.; STRAND 177 181 {ECO:0000244|PDB:2QNR}.; STRAND 236 238 {ECO:0000244|PDB:2QNR}.; STRAND 243 245 {ECO:0000244|PDB:2QA5}.; STRAND 254 258 {ECO:0000244|PDB:2QNR}.; STRAND 261 264 {ECO:0000244|PDB:2QNR}.,TURN 172 174 {ECO:0000244|PDB:2QNR}.; TURN 268 270 {ECO:0000244|PDB:2QNR}.,DOMAIN 34 306 Septin-type G.,,,,,1.108033241,-0.528,41.49,59.6,60.6Q16181,SEPT7_HUMAN,reviewed,Septin-7 (CDC10 protein homolog),SEPT7 CDC10,Homo sapiens (Human),437,GO:0005525; GO:0015629; GO:0043679; GO:0005930; GO:0060271; GO:0032154; GO:0000777; GO:0000910; GO:0005737; GO:0070062; GO:0042802; GO:0015630; GO:0030496; GO:0007067; GO:0005730; GO:0005634; GO:0005886; GO:0051291; GO:0016476; GO:0031105; GO:0005819; GO:0001725; GO:0005198; GO:0045202,989;,MSVSARSAAAEERSVNSSTMVAQQKNLEGYVGFANLPNQVYRKSVKRGFEFTLMVVGESGLGKSTLINSLFLTDLYSPEYPGPSHRIKKTVQVEQSKVLIKEGGVQLLLTIVDTPGFGDAVDNSNCWQPVIDYIDSKFEDYLNAESRVNRRQMPDNRVQCCLYFIAPSGHGLKPLDIEFMKRLHEKVNIIPLIAKADTLTPEECQQFKKQIMKEIQEHKIKIYEFPETDDEEENKLVKKIKDRLPLAVVGSNTIIEVNGKRVRGRQYPWGVAEVENGEHCDFTILRNMLIRTHMQDLKDVTNNVHYENYRSRKLAAVTYNGVDNNKNKGQLTKSPLAQMEEERREHVAKMKKMEMEMEQVFEMKVKEKVQKLKDSEAELQRRHEQMKKNLEAQHKELEEKRRQFEDEKANWEAQQRILEQQNSSRTLEKNKKKGKIF,,,,PF00735;,hsa:989;,,,"SUBUNIT: Septins polymerize into heterooligomeric protein complexes that form filaments, and associate with cellular membranes, actin filaments and microtubules. GTPase activity is required for filament formation. Filaments are assembled from asymmetrical heterotrimers, composed of SEPT2, SEPT6 and SEPT7 that associate head-to-head to form a hexameric unit. Within the trimer, directly interacts with SEPT6, while interaction with SEPT2 seems indirect. In the absence of SEPT6, forms homodimers. Interacts directly with CENPE and links CENPE to septin filaments composed of SEPT2, SEPT6 and SEPT7. Interacts with SEPT5 and SEPT8 (By similarity). Interacts with SEPT9 and SEPT11. {ECO:0000250, ECO:0000269|PubMed:15485874, ECO:0000269|PubMed:16914550, ECO:0000269|PubMed:17637674, ECO:0000269|PubMed:18460473, ECO:0000269|PubMed:19145258}.",HELIX 63 70 {ECO:0000244|PDB:3T5D}.; HELIX 128 146 {ECO:0000244|PDB:3T5D}.; HELIX 174 183 {ECO:0000244|PDB:3T5D}.; HELIX 196 198 {ECO:0000244|PDB:3T5D}.; HELIX 201 217 {ECO:0000244|PDB:3T5D}.; HELIX 238 242 {ECO:0000244|PDB:3T5D}.; HELIX 282 290 {ECO:0000244|PDB:3T5D}.; HELIX 294 303 {ECO:0000244|PDB:3T5D}.; HELIX 305 315 {ECO:0000244|PDB:3T5D}.,STRAND 50 57 {ECO:0000244|PDB:3T5D}.; STRAND 71 73 {ECO:0000244|PDB:3T5D}.; STRAND 94 100 {ECO:0000244|PDB:3T5D}.; STRAND 107 113 {ECO:0000244|PDB:3T5D}.; STRAND 147 149 {ECO:0000244|PDB:3TW4}.; STRAND 160 165 {ECO:0000244|PDB:3T5D}.; STRAND 189 195 {ECO:0000244|PDB:3T5D}.; STRAND 245 247 {ECO:0000244|PDB:3T5D}.; STRAND 264 266 {ECO:0000244|PDB:3T5D}.; STRAND 271 275 {ECO:0000244|PDB:3T5D}.,TURN 124 127 {ECO:0000244|PDB:3T5D}.; TURN 184 186 {ECO:0000244|PDB:3T5D}.; TURN 277 279 {ECO:0000244|PDB:3T5D}.; TURN 291 293 {ECO:0000244|PDB:3T5D}.,DOMAIN 47 316 Septin-type G.,,,,,1.14416476,-0.789,50.69,37.7,38.7Q9UHD8,SEPT9_HUMAN,reviewed,Septin-9 (MLL septin-like fusion protein MSF-A) (MLL septin-like fusion protein) (Ovarian/Breast septin) (Ov/Br septin) (Septin D1),SEPT9 KIAA0991 MSF,Homo sapiens (Human),586,GO:0005525; GO:0006184; GO:0003924; GO:0015629; GO:0007049; GO:0051301; GO:0005737; GO:0005874; GO:0048471; GO:0051291; GO:0001725,10801;,MKKSYSGGTRTSSGRLRRLGDSSGPALKRSFEVEEVETPNSTPPRRVQTPLLRATVASSTQKFQDLGVKNSEPSARHVDSLSQRSPKASLRRVELSGPKAAEPVSRRTELSIDISSKQVENAGAIGPSRFGLKRAEVLGHKTPEPAPRRTEITIVKPQESAHRRMEPPASKVPEVPTAPATDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQEATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFNIMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTVIDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGHSLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDEDSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLLIRTHMQNIKDITSSIHFEAYRVKRLNEGSSAMANGMEEKEPEAPEM,"DISEASE: Note=A chromosomal aberration involving SEPT9/MSF is found in therapy-related acute myeloid leukemia (t-AML). Translocation t(11;17)(q23;q25) with KMT2A/MLL1. {ECO:0000269|PubMed:10339604}.; DISEASE: Hereditary neuralgic amyotrophy (HNA) [MIM:162100]: Autosomal dominant form of recurrent focal neuropathy characterized clinically by acute, recurrent episodes of brachial plexus neuropathy with muscle weakness and atrophy preceded by severe pain in the affected arm. HNA is triggered by environmental factors such as infection or parturition. {ECO:0000269|PubMed:16186812, ECO:0000269|PubMed:17546647, ECO:0000269|PubMed:18492087, ECO:0000269|PubMed:19451530}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF00735;,hsa:10801;,,,"SUBUNIT: Septins polymerize into heterooligomeric protein complexes that form filaments, and associate with cellular membranes, actin filaments, and microtubules. GTPase activity is required for filament formation. Interacts with SEPT2, SEPT6, SEPT7, SEPT11 and SEPT14. Interacts with RTKN and ARHGEF18. In a mesenchymal cell line, Rho/RTKN signals cause disruption of wild-type septin filaments, but not of those containing isoform 2 variants HNA Trp-106 and Phe-111. In a mesenchymal cell line, isoform 2 variants HNA Trp-106 and Phe-111, but not wild type, form filaments with SEPT4. {ECO:0000269|PubMed:15485874, ECO:0000269|PubMed:15558029, ECO:0000269|PubMed:16007136, ECO:0000269|PubMed:17546647, ECO:0000269|PubMed:17922164, ECO:0000269|PubMed:19145258}.",,,,DOMAIN 295 567 Septin-type G.,,,,,0.853242321,-0.663,65.41,226,227P12236,ADT3_HUMAN,reviewed,"ADP/ATP translocase 3 (ADP,ATP carrier protein 3) (ADP,ATP carrier protein, isoform T2) (ANT 2) (Adenine nucleotide translocator 3) (ANT 3) (Solute carrier family 25 member 6) [Cleaved into: ADP/ATP translocase 3, N-terminally processed]",SLC25A6 ANT3 CDABP0051,Homo sapiens (Human),298,GO:0015866; GO:0015867; GO:0005471; GO:0046732; GO:0006915; GO:0044267; GO:0006112; GO:0016021; GO:0005743; GO:0005744; GO:0005739; GO:0019048; GO:0005634; GO:0006626; GO:0050796; GO:0044281; GO:0019058; GO:0016032,293;,MTEQAISFAKDFLAGGIAAAISKTAVAPIERVKLLLQVQHASKQIAADKQYKGIVDCIVRIPKEQGVLSFWRGNLANVIRYFPTQALNFAFKDKYKQIFLGGVDKHTQFWRYFAGNLASGGAAGATSLCFVYPLDFARTRLAADVGKSGTEREFRGLGDCLVKITKSDGIRGLYQGFSVSVQGIIIYRAAYFGVYDTAKGMLPDPKNTHIVVSWMIAQTVTAVAGVVSYPFDTVRRRMMMQSGRKGADIMYTGTVDCWRKIFRDEGGKAFFKGAWSNVLRGMGGAFVLVLYDELKKVI,,,,PF00153;,hsa:293;,,,"SUBUNIT: Found in a complex with ARL2, ARL2BP and SLC25A6 (By similarity). Homodimer. Interacts with influenza A virus PB1-F2 protein and HIV-1 Vpr. {ECO:0000250, ECO:0000269|PubMed:16120388, ECO:0000269|PubMed:16201016}.",,,,,,,,,1.342281879,0.075,32.87,3.45,4.45P51532,SMCA4_HUMAN,reviewed,Transcription activator BRG1 (EC 3.6.4.-) (ATP-dependent helicase SMARCA4) (BRG1-associated factor 190A) (BAF190A) (Mitotic growth and transcription activator) (Protein BRG-1) (Protein brahma homolog 1) (SNF2-beta) (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4),SMARCA4 BAF190A BRG1 SNF2B SNF2L4,Homo sapiens (Human),1647,GO:0005524; GO:0006200; GO:0043044; GO:0010424; GO:0070182; GO:0008094; GO:0000977; GO:0001105; GO:0016514; GO:0030957; GO:0050681; GO:0035887; GO:0001832; GO:0001835; GO:0000902; GO:0003682; GO:0006338; GO:0060318; GO:0035116; GO:0048562; GO:0048730; GO:0030198; GO:0005615; GO:0030900; GO:0007403; GO:0060347; GO:0004386; GO:0000792; GO:0030902; GO:0043966; GO:0030216; GO:0070307; GO:0001889; GO:0070577; GO:0016020; GO:0006346; GO:0071565; GO:2000134; GO:0060766; GO:0030308; GO:0000122; GO:0007070; GO:0045892; GO:0003407; GO:0071564; GO:0000790; GO:0005719; GO:0005730; GO:0006337; GO:0005634; GO:0002039; GO:0005726; GO:0043923; GO:0043388; GO:0030177; GO:0051091; GO:0045944; GO:0045893; GO:0047485; GO:0043234; GO:0006357; GO:0019827; GO:0003713; GO:0003714; GO:0001570,6597;,MSTPDPPLGGTPRPGPSPGPGPSPGAMLGPSPGPSPGSAHSMMGPSPGPPSAGHPIPTQGPGGYPQDNMHQMHKPMESMHEKGMSDDPRYNQMKGMGMRSGGHAGMGPPPSPMDQHSQGYPSPLGGSEHASSPVPASGPSSGPQMSSGPGGAPLDGADPQALGQQNRGPTPFNQNQLHQLRAQIMAYKMLARGQPLPDHLQMAVQGKRPMPGMQQQMPTLPPPSVSATGPGPGPGPGPGPGPGPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGPPKPWPEGPMANAAAPTSTPQKLIPPQPTGRPSPAPPAVPPAASPVMPPQTQSPGQPAQPAPMVPLHQKQSRITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGSLAGDLRTKATIELKALRLLNFQRQLRQEVVVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQQKIEQERKRRQKHQEYLNSILQHAKDFKEYHRSVTGKIQKLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYRKLIDQKKDKRLAYLLQQTDEYVANLTELVRQHKAAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTGTDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSEVDARHIIENAKQDVDDEYGVSQALARGLQSYYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGSPAARRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLTGTPLQNKLPELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIIRRLHKVLRPFLLRRLKKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAKGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPYMFQHIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRILPKLRATNHKVLLFCQMTSLMTIMEDYFAYRGFKYLRLDGTTKAEDRGMLLKTFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILEHEEQDESRHCSTGSGSASFAHTAPPPAGVNPDLEEPPLKEEDEVPDDETVNQMIARHEEEFDLFMRMDLDRRREEARNPKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKMFGRGSRHRKEVDYSDSLTEKQWLKAIEEGTLEEIEEEVRQKKSSRKRKRDSDAGSSTPTTSTRSRDKDDESKKQKKRGRPPAEKLSPNPPNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKEDDSEGEESEEEEEGEEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGSEED,"DISEASE: Rhabdoid tumor predisposition syndrome 2 (RTPS2) [MIM:613325]: A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood. {ECO:0000269|PubMed:20137775}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mental retardation, autosomal dominant 16 (MRD16) [MIM:614609]: A disease characterized by multiple congenital anomalies and mental retardation. Mental retardation is defined by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD16 patients manifest developmental delay, absent or hypoplastic fifth fingernails or toenails, thick eyebrows and long eyelashes, hirsutism. Additional findings include hypotonia, microcephaly, seizures, a Dandy-Walker malformation, and vision and hearing problems. {ECO:0000269|PubMed:22426308}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF07533;PF00439;PF00271;PF07529;PF08880;PF14619;PF00176;,hsa:6597;,,,"SUBUNIT: Component of the CREST-BRG1 complex, at least composed of SMARCA4/BRG1/BAF190A, SS18L1/CREST, HDAC1, RB1 and SP1 (By similarity). Interacts with NR3C1, PGR, SMARD1, TOPBP1 and ZMIM2/ZIMP7. Component of the BAF complex, which includes at least actin (ACTB), ARID1A, ARID1B/BAF250, SMARCA2, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, IKFZ1, and one or more of SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. Interacts directly with IKFZ1 in the BAF complex. In muscle cells, the BAF complex also contains DPF3. Component of the BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1/BAF190A, and TRRAP, which preferentially acetylates histone H4 (and H2A) within nucleosomes. Component of the WINAC complex, at least composed of SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCE1, ACTL6A, BAZ1B/WSTF, ARID1A, SUPT16H, CHAF1A and TOP2B. Interacts with (via the bromodomain) with TERT; the interaction regulates Wnt-mediated signaling. Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin. Interacts with PHF10/BAF45A (By similarity). Interacts with MYOG (By similarity). Interacts with ZEB1 (via N-terminus). {ECO:0000250, ECO:0000269|PubMed:10204490, ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12837248, ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15075294, ECO:0000269|PubMed:16051670, ECO:0000269|PubMed:17274598, ECO:0000269|PubMed:17582821, ECO:0000269|PubMed:18765789, ECO:0000269|PubMed:19571879, ECO:0000269|PubMed:20418909, ECO:0000269|PubMed:9590696}.",HELIX 1456 1471 {ECO:0000244|PDB:2GRC}.; HELIX 1481 1485 {ECO:0000244|PDB:2GRC}.; HELIX 1495 1500 {ECO:0000244|PDB:2GRC}.; HELIX 1507 1515 {ECO:0000244|PDB:2GRC}.; HELIX 1522 1539 {ECO:0000244|PDB:2GRC}.; HELIX 1545 1567 {ECO:0000244|PDB:2GRC}.,STRAND 1542 1544 {ECO:0000244|PDB:2H60}.,TURN 1475 1477 {ECO:0000244|PDB:2GRC}.; TURN 1491 1493 {ECO:0000244|PDB:2GRC}.,DOMAIN 171 206 QLQ. {ECO:0000255|PROSITE-ProRule:PRU01001}.; DOMAIN 460 532 HSA. {ECO:0000255|PROSITE-ProRule:PRU00549}.; DOMAIN 766 931 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 1084 1246 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.; DOMAIN 1477 1547 Bromo. {ECO:0000255|PROSITE-ProRule:PRU00035}.,,,,,0.607164542,-0.839,184.68,7.53,8.53O60264,SMCA5_HUMAN,reviewed,SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5) (EC 3.6.4.-) (Sucrose nonfermenting protein 2 homolog) (hSNF2H),SMARCA5 SNF2H WCRF135,Homo sapiens (Human),1052,GO:0005524; GO:0006200; GO:0043044; GO:0016887; GO:0034080; GO:0003677; GO:0006352; GO:0016589; GO:0031213; GO:0003682; GO:0006338; GO:0000183; GO:0005677; GO:0000793; GO:0006302; GO:0004386; GO:0005730; GO:0005654; GO:0006334; GO:0016584; GO:0005634; GO:0006357,8467;,MSSAAEPPPPPPPESAPSKPAASIASGGSNSSNKGGPEGVAAQAVASAASAGPADAEMEEIFDDASPGKQKEIQEPDPTYEEKMQTDRANRFEYLLKQTELFAHFIQPAAQKTPTSPLKMKPGRPRIKKDEKQNLLSVGDYRHRRTEQEEDEELLTESSKATNVCTRFEDSPSYVKWGKLRDYQVRGLNWLISLYENGINGILADEMGLGKTLQTISLLGYMKHYRNIPGPHMVLVPKSTLHNWMSEFKRWVPTLRSVCLIGDKEQRAAFVRDVLLPGEWDVCVTSYEMLIKEKSVFKKFNWRYLVIDEAHRIKNEKSKLSEIVREFKTTNRLLLTGTPLQNNLHELWSLLNFLLPDVFNSADDFDSWFDTNNCLGDQKLVERLHMVLRPFLLRRIKADVEKSLPPKKEVKIYVGLSKMQREWYTRILMKDIDILNSAGKMDKMRLLNILMQLRKCCNHPYLFDGAEPGPPYTTDMHLVTNSGKMVVLDKLLPKLKEQGSRVLIFSQMTRVLDILEDYCMWRNYEYCRLDGQTPHDERQDSINAYNEPNSTKFVFMLSTRAGGLGINLATADVVILYDSDWNPQVDLQAMDRAHRIGQTKTVRVFRFITDNTVEERIVERAEMKLRLDSIVIQQGRLVDQNLNKIGKDEMLQMIRHGATHVFASKESEITDEDIDGILERGAKKTAEMNEKLSKMGESSLRNFTMDTESSVYNFEGEDYREKQKIAFTEWIEPPKRERKANYAVDAYFREALRVSEPKAPKAPRPPKQPNVQDFQFFPPRLFELLEKEILFYRKTIGYKVPRNPELPNAAQAQKEEQLKIDEAESLNDEELEEKEKLLTQGFTNWNKRDFNQFIKANEKWGRDDIENIAREVEGKTPEEVIEYSAVFWERCNELQDIEKIMAQIERGEARIQRRISIKKALDTKIGRYKAPFHQLRISYGTNKGKNYTEEEDRFLICMLHKLGFDKENVYDELRQCIRNSPQFRFDWFLKSRTAMELQRRCNTLITLIERENMELEEKEKAEKKKRGPKPSTQKRKMDGAPDGRGRKKKLKL,,,,PF13892;PF09110;PF00271;PF09111;PF00176;,hsa:8467;,,,"SUBUNIT: Catalytic subunit of the four known chromatin-remodeling complexes: CHRAC, RSF, ACF/WCRF, and WICH. Each complex contains subunits which may regulate the specificity or catalytic activity of SMARCA5. ACF/WCRF contains BAZ1A; CHRAC contains BAZ1A, CHRAC1, and POLE3; RSF contains RSF1; WICH contains BAZ1B/WSTF. SMARCA5 is the catalytic subunit of the NoRC chromatin-remodeling complex, which also contains BAZ2A/TIP5. The BAZ2A/TIP5 subunit of NoRC also interacts with DNMT1, DNMT3B and HDAC1, which allows NoRC to actively suppress rDNA transcription by a combination of nucleosome remodeling, histone deacetylation, and DNA methylation. Catalytic subunit of SMARCA5/cohesin/NuRD complexes. Component of the B-WICH complex, at least composed of SMARCA5/SNF2H, BAZ1B/WSTF, SF3B1, DEK, MYO1C, ERCC6, MYBBP1A and DDX21. Interacts with MYO1C (By similarity). {ECO:0000250}.",,,,DOMAIN 192 357 Helicase ATP-binding. {ECO:0000255|PROSITE-ProRule:PRU00541}.; DOMAIN 487 638 Helicase C-terminal. {ECO:0000255|PROSITE-ProRule:PRU00542}.; DOMAIN 840 892 SANT 1. {ECO:0000255|PROSITE-ProRule:PRU00624}.; DOMAIN 943 1007 SANT 2. {ECO:0000255|PROSITE-ProRule:PRU00624}.,,,,,1.140684411,-0.719,121.92,15.9,16.9Q92922,SMRC1_HUMAN,reviewed,SWI/SNF complex subunit SMARCC1 (BRG1-associated factor 155) (BAF155) (SWI/SNF complex 155 kDa subunit) (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 1),SMARCC1 BAF155,Homo sapiens (Human),1105,GO:0043044; GO:0003677; GO:0016514; GO:0001741; GO:0003682; GO:0006338; GO:0008286; GO:0071565; GO:0007399; GO:0071564; GO:0000790; GO:0005654; GO:0006337; GO:0009887; GO:0045944; GO:0045893; GO:0047485; GO:0043234; GO:0006357; GO:0003713; GO:0006351,6599;,MAAAAGGGGPGTAVGATGSGIAAAAAGLAVYRRKDGGPATKFWESPETVSQLDSVRVWLGKHYKKYVHADAPTNKTLAGLVVQLLQFQEDAFGKHVTNPAFTKLPAKCFMDFKAGGALCHILGAAYKYKNEQGWRRFDLQNPSRMDRNVEMFMNIEKTLVQNNCLTRPNIYLIPDIDLKLANKLKDIIKRHQGTFTDEKSKASHHIYPYSSSQDDEEWLRPVMRKEKQVLVHWGFYPDSYDTWVHSNDVDAEIEDPPIPEKPWKVHVKWILDTDIFNEWMNEEDYEVDENRKPVSFRQRISTKNEEPVRSPERRDRKASANARKRKHSPSPPPPTPTESRKKSGKKGQASLYGKRRSQKEEDEQEDLTKDMEDPTPVPNIEEVVLPKNVNLKKDSENTPVKGGTVADLDEQDEETVTAGGKEDEDPAKGDQSRSVDLGEDNVTEQTNHIIIPSYASWFDYNCIHVIERRALPEFFNGKNKSKTPEIYLAYRNFMIDTYRLNPQEYLTSTACRRNLTGDVCAVMRVHAFLEQWGLVNYQVDPESRPMAMGPPPTPHFNVLADTPSGLVPLHLRSPQVPAAQQMLNFPEKNKEKPVDLQNFGLRTDIYSKKTLAKSKGASAGREWTEQETLLLLEALEMYKDDWNKVSEHVGSRTQDECILHFLRLPIEDPYLENSDASLGPLAYQPVPFSQSGNPVMSTVAFLASVVDPRVASAAAKAALEEFSRVREEVPLELVEAHVKKVQEAARASGKVDPTYGLESSCIAGTGPDEPEKLEGAEEEKMEADPDGQQPEKAENKVENETDEGDKAQDGENEKNSEKEQDSEVSEDTKSEEKETEENKELTDTCKERESDTGKKKVEHEISEGNVATAAAAALASAATKAKHLAAVEERKIKSLVALLVETQMKKLEIKLRHFEELETIMDREKEALEQQRQQLLTERQNFHMEQLKYAELRARQQMEQQQHGQNPQQAHQHSGGPGLAPLGAAGHPGMMPHQQPPPYPLMHHQMPPPHPPQPGQIPGPGSMMPGQHMPGRMIPTVAANIHPSGSGPTPPGMPPMPGNILGPRVPLTAPNGMYPPPPQQQPPPPPPADGVPPPPAPGPPASAAP,,,,PF00249;PF04433;,hsa:6599;,,,"SUBUNIT: Component of 6 multiprotein chromatin-remodeling complexes: Swi/Snf-A (BAF), Swi/Snf-B (PBAF), Brm, Brg1(I), WINAC and Brg1(II). Each of the five complexes contains a catalytic subunit (either SMARCA4 or SMARCA2), and at least SMARCE1, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCC2 and SMARCB1. Other subunits specific to each of the complexes may also be present. Component of the BAF complex, which includes at least actin (ACTB), ARID1A, ARID1B/BAF250, SMARCA2, SMARCA4/BRG1, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more of SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. In muscle cells, the BAF complex also contains DPF3. May also interact with the SIN3A histone deacetylase transcription repressor complex in conjunction with SMARCA2 and SMARCA4. The minimal complex composed of SMARCC1 and SMARCA4 seems to be able to associate with cyclin such as CCNE1 or transcription factors such as KLF1 or GATA1. Component of the WINAC complex, at least composed of SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCE1, ACTL6A, BAZ1B/WSTF, ARID1A, SUPT16H, CHAF1A and TOP2B. Interacts with NR3C1 and SMARD1. Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin (By similarity). Interacts with TRIP12; leading to disrupt interaction between TRIP12 and SMARCE1 and prevent SMARCE1 ubiquitination. {ECO:0000250, ECO:0000269|PubMed:11238380, ECO:0000269|PubMed:12837248, ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:18765789, ECO:0000269|PubMed:20829358, ECO:0000269|PubMed:9891079}.",HELIX 625 637 {ECO:0000244|PDB:2YUS}.; HELIX 642 649 {ECO:0000244|PDB:2YUS}.; HELIX 654 661 {ECO:0000244|PDB:2YUS}.,STRAND 638 640 {ECO:0000244|PDB:2YUS}.,,DOMAIN 449 546 SWIRM. {ECO:0000255|PROSITE-ProRule:PRU00247}.; DOMAIN 618 669 SANT. {ECO:0000255|PROSITE-ProRule:PRU00624}.,,,,,0.814479638,-0.814,122.89,16.7,17.7Q9NTJ3,SMC4_HUMAN,reviewed,Structural maintenance of chromosomes protein 4 (SMC protein 4) (SMC-4) (Chromosome-associated polypeptide C) (hCAP-C) (XCAP-C homolog),SMC4 CAPC SMC4L1,Homo sapiens (Human),1288,GO:0005524; GO:0051301; GO:0000796; GO:0005737; GO:0005829; GO:0051383; GO:0010032; GO:0045132; GO:0000278; GO:0007076; GO:0000070; GO:0005654; GO:0005634; GO:0046982,10051;,MPRKGTQPSTARRREEGPPPPSPDGASSDAEPEPPSGRTESPATAAETASEELDNRSLEEILNSIPPPPPPAMTNEAGAPRLMITHIVNQNFKSYAGEKILGPFHKRFSCIIGPNGSGKSNVIDSMLFVFGYRAQKIRSKKLSVLIHNSDEHKDIQSCTVEVHFQKIIDKEGDDYEVIPNSNFYVSRTACRDNTSVYHISGKKKTFKDVGNLLRSHGIDLDHNRFLILQGEVEQIAMMKPKGQTEHDEGMLEYLEDIIGCGRLNEPIKVLCRRVEILNEHRGEKLNRVKMVEKEKDALEGEKNIAIEFLTLENEIFRKKNHVCQYYIYELQKRIAEMETQKEKIHEDTKEINEKSNILSNEMKAKNKDVKDTEKKLNKITKFIEENKEKFTQLDLEDVQVREKLKHATSKAKKLEKQLQKDKEKVEEFKSIPAKSNNIINETTTRNNALEKEKEKEEKKLKEVMDSLKQETQGLQKEKESREKELMGFSKSVNEARSKMDVAQSELDIYLSRHNTAVSQLTKAKEALIAASETLKERKAAIRDIEGKLPQTEQELKEKEKELQKLTQEETNFKSLVHDLFQKVEEAKSSLAMNRSRGKVLDAIIQEKKSGRIPGIYGRLGDLGAIDEKYDVAISSCCHALDYIVVDSIDIAQECVNFLKRQNIGVATFIGLDKMAVWAKKMTEIQTPENTPRLFDLVKVKDEKIRQAFYFALRDTLVADNLDQATRVAYQKDRRWRVVTLQGQIIEQSGTMTGGGSKVMKGRMGSSLVIEISEEEVNKMESQLQNDSKKAMQIQEQKVQLEERVVKLRHSEREMRNTLEKFTASIQRLIEQEEYLNVQVKELEANVLATAPDKKKQKLLEENVSAFKTEYDAVAEKAGKVEAEVKRLHNTIVEINNHKLKAQQDKLDKINKQLDECASAITKAQVAIKTADRNLQKAQDSVLRTEKEIKDTEKEVDDLTAELKSLEDKAAEVVKNTNAAEESLPEIQKEHRNLLQELKVIQENEHALQKDALSIKLKLEQIDGHIAEHNSKIKYWHKEISKISLHPIEDNPIEEISVLSPEDLEAIKNPDSITNQIALLEARCHEMKPNLGAIAEYKKKEELYLQRVAELDKITYERDSFRQAYEDLRKQRLNEFMAGFYIITNKLKENYQMLTLGGDAELELVDSLDPFSEGIMFSVRPPKKSWKKIFNLSGGEKTLSSLALVFALHHYKPTPLYFMDEIDAALDFKNVSIVAFYIYEQTKNAQFIIISLRNNMFEISDRLIGIYKTYNITKSVAVNPKEIASKGLC,,,"DOMAIN: The hinge domain, which separates the large intramolecular coiled coil regions, allows the heterodimerization with SMC2, forming a V-shaped heterodimer. {ECO:0000250}.",PF06470;PF02463;,hsa:10051;,,,"SUBUNIT: Forms a heterodimer with SMC2. Component of the condensin complex, which contains the SMC2 and SMC4 heterodimer, and three non SMC subunits that probably regulate the complex: BRRN1/CAPH, CNAP1/CAPD2 and CAPG. {ECO:0000269|PubMed:10958694, ECO:0000269|PubMed:11136719}.",,,,,,,,,0.931677019,-0.691,147.21,5.7,6.7Q16637,SMN_HUMAN,reviewed,Survival motor neuron protein (Component of gems 1) (Gemin-1),SMN1 SMN SMNT; SMN2 SMNC,Homo sapiens (Human),294,GO:0015030; GO:0097504; GO:0003723; GO:0016070; GO:0032797; GO:0034719; GO:0030018; GO:0005737; GO:0005829; GO:0010467; GO:0042802; GO:0034660; GO:0007399; GO:0005654; GO:0005634; GO:0005681; GO:0000245; GO:0000387,6606;6607;,MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN,"DISEASE: Spinal muscular atrophy 1 (SMA1) [MIM:253300]: A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit. {ECO:0000269|PubMed:10732817, ECO:0000269|PubMed:15249625, ECO:0000269|PubMed:15580564, ECO:0000269|PubMed:7813012, ECO:0000269|PubMed:9147655}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 2 (SMA2) [MIM:253550]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. It has intermediate severity, with onset between 6 and 18 months. Patients do not reach the motor milestone of standing, and survive into adulthood. {ECO:0000269|PubMed:10732802, ECO:0000269|PubMed:9158159, ECO:0000269|PubMed:9837824}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 3 (SMA3) [MIM:253400]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is after 18 months. Patients develop ability to stand and walk and survive into adulthood. {ECO:0000269|PubMed:10732817, ECO:0000269|PubMed:9158159, ECO:0000269|PubMed:9837824}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 4 (SMA4) [MIM:271150]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is in adulthood, disease progression is slow, and patients can stand and walk. Note=The disease is caused by mutations affecting the gene represented in this entry.",,"DOMAIN: The Tudor domain mediates association with dimethylarginines, which are common in snRNP proteins.",PF06003;,hsa:6606;hsa:6607;,,,"SUBUNIT: Homodimer. Part of the core SMN complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8 and STRAP/UNRIP. Part of the SMN-Sm complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8, STRAP/UNRIP and the Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG. Component of an import snRNP complex composed of KPNB1, RNUT1, SMN1 and ZNF259. Interacts with DDX20, FBL, NOLA1, RNUT1, SYNCRIP and with several spliceosomal snRNP core Sm proteins, including SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE and ILF3. Interacts with OSTF1, LSM10, LSM11 and RPP20/POP7. Interacts (via C-terminal region) with ZPR1 (via C-terminal region). Interacts (via Tudor domain) with COIL. {ECO:0000269|PubMed:11283611, ECO:0000269|PubMed:11551898, ECO:0000269|PubMed:11574476, ECO:0000269|PubMed:11641277, ECO:0000269|PubMed:12065586, ECO:0000269|PubMed:12095920, ECO:0000269|PubMed:12975319, ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:16087681, ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:22101937, ECO:0000269|PubMed:9323129}.",HELIX 38 47 {ECO:0000244|PDB:3S6N}.; HELIX 138 140 {ECO:0000244|PDB:4QQ6}.; HELIX 263 280 {ECO:0000244|PDB:4GLI}.,STRAND 97 101 {ECO:0000244|PDB:4QQ6}.; STRAND 108 117 {ECO:0000244|PDB:4QQ6}.; STRAND 122 127 {ECO:0000244|PDB:4QQ6}.; STRAND 133 137 {ECO:0000244|PDB:4QQ6}.,TURN 87 90 {ECO:0000244|PDB:4A4E}.; TURN 103 105 {ECO:0000244|PDB:4QQ6}.; TURN 118 121 {ECO:0000244|PDB:4QQ6}.; TURN 128 130 {ECO:0000244|PDB:4QQ6}.,DOMAIN 91 151 Tudor. {ECO:0000255|PROSITE-ProRule:PRU00211}.,,,,,2.721088435,-0.77,31.85,133,134Q7KZF4,SND1_HUMAN,reviewed,Staphylococcal nuclease domain-containing protein 1 (100 kDa coactivator) (EBNA2 coactivator p100) (Tudor domain-containing protein 11) (p100 co-activator),SND1 TDRD11,Homo sapiens (Human),910,GO:0016442; GO:0005737; GO:0097433; GO:0070062; GO:0031047; GO:0042470; GO:0016020; GO:0005739; GO:0004518; GO:0005634; GO:0001649; GO:0044822; GO:0006355; GO:0003712; GO:0006351; GO:0016032,27044;,MASSAQSGGSSGGPAVPTVQRGIIKMVLSGCAIIVRGQPRGGPPPERQINLSNIRAGNLARRAAATQPDAKDTPDEPWAFPAREFLRKKLIGKEVCFTIENKTPQGREYGMIYLGKDTNGENIAESLVAEGLATRREGMRANNPEQNRLSECEEQAKAAKKGMWSEGNGSHTIRDLKYTIENPRHFVDSHHQKPVNAIIEHVRDGSVVRALLLPDYYLVTVMLSGIKCPTFRREADGSETPEPFAAEAKFFTESRLLQRDVQIILESCHNQNILGTILHPNGNITELLLKEGFARCVDWSIAVYTRGAEKLRAAERFAKERRLRIWRDYVAPTANLDQKDKQFVAKVMQVLNADAIVVKLNSGDYKTIHLSSIRPPRLEGENTQDKNKKLRPLYDIPYMFEAREFLRKKLIGKKVNVTVDYIRPASPATETVPAFSERTCATVTIGGINIAEALVSKGLATVIRYRQDDDQRSSHYDELLAAEARAIKNGKGLHSKKEVPIHRVADISGDTQKAKQFLPFLQRAGRSEAVVEYVFSGSRLKLYLPKETCLITFLLAGIECPRGARNLPGLVQEGEPFSEEATLFTKELVLQREVEVEVESMDKAGNFIGWLHIDGANLSVLLVEHALSKVHFTAERSSYYKSLLSAEEAAKQKKEKVWAHYEEQPVEEVMPVLEEKERSASYKPVFVTEITDDLHFYVQDVETGTQLEKLMENMRNDIASHPPVEGSYAPRRGEFCIAKFVDGEWYRARVEKVESPAKIHVFYIDYGNREVLPSTRLGTLSPAFSTRVLPAQATEYAFAFIQVPQDDDARTDAVDSVVRDIQNTQCLLNVEHLSAGCPHVTLQFADSKGDVGLGLVKEGLVMVEVRKEKQFQKVITEYLNAQESAKSARLNLWRYGDFRADDADEFGYSR,,,,PF00565;PF00567;,hsa:27044;,,,SUBUNIT: Binds to acidic transactivation domain of EBNA2. Interacts with EAV NSP1. Interacts with GTF2E1 and GTF2E2. Forms a ternary complex with STAT6 and POLR2A. Interacts with STAT5 (By similarity). {ECO:0000250}.,HELIX 29 31 {ECO:0000244|PDB:4QMG}.; HELIX 79 90 {ECO:0000244|PDB:4QMG}.; HELIX 123 129 {ECO:0000244|PDB:4QMG}.; HELIX 144 159 {ECO:0000244|PDB:4QMG}.; HELIX 162 164 {ECO:0000244|PDB:4QMG}.; HELIX 170 172 {ECO:0000244|PDB:4QMG}.; HELIX 183 188 {ECO:0000244|PDB:4QMG}.; HELIX 245 256 {ECO:0000244|PDB:4QMG}.; HELIX 284 290 {ECO:0000244|PDB:4QMG}.; HELIX 301 303 {ECO:0000244|PDB:4QMG}.; HELIX 308 320 {ECO:0000244|PDB:4QMG}.; HELIX 324 326 {ECO:0000244|PDB:4QMG}.; HELIX 384 386 {ECO:0000244|PDB:3BDL}.; HELIX 392 395 {ECO:0000244|PDB:3BDL}.; HELIX 399 410 {ECO:0000244|PDB:3BDL}.; HELIX 450 456 {ECO:0000244|PDB:3BDL}.; HELIX 476 488 {ECO:0000244|PDB:3BDL}.; HELIX 492 494 {ECO:0000244|PDB:3BDL}.; HELIX 511 523 {ECO:0000244|PDB:3BDL}.; HELIX 578 589 {ECO:0000244|PDB:3BDL}.; HELIX 618 624 {ECO:0000244|PDB:3BDL}.; HELIX 632 634 {ECO:0000244|PDB:3BDL}.; HELIX 640 653 {ECO:0000244|PDB:3BDL}.; HELIX 656 658 {ECO:0000244|PDB:3BDL}.; HELIX 701 703 {ECO:0000244|PDB:3OMC}.; HELIX 706 720 {ECO:0000244|PDB:2HQX}.; HELIX 774 776 {ECO:0000244|PDB:2HQX}.; HELIX 782 784 {ECO:0000244|PDB:2HQX}.; HELIX 807 821 {ECO:0000244|PDB:3OMC}.; HELIX 851 857 {ECO:0000244|PDB:3OMC}.; HELIX 869 871 {ECO:0000244|PDB:3OMC}.; HELIX 872 887 {ECO:0000244|PDB:3OMC}.; HELIX 891 893 {ECO:0000244|PDB:3OMC}.,STRAND 20 27 {ECO:0000244|PDB:4QMG}.; STRAND 33 36 {ECO:0000244|PDB:4QMG}.; STRAND 40 43 {ECO:0000244|PDB:4QMG}.; STRAND 46 51 {ECO:0000244|PDB:4QMG}.; STRAND 54 56 {ECO:0000244|PDB:4QMG}.; STRAND 94 102 {ECO:0000244|PDB:4QMG}.; STRAND 108 117 {ECO:0000244|PDB:4QMG}.; STRAND 120 122 {ECO:0000244|PDB:4QMG}.; STRAND 132 135 {ECO:0000244|PDB:4QMG}.; STRAND 165 167 {ECO:0000244|PDB:4QMG}.; STRAND 177 179 {ECO:0000244|PDB:4QMG}.; STRAND 195 204 {ECO:0000244|PDB:4QMG}.; STRAND 207 212 {ECO:0000244|PDB:4QMG}.; STRAND 217 223 {ECO:0000244|PDB:4QMG}.; STRAND 260 269 {ECO:0000244|PDB:4QMG}.; STRAND 272 278 {ECO:0000244|PDB:4QMG}.; STRAND 341 351 {ECO:0000244|PDB:3BDL}.; STRAND 355 359 {ECO:0000244|PDB:3BDL}.; STRAND 365 370 {ECO:0000244|PDB:3BDL}.; STRAND 414 425 {ECO:0000244|PDB:3BDL}.; STRAND 432 435 {ECO:0000244|PDB:3BDL}.; STRAND 438 445 {ECO:0000244|PDB:3BDL}.; STRAND 459 462 {ECO:0000244|PDB:3BDL}.; STRAND 526 544 {ECO:0000244|PDB:3BDL}.; STRAND 549 559 {ECO:0000244|PDB:3BDL}.; STRAND 565 567 {ECO:0000244|PDB:3BDL}.; STRAND 570 572 {ECO:0000244|PDB:3BDL}.; STRAND 593 601 {ECO:0000244|PDB:3BDL}.; STRAND 607 613 {ECO:0000244|PDB:3BDL}.; STRAND 627 630 {ECO:0000244|PDB:3BDL}.; STRAND 683 690 {ECO:0000244|PDB:3OMC}.; STRAND 694 700 {ECO:0000244|PDB:3OMC}.; STRAND 735 739 {ECO:0000244|PDB:2HQX}.; STRAND 745 755 {ECO:0000244|PDB:2HQX}.; STRAND 758 763 {ECO:0000244|PDB:2HQX}.; STRAND 769 772 {ECO:0000244|PDB:2HQX}.; STRAND 793 798 {ECO:0000244|PDB:3OMC}.; STRAND 824 832 {ECO:0000244|PDB:3OMC}.; STRAND 835 837 {ECO:0000244|PDB:3OMC}.; STRAND 839 844 {ECO:0000244|PDB:3OMC}.; STRAND 860 863 {ECO:0000244|PDB:3OMC}.,TURN 189 192 {ECO:0000244|PDB:4QMG}.; TURN 213 216 {ECO:0000244|PDB:4QMG}.; TURN 298 300 {ECO:0000244|PDB:4QMG}.; TURN 352 354 {ECO:0000244|PDB:3BDL}.; TURN 387 389 {ECO:0000244|PDB:3BDL}.; TURN 545 548 {ECO:0000244|PDB:3BDL}.; TURN 725 727 {ECO:0000244|PDB:2HQX}.; TURN 764 766 {ECO:0000244|PDB:2HQX}.; TURN 786 788 {ECO:0000244|PDB:2HQX}.; TURN 845 847 {ECO:0000244|PDB:3OMC}.,DOMAIN 18 166 TNase-like 1. {ECO:0000255|PROSITE-ProRule:PRU00272}.; DOMAIN 193 328 TNase-like 2. {ECO:0000255|PROSITE-ProRule:PRU00272}.; DOMAIN 341 496 TNase-like 3. {ECO:0000255|PROSITE-ProRule:PRU00272}.; DOMAIN 525 660 TNase-like 4. {ECO:0000255|PROSITE-ProRule:PRU00272}.; DOMAIN 729 787 Tudor. {ECO:0000255|PROSITE-ProRule:PRU00211}.,,,,,1.318681319,-0.426,102.01,14.5,15.5O15042,SR140_HUMAN,reviewed,U2 snRNP-associated SURP motif-containing protein (140 kDa Ser/Arg-rich domain protein) (U2-associated protein SR140),U2SURP KIAA0332 SR140,Homo sapiens (Human),1029,GO:0006396; GO:0005654; GO:0000166; GO:0005634; GO:0044822,23350;,MADKTPGGSQKASSKTRSSDVHSSGSSDAHMDASGPSDSDMPSRTRPKSPRKHNYRNESARESLCDSPHQNLSRPLLENKLKAFSIGKMSTAKRTLSKKEQEELKKKEDEKAAAEIYEEFLAAFEGSDGNKVKTFVRGGVVNAAKEEHETDEKRGKIYKPSSRFADQKNPPNQSSNERPPSLLVIETKKPPLKKGEKEKKKSNLELFKEELKQIQEERDERHKTKGRLSRFEPPQSDSDGQRRSMDAPSRRNRSSGVLDDYAPGSHDVGDPSTTNLYLGNINPQMNEEMLCQEFGRFGPLASVKIMWPRTDEERARERNCGFVAFMNRRDAERALKNLNGKMIMSFEMKLGWGKAVPIPPHPIYIPPSMMEHTLPPPPSGLPFNAQPRERLKNPNAPMLPPPKNKEDFEKTLSQAIVKVVIPTERNLLALIHRMIEFVVREGPMFEAMIMNREINNPMFRFLFENQTPAHVYYRWKLYSILQGDSPTKWRTEDFRMFKNGSFWRPPPLNPYLHGMSEEQETEAFVEEPSKKGALKEEQRDKLEEILRGLTPRKNDIGDAMVFCLNNAEAAEEIVDCITESLSILKTPLPKKIARLYLVSDVLYNSSAKVANASYYRKFFETKLCQIFSDLNATYRTIQGHLQSENFKQRVMTCFRAWEDWAIYPEPFLIKLQNIFLGLVNIIEEKETEDVPDDLDGAPIEEELDGAPLEDVDGIPIDATPIDDLDGVPIKSLDDDLDGVPLDATEDSKKNEPIFKVAPSKWEAVDESELEAQAVTTSKWELFDQHEESEEEENQNQEEESEDEEDTQSSKSEEHHLYSNPIKEEMTESKFSKYSEMSEEKRAKLREIELKVMKFQDELESGKRPKKPGQSFQEQVEHYRDKLLQREKEKELERERERDKKDKEKLESRSKDKKEKDECTPTRKERKRRHSTSPSPSRSSSGRRVKSPSPKSERSERSERSHKESSRSRSSHKDSPRDVSKKAKRSPSGSRTPKRSRRSRSRSPKKSGKKSRSQSRSPHRSHKKSKKNKH,,,,PF08312;PF00076;PF01805;,hsa:23350;,,,SUBUNIT: Interacts with ERBB4. {ECO:0000269|PubMed:20858735}.,,,,DOMAIN 274 355 RRM. {ECO:0000255|PROSITE-ProRule:PRU00176}.; DOMAIN 534 679 CID. {ECO:0000255|PROSITE-ProRule:PRU00724}.,,,,,0.777453839,-1.143,118.31,89.6,90.6Q04837,SSBP_HUMAN,reviewed,"Single-stranded DNA-binding protein, mitochondrial (Mt-SSB) (MtSSB) (PWP1-interacting protein 17)",SSBP1 SSBP,Homo sapiens (Human),148,GO:0006260; GO:0003682; GO:0070062; GO:0042645; GO:0005739; GO:0070584; GO:0005634; GO:0044822; GO:0051096; GO:0003697,6742;,MFRRPVLQVLRQFVRHESETTTSLVLERSLNRVHLLGRVGQDPVLRQVEGKNPVTIFSLATNEMWRSGDSEVYQLGDVSQKTTWHRISVFRPGLRDVAYQYVKKGSRIYLEGKIDYGEYMDKNNVRRQATTIIADNIIFLSDQTKEKE,,,,PF00436;,hsa:6742;,,,"SUBUNIT: Homotetramer (By similarity). Interacts with MPG/AAG, through inhibition of its glycosylase activity it potentially prevents formation of DNA breaks in ssDNA, ensuring that base removal primarily occurs in dsDNA. {ECO:0000250, ECO:0000269|PubMed:23290262}.",HELIX 94 101 {ECO:0000244|PDB:3ULL}.,STRAND 30 39 {ECO:0000244|PDB:3ULL}.; STRAND 44 46 {ECO:0000244|PDB:3ULL}.; STRAND 48 51 {ECO:0000244|PDB:1S3O}.; STRAND 54 65 {ECO:0000244|PDB:3ULL}.; STRAND 79 89 {ECO:0000244|PDB:3ULL}.; STRAND 107 115 {ECO:0000244|PDB:3ULL}.; STRAND 119 126 {ECO:0000244|PDB:3ULL}.; STRAND 130 138 {ECO:0000244|PDB:3ULL}.,,DOMAIN 30 141 SSB.,,,,,0,-0.561,17.26,107,108Q9Y3F4,STRAP_HUMAN,reviewed,Serine-threonine kinase receptor-associated protein (MAP activator with WD repeats) (UNR-interacting protein) (WD-40 repeat protein PT-WD),STRAP MAWD UNRIP,Homo sapiens (Human),350,GO:0032797; GO:0034719; GO:0005737; GO:0005829; GO:0030277; GO:0010633; GO:0050680; GO:0010719; GO:0060394; GO:0000122; GO:0030512; GO:0005654; GO:0005634; GO:0005886; GO:0044822; GO:0000387; GO:0007179,11171;,MAMRQTPLTCSGHTRPVVDLAFSGITPYGYFLISACKDGKPMLRQGDTGDWIGTFLGHKGAVWGATLNKDATKAATAAADFTAKVWDAVSGDELMTLAHKHIVKTVDFTQDSNYLLTGGQDKLLRIYDLNKPEAEPKEISGHTSGIKKALWCSEDKQILSADDKTVRLWDHATMTEVKSLNFNMSVSSMEYIPEGEILVITYGRSIAFHSAVSLDPIKSFEAPATINSASLHPEKEFLVAGGEDFKLYKYDYNSGEELESYKGHFGPIHCVRFSPDGELYASGSEDGTLRLWQTVVGKTYGLWKCVLPEEDSGELAKPKIGFPETTEEELEEIASENSDCIFPSAPDVKA,,,,PF00400;,hsa:11171;,,,"SUBUNIT: Part of the core SMN complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8 and STRAP/UNRIP. Part of the SMN-Sm complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6, GEMIN7, GEMIN8, STRAP/UNRIP and the Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG. Interacts directly with GEMIN6 and GEMIN7. Associates with the SMN complex in the cytoplasm but not in the nucleus. Also interacts with CSDE1/UNR and MAWBP. Interacts with PDPK1. {ECO:0000269|PubMed:10049359, ECO:0000269|PubMed:15848170, ECO:0000269|PubMed:16159890, ECO:0000269|PubMed:16251192, ECO:0000269|PubMed:18984161}.",,,,,,,,,1.714285714,-0.316,38.44,45.4,46.4P61956,SUMO2_HUMAN,reviewed,Small ubiquitin-related modifier 2 (SUMO-2) (HSMT3) (SMT3 homolog 2) (SUMO-3) (Sentrin-2) (Ubiquitin-like protein SMT3B) (Smt3B),SUMO2 SMT3B SMT3H2,Homo sapiens (Human),95,GO:0016605; GO:0019789; GO:0044267; GO:0005654; GO:0005634; GO:0044822; GO:0032436; GO:0045944; GO:0043687; GO:0016925; GO:0031625,6613;,MADEKPKEGVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVY,,,,PF11976;,hsa:6613;,,,"SUBUNIT: Homotrimer (Potential). Crystal packing analysis suggests a possible trimeric assembly, of which the biological significance remains to be determined. Interacts with SAE2 and UBE2I. Covalently attached to a number of proteins. Interacts with PELP1. Interacts with USP25; the interaction sumoylates USP25. Interacts with SIMC1, CASP8AP2, RNF111 AND SOBP (via SIM domains). Interacts with MTA1. {ECO:0000269|PubMed:12924945, ECO:0000269|PubMed:15479240, ECO:0000269|PubMed:16567619, ECO:0000269|PubMed:18538659, ECO:0000269|PubMed:21965678, ECO:0000269|PubMed:23086935, ECO:0000305}.",HELIX 41 51 {ECO:0000244|PDB:1WM3}.,STRAND 11 13 {ECO:0000244|PDB:2RPQ}.; STRAND 18 23 {ECO:0000244|PDB:1WM3}.; STRAND 29 34 {ECO:0000244|PDB:1WM3}.; STRAND 59 62 {ECO:0000244|PDB:1WM3}.; STRAND 65 67 {ECO:0000244|PDB:2RPQ}.; STRAND 82 87 {ECO:0000244|PDB:1WM3}.; STRAND 90 93 {ECO:0000244|PDB:2AWT}.,TURN 14 16 {ECO:0000244|PDB:2RPQ}.; TURN 25 27 {ECO:0000244|PDB:2CKH}.; TURN 55 57 {ECO:0000244|PDB:1WM3}.; TURN 73 77 {ECO:0000244|PDB:1WM3}.,DOMAIN 16 95 Ubiquitin-like. {ECO:0000255|PROSITE-ProRule:PRU00214}.,,,,,1.052631579,-0.893,10.87,4.07,5.07Q8NI27,THOC2_HUMAN,reviewed,THO complex subunit 2 (Tho2) (hTREX120),THOC2 CXorf3,Homo sapiens (Human),1593,GO:0003723; GO:0008380; GO:0000347; GO:0000445; GO:0006406; GO:0006397; GO:0016607; GO:0005654; GO:0016973; GO:0000346; GO:0046784,57187;,MAAAAVVVPAEWIKNWEKSGRGEFLHLCRILSENKSHDSSTYRDFQQALYELSYHVIKGNLKHEQASNVLSDISEFREDMPSILADVFCILDIETNCLEEKSKRDYFTQLVLACLYLVSDTVLKERLDPETLESLGLIKQSQQFNQKSVKIKTKLFYKQQKFNLLREENEGYAKLIAELGQDLSGSITSDLILENIKSLIGCFNLDPNRVLDVILEVFECRPEHDDFFISLLESYMSMCEPQTLCHILGFKFKFYQEPNGETPSSLYRVAAVLLQFNLIDLDDLYVHLLPADNCIMDEHKREIAEAKQIVRKLTMVVLSSEKMDEREKEKEKEEEKVEKPPDNQKLGLLEALLKIGDWQHAQNIMDQMPPYYAASHKLIALAICKLIHITIEPLYRRVGVPKGAKGSPVNALQNKRAPKQAESFEDLRRDVFNMFCYLGPHLSHDPILFAKVVRIGKSFMKEFQSDGSKQEDKEKTEVILSCLLSITDQVLLPSLSLMDCNACMSEELWGMFKTFPYQHRYRLYGQWKNETYNSHPLLVKVKAQTIDRAKYIMKRLTKENVKPSGRQIGKLSHSNPTILFDYILSQIQKYDNLITPVVDSLKYLTSLNYDVLAYCIIEALANPEKERMKHDDTTISSWLQSLASFCGAVFRKYPIDLAGLLQYVANQLKAGKSFDLLILKEVVQKMAGIEITEEMTMEQLEAMTGGEQLKAEGGYFGQIRNTKKSSQRLKDALLDHDLALPLCLLMAQQRNGVIFQEGGEKHLKLVGKLYDQCHDTLVQFGGFLASNLSTEDYIKRVPSIDVLCNEFHTPHDAAFFLSRPMYAHHISSKYDELKKSEKGSKQQHKVHKYITSCEMVMAPVHEAVVSLHVSKVWDDISPQFYATFWSLTMYDLAVPHTSYEREVNKLKVQMKAIDDNQEMPPNKKKKEKERCTALQDKLLEEEKKQMEHVQRVLQRLKLEKDNWLLAKSTKNETITKFLQLCIFPRCIFSAIDAVYCARFVELVHQQKTPNFSTLLCYDRVFSDIIYTVASCTENEASRYGRFLCCMLETVTRWHSDRATYEKECGNYPGFLTILRATGFDGGNKADQLDYENFRHVVHKWHYKLTKASVHCLETGEYTHIRNILIVLTKILPWYPKVLNLGQALERRVHKICQEEKEKRPDLYALAMGYSGQLKSRKSYMIPENEFHHKDPPPRNAVASVQNGPGGGPSSSSIGSASKSDESSTEETDKSRERSQCGVKAVNKASSTTPKGNSSNGNSGSNSNKAVKENDKEKGKEKEKEKKEKTPATTPEARVLGKDGKEKPKEERPNKDEKARETKERTPKSDKEKEKFKKEEKAKDEKFKTTVPNAESKSTQEREREKEPSRERDIAKEMKSKENVKGGEKTPVSGSLKSPVPRSDIPEPEREQKRRKIDTHPSPSHSSTVKDSLIELKESSAKLYINHTPPPLSKSKEREMDKKDLDKSRERSREREKKDEKDRKERKRDHSNNDREVPPDLTKRRKEENGTMGVSKHKSESPCESPYPNEKDKEKNKSKSSGKEKGSDSFKSEKMDKISSGGKKESRHDKEKIEKKEKRDSSGGKEEKKHHKSSDKHR,,,,PF11262;PF11732;,hsa:57187;,,,"SUBUNIT: Component of the THO complex, which is composed of THOC1, THOC2, THOC3, THOC5, THOC6 and THOC7; together with at least ALYREF/THOC4, DDX39B, SARNP/CIP29 and CHTOP, THO forms the transcription/export (TREX) complex which seems to have a dynamic structure involving ATP-dependent remodeling. Interacts with THOC1, POLDIP3 and ZC3H11A. {ECO:0000269|PubMed:11979277, ECO:0000269|PubMed:15833825, ECO:0000269|PubMed:15870275, ECO:0000269|PubMed:15998806, ECO:0000269|PubMed:22928037}.",,,,,,,,,2.071563089,-0.77,182.8,2.82,3.82Q9C0C2,TB182_HUMAN,reviewed,182 kDa tankyrase-1-binding protein,TNKS1BP1 KIAA1741 TAB182,Homo sapiens (Human),1729,GO:0030014; GO:0016070; GO:0030506; GO:0005737; GO:0005856; GO:0005829; GO:0019899; GO:0010467; GO:0016071; GO:0005724; GO:0000288; GO:0000289; GO:0005654; GO:0005634; GO:0005886; GO:0007004,85456;,MKVSTLRESSAMASPLPREMEEELVPTGSEPGDTRAKPPVKPKPRALPAKPALPAKPSLLVPVGPRPPRGPLAELPSARKMNMLAGPQPYGGSKRPLPFAPRPAVEASTGGEATQETGKEEAGKEEPPPLTPPARCAAPGGVRKAPAPFRPASERFAATTVEEILAKMEQPRKEVLASPDRLWGSRLTFNHDGSSRYGPRTYGTTTAPRDEDGSTLFRGWSQEGPVKSPAECREEHSKTPEERSLPSDLAFNGDLAKAASSELPADISKPWIPSSPAPSSENGGPASPGLPAEASGSGPGSPHLHPPDKSSPCHSQLLEAQTPEASQASPCPAVTPSAPSAALPDEGSRHTPSPGLPAEGAPEAPRPSSPPPEVLEPHSLDQPPATSPRPLIEVGELLDLTRTFPSGGEEEAKGDAHLRPTSLVQRRFSEGVLQSPSQDQEKLGGSLAALPQGQGSQLALDRPFGAESNWSLSQSFEWTFPTRPSGLGVWRLDSPPPSPITEASEAAEAAEAGNLAVSSREEGVSQQGQGAGSAPSGSGSSWVQGDDPSMSLTQKGDGESQPQFPAVPLEPLPTTEGTPGLPLQQAEERYESQEPLAGQESPLPLATREAALPILEPVLGQEQPAAPDQPCVLFADAPEPGQALPVEEEAVTLARAETTQARTEAQDLCRASPEPPGPESSSRWLDDLLASPPPSGGGARRGAGAELKDTQSPSTCSEGLLGWSQKDLQSEFGITGDPQPSSFSPSSWCQGASQDYGLGGASPRGDPGLGERDWTSKYGQGAGEGSTREWASRCGIGQEEMEASSSQDQSKVSAPGVLTAQDRVVGKPAQLGTQRSQEADVQDWEFRKRDSQGTYSSRDAELQDQEFGKRDSLGTYSSRDVSLGDWEFGKRDSLGAYASQDANEQGQDLGKRDHHGRYSSQDADEQDWEFQKRDVSLGTYGSRAAEPQEQEFGKSAWIRDYSSGGSSRTLDAQDRSFGTRPLSSGFSPEEAQQQDEEFEKKIPSVEDSLGEGSRDAGRPGERGSGGLFSPSTAHVPDGALGQRDQSSWQNSDASQEVGGHQERQQAGAQGPGSADLEDGEMGKRGWVGEFSLSVGPQREAAFSPGQQDWSRDFCIEASERSYQFGIIGNDRVSGAGFSPSSKMEGGHFVPPGKTTAGSVDWTDQLGLRNLEVSSCVGSGGSSEARESAVGQMGWSGGLSLRDMNLTGCLESGGSEEPGGIGVGEKDWTSDVNVKSKDLAEVGEGGGHSQARESGVGQTDWSGVEAGEFLKSRERGVGQADWTPDLGLRNMAPGAVCSPGESKELGVGQMDWGNNLGLRDLEVTCDPDSGGSQGLRGCGVGQMDWTQDLAPQNVELFGAPSEAREHGVGGVSQCPEPGLRHNGSLSPGLEARDPLEARELGVGETSGPETQGEDYSSSSLEPHPADPGMETGEALSFGASPGRCPARPPPSGSQGLLEEMLAASSSKAVARRESAASGLGGLLEEEGAGAGAAQEEVLEPGRDSPPSWRPQPDGEASQTEDVDGTWGSSAARWSDQGPAQTSRRPSQGPPARSPSQDFSFIEDTEILDSAMYRSRANLGRKRGHRAPVIRPGGTLGLSEAADSDAHLFQDSTEPRASRVPSSDEEVVEEPQSRRTRMSLGTKGLKVNLFPGLSPSALKAKLRPRNRSAEEGELAESKSSQKESAVQRSKSCKVPGLGKPLTLPPKPEKSSGSEGSSPNWLQALKLKKKKV,,,,,hsa:85456;,,,SUBUNIT: Binds to the ANK repeat domain of TNKS1 and TNKS2.,,,,,,,,,1.041064199,-0.803,181.83,614,615Q71U36,TBA1A_HUMAN,reviewed,Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin alpha-3 chain),TUBA1A TUBA3,Homo sapiens (Human),451,GO:0051084; GO:0000086; GO:0005525; GO:0003924; GO:0051301; GO:0044267; GO:0005881; GO:0036464; GO:0030705; GO:0005829; GO:0070062; GO:0005874; GO:0007017; GO:0000278; GO:0005634; GO:0006457; GO:0051258; GO:0055037; GO:0005200; GO:0005198,7846;,MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLDRIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLIGQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRTIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY,"DISEASE: Lissencephaly 3 (LIS3) [MIM:611603]: A classic type lissencephaly associated with psychomotor retardation and seizures. Features include agyria or pachygyria or laminar heterotopia, severe mental retardation, motor delay, variable presence of seizures, and abnormalities of corpus callosum, hippocampus, cerebellar vermis and brainstem. {ECO:0000269|PubMed:17584854}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF00091;PF03953;,hsa:7846;,,,SUBUNIT: Dimer of alpha and beta chains. A typical microtubule is a hollow water-filled tube with an outer diameter of 25 nm and an inner diameter of 15 nM. Alpha-beta heterodimers associate head-to-tail to form protofilaments running lengthwise along the microtubule wall with the beta-tubulin subunit facing the microtubule plus end conferring a structural polarity. Microtubules usually have 13 protofilaments but different protofilament numbers can be found in some organisms and specialized cells.,,,,,,,,,2.66075388,-0.229,50.14,169,170Q96HX0,Q96HX0_HUMAN,unreviewed,TUBB2C protein (Fragment),TUBB2C,Homo sapiens (Human),227,GO:0005525; GO:0003924; GO:0005874; GO:0005634; GO:0051258; GO:0051225; GO:0005200,,TPTYGDLNHLVSATMSGVTTCLRFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQMFDAKNMMAACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRGLKMSATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVSEYQQYQDATAEEEGEFEEEAEEEVA,,,,PF03953;,,,,,,,,,,,,,1.321585903,-0.418,25.88,91,92P0CG48,UBC_HUMAN,reviewed,Polyubiquitin-C [Cleaved into: Ubiquitin],UBC,Homo sapiens (Human),685,GO:0006977; GO:0006281; GO:0038095; GO:0000082; GO:0000086; GO:0007249; GO:0007254; GO:0002755; GO:0002756; GO:0007220; GO:0007219; GO:0016070; GO:0050852; GO:0035666; GO:0000187; GO:0031145; GO:0042590; GO:0002479; GO:0002474; GO:0006915; GO:0097190; GO:0005975; GO:0071456; GO:0019221; GO:0005829; GO:0030666; GO:0016197; GO:0010008; GO:0097009; GO:0007173; GO:0070062; GO:0060613; GO:0008585; GO:0007144; GO:0008543; GO:0010467; GO:0006006; GO:0005978; GO:0021888; GO:0045087; GO:0075733; GO:0034220; GO:0016071; GO:0007141; GO:0061024; GO:0000278; GO:0043066; GO:0042059; GO:0000122; GO:0030512; GO:0032480; GO:0051436; GO:0048011; GO:0005654; GO:0035872; GO:0070423; GO:0005886; GO:0044822; GO:0043123; GO:0051092; GO:0043065; GO:0045944; GO:0032481; GO:0051437; GO:0002020; GO:0000209; GO:0042981; GO:0061418; GO:0032479; GO:0051439; GO:0072520; GO:0044281; GO:0051403; GO:0034166; GO:0034134; GO:0034138; GO:0034142; GO:0034146; GO:0034162; GO:0038123; GO:0038124; GO:0002224; GO:0006367; GO:0006351; GO:0007179; GO:0055085; GO:0010992; GO:0019058; GO:0016032; GO:0019082; GO:0019068,7316;,MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGV,,,,PF00240;,hsa:7316;,,,,HELIX 555 565 {ECO:0000244|PDB:2GBM}.; HELIX 589 591 {ECO:0000244|PDB:3B08}.; HELIX 631 642 {ECO:0000244|PDB:1OGW}.; HELIX 646 648 {ECO:0000244|PDB:1OGW}.; HELIX 664 667 {ECO:0000244|PDB:1OGW}.,STRAND 534 539 {ECO:0000244|PDB:2GBJ}.; STRAND 540 542 {ECO:0000244|PDB:2W9N}.; STRAND 544 548 {ECO:0000244|PDB:2GBM}.; STRAND 568 570 {ECO:0000244|PDB:2GBM}.; STRAND 573 577 {ECO:0000244|PDB:3B08}.; STRAND 579 581 {ECO:0000244|PDB:3N3K}.; STRAND 586 588 {ECO:0000244|PDB:1SIF}.; STRAND 598 603 {ECO:0000244|PDB:3B08}.; STRAND 610 615 {ECO:0000244|PDB:1OGW}.; STRAND 616 618 {ECO:0000244|PDB:4K1R}.; STRAND 620 624 {ECO:0000244|PDB:1OGW}.; STRAND 627 630 {ECO:0000244|PDB:1G6J}.; STRAND 649 653 {ECO:0000244|PDB:1OGW}.; STRAND 654 657 {ECO:0000244|PDB:4BVU}.; STRAND 660 663 {ECO:0000244|PDB:3JSV}.; STRAND 674 679 {ECO:0000244|PDB:1OGW}.,,DOMAIN 1 76 Ubiquitin-like 1. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 77 152 Ubiquitin-like 2. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 153 228 Ubiquitin-like 3. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 229 304 Ubiquitin-like 4. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 305 380 Ubiquitin-like 5. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 381 456 Ubiquitin-like 6. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 457 532 Ubiquitin-like 7. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 533 608 Ubiquitin-like 8. {ECO:0000255|PROSITE-ProRule:PRU00214}.; DOMAIN 609 684 Ubiquitin-like 9. {ECO:0000255|PROSITE-ProRule:PRU00214}.,,,,,0,-0.483,77.06,6.65,7.65Q5T4S7,UBR4_HUMAN,reviewed,E3 ubiquitin-protein ligase UBR4 (EC 6.3.2.-) (600 kDa retinoblastoma protein-associated factor) (N-recognin-4) (Retinoblastoma-associated factor of 600 kDa) (RBAF600) (p600) (Zinc finger UBR1-type protein 1),UBR4 KIAA0462 KIAA1307 RBAF600 ZUBR1,Homo sapiens (Human),5183,GO:0005813; GO:0005737; GO:0016021; GO:0016874; GO:0016020; GO:0005654; GO:0042787; GO:0004842; GO:0016032; GO:0008270,23352;,MATSGGEEAAAAAPAPGTPATGADTTPGWEVAVRPLLSASYSAFEMKELPQLVASVIESESEILHHEKQYEPFYSSFVALSTHYITTVCSLIPRNQLQSVAAACKVLIEFSLLRLENPDEACAVSQKHLILLIKGLCTGCSRLDRTEIITFTAMMKSAKLPQTVKTLSDVEDQKELASPVSPELRQKEVQMNFLNQLTSVFNPRTVASQPISTQTLVEGENDEQSSTDQASAIKTKNVFIAQNVASLQELGGSEKLLRVCLNLPYFLRYINRFQDAVLANSFFIMPATVADATAVRNGFHSLVIDVTMALDTLSLPVLEPLNPSRLQDVTVLSLSCLYAGVSVATCMAILHVGSAQQVRTGSTSSKEDDYESDAATIVQKCLEIYDMIGQAISSSRRAGGEHYQNFQLLGAWCLLNSLFLILNLSPTALADKGKEKDPLAALRVRDILSRTKEGVGSPKLGPGKGHQGFGVLSVILANHAIKLLTSLFQDLQVEALHKGWETDGPPAALSIMAQSTSIQRIQRLIDSVPLMNLLLTLLSTSYRKACVLQRQRKGSMSSDASASTDSNTYYEDDFSSTEEDSSQDDDSEPILGQWFEETISPSKEKAAPPPPPPPPPLESSPRVKSPSKQAPGEKGNILASRKDPELFLGLASNILNFITSSMLNSRNNFIRNYLSVSLSEHHMATLASIIKEVDKDGLKGSSDEEFAAALYHFNHSLVTSDLQSPNLQNTLLQQLGVAPFSEGPWPLYIHPQSLSVLSRLLLIWQHKASAQGDPDVPECLKVWDRFLSTMKQNALQGVVPSETEDLNVEHLQMLLLIFHNFTETGRRAILSLFVQIIQELSVNMDAQMRFVPLILARLLLIFDYLLHQYSKAPVYLFEQVQHNLLSPPFGWASGSQDSNSRRATTPLYHGFKEVEENWSKHFSSDAVPHPRFYCVLSPEASEDDLNRLDSVACDVLFSKLVKYDELYAALTALLAAGSQLDTVRRKENKNVTALEACALQYYFLILWRILGILPPSKTYINQLSMNSPEMSECDILHTLRWSSRLRISSYVNWIKDHLIKQGMKAEHASSLLELASTTKCSSVKYDVEIVEEYFARQISSFCSIDCTTILQLHEIPSLQSIYTLDAAISKVQVSLDEHFSKMAAETDPHKSSEITKNLLPATLQLIDTYASFTRAYLLQNFNEEGTTEKPSKEKLQGFAAVLAIGSSRCKANTLGPTLVQNLPSSVQTVCESWNNINTNEFPNIGSWRNAFANDTIPSESYISAVQAAHLGTLCSQSLPLAASLKHTLLSLVRLTGDLIVWSDEMNPPQVIRTLLPLLLESSTESVAEISSNSLERILGPAESDEFLARVYEKLITGCYNILANHADPNSGLDESILEECLQYLEKQLESSQARKAMEEFFSDSGELVQIMMATANENLSAKFCNRVLKFFTKLFQLTEKSPNPSLLHLCGSLAQLACVEPVRLQAWLTRMTTSPPKDSDQLDVIQENRQLLQLLTTYIVRENSQVGEGVCAVLLGTLTPMATEMLANGDGTGFPELMVVMATLASAGQGAGHLQLHNAAVDWLSRCKKYLSQKNVVEKLNANVMHGKHVMILECTCHIMSYLADVTNALSQSNGQGPSHLSVDGEERAIEVDSDWVEELAVEEEDSQAEDSDEDSLCNKLCTFTITQKEFMNQHWYHCHTCKMVDGVGVCTVCAKVCHKDHEISYAKYGSFFCDCGAKEDGSCLALVKRTPSSGMSSTMKESAFQSEPRISESLVRHASTSSPADKAKVTISDGKVADEEKPKKSSLCRTVEGCREELQNQANFSFAPLVLDMLNFLMDAIQTNFQQASAVGSSSRAQQALSELHTVEKAVEMTDQLMVPTLGSQEGAFENVRMNYSGDQGQTIRQLISAHVLRRVAMCVLSSPHGRRQHLAVSHEKGKITVLQLSALLKQADSSKRKLTLTRLASAPVPFTVLSLTGNPCKEDYLAVCGLKDCHVLTFSSSGSVSDHLVLHPQLATGNFIIKAVWLPGSQTELAIVTADFVKIYDLCVDALSPTFYFLLPSSKIRDVTFLFNEEGKNIIVIMSSAGYIYTQLMEEASSAQQGPFYVTNVLEINHEDLKDSNSQVAGGGVSVYYSHVLQMLFFSYCQGKSFAATISRTTLEVLQLFPINIKSSNGGSKTSPALCQWSEVMNHPGLVCCVQQTTGVPLVVMVKPDTFLIQEIKTLPAKAKIQDMVAIRHTACNEQQRTTMILLCEDGSLRIYMANVENTSYWLQPSLQPSSVISIMKPVRKRKTATITTRTSSQVTFPIDFFEHNQQLTDVEFGGNDLLQVYNAQQIKHRLNSTGMYVANTKPGGFTIEISNNNSTMVMTGMRIQIGTQAIERAPSYIEIFGRTMQLNLSRSRWFDFPFTREEALQADKKLNLFIGASVDPAGVTMIDAVKIYGKTKEQFGWPDEPPEEFPSASVSNICPSNLNQSNGTGDSDSAAPTTTSGTVLERLVVSSLEALESCFAVGPIIEKERNKNAAQELATLLLSLPAPASVQQQSKSLLASLHTSRSAYHSHKDQALLSKAVQCLNTSSKEGKDLDPEVFQRLVITARSIAIMRPNNLVHFTESKLPQMETEGMDEGKEPQKQLEGDCCSFITQLVNHFWKLHASKPKNAFLAPACLPGLTHIEATVNALVDIIHGYCTCELDCINTASKIYMQMLLCPDPAVSFSCKQALIRVLRPRNKRRHVTLPSSPRSNTPMGDKDDDDDDDADEKMQSSGIPNGGHIRQESQEQSEVDHGDFEMVSESMVLETAENVNNGNPSPLEALLAGAEGFPPMLDIPPDADDETMVELAIALSLQQDQQGSSSSALGLQSLGLSGQAPSSSSLDAGTLSDTTASAPASDDEGSTAATDGSTLRTSPADHGGSVGSESGGSAVDSVAGEHSVSGRSSAYGDATAEGHPAGPGSVSSSTGAISTTTGHQEGDGSEGEGEGETEGDVHTSNRLHMVRLMLLERLLQTLPQLRNVGGVRAIPYMQVILMLTTDLDGEDEKDKGALDNLLSQLIAELGMDKKDVSKKNERSALNEVHLVVMRLLSVFMSRTKSGSKSSICESSSLISSATAAALLSSGAVDYCLHVLKSLLEYWKSQQNDEEPVATSQLLKPHTTSSPPDMSPFFLRQYVKGHAADVFEAYTQLLTEMVLRLPYQIKKITDTNSRIPPPVFDHSWFYFLSEYLMIQQTPFVRRQVRKLLLFICGSKEKYRQLRDLHTLDSHVRGIKKLLEEQGIFLRASVVTASSGSALQYDTLISLMEHLKACAEIAAQRTINWQKFCIKDDSVLYFLLQVSFLVDEGVSPVLLQLLSCALCGSKVLAALAASSGSSSASSSSAPVAASSGQATTQSKSSTKKSKKEEKEKEKDGETSGSQEDQLCTALVNQLNKFADKETLIQFLRCFLLESNSSSVRWQAHCLTLHIYRNSSKSQQELLLDLMWSIWPELPAYGRKAAQFVDLLGYFSLKTPQTEKKLKEYSQKAVEILRTQNHILTNHPNSNIYNTLSGLVEFDGYYLESDPCLVCNNPEVPFCYIKLSSIKVDTRYTTTQQVVKLIGSHTISKVTVKIGDLKRTKMVRTINLYYNNRTVQAIVELKNKPARWHKAKKVQLTPGQTEVKIDLPLPIVASNLMIEFADFYENYQASTETLQCPRCSASVPANPGVCGNCGENVYQCHKCRSINYDEKDPFLCNACGFCKYARFDFMLYAKPCCAVDPIENEEDRKKAVSNINTLLDKADRVYHQLMGHRPQLENLLCKVNEAAPEKPQDDSGTAGGISSTSASVNRYILQLAQEYCGDCKNSFDELSKIIQKVFASRKELLEYDLQQREAATKSSRTSVQPTFTASQYRALSVLGCGHTSSTKCYGCASAVTEHCITLLRALATNPALRHILVSQGLIRELFDYNLRRGAAAMREEVRQLMCLLTRDNPEATQQMNDLIIGKVSTALKGHWANPDLASSLQYEMLLLTDSISKEDSCWELRLRCALSLFLMAVNIKTPVVVENITLMCLRILQKLIKPPAPTSKKNKDVPVEALTTVKPYCNEIHAQAQLWLKRDPKASYDAWKKCLPIRGIDGNGKAPSKSELRHLYLTEKYVWRWKQFLSRRGKRTSPLDLKLGHNNWLRQVLFTPATQAARQAACTIVEALATIPSRKQQVLDLLTSYLDELSIAGECAAEYLALYQKLITSAHWKVYLAARGVLPYVGNLITKEIARLLALEEATLSTDLQQGYALKSLTGLLSSFVEVESIKRHFKSRLVGTVLNGYLCLRKLVVQRTKLIDETQDMLLEMLEDMTTGTESETKAFMAVCIETAKRYNLDDYRTPVFIFERLCSIIYPEENEVTEFFVTLEKDPQQEDFLQGRMPGNPYSSNEPGIGPLMRDIKNKICQDCDLVALLEDDSGMELLVNNKIISLDLPVAEVYKKVWCTTNEGEPMRIVYRMRGLLGDATEEFIESLDSTTDEEEDEEEVYKMAGVMAQCGGLECMLNRLAGIRDFKQGRHLLTVLLKLFSYCVKVKVNRQQLVKLEMNTLNVMLGTLNLALVAEQESKDSGGAAVAEQVLSIMEIILDESNAEPLSEDKGNLLLTGDKDQLVMLLDQINSTFVRSNPSVLQGLLRIIPYLSFGEVEKMQILVERFKPYCNFDKYDEDHSGDDKVFLDCFCKIAAGIKNNSNGHQLKDLILQKGITQNALDYMKKHIPSAKNLDADIWKKFLSRPALPFILRLLRGLAIQHPGTQVLIGTDSIPNLHKLEQVSSDEGIGTLAENLLEALREHPDVNKKIDAARRETRAEKKRMAMAMRQKALGTLGMTTNEKGQVVTKTALLKQMEELIEEPGLTCCICREGYKFQPTKVLGIYTFTKRVALEEMENKPRKQQGYSTVSHFNIVHYDCHLAAVRLARGREEWESAALQNANTKCNGLLPVWGPHVPESAFATCLARHNTYLQECTGQREPTYQLNIHDIKLLFLRFAMEQSFSADTGGGGRESNIHLIPYIIHTVLYVLNTTRATSREEKNLQGFLEQPKEKWVESAFEVDGPYYFTVLALHILPPEQWRATRVEILRRLLVTSQARAVAPGGATRLTDKAVKDYSAYRSSLLFWALVDLIYNMFKKVPTSNTEGGWSCSLAEYIRHNDMPIYEAADKALKTFQEEFMPVETFSEFLDVAGLLSEITDPESFLKDLLNSVP,,,,PF13764;PF02207;,hsa:23352;,,,"SUBUNIT: Interacts with RB1 and calmodulin. Interacts with protein E7 from papilloma virus HPV-16, HPV-6B and HPV-11. {ECO:0000269|PubMed:16061792, ECO:0000269|PubMed:16214886}.",,,,,,,,,2.392436813,-0.2,573.94,119,120Q9P0L0,VAPA_HUMAN,reviewed,Vesicle-associated membrane protein-associated protein A (VAMP-A) (VAMP-associated protein A) (VAP-A) (33 kDa VAMP-associated protein) (VAP-33),VAPA VAP33,Homo sapiens (Human),249,GO:0090114; GO:0006888; GO:0033149; GO:0000139; GO:0008219; GO:0005783; GO:0005789; GO:0016021; GO:0061025; GO:0008017; GO:0015630; GO:0044828; GO:0031175; GO:0005886; GO:0044829; GO:0044791; GO:0043123; GO:0019904; GO:0046982; GO:0070972; GO:0004871; GO:0007165; GO:0044281; GO:0030148; GO:0006665; GO:0005198; GO:0031982,9218;,MASASGAMAKHEQILVLDPPTDLKFKGPFTDVVTTNLKLRNPSDRKVCFKVKTTAPRRYCVRPNSGIIDPGSTVTVSVMLQPFDYDPNEKSKHKFMVQTIFAPPNTSDMEAVWKEAKPDELMDSKLRCVFEMPNENDKLNDMEPSKAVPLNASKQDGPMPKPHSVSLNDTETRKLMEECKRLQGEMMKLSEENRHLRDEGLRLRKVAHSDKPGSTSTASFRDNVTSPLPSLLVVIAAIFIGFFLGKFIL,,,,PF00635;,hsa:9218;,,,"SUBUNIT: Homodimer, and heterodimer with VAPB. Interacts with VAMP1, VAMP2, STX1A, BET1, SEC22C and with the C-terminal domain of OCLN. Interacts with OSBPL1A. Interacts (via MSP domain) with ZFYVE27; may retain ZFYVE27 in the endoplasmic reticulum and regulate its function in cell projections formation. Interacts with OSBP. Interacts (via C-terminus) with RSAD2/viperin (via C-terminus). Interacts with HCV protein NS5A and NS5B. Interacts with IFITM3. {ECO:0000269|PubMed:10523508, ECO:0000269|PubMed:11511104, ECO:0000269|PubMed:19289470, ECO:0000269|PubMed:20178991, ECO:0000269|PubMed:21957124, ECO:0000269|PubMed:23601107, ECO:0000269|PubMed:9657962}.",HELIX 109 115 {ECO:0000244|PDB:2RR3}.,STRAND 14 21 {ECO:0000244|PDB:2RR3}.; STRAND 23 27 {ECO:0000244|PDB:2RR3}.; STRAND 33 40 {ECO:0000244|PDB:2RR3}.; STRAND 43 45 {ECO:0000244|PDB:2RR3}.; STRAND 47 54 {ECO:0000244|PDB:2RR3}.; STRAND 59 63 {ECO:0000244|PDB:2RR3}.; STRAND 65 68 {ECO:0000244|PDB:2RR3}.; STRAND 73 80 {ECO:0000244|PDB:2RR3}.; STRAND 94 101 {ECO:0000244|PDB:2RR3}.; STRAND 122 131 {ECO:0000244|PDB:2RR3}.,TURN 56 58 {ECO:0000244|PDB:2RR3}.; TURN 118 120 {ECO:0000244|PDB:2RR3}.,DOMAIN 14 131 MSP. {ECO:0000255|PROSITE-ProRule:PRU00132}.,,,,,1.606425703,-0.468,27.9,471,472P21796,VDAC1_HUMAN,reviewed,Voltage-dependent anion-selective channel protein 1 (VDAC-1) (hVDAC1) (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) (Porin 31HL) (Porin 31HM),VDAC1 VDAC,Homo sapiens (Human),283,GO:0006820; GO:0006915; GO:0001662; GO:0030855; GO:0070062; GO:0007612; GO:0016020; GO:0005743; GO:0042645; GO:0005741; GO:0005739; GO:0007270; GO:0005634; GO:0005886; GO:0046930; GO:0015288; GO:0019901; GO:0016032; GO:0008308,7416;,MAVPPTYADLGKSARDVFTKGYGFGLIKLDLKTKSENGLEFTSSGSANTETTKVTGSLETKYRWTEYGLTFTEKWNTDNTLGTEITVEDQLARGLKLTFDSSFSPNTGKKNAKIKTGYKREHINLGCDMDFDIAGPSIRGALVLGYEGWLAGYQMNFETAKSRVTQSNFAVGYKTDEFQLHTNVNDGTEFGGSIYQKVNKKLETAVNLAWTAGNSNTRFGIAAKYQIDPDACFSAKVNNSSLIGLGYTQTLKPGIKLTLSALLDGKNVNAGGHKLGLGLEFQA,,,DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed by 19 beta-strands. The helical N-terminus folds back into the pore opening and plays a role in voltage-gated channel activity.,PF01459;,hsa:7416;,,,SUBUNIT: Interacts with hexokinases (By similarity). Interacts with BCL2L1. Interacts with BOP/C22orf29 (via BH3 domain). Interacts with influenza A virus PB1-F2 protein. Interacts with HK1. The HK1-VDAC1 complex interacts with ATF2 (By similarity). {ECO:0000250}.,HELIX 268 270 {ECO:0000244|PDB:2K4T}.,STRAND 26 33 {ECO:0000244|PDB:2K4T}.; STRAND 40 51 {ECO:0000244|PDB:2K4T}.; STRAND 55 62 {ECO:0000244|PDB:2K4T}.; STRAND 66 76 {ECO:0000244|PDB:2K4T}.; STRAND 80 88 {ECO:0000244|PDB:2K4T}.; STRAND 95 103 {ECO:0000244|PDB:2K4T}.; STRAND 110 119 {ECO:0000244|PDB:2K4T}.; STRAND 124 135 {ECO:0000244|PDB:2K4T}.; STRAND 137 146 {ECO:0000244|PDB:2K4T}.; STRAND 149 158 {ECO:0000244|PDB:2K4T}.; STRAND 167 174 {ECO:0000244|PDB:2K4T}.; STRAND 176 185 {ECO:0000244|PDB:2K4T}.; STRAND 189 196 {ECO:0000244|PDB:2K4T}.; STRAND 203 211 {ECO:0000244|PDB:2K4T}.; STRAND 217 228 {ECO:0000244|PDB:2K4T}.; STRAND 231 241 {ECO:0000244|PDB:2K4T}.; STRAND 243 250 {ECO:0000244|PDB:2K4T}.; STRAND 252 254 {ECO:0000244|PDB:2K4T}.; STRAND 256 264 {ECO:0000244|PDB:2K4T}.; STRAND 274 282 {ECO:0000244|PDB:2K4T}.,TURN 7 10 {ECO:0000244|PDB:2K4T}.; TURN 36 38 {ECO:0000244|PDB:2K4T}.; TURN 77 79 {ECO:0000244|PDB:2K4T}.; TURN 105 107 {ECO:0000244|PDB:2K4T}.; TURN 159 162 {ECO:0000244|PDB:2K4T}.; TURN 186 188 {ECO:0000244|PDB:2K4T}.,,,,,,0.706713781,-0.411,30.78,386,387P45880,VDAC2_HUMAN,reviewed,Voltage-dependent anion-selective channel protein 2 (VDAC-2) (hVDAC2) (Outer mitochondrial membrane protein porin 2),VDAC2,Homo sapiens (Human),294,GO:0006820; GO:0070062; GO:0005743; GO:0042645; GO:0005741; GO:0005739; GO:2001243; GO:0032272; GO:0000166; GO:0005634; GO:0046930; GO:0015288; GO:0008308,7417;,MATHGQTCARPMCIPPSYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVTGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSSYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRNNFAVGYRTGDFQLHTNVNDGTEFGGSIYQKVCEDLDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSINAGGHKVGLALELEA,,,DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed by 19 beta-strands. {ECO:0000250}.,PF01459;,hsa:7417;,,,SUBUNIT: Interacts with hexokinases. {ECO:0000250}.,,,,,,,,,3.06122449,-0.274,31.57,162,163Q9Y277,VDAC3_HUMAN,reviewed,Voltage-dependent anion-selective channel protein 3 (VDAC-3) (hVDAC3) (Outer mitochondrial membrane protein porin 3),VDAC3,Homo sapiens (Human),283,GO:0015853; GO:0070062; GO:0005741; GO:0005739; GO:0000166; GO:0005634; GO:0046930; GO:0015288; GO:0008308,7419;,MCNTPTYCDLGKAAKDVFNKGYGFGMVKIDLKTKSCSGVEFSTSGHAYTDTGKASGNLETKYKVCNYGLTFTQKWNTDNTLGTEISWENKLAEGLKLTLDTIFVPNTGKKSGKLKASYKRDCFSVGSNVDIDFSGPTIYGWAVLAFEGWLAGYQMSFDTAKSKLSQNNFALGYKAADFQLHTHVNDGTEFGGSIYQKVNEKIETSINLAWTAGSNNTRFGIAAKYMLDCRTSLSAKVNNASLIGLGYTQTLRPGVKLTLSALIDGKNFSAGGHKVGLGFELEA,,,DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed by 19 beta-strands. {ECO:0000250}.,PF01459;,hsa:7419;,,,,,,,,,,,,2.120141343,-0.28,30.66,3145,3146P08670,VIME_HUMAN,reviewed,Vimentin,VIM,Homo sapiens (Human),466,GO:0060020; GO:0006915; GO:0014002; GO:0031252; GO:0006921; GO:0006928; GO:0005737; GO:0005856; GO:0005829; GO:0003725; GO:0070062; GO:0005925; GO:0001948; GO:0042802; GO:0005882; GO:0045111; GO:0045109; GO:0070307; GO:0030049; GO:0010977; GO:0043005; GO:0005777; GO:0005886; GO:0010628; GO:0008022; GO:0097110; GO:0005200; GO:0005212; GO:0016032,7431;,MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE,"DISEASE: Cataract 30 (CTRCT30) [MIM:116300]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Note=The disease is caused by mutations affecting the gene represented in this entry.",,DOMAIN: The central alpha-helical coiled-coil rod region mediates elementary homodimerization.,PF00038;PF04732;,hsa:7431;,,,"SUBUNIT: Homopolymer assembled from elementary dimers. Interacts with HCV core protein. Interacts with LGSN and SYNM. Interacts (via rod region) with PLEC (via CH 1 domain). Interacts with SLC6A4. Interacts with STK33. Interacts with LARP6. Interacts with RAB8B. Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton. Interacts with TOR1AIP1. Interacts with BCAS3. {ECO:0000269|PubMed:15846844, ECO:0000269|PubMed:16361107, ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:18811945, ECO:0000269|PubMed:18827015, ECO:0000269|PubMed:19270731, ECO:0000269|PubMed:20176112, ECO:0000269|PubMed:21746880}.",HELIX 102 135 {ECO:0000244|PDB:1GK7}.; HELIX 155 207 {ECO:0000244|PDB:3SWK}.; HELIX 210 234 {ECO:0000244|PDB:3SWK}.; HELIX 266 334 {ECO:0000244|PDB:3TRT}.; HELIX 385 405 {ECO:0000244|PDB:1GK6}.,,TURN 244 248 {ECO:0000244|PDB:3UF1}.,,,,,,0.214592275,-0.823,53.66,127,128P23381,SYWC_HUMAN,reviewed,"Tryptophan--tRNA ligase, cytoplasmic (EC 6.1.1.2) (Interferon-induced protein 53) (IFP53) (Tryptophanyl-tRNA synthetase) (TrpRS) (hWRS) [Cleaved into: T1-TrpRS; T2-TrpRS]",WARS IFI53 WRS,Homo sapiens (Human),471,GO:0005524; GO:0001525; GO:0005737; GO:0005829; GO:0070062; GO:0010467; GO:0008285; GO:0005634; GO:0045765; GO:0006418; GO:0006412; GO:0004830; GO:0006436,7453;,MPNSEPASLLELFNSIATQGELVRSLKAGNASKDEIDSAVKMLVSLKMSYKAAAGEDYKADCPPGNPAPTSNHGPDATEAEEDFVDPWTVQTSSAKGIDYDKLIVRFGSSKIDKELINRIERATGQRPHHFLRRGIFFSHRDMNQVLDAYENKKPFYLYTGRGPSSEAMHVGHLIPFIFTKWLQDVFNVPLVIQMTDDEKYLWKDLTLDQAYSYAVENAKDIIACGFDINKTFIFSDLDYMGMSSGFYKNVVKIQKHVTFNQVKGIFGFTDSDCIGKISFPAIQAAPSFSNSFPQIFRDRTDIQCLIPCAIDQDPYFRMTRDVAPRIGYPKPALLHSTFFPALQGAQTKMSASDPNSSIFLTDTAKQIKTKVNKHAFSGGRDTIEEHRQFGGNCDVDVSFMYLTFFLEDDDKLEQIRKDYTSGAMLTGELKKALIEVLQPLIAEHQARRKEVTDEIVKEFMTPRKLSFDFQ,,,,PF00579;PF00458;,hsa:7453;,,P23381;,SUBUNIT: Homodimer. Isoform 1 and isoform 2 interact with an oxidized form of GAPDH. GAPDH stimulates the aminoacylation activity of isoform 2.,HELIX 8 28 {ECO:0000244|PDB:1R6T}.; HELIX 33 53 {ECO:0000244|PDB:1R6T}.; HELIX 103 106 {ECO:0000244|PDB:1R6U}.; HELIX 114 124 {ECO:0000244|PDB:1R6U}.; HELIX 130 133 {ECO:0000244|PDB:1R6U}.; HELIX 143 150 {ECO:0000244|PDB:1R6U}.; HELIX 171 187 {ECO:0000244|PDB:1R6U}.; HELIX 197 203 {ECO:0000244|PDB:1R6U}.; HELIX 208 223 {ECO:0000244|PDB:1R6U}.; HELIX 229 231 {ECO:0000244|PDB:1R6U}.; HELIX 237 240 {ECO:0000244|PDB:1R6U}.; HELIX 241 243 {ECO:0000244|PDB:1R6U}.; HELIX 247 256 {ECO:0000244|PDB:1R6U}.; HELIX 260 267 {ECO:0000244|PDB:1R6U}.; HELIX 275 285 {ECO:0000244|PDB:1R6U}.; HELIX 286 288 {ECO:0000244|PDB:1R6U}.; HELIX 290 292 {ECO:0000244|PDB:1R6U}.; HELIX 294 297 {ECO:0000244|PDB:1R6U}.; HELIX 311 313 {ECO:0000244|PDB:1R6U}.; HELIX 314 323 {ECO:0000244|PDB:1R6U}.; HELIX 324 327 {ECO:0000244|PDB:1R6U}.; HELIX 365 374 {ECO:0000244|PDB:1R6U}.; HELIX 384 390 {ECO:0000244|PDB:1R6U}.; HELIX 398 406 {ECO:0000244|PDB:1R6U}.; HELIX 410 422 {ECO:0000244|PDB:1R6U}.; HELIX 430 450 {ECO:0000244|PDB:1R6U}.; HELIX 454 460 {ECO:0000244|PDB:1R6U}.,STRAND 54 56 {ECO:0000244|PDB:1R6T}.; STRAND 84 86 {ECO:0000244|PDB:1R6U}.; STRAND 89 91 {ECO:0000244|PDB:1R6U}.; STRAND 136 142 {ECO:0000244|PDB:1R6U}.; STRAND 156 162 {ECO:0000244|PDB:1R6U}.; STRAND 191 195 {ECO:0000244|PDB:1R6U}.; STRAND 232 236 {ECO:0000244|PDB:1R6U}.; STRAND 271 274 {ECO:0000244|PDB:1ULH}.; STRAND 304 310 {ECO:0000244|PDB:1R6U}.; STRAND 333 337 {ECO:0000244|PDB:1R6U}.; STRAND 345 349 {ECO:0000244|PDB:1R6U}.; STRAND 354 357 {ECO:0000244|PDB:1R6U}.; STRAND 360 362 {ECO:0000244|PDB:2AZX}.; STRAND 423 425 {ECO:0000244|PDB:1R6U}.,TURN 100 102 {ECO:0000244|PDB:1R6U}.; TURN 151 153 {ECO:0000244|PDB:1R6U}.; TURN 224 226 {ECO:0000244|PDB:1R6U}.; TURN 394 396 {ECO:0000244|PDB:1R6U}.,DOMAIN 8 64 WHEP-TRS. {ECO:0000255|PROSITE-ProRule:PRU00531}.,,,,,1.27388535,-0.365,53.17,2.88,3.88Q9UNX4,WDR3_HUMAN,reviewed,WD repeat-containing protein 3,WDR3,Homo sapiens (Human),943,GO:0034388; GO:0000462; GO:0031965; GO:0005730; GO:0005634; GO:0044822; GO:0032040; GO:0030515,10885;,MGLTKQYLRYVASAVFGVIGSQKGNIVFVTLRGEKGRYVAVPACEHVFIWDLRKGEKILILQGLKQEVTCLCPSPDGLHLAVGYEDGSIRIFSLLSGEGNVTFNGHKAAITTLKYDQLGGRLASGSKDTDIIVWDVINESGLYRLKGHKDAITQALFLREKNLLVTSGKDTMVKWWDLDTQHCFKTMVGHRTEVWGLVLLSEEKRLITGASDSELRVWDIAYLQEIEDPEEPDPKKIKGSSPGIQDTLEAEDGAFETDEAPEDRILSCRKAGSIMREGRDRVVNLAVDKTGRILACHGTDSVLELFCILSKKEIQKKMDKKMKKARKKAKLHSSKGEEEDPEVNVEMSLQDEIQRVTNIKTSAKIKSFDLIHSPHGELKAVFLLQNNLVELYSLNPSLPTPQPVRTSRITIGGHRSDVRTLSFSSDNIAVLSAAADSIKIWNRSTLQCIRTMTCEYALCSFFVPGDRQVVIGTKTGKLQLYDLASGNLLETIDAHDGALWSMSLSPDQRGFVTGGADKSVKFWDFELVKDENSTQKRLSVKQTRTLQLDEDVLCVSYSPNQKLLAVSLLDCTVKIFYVDTLKFFLSLYGHKLPVICMDISHDGALIATGSADRNVKIWGLDFGDCHKSLFAHDDSVMYLQFVPKSHLFFTAGKDHKIKQWDADKFEHIQTLEGHHQEIWCLAVSPSGDYVVSSSHDKSLRLWERTREPLILEEEREMEREAEYEESVAKEDQPAVPGETQGDSYFTGKKTIETVKAAERIMEAIELYREETAKMKEHKAICKAAGKEVPLPSNPILMAYGSISPSAYVLEIFKGIKSSELEESLLVLPFSYVPDILKLFNEFIQLGSDVELICRCLFFLLRIHFGQITSNQMLVPVIEKLRETTISKVSQVRDVIGFNMAGLDYLKRECEAKSEVMFFADATSHLEEKKRKRKKREKLILTLT,,,,PF04003;PF00400;,hsa:10885;,,,,,,,,,,,,2.014846235,-0.256,106.11,124,125P54577,SYYC_HUMAN,reviewed,"Tyrosine--tRNA ligase, cytoplasmic (EC 6.1.1.1) (Tyrosyl-tRNA synthetase) (TyrRS) [Cleaved into: Tyrosine--tRNA ligase, cytoplasmic, N-terminally processed]",YARS,Homo sapiens (Human),528,GO:0005524; GO:0006915; GO:0005737; GO:0005829; GO:0005615; GO:0010467; GO:0005153; GO:0005634; GO:0044822; GO:0004871; GO:0007165; GO:0006418; GO:0000049; GO:0004831; GO:0006437,8565;,MGDAPSPEEKLHLITRNLQEVLGEEKLKEILKERELKIYWGTATTGKPHVAYFVPMSKIADFLKAGCEVTILFADLHAYLDNMKAPWELLELRVSYYENVIKAMLESIGVPLEKLKFIKGTDYQLSKEYTLDVYRLSSVVTQHDSKKAGAEVVKQVEHPLLSGLLYPGLQALDEEYLKVDAQFGGIDQRKIFTFAEKYLPALGYSKRVHLMNPMVPGLTGSKMSSSEEESKIDLLDRKEDVKKKLKKAFCEPGNVENNGVLSFIKHVLFPLKSEFVILRDEKWGGNKTYTAYVDLEKDFAAEVVHPGDLKNSVEVALNKLLDPIREKFNTPALKKLASAAYPDPSKQKPMAKGPAKNSEPEEVIPSRLDIRVGKIITVEKHPDADSLYVEKIDVGEAEPRTVVSGLVQFVPKEELQDRLVVVLCNLKPQKMRGVESQGMLLCASIEGINRQVEPLDPPAGSAPGEHVFVKGYEKGQPDEELKPKKKVFEKLQADFKISEECIAQWKQTNFMTKLGSISCKSLKGGNIS,"DISEASE: Charcot-Marie-Tooth disease, dominant, intermediate type, C (CMTDIC) [MIM:608323]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. {ECO:0000269|PubMed:16429158}. Note=The disease is caused by mutations affecting the gene represented in this entry.",,,PF00579;PF01588;,hsa:8565;,,,"SUBUNIT: Homodimer. {ECO:0000269|PubMed:12427973, ECO:0000269|PubMed:14671330}.",HELIX 7 15 {ECO:0000244|PDB:1N3L}.; HELIX 24 31 {ECO:0000244|PDB:1N3L}.; HELIX 50 52 {ECO:0000244|PDB:1N3L}.; HELIX 53 64 {ECO:0000244|PDB:1N3L}.; HELIX 75 80 {ECO:0000244|PDB:1N3L}.; HELIX 87 108 {ECO:0000244|PDB:1N3L}.; HELIX 120 122 {ECO:0000244|PDB:1N3L}.; HELIX 127 137 {ECO:0000244|PDB:1N3L}.; HELIX 142 148 {ECO:0000244|PDB:1N3L}.; HELIX 161 176 {ECO:0000244|PDB:1N3L}.; HELIX 186 188 {ECO:0000244|PDB:1N3L}.; HELIX 189 198 {ECO:0000244|PDB:1N3L}.; HELIX 199 202 {ECO:0000244|PDB:1N3L}.; HELIX 238 246 {ECO:0000244|PDB:1N3L}.; HELIX 259 266 {ECO:0000244|PDB:1N3L}.; HELIX 281 283 {ECO:0000244|PDB:1N3L}.; HELIX 292 300 {ECO:0000244|PDB:1N3L}.; HELIX 306 327 {ECO:0000244|PDB:1N3L}.; HELIX 331 340 {ECO:0000244|PDB:1N3L}.; HELIX 365 367 {ECO:0000244|PDB:1NTG}.; HELIX 412 414 {ECO:0000244|PDB:1NTG}.; HELIX 483 485 {ECO:0000244|PDB:1NTG}.; HELIX 487 492 {ECO:0000244|PDB:1NTG}.,STRAND 19 22 {ECO:0000244|PDB:1N3L}.; STRAND 37 42 {ECO:0000244|PDB:1N3L}.; STRAND 68 73 {ECO:0000244|PDB:1N3L}.; STRAND 115 119 {ECO:0000244|PDB:1N3L}.; STRAND 180 185 {ECO:0000244|PDB:1N3L}.; STRAND 208 212 {ECO:0000244|PDB:1N3L}.; STRAND 247 249 {ECO:0000244|PDB:1Q11}.; STRAND 275 277 {ECO:0000244|PDB:1N3L}.; STRAND 287 291 {ECO:0000244|PDB:1N3L}.; STRAND 370 380 {ECO:0000244|PDB:1NTG}.; STRAND 388 393 {ECO:0000244|PDB:1NTG}.; STRAND 395 398 {ECO:0000244|PDB:1NTG}.; STRAND 400 405 {ECO:0000244|PDB:1NTG}.; STRAND 419 423 {ECO:0000244|PDB:1NTG}.; STRAND 429 431 {ECO:0000244|PDB:1NTG}.; STRAND 434 436 {ECO:0000244|PDB:1NTG}.; STRAND 442 454 {ECO:0000244|PDB:1NTG}.; STRAND 466 469 {ECO:0000244|PDB:1NTG}.; STRAND 479 481 {ECO:0000244|PDB:1NTG}.; STRAND 495 497 {ECO:0000244|PDB:1NTG}.; STRAND 501 505 {ECO:0000244|PDB:1NTG}.; STRAND 508 512 {ECO:0000244|PDB:1NTG}.; STRAND 526 528 {ECO:0000244|PDB:1NTG}.,TURN 81 84 {ECO:0000244|PDB:1N3L}.; TURN 123 125 {ECO:0000244|PDB:1N3L}.; TURN 149 152 {ECO:0000244|PDB:1N3L}.; TURN 267 273 {ECO:0000244|PDB:1N3L}.; TURN 407 409 {ECO:0000244|PDB:1NTG}.; TURN 415 417 {ECO:0000244|PDB:1NTG}.,DOMAIN 364 468 tRNA-binding. {ECO:0000255|PROSITE-ProRule:PRU00209}.,,,,,1.136363636,-0.362,59.15,253,254Q15942,ZYX_HUMAN,reviewed,Zyxin (Zyxin-2),ZYX,Homo sapiens (Human),572,GO:0007155; GO:0005913; GO:0007267; GO:0007160; GO:0005737; GO:0005925; GO:0005887; GO:0007229; GO:0005634; GO:0005886; GO:0044822; GO:0050727; GO:0007165; GO:0001725; GO:0043149; GO:0007179; GO:0016032; GO:0008270,7791;,MAAPRPSPAISVSVSAPAFYAPQKKFGPVVAPKPKVNPFRPGDSEPPPAPGAQRAQMGRVGEIPPPPPEDFPLPPPPLAGDGDDAEGALGGAFPPPPPPIEESFPPAPLEEEIFPSPPPPPEEEGGPEAPIPPPPQPREKVSSIDLEIDSLSSLLDDMTKNDPFKARVSSGYVPPPVATPFSSKSSTKPAAGGTAPLPPWKSPSSSQPLPQVPAPAQSQTQFHVQPQPQPKPQVQLHVQSQTQPVSLANTQPRGPPASSPAPAPKFSPVTPKFTPVASKFSPGAPGGSGSQPNQKLGHPEALSAGTGSPQPPSFTYAQQREKPRVQEKQHPVPPPAQNQNQVRSPGAPGPLTLKEVEELEQLTQQLMQDMEHPQRQNVAVNELCGRCHQPLARAQPAVRALGQLFHIACFTCHQCAQQLQGQQFYSLEGAPYCEGCYTDTLEKCNTCGEPITDRMLRATGKAYHPHCFTCVVCARPLEGTSFIVDQANRPHCVPDYHKQYAPRCSVCSEPIMPEPGRDETVRVVALDKNFHMKCYKCEDCGKPLSIEADDNGCFPLDGHVLCRKCHTARAQT,,,,PF00412;,hsa:7791;,,,"SUBUNIT: Interacts with HPV type 6 protein E6. Does not interact significantly with E6 proteins from HPV types 11, 16, or 18. Interacts, via the Pro-rich regions, with the EVH1 domains of ENAH, EVL and VASP. Interacts with the first LIM domain of TES. Interacts with NEBL (isoform 2). {ECO:0000269|PubMed:10801818, ECO:0000269|PubMed:11689660, ECO:0000269|PubMed:12695497, ECO:0000269|PubMed:18158903}.",,,,DOMAIN 384 443 LIM zinc-binding 1. {ECO:0000255|PROSITE-ProRule:PRU00125}.; DOMAIN 444 503 LIM zinc-binding 2. {ECO:0000255|PROSITE-ProRule:PRU00125}.; DOMAIN 504 570 LIM zinc-binding 3. {ECO:0000255|PROSITE-ProRule:PRU00125}.,,,,,3.671328671,-0.63,61.29,,